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Abstract
Thyroid diseases number amongst the most widespread and chronic 
conditions in the population. They are symptomatically vague, difficult to 
diagnose, and are more prevalent in women than men. Since the hormones 
produced by the gland control cell metabolism in the body, symptoms of 
glandular failure are elusively diverse and non-specific and are easily 
attributable to other diseases or no disease at all.
Consequently, a definitive diagnosis conventionally relies on a blood test to 
measure the function of the gland. However, as observed in the clinic, such 
a diagnosis is often partial and is not compatible with the clinical symptoms 
some patients present. Predictably, many patients feel such tests are 
inaccurate measures of the extent of their disease and do not match their 
own interpretations of clinical symptoms or experiences of suffering. In 
response, many clinicians express concern that patients are incorrectly 
attributing their symptoms to thyroid disease and as a consequence are 
demanding treatments which are not necessary
This qualitative study investigates the indeterminate aspects of thyroid 
dysfunction by exploring how a contest over meaning is manifest in the 
clinic, particularly with regards to how embodied clinical symptoms and dis­
embodied biochemical measures are used as evidence for and against 
decisions over diagnosis and treatment. The thesis identifies that, due to 
the vague nature of both symptomatic and biochemical evidence, thyroid 
disease is a location where medicalisation is impossible. Subsequently, 
using the available discourses of the clinic, specifically EBM and patient 
centred medicine, clinicians and patients construct various orders of thyroid 
biology and pathology, in an attempt to satisfy diagnostic strategies and 
treatment needs.
As a consequence the thesis can add to the analytical purchase of the 
anthropologist Paul Rabinow’s concept of biosociality and theories of 
governmentality more generally. That is, it demonstrates how practices of 
re-making thyroid biology are possible, not because of a new found 
molecular control over thyroid biology, but due to the non-compliant nature 
of thyroid biology and the technical deficiency of current diagnostic and 
treatment strategies deployed to attend to it within the clinic.
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Chapter 1
Introduction: the accuracies and vagaries of thyroid disease
Tanya, a woman in her mid forties who had attended a thyroid clinic for a 
thyroid swelling provided a typical account of her experience when I 
interviewed her for this study at her home in London in June of 2006. She 
had visited her GP during 1989/90 because she noticed that her neck had 
started to swell. Her regular GP was away on holiday so she saw a locum 
who, after examining the swelling, referred her to a consultant surgeon. 
During the consultation with the surgeon, in which Tanya thought that he 
was ‘rather showing off in front of the medical students who were 
observing the clinic, he told her that her thyroid gland was swollen and that 
it would ‘have to come out’. He also offered to conduct a biopsy in order to 
determine whether the gland was cancerous, but warned that such a test 
could only show the presence of cancer if the biopsy needle hit the ‘right 
spot’. He also said that he couldn’t tell what type of goitre it was -  smooth 
or nodular1. Therefore, removal of the gland was considered to be the best 
option.
Tanya recounted having been ‘fairly horrified’ by the prospect of the 
removal of her thyroid gland because people she knew whose thyroid 
glands had been removed had encountered problems returning to full 
health after the operation. After its removal, the hormones produced by the 
thyroid gland proved hard to replace, causing chronic problems such as 
continued lethargy, depression and excessive weight gain. After the 
appointment with the surgeon, Tanya went back to her regular GP to 
express her concerns. Her GP had returned from holiday and was 
surprised to learn that the locum had referred her to a surgeon and not to a 
specialist endocrinologist, who would be more familiar with diseases of the 
thyroid gland. She referred Tanya to an endocrinologist for a second 
opinion. After waiting six months, Tanya was scheduled for an appointment 
during which the endocrinologist scanned her neck and told her that it was 
a ‘simple goitre’ and of no medical consequence. Not entirely reassured by
1 A smooth goitre is a uniform swelling of the gland that is ‘normal’, but also, can be 
a sign of a thyroid problem. A nodular goitre occurs when a number of lumps 
develop in the gland. Again these can be normal and asymptomatic, but can also 
be a sign of a thyroid problem. The relationship between thyroid abnormalities and 
thyroid disease is discussed in detail in Chapter five.
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this second diagnosis, Tanya agreed with her GP that she would have an 
annual thyroid function test in case her gland failed in the future -  a risk for 
individuals who have goitres, according to the current literature concerning 
thyroid disease.
Tanya had annual tests, but after fourteen or fifteen years she decided to 
have her thyroid checked again more thoroughly. It worried her that her 
neck appeared to swell at times of stress, and she found this symptom 
troubling. In preparation for an appointment with the endocrinologist, she 
conducted some research on the Internet where she discovered patient-run 
websites claiming that the blood tests were ‘a rather blunt instrument’ for 
measuring the health of the gland. This discovery strengthened her concern 
that there might in fact be something wrong with her thyroid gland that had 
eluded diagnosis. Given her past experience of a range of conflicting 
diagnoses, Tanya’s doubts did not seem far-fetched. For example, in 
addition to the confusion about her abnormal thyroid gland Tanya had her 
case of appendicitis misdiagnosed as a urinary tract infection and then 
ovarian cysts. Before the correct diagnosis was reached her appendix 
ruptured making her very unwell and consequently she has ’light worries 
about the reliability of the NHS’.
When Tanya mentioned her suspicions about her thyroid gland to her GP, 
her GP said that she did not know enough about the subject to comment on 
the claims, so Tanya left some information with her. When Tanya next saw 
the consultant, she mentioned this literature to him and he ‘rather poo 
pooed it’. Tanya resigned herself to the fact that both her GP and the 
consultant appeared to believe that there was nothing wrong with her. 
However, on reading about some of the symptoms of an underactive 
thyroid gland (one of the diseases that can affect the thyroid) Tanya 
suspected again that there might be something wrong with her. She has 
problems losing weight (although admits to ‘slightly over-eating’) and has 
dry skin and thinning hair, both of which are classic clinical symptoms of the 
disease.
So, is there anything wrong with Tanya? She has been monitored for an 
abnormality in her thyroid gland for over fifteen years, however, there has 
been no diagnosis of a disease so far. So, is she just unnecessarily anxious 
because she has read scientifically suspect claims on the internet? Or are
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the blood tests currently used in the diagnosis of thyroid disease 
insufficient? Is thyroid disease ‘too vague’ a condition to measure 
accurately - is its diagnostic profile too similar to the metabolic strains of 
modern urban life? As this thesis demonstrates, one thing is apparent: 
none of these clinical diagnoses, professional opinions, or patient concerns 
can either be wholly discounted or positively affirmed. It is instead the 
dynamic between them that largely defines the experience of thyroid 
disorder for patients and health professionals alike.
This dynamic between clinical diagnoses, professional opinions and patient 
concerns demonstrated in the case of thyroid disease has significant 
consequences for the concept of medicalisation (Zola 1972), insofar as this 
term is taken to refer to the power of authoritative expert knowledge to 
subordinate other truth claims, and discipline the bodies of its subjects. As 
is described by this ethnographic study of thyroid disease, a tidal wave of 
changes affecting health professions, identities and management has 
resulted in both a pluralisation and disintegration of this familiar sociological 
concept. Caught in the interstices of conflicting models of care and cure, 
Tanya’s goitre was alternately identified as something that required 
examination, ‘that had to come out’, that ‘needed to be monitored’, that may 
have been wrongly diagnosed, and that was ‘nothing to worry about’. The 
multiple and contradictory accounts of thyroid disease typified by Tanya’s 
case are repeatedly confirmed by the data collected for this ethnographic 
study based in a weekly NHS thyroid clinic, and drawn from over 20 
interviews with the clinicians and patients who ran and attended the clinic. 
As in Tanya’s case, depictions of thyroid disease, its diagnosis and its 
treatment vary greatly between medical professionals, among internet 
sources, and in formal accounts of thyroid disease found in clinical practice 
guidelines and textbooks. There is a corresponding feeling amongst 
clinicians and biochemists that diagnose and treat thyroid disease that this 
once ‘simple’ disease has become increasingly complicated and frustrating. 
They suspect that there is something about the contemporary clinical 
encounter that makes this well established, common and straightforward 
disease unnecessarily complicated. But what would this be? Has thyroid 
disease changed as a result? Is it atypical, or does it instead represent a 
pattern that is becoming more common, as the progress of what Marilyn 
Strathern calls a ‘post pluralist’ society transforms formerly unassailable 
truth claims into matters of choice?
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It used to be so easy..
In the preface to his 1947 book The Conquest of the Unknown: The Story
of the Endocrine Glands, doctor and author George Bankoff claims that the
mysterious nature of the endocrine glands, the relationship between our
biology and our behaviour, had been well acknowledged even before the
dawn of the Christian era where the magic of human organs was
embedded with folklore. Bankoff describes how tribal warriors ate animal
organs to increase strength and banish fear before battle; cowards were
made to eat the hearts of enemies to give them courage. He also refers to
the doctrine of the medieval Swiss physician Paracelsus: ‘Heart cures
heart, spleen cures spleen, lungs cure lungs’ (1947 :vi) and suggests he
was the first to realise that the human body possesses substances that
‘Science’ (capitalization in the original) later named hormones. Therefore,
Bankoff is implying that when he published his history of the endocrine
glands this once unknown, mysterious and magical system had been
conquered by modern science and was a basic unequivocal fact of human
physiology. In fact, Bankoff considers knowledge about the endocrine
system so certain and straightforward it can be communicated to the ‘lay
man’ with confidence in order to help him decipher the mysteries and
workings of the body:
All medical writers have one paramount aim: to bring out the 
mysteries of medicine for the layman..! will not enter into the 
debatable question of whether the layman ought to know about 
the mysteries of his body and the workings of his mind and 
glands. No doubt some will say that he must remain ignorant of 
his ills and his body organs. They will tell you that a little 
knowledge is dangerous and that giving the layman a 
superficial knowledge of the functions of his body might lead 
him astray and make him imagine all the possible ills that can 
befall him. That may be so, but I am not convinced and I am 
entirely of the opposite view. I believe that the sooner we give 
our patient -  the layman- sound knowledge of the working of his 
body, the better we will serve him[...]He will be more intelligent 
and will seek the advice of his doctor more readily, thus 
avoiding perhaps many grave consequences (Bankoff 1947: v -
vi)
Bankoffs assumption that if doctors are open with patients medicine will 
‘serve them better’ though the communication of ‘sound knowledge’ 
assumes that medical knowledge advances in a straightforward and 
progressive manner. Bankoff assumes that through biomedical research
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and innovation, complex systems will be revealed and fit neatly into our 
increasingly complete understanding of the mechanisms of the body, 
health, disease and illness. However, as this study demonstrates, the 
march of medical progress is by no means straightforward. Often, ironically, 
the more we ‘know’ about the body and disease and the more techniques 
we develop to manipulate them, the less we understand as a result. For 
instance, in the case of thyroid disease, biochemical diagnostic tests have 
been developed that can detect not only overt disease but also subclinical 
states of thyroid pathology which, according to current professional 
wisdom, ‘may or may not’ result in symptoms for the patient. More 
generally, innovations that can save, extend and ‘enhance’ our lives, such 
as genetic screening, new reproductive technologies, organ transplantation 
and mood altering drugs have also resulted in the emergence of new 
questions and challenges, or what might be described as a sense of deficit 
that is directly engendered by technological progress. Improved medical 
knowledge has enabled unprecedented control over human health by 
facilitating the prevention, treatment, and often cure of a wide array of 
chronic and life threatening, as well as simply inconvenient pathology -  
from heart disease to headaches. However, as this thesis will demonstrate, 
such changes have at the same time both continuously and dramatically 
remodelled the medical landscape, creating new challenges for the medical 
profession and patients. As Nikolas Rose claims in the introduction to The 
Politics of Life Itself such technical and social shifts ‘have generated hopes 
and fears, expectations and trepidation, celebration and condemnation’ 
(2006:1).
The sociological complexity of contemporary medical and scientific 
progress - and its implications for professional and patients’ understandings 
and experiences of disease - have understandably emerged as one of the 
most important contemporary arenas of social and cultural theory. The 
sociologists Ulrich Beck (1992) and Anthony Giddens (1990) have, in 
different ways, identified that modernization has produced a number of 
risks, such as the discovery of new diseases, pollution and crime, that have 
led to a distrust in government and experts, including the medical 
profession. Anthropologists such as Donna Haraway (1990), Margaret Lock 
(1994), Emily Martin (1987), Rayna Rapp (1999), Marilyn Strathern (1992a) 
and Paul Rabinow (1992) have identified the constantly shifting meanings 
of the biological and natural across a range of biomedical contexts. The
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ability of such studies to draw attention to the fluctuating and situated 
boundaries of biology, health disease and illness inform the approach used 
in this study of thyroid disease. In particular, they have helped to develop a 
theoretical and methodological approach that can grapple with, and 
account for, the non-compliant and indeterminate nature of thyroid 
pathologies.
The anomalous nature of thyroid disease, which is the subject of this thesis, 
can be said to represent the ‘new typical’ idiom of disease - where ‘at risk’ 
epidemiological populations grapple with uncertain competing and 
disparate medical knowledge (e.g. biochemical, genetic, immunological and 
dietary) in order to acquire and maintain acceptable levels health. It is these 
practices of grappling with health that make thyroid disease not only 
‘typical’ in the context of the contemporary clinical encounter, but also, 
mundane and often unsatisfactory for both patients and clinicians. Often the 
treatment for thyroid disease does not result in a triumphant ‘cure’ but an 
uneasy strategy of disease management negotiated by doctors and 
patients that contradicts the perceived precision of diagnostic tests and the 
medical profession’s knowledge of thyroid hormone action. In addition, as is 
described in the next section of this chapter, thyroid disease and its 
treatments were the result of a flurry of research and innovation during the 
nineteenth and early part of the twentieth century. During this period the 
endocrine system, and its role as a regulatory system that enabled the 
body to maintain a balanced internal environment, was assumed to be 
synonymous with the ‘internal secretions’ - what we now call hormones. 
Although thyroid disease has been redefined under subsequent medical 
metanarratives, such as immunology, development, and more recently 
molecular biology (Porter 1997,Borell 1985,Medvei 1993) its treatments 
have remained largely unchanged since the late nineteenth century and 
there is very little research or innovation in the field (Walsh 2002a).
The major change ushered in by twentieth century medicine is the extent to 
which endocrinology, combined with clinical biochemistry, can be used to 
detect, and calibrate, the levels of specific substances such as thyroid 
hormones. The isolation of thyroid hormones and the subsequent mass 
production of synthetic replacements2 and blood tests that measure thyroid
2 Thyroid hormones were first synthesized by British biochemists Charles 
Harrington and George Barger in 1927 Charles Harrington and George Barger.
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function have resulted in a robust biochemical model of the disease 
corresponding to standardised diagnostic and treatment practices. 
However, as will become clear, the ‘straightforwardness’ of thyroid disease 
as the measurable malfunction of a biochemical mechanism comes at a 
cost. That is, the disciplining of thyroid disease through the idiom of 
biochemistry clashes with the experiences of some patients as well as 
additional contemporary bureaucratic and political discourses that aim to 
rationalise health services resources and place the patients at the centre of 
the medical encounter. More specifically, it will be demonstrated that whilst 
this model does account for a biomedical ‘truth’ of thyroid disease, it does 
so in a broader community of truths that jostle for position in the context of 
the ‘post-pluralist’ medical encounter. Therefore, as this thesis concludes, it 
is the relationships and interactions between these varied truths and their 
corresponding practices which ultimately constitute thyroid disease within 
the contemporary National Health Services (NHS) in the United Kingdom. 
In the following section the development of the formal biomedical account 
of thyroid biology and pathology will be summarised. Towards the end of 
this chapter, this formal account of the endocrine system, and specifically 
thyroid disease, will be used as an empirical location where a number of 
more general questions will be posed with regards to the politics of 
contemporary biomedical practice within western healthcare contexts.
A brief history of thyroid disease
In 1854 the French physiologist Claude Bernard developed the concept 
‘milieu interieur’ or the ‘environment within’ that described the way in which 
the body produces chemicals -  what we now call hormones- that maintain 
certain internal conditions necessary for survival. Bernard suggested that;
All of the vital mechanisms, however varied they may be, have 
always one goal, to maintain the uniformity of the conditions of 
life in the internal environment!....]The stability of the internal 
environment is the condition for the free and independent life 
(Bernard 1974: 84)
The idea that there was a ‘vital mechanism’ that resulted in the ‘uniformity’ 
and ‘stability’ of the body’s ‘internal environment’ enabled physiologists 
such as Bernard to ascribe a communication-like function to the glands of 
the body and to surmise that they were the mechanisms that secreted
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substances that controlled this regulatory system. Before the concept of 
internal regulation, the organs of the endocrine system had been 
comprehensively described anatomically, but not in terms of physiological 
function. As the medical historian Ted Porter claims, in the seventeenth 
century a flurry of anatomical studies described organs but were unable to 
visualize the function of, ‘enigmatic tube like ducts carrying off the 
secretions of such organs as the liver’ (1997: 562). However, the 
introduction of Bernard’s concept meant that a hypothesis of function of 
these previously mysterious organs was developed and formed the basis 
for a number of gland-specific experiments that could investigate and 
ascribe function to them. For instance, in 1856 the Mauritian physiologist 
Charles-£douard Brown-Sequard demonstrated that Addisons disease was 
a result of the failure of the adrenal glands by removing them in animals 
and studying the consequences (Porter 1997: 563) In 1902 in England, 
physiologists William Bayliss and Ernest Starling (Borell 1985: 11) found 
that when they injected hydrochloric acid into a dog’s duodenum the 
pancreas produced pancreatic juice. They concluded that the duodenum 
must secrete a substance that sent a message to the pancreas and 
prompted it into action. In 1905, following his work with Bayliss on the 
function of the pancreas, Starling adopted the word ‘hormone’ meaning ‘I 
excite’ in Greek as a name for these secretions (Porter 1997: 563).
The research triggered by Bernard’s hypothesis also prompted further 
investigation into the function of the thyroid gland. The medical historian 
T.C. Golding notes that descriptions of the thyroid gland and swellings of 
the neck caused by thyroid abnormalities have appeared in writings for 
thousands of years. For instance, Marco Polo mentions such abnormalities 
in certain areas of Asia during the thirteenth century and Galen and the 
Roman author Juvenal both mentioned the gland, its propensity to swell 
and a number of hypothetical functions for it (Golding 1952:55). In the 
United Kingdom, ‘Derbyshire Neck’ was a common occurrence in the Peak 
District - a phenomenon that also occurred in mountainous areas around 
the world due to the low levels of iodine in the water supply that impaired 
the glands’ ability to produce hormones (Bayliss and Tunbridge 1998a: 
115). Moreover, in the first half of the nineteenth century the Irish physician 
Robert Graves (Graves 1835) and the German physician Karl von Basedow 
(Bayliss and Tunbridge 1998a: 183) independently described a number of 
symptoms, such as bulging eyes and palpitations that occurred along side
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swelling of the thyroid gland -  what we would today diagnose as 
hyperthyroidism (or Graves/ von Badesow disease depending on your 
geographical location). However, in 1844 conjecture about the function of 
the thyroid became associated with the concept of internal regulation when 
the English surgeon John Simon claimed that the gland secreted a 
substance that passed into the circulatory system. Moreover, at around this 
time in Bern the physiologist Moritz Schiff demonstrated that when the 
thyroid glands of guinea pigs and dogs were removed they died, suggesting 
that the thyroid gland was necessary for life. (Porter 1997: 563). In 1850, 
the English physician Thomas Blizzard Curling performed autopsies on two 
‘mentally deficient’ children which revealed that they didn’t have thyroid 
glands (Medvei 1993: 135). And finally, in 1873 the Queen Victoria’s 
personal physician Sir William Gull formally described a set of symptoms 
that occurred in a woman whose thyroid gland had become swollen and 
atrophied
Miss B...became insensibly more and more languid, with a 
general increase of bulk...Her face altering from oval to 
round,...the tongue broad and thick , the voice guttural, and the 
pronunciation as if it were too large for the mouth 
(creatnoid)...There has been a distinct change in the mental 
state. The mind, which had previously been active and 
inquisitive, assumed a gentle, placid indifference, 
corresponding to the muscular languor, but the intellect was 
unimpaired!...]The change in the skin id remarkable. The 
texture being peculiarly smooth and fine, and the complexion 
fair, at a first hasty glance there might be supposed to be a 
general slight oedema of it...The beautiful delicate rose-purple 
tint of the cheek is entirely different from what one sees in the 
bloated face of renal anasarca. (Gull 1873-1874)
Gull named the swelling and wasting of the gland and these associated 
symptoms myxoedema, or what we would now call hypothyroidism or an 
underactive thyroid gland. Subsequently, in 1891, Gull’s fellow English 
physician George Redmayne Murray began to develop a cure by linking the 
failure of the thyroid gland with an impaired ability to produce secretions 
(hormones). In an experimental treatment, he administered an extract of a 
sheep’s thyroid gland by injection to a 46 year old woman with myxoedema 
and her symptoms improved (Murray 1891).
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Figure 1: Clinical photographs of a 55 year old woman with myxoedema (Wellcome 
Collection)
This practice of ‘organotherapy’3 soon became a common approach to 
treating endocrine disorders and throughout the early twentieth century a 
programme of research was established that attempted to isolate the 
properties of endocrine glands and their hormones. For instance, in 1921, 
with the help of the chemist J.B. Collip, medical scientists Frederick Banting 
and Charles Best (2007) identified and then isolated insulin and thus 
developed a cure for diabetes. Also, in 1929 G.W . Corner and Willard Allen 
(1929) identified the role of the corpus leuteum in the production of the 
pregnancy hormone progesterone. Over the next few years a number of 
other sex hormones were discovered and in the early 1940’s progesterone 
was synthesized by American biochemist Russell E. Marker using extracts 
from a wild Mexican Yam  (1947). This field of research would eventually 
result in the development of the contraceptive pill (Borell 1987), and 
techniques used in reproductive medicine (Borell 1985, Parkes 1966), as 
well as number of physiological theories that attempted to establish the 
biological basis of sexual difference (Oudshoorn 1994).
The isolation of thyroid hormones began with the identification of iodine in 
the thyroid gland by the German chemist Eugene Baumann in 1885. After 
this discovery it became clear that iodine deficiency caused an overgrowth
3 Organography was first developed by Brown-Sequard in 1889 and took the form 
of injecting men with the invigorating substance contained in the testes as a 
rejuvenating agent to improve physical strength and mental activity. Although a 
practice that was designed to enhance the physical performance of men didn’t 
become established, it did pave the way for the development for future hormonal 
treatments (Medvei 1982: 289).
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in thyroid cells resulting in goitres, and soon after the Austrian psychiatrist 
Julius Wagner von Jaurre began to successfully treat goitres with iodine 
(Medvei 1993:140). This identification of the iodine-rich nature of the thyroid 
secretions directed research that would eventually isolate thyroid 
hormones, and in 1927 British biochemists Charles Harrington and George 
Barger (1927) synthesized thyroxine, and synthetic thyroxine, or 
Levothyroxine finally became commercially available in 1950 (Wiersinga 
2001). Interestingly in contrast to the perceived wisdom of contemporary 
prescribing practices, the medical profession was reluctant to prescribe 
Levothyroxine and continued to use thyroid extract derived from pig, sheep 
and cow thyroid glands until the 1970’s and early 1980’s (Macgregor 1961, 
Jackson and Cobb 1978).
In sum, the ‘unknown world’ of the endocrine system which, according to 
Bankoff had been enshrined in folklore for centuries, was gradually 
conquered throughout the mid 18th to the mid 19th century. Scientifically, 
Bernard’s concept of ‘milieu interieur’ presented a rationale that formed the 
basis for the experimentation that eventually assigned the specific functions 
to the glands of the endocrine system with which we are familiar today. 
Long associated with the birth of modern physiology, Bernard’s model of 
endocrinology gave much needed precision to the study of metabolic 
processes, and was key to the development of the theory of homeostasis, 
first posited by the American physiologist Walter Cannon in 1932. The 
concept of homeostasis explains the body’s capacity to maintain a stable 
internal environment by the regulation of hormones, which had clear 
implications for definitions of health and illness, and medical 
understandings of both. Interestingly, as Roy Porter (1997: 562) notes, 
Cannon’s concept not only crystallized the field of endocrinology but also 
provided a scientific basis for his conservative political philosophy that 
valued social stability and order. To be more precise, Cannon’s ‘discovery’ 
of the body’s ability to maintain itself through internal regulation provided 
evidence that such order and stability was present in biology and therefore 
an a priori principle that should govern human society.
This connection between biology, the endocrine system, and styles of 
knowledge was also apparent to the French physician and philosopher 
Georges Canguilhem who stated that ‘interpreted in a certain way, 
contemporary biology is, somehow , a philosophy of life’ (1994: 318).
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Canguilhem’s claims that the development of concepts such as that of 
internal regulation, and the consequent emergence of disciplines such as 
endocrinology and biochemistry, produced a specialist and standardized 
understanding of biological processes were a primary influence on 
Foucault, and his theory of biopower4 (Foucault 1981). The idea that there 
is an inherent system of regulation within biological organisms that can be 
known by the medical profession provides a baseline of ‘normal function’ 
which can then be used to epistemologically discipline the material body 
through rational and authoritative categories of normal and pathological or 
healthy and diseased. Moreover, for Canguilhem such approaches 
fundamentally ignore the relationship between states of illness as an ability 
to adapt to ones environment, that is, the ways in which disease and illness 
are socially and biologically intertwined in context. In turn, as Canguilhem’s 
pupil Michel Foucault would later claim in The Birth of the Clinic (1973), 
concepts such as the endocrine system developed throughout the 18th and 
19th century by the emerging medical profession were part of a broader 
revolution in the structure and production of knowledge, with direct 
consequences for systems of governance. Through the expert gaze of the 
medical profession, a rational and scientific ‘truth’ of the body, health and 
disease was established whose authority could in turn be deployed as a 
range of management strategies over individuals and national populations. 
As Nikolas Rose (2001: 3) notes, following Foucault,, various biopolitical 
strategies were developed during the 20th century, such as free milk in 
schools and health visits for new mothers, in order to promote a healthy 
population and instil an ethic of ‘care of the self through both state 
intervention and the ‘responsible’ practices of individual citizens.
However, although the idiom of biological regulation still plays a pivotal role 
in the diagnosis and treatment of thyroid disease, it is increasingly apparent 
that the authority of this model - and medical authority more generally - is 
threatened, and has altered in response to a number of technical and social 
arrangements. As demonstrated by this thesis, far from making the 
diagnosis and management of thyroid disease simpler and more effective, 
thyroid function tests often result in dissatisfaction for both clinicians and 
patients. Often, these tests discipline the biological function of the thyroid
4 Foucault famously defines Biopower as ‘an explosion of numerous and diverse 
techniques for achieving the subjugations of bodies and the control of populations.’ 
(1981: 140).
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gland ‘to a fault’, isolating biochemical activity as the key explanatory factor 
that informs diagnosis and treatment. The result is an impoverished view of 
the general health of the patients, in which their symptom reporting is 
undervalued and subjugated to the results of standardised thyroid function 
tests. In many ways this demonstrates Canguilhem’s assertion that 
understandings of biology, health, disease and illness achieved through 
mechanical and technical measures based on fixed concepts and 
standards reduces the patient to an isolated organism whose health is not 
considered in terms of broader environmental milieus. Therefore, as the 
title of this thesis suggests non-compliance in the context of thyroid disease 
has meaning the beyond how individual patients interpret and perform the 
advice of their doctor through, for example, the ingestion of prescribed 
medicines and the observance of regimes disease management. Thyroid 
biology and pathology is itself is non-compliant because often when it is 
experienced by patients and grappled with by clinicians it does not behave 
how it is ‘supposed to’. It does not follow the mechanical and technical rules 
established by biomedical epistemologies and as a consequence is 
constantly negotiated in an array of contradictory ways by the patients and 
professionals who encounter it.
Consequently, this study will investigate how the traditional biomedical 
model of thyroid disease operates in the ‘post plural’ context of the 
contemporary clinical encounter. Specifically, how the value of biochemical 
evidence provided by formal biomedical knowledge and practices is 
negotiated by patients who have sought and developed alternative models 
of thyroid biology and pathology that account for their personal experiences 
of thyroid disease. After a review of the appropriate theoretical literature 
and an outline of the methodological approach of the study (chapters two 
and three), chapter four introduces thyroid disease through an analysis of 
the relevant clinical and patient support group literature and data collected 
during a twelve month period of fieldwork. In chapter five, the evidence 
used to diagnose and guide the treatment of thyroid disease is presented 
and analysed using data from interviews, participant observation and 
secondary materials. On the basis of these findings I argue that much of 
the factual evidence encountered in the context of thyroid treatment is 
highly indeterminate and is deployed by various patients, patients’ support 
groups and clinical professionals to construct competing orders of thyroid 
biology and pathology that fulfil a wide range of multiple and contradictory
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rights, needs, responsibilities, duties, obligations, and desires. This chapter 
concludes by asking how thyroid disease is experienced and constituted by 
these various groups, and speculates on what kind of sociological model of 
‘medicalisation’ can comprehend such a diverse range of activities. Which 
evidence is most highly valued by whom, in which context, and why? What 
forces discipline and shape these forms of evidence -  especially when they 
are in tension, or even in direct conflict? And what are the practical 
implications of these competing evidentiary discourses for the 
categorisation and treatment of thyroid disease within the NHS? In chapter 
six, these issues of evidential indeterminacy are further examined through 
an analysis of how thyroid disease is practiced by clinicians and patients in 
order to justify various diagnostic and treatment outcomes. Drawing on the 
work of Annemarie Mol, this chapter concludes that thyroid disease is not a 
singular entity (i.e. a malfunction of the biochemical function of the thyroid 
disease that can be picked up by thyroid function tests), but a nexus of 
practices and ‘modes of ordering’ thyroid biology that interact with each 
other. By widening Mol’s thesis to engage with Strathern’s models of 
context in a post-plural world, I suggest a means of re-conceiving the 
relationality at the heart of medicalisation, asking what are the implications 
of these relational modes of ordering on the definitions and actual 
conditions of thyroid health?
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Chapter 2
Literature review: knowing and doing the body
Within social studies of biomedicine, the body is increasingly recognized as 
being in a continuous state of flux, a site though which various social 
relationships, political constellations and deployments are enacted (Martin 
1994, Martin 1987, Lock and Gordon 1988, Lock 1994, Fausto-Sterling 
1985, Duden 1991, Rose and Novas 2004). Feminist analysis of the 
relationship between reproduction and embodiment (Oakley 1980: 40, 
Oakley 1984, Tew 1990, Boston Women's Health Book 1974, Ehrenreich 
and English 1973, Martin 1987) has been one of the most important strands 
in what has later come to be known as the ‘sociology of the body' (Turner 
1996, Shilling 2003, Featherstone et al. 1990). Current trends within the 
social sciences including an interest in the body, embodiment, as well as 
knowledges about the body such as medicine anatomy and biology owe a 
great debt to the insights provided by this literature. For example, the 
feminist sociologist Charlotte Perkins Gilman vividly demonstrated in her 
semi-autobiographical account of post-partum depression, The Yellow 
Wallpaper, how pregnancy and childbirth became the preserve of the male 
dominated medical profession as it emerged during the nineteenth century 
and became progressively pathologised, medicalised, and associated with 
mental illness. Subsequently, over the course of the twentieth century, an 
array of technologies, such as prenatal scans and diagnostic tests (see 
Rapp 1999a), have been introduced in order to manage perinatal care 
more extensively. In a pattern that has been repeated in other areas5 
conception, gestation and childbirth have become ‘medical problems’ for 
which the monitoring of women before, after and during pregnancy is not 
only standard practice but has also become a social responsibility in order 
to secure the health of their child and future generations.
5 For example see Horwitz and Wakefield (2007) on depression, Martin (2007) on 
depression, Young (1995) on post traumatic stress disorder and Lane (2007) on 
social anxiety disorder.
23
This example demonstrates, as the sociologist Irving Zola (1972) claimed 
nearly forty years ago, the concept of medicalisation, which can be 
understood as a process through which the normal aspects of everyday life 
and individual behaviour came to be placed under the control of medical 
expertise and subject to various biomedical and technical solutions. In 
addition, as Ivan lllich famously claimed ‘Professionally organised medicine 
has come to function as a domineering moral enterprise that advertises 
industrial expansion as a war against suffering’ (1975: 133). As a result, he 
argues that we have been stripped of our ability to cope with disease, even 
when there are many instances in which medical interventions actually 
cause disease and suffering through a number of iatrogenic interventions. 
However, although a number of technologies have aided in the process of 
medicalisation, over the last two decades it is also clear that they have not 
colonised, but rather disrupted, traditional formulations of the body, health 
and illness. As the sociologist Aditya Bharadwaj states, a number of 
anthropological studies located at the sites of biomedical innovation 
(Rabinow 1992, Latour 1993, Strathern 1992b, Haraway 1990), have 
‘conceptualised the constructed nature of the biological, organic, natural 
and their shifting meanings’ and thus ‘problematised the post/ late modem 
bioscapes’ (2008: 98). That is, technologies that have enabled us to 
‘engineer our vitality’ (Rose 2006: 4), such as genetic diagnosis, mood 
altering drugs, new reproductive technologies, organ transplantation and 
regenerative medicine, have also resulted in multiple accounts of the body 
and concurrent practices, networks and identities (see Gibbon 2007, Rose 
2003, Franklin 1997, Lock 2002).
Thus, as the medical anthropologist, Margaret Lock states with regard to 
the social scientific investigation of the body and the medical sciences, 
such projects are embarking on ‘a rigorous questioning of what are so often 
assumed to be natural categories of thought and classification’ (2001: 480). 
However, as Lock also notes, this re-conceptualizing of the body by 
contextualizing the truth claims of medicine is not the only aim of such 
projects. Lock states that it is also critical to investigate ‘how and why 
certain representations become dominant at specific times and exposing 
the hegemony they exert over everyday life and practices associated with 
health and illness’ (2001: 480). This project will attempt to contribute to this 
trajectory of social scientific enquiry. Specifically, in terms of how the 
technical innovation (or lack thereof) that currently constitutes the diagnosis
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and treatment of thyroid disease within the NHS shapes the diagnostic 
categories of thyroid pathologies and the practices and experiences of 
clinicans and patients.
The following review will sketch out the key literatures that provide a 
theoretical framework through which these questions can be explored. 
First, the changing relationship between the body, systems of governance 
and subjectivity will be discussed. Second these relationships will be linked 
to debates that address the changing nature of medical authority, clinical 
practices and broad definitions of health, disease and illness. Finally, the 
empirical location of thyroid disease, specifically the relationship between 
professional and patient accounts and experiences, will be introduced.
Bodies, governance and subjectivity
In her account of the emergence of specifically female physiological 
drawings of skeletons, the feminist historian Londa Schiebinger (2000) 
asserts that, in 1796, the German anatomist Samuel Thomas von 
Soemmering published what he claimed to be the first illustration of the 
female skeleton. This claim, as Schiebinger notes, was remarkable as not 
even the father of anatomy; Andreas Vesalius claimed that sex was the 
determinant of bodily difference. For Vesalius, the organs and skeletons of 
the sexes were understood to be the same, excepting the reproductive 
organs and the shape of the male and female bodies. In this sense, the 
differences between the male and female body were neither essential nor 
fixed. In other words, as Schiebinger points out, although sex difference 
was acknowledged in the anatomical illustrations of the Renaissance, the 
need to differentiate between the sexes was not as urgent. The question 
then, as Schiebinger poses it, is why was the female skeleton discovered at 
this point? That is, what were the conditions that led von Soemmering and 
his contemporaries to distinguish ‘sex differences in every bone, muscle 
nerve, and vein of the human body’? (2000: 25)
As Schiebinger goes on to discuss, the need to differentiate between the 
sexes anatomically was intrinsically linked to broader power relationships 
embedded in the natural law philosophy that shaped the political landscape 
of the time, and that was espoused by political philosophers such as John 
Locke (Locke and Goldie 1994). This style of political philosophy looked to
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nature as a means of defining and sanctioning social conventions and 
roles. For instance, the female pelvis was depicted as noticeably larger 
than the male so as to confirm women’s innate ability to nurture children. 
The female skull was represented as distinctly smaller in comparison to the 
male, in order to confirm women’s inferior intellectual capacity. In this way, 
women were deemed ‘naturally’ to belong to the private sphere of the 
home, as they did not have the intellectual capacity to perform a role in the 
public sphere. The fabric of their very being was shown to be designed for 
another function altogether, to reproduce and rear children. Both of these 
‘anatomical facts’, reinforced the exclusion of women from the public 
sphere and their confinement in the domestic sphere.
The ‘natural facts’ of the body, therefore, came to be used as evidence of 
the natural inequality between men and women and their positioning as 
innately ‘rational’ (men) and ‘natural’ (women) creatures. This ‘feminization 
of feeling and masculinisation of reason’ (Schiebinger 2000: 25) during the 
early development of modem science reflected and reproduced broader 
divisions of labour and power within European society. That is, the gender 
relationships embedded in the emergence of disciplines such as 
physiology, became a ‘natural irrefutable fact’ of scientific knowledge more 
generally. In this context, science became, as the Science Studies scholar 
Sharon Traweek (1988:162) phrases it, a ‘culture of no culture’ in which 
the masculine political culture, that was so fundamental to its inception and 
reproduction, was made to disappear by a dialect of objectivity and nature. 
Therefore, as the medical anthropologists Robert Hahn and Arthur 
Kleinman point out, the claims of biomedical practitioners, that their domain 
is distinct ‘from morality and aesthetics, religion and politics and social 
organization’ (1983: 306) are rooted in this historical cultural idiom. 
Consequently, biomedicine can be defined as day-to-day medical practice 
that is embedded in a ‘value system characteristic of an industrial- 
capitalistic view of the world in which the idea of science represents an 
objective and value-free body of knowledge’ (Lock and Gordon 1988: 3). 
Biomedicine, therefore, can be interpreted as an ethnomedicine (Hahn and 
Kleinman 1983), a socio-cultural system that makes, and is constrained by, 
nature -  ‘the product of a dialect between culture and nature’. (Lock 2001: 
479)
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The multiple and situated understandings of the body described above are 
consolidated in sociological and anthropological approaches to the body 
that can broadly be identified as ‘social constructionist’ (Nettleton 1995: 
107). Such approaches include those that contend that the physical base of 
the body is shaped by social practices (Shilling 2003). For instance, if we 
again think back to the treatments that Toni was offered for her thyroid 
abnormality, the impacts of social practices are clearly visible. The surgeon 
wanted to remove her thyroid gland and the endocrinologist wanted to 
monitor it through blood chemistry. These differing approaches express the 
professional practices and expertise that define the medical sub-disciplines 
of these two specialists and, more broadly, how medical knowledge is 
organised.
The work of the anthropologist Mary Douglas has also helped to define this 
broad social constructionist approach. She argues that the social body 
mediates the perception of the physical body and vice versa. That is:
The social body constrains the way the physical body is 
perceived. The physical experience of the body, always 
modified by the social categories through which it is known, 
sustains a particular view of society. There is a continual 
exchange of meanings between the two kinds of bodily 
experience so that each reinforces the categories of the other. 
(1966: xiii)
These approaches identify the symbiotic relationship between the physical 
and social bodies. Specifically, they support the claim that biomedicine is 
an ethnomedicine - as its object, ‘the body’ is revealed to be the result of a 
particular relationship between biology and society. Therefore, returning to 
Lock’s concerns, we should ask: how and why do certain representations of 
the body become dominant at specific times? What are the politics of these 
representations? And how do these representations impact on the practices 
associated with health and illness?
In the Birth of the Clinic (1976), Foucault provides a way of thinking about 
these questions by mapping the changes in the structure of medical 
knowledge. As Foucault demonstrates, the practice of autopsies from the 
18th century onwards provided direct visual access to disease (Sullivan 
2003: 1596). Opening up the body and finding physical disease in tissues 
meant that the physician was able to collect evidence of disease that was
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independent from the patient’s experience of it (Armstrong 1984). 
Therefore, the symptoms reported by individual patients became clues to a 
‘disease puzzle’ that the doctor could solve using their specialist expertise. 
Subsequently, the power and the authority of the medical profession was 
established through these specialist practices as they alone had the 
knowledge and expertise to translate symptoms into diagnosis and, finally, 
treatments and cures. The consolidation of such techniques by the 
emerging and increasingly powerful medical profession also contributed to 
the development of a range of governmental technologies that exercised 
power through intervening in the fields of health and reproduction.
Foucault’s concept of ‘biopower’ describes ‘the explosion of numerous and 
diverse techniques for achieving the subjugation of bodies and the control 
of populations’ (Foucault 1981: 140). Institutions such as hospitals, schools 
and prisons came to produce certain knowledges that in turn shaped the 
ways in which the bodies of the population were regulated, trained and 
maintained. The recording of mortality, morbidity rates and literacy rates, 
for example, monitored the population and provided a mechanism through 
which its health could be intervened upon by the state. For instance, 
Nikolas Rose (2001) identifies two such biopolitical strategies that emerged 
throughout Western Europe and the United States during the 19th and 20th 
centuries: the maximisation of a healthy population via the machinery of the 
State (for example, the compulsory medical inspection of school children 
and health visitors for new mothers) and the formation of the Eugenics 
movement. The Eugenics movement attempted to reduce the burden of 
disease and ‘bad stock’ on the nation by guiding the reproductive futures of 
individual citizens. It endorsed practices ranging from the promotion of 
‘good breeding’ to enforced sterilization. Both of these strategies attempted 
to shape healthy bodies via biomedical practices, which in turn became a 
measure of the health and strength of the nation in comparison with other 
national populations. However, as Rose goes on to demonstrate, this way 
of knowing and governing the bodies of a population has been dislodged by 
the re-formulation of styles of governance and technical developments 
within biomedical knowledge in the late twentieth century. That is, although 
the health of the nation is still a central concern, the rationale for this 
interest is no longer framed in terms of a struggle between vigorous 
national populations. Within late modern Western societies, a nation’s 
health is now cast in economic terms in correlation with the neo-liberal
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paradigm of governance that is dominant within these locations (Barry et al. 
1996). The ‘body as a project’ (Shilling 2003) and the maintenance of 
health through consumer choice means that individual citizens are 
responsible for maintaining their health through various lifestyle choices 
and health-promoting practices such as healthy eating, exercise and stress 
management. This contemporary formulation of governmental technologies 
can be clearly demonstrated in terms of current health policy initiates within 
the United Kingdom.
In 2001 former banker Derek Wanless published a report commissioned by 
HM Treasury entitled Securing Our Future Health: Taking a Long-Term 
View (2001). The report was designed to assess the long-term resource 
requirements for the National Health Service (NHS) and concluded that, in 
order to deliver high quality health care, there must not only be an increase 
in resource provision, but also concurrent systemic reforms that would 
ensure these additional resources are used effectively. The aim of these 
reforms is to create what Wanless terms a ‘fully engaged scenario’ 2022. 
As Wanless claims:
Individuals are ultimately responsible for their own and their 
children’s health and it is the aggregate actions of individuals 
which will ultimately be responsible for whether or not such an 
optimistic scenario as ‘fully engaged’ unfolds. People need to 
be supported more actively to make better decisions about their 
own health and welfare because there are widespread, 
systematic failures that influence the decisions that individuals 
currently make. (Wanless 2004: 4)
As described above, the ‘fully engaged scenario’ consists of high levels of 
public engagement with regard to personal health, resulting in an increase 
in life expectancy, an improvement in health status and confidence in the 
system due to the delivery of high quality care. According to Wanless, the 
key to realising this scenario is an increase in public health provision and 
specifically, the uptake of high rates of technology, particularly pertaining to 
disease prevention.
In 2003, Wanless received a further commission from the then Prime 
Minister Tony Blair, the Chancellor Gordon Brown and the Secretary of 
State for Health, Alan Milburn, to provide an update of the challenges 
envisaged in order to implement the ‘fully engaged scenario’. 
Subsequently, in February 2004, Securing Good Health for the Whole
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Population (Wanless 2004) was published. In the conclusion to this report, 
a shift was highlighted from the infectious diseases of the 19th and early 
20th centuries to chronic disease throughout the 20th and 21st centuries, 
such as coronary heart disease and cancer, that are strongly related to 
lifestyle factors. Therefore, the cause of disease and explanation of 
symptoms have, to some extent, been relocated to the patient’s social 
world (Armstrong and Caldwell 2004). Subsequently, ‘quality of life’ and 
patient experiences of illness are now considered to be an important 
‘outcome measure’ for healthcare. Consequently, definitions of health and 
illness have been extended to include patients’ evaluations of health. 
However, such ‘quality of life’ measures demand that patients take on a 
new set of responsibilities in order to maintain good health.
For example, the Wanless report called for ‘NHS users’ (patients) to make 
‘responsible choices’ about their health by avoiding risk factors such as 
poor diet and smoking. This change in behaviour would in turn, it surmised, 
eventually take pressure off NHS resources by creating a healthier and 
lower maintenance population for it to serve. In 2006, the NHS launched 
the Patient Choice Initiative in order to facilitate ‘responsible choices’ that 
would promote the ‘fully engaged scenario’. This project ‘is designed to give 
you more choice about when, where and how your healthcare needs are 
met’ (NHS Direct 2006). This includes the introduction of GPs with special 
interest (GpwSI’s), who can perform minor procedures traditionally carried 
out in hospitals, electronic booking systems for appointments at both GP 
and hospital level and the choice between four local hospitals if an 
individual needs to be admitted for a procedure. All of these initiatives are 
designed to offer a more flexible healthcare service, as well as to allow 
patients to make decisions about when and where they receive their health 
care. This choice agenda, promoted by the ethos and organization of the 
NHS, means that the body, via an emphasis on disease prevention enacted 
at an individual level, is increasingly becoming a recognised site of social 
interaction and citizenship. For instance, in January 2009 the NHS 
constitution was released and its aims were as follows:
The Constitution establishes the principles and values of the 
NHS in England. It sets out rights to which patients, public and 
staff are entitled, and pledges which the NHS is committed to 
achieve, together with responsibilities which the public, patients 
and staff owe to one another to ensure that the NHS operates 
fairly and effectively. All NHS bodies and private and third
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sector providers supplying NHS services will be required by law 
to take account of the Constitution ain their decisions and 
actions.(The Department of Health 2009: 2)
Therefore, the constitution not only sets out responsibilities for the state 
with regard to healthcare, but also, responsibilities for patients or citizens 
who are expected to access and use health services in particular ways. 
Consequently, for the body of the citizen to access health services and 
remain healthy a contractual arrangement based around particular 
principles, values, rights and responsibilities has been established.
As suggested earlier, knowledge about the body shapes, and is shaped by, 
the same processes through which contemporary power relationships are 
enacted. For instance, the eugenic body depended on consistency and 
predictability: the vigorous, healthy body embodied the health and future 
prospects of the nation state that was measured in terms of vitality, 
potential and fitness. In the current era, in which power is organised less 
through the nation state and must be more responsive to global neoliberal 
economies, the health of the contemporary body depends on contingency 
and flexibility. Subsequently, as Emily Martin describes in her assessment 
of contemporary America’s understandings of health and immunity, bodies 
are no longer understood as ‘sharply bound machines’ but as ‘blurrily 
bound and complex systems’ (Martin 1994: 40). This new understanding of 
biological mechanisms as informational systems, such as the immune 
system and, more recently the genome, has reinforced this contingent, 
‘reprogrammable’ understanding of the fluid, or liquid, body. Moreover, this 
conceptualisation of the body can be interpreted as an example of Lock’s 
claim that the body is constituted via dialectic between nature and culture 
(Lock 2001: 479). For example, the identification of genetic predispositions 
to certain illnesses can mean one is pre-symptomatic, generating issues of 
responsibility around care of the self. In this sense, it is assumed that the 
predictive nature of genetic information is intrinsically linked to some 
degree of choice. One might begin side-stepping environmental factors that 
might trigger ‘the gene’ for a disease, for example by altering lifestyle 
through diet (Martin 1998).
In response to these developments in biomedical knowledge and the 
political governance of health, the anthropologist Paul Rabinow (1992) 
predicted that ‘the new genetics’ would prove a powerful force in the
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reshaping of society. Unlike previous theories of the relationship between 
the social and the biological, such as sociobiology (Wilson 1976), where the 
biological was a metaphor through which social projects were cast, the 
provisional, informational and manoeuvrable qualities of genetic information 
problematise the separation between society and biology. Subsequently, as 
Rabinow states:
If sociobiology is culture constructed on the basis of a metaphor 
of nature, then in bio-sociality, nature will be modelled on 
culture understood as practice. Nature will be known and 
remade through technique and will finally become artificial, just 
as culture becomes natural (Rabinow 1992: 99)
As Rabinow suggests, whereas the body and disease were once perceived 
to be natural -  and thus fixed and inevitable -  technological and conceptual 
innovation within the life sciences, such as the advent of genomics, means 
that these ‘facts of life’ are, to some extent, manipulable and controllable 
through intervention and technique. Consequently, the fixed category of the 
‘natural body’ is no longer a tenable baseline on which social organisation 
can be orientated: once the body -  as the object of biomedicine -  has been 
revealed to be the product of artifice as much as nature, the authority of the 
biomedical sciences and the medical profession -  founded on a conception 
of the fixed ‘natural body’ -  is undermined.
As a result the, ‘natural facts’ of the body and disease are revealed to be, to 
some extent, social constructions - products of certain accepted ways of 
knowing and practicing. This unification of nature and culture within the 
work of theorists, such as Rabinow, means that the body is increasingly 
recognised as a site where social relationships and identities are 
performed. As Nikolas Rose and Carlos Novas (2004) argue in their 
account of ‘Biological Citizenship’, collectives are increasingly formed 
around biomedical classifications. Groups base themselves on specific 
conditions that an individual and/or members of their family suffer from in 
order to campaign for better treatment and access to services, to combat 
social stigma and to create networks through which fellow members of their 
community can be supported. The formation of such communities 
increases individuals’ knowledge about the specific shared conditions -  
both within the group itself and the wider community its campaigns 
address. This increased access to information regarding a condition in turn 
increases the responsibility of individuals to use that information in order to
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avoid disease, a responsibility that derives from the control that one is now 
perceived to have over one’s body through various self-employed 
healthcare strategies.
However, the agency that is often ascribed to the biosocial body has to be 
tempered and interrogated across a range of contexts. As Sahra Gibbon 
and Carlos Novas observe in the editors’ introduction to their recent 
collection Biosocialities, Genetics and the Social Sciences:
Although Rabinow’s much referenced concept of biosociality 
has provided a reflective starting point for this collection, the 
chapters collated here bring a much needed diversity to an 
understanding of the way that different biosocialities are 
brought to bear on a range of comparative arenas. Here the 
question of novelty, as well as ideas of contingency are not only 
subject to renewed critical scrutiny but are themselves brought 
into productive interface with what Sunder Rajan (this volume) 
usefully terms the multiple ‘over determinations’ associated with 
these developments. Indeed an important feature of this book is 
the way that a number of it’s contributors shed light on the 
spaces, practices and persons which they suggest a notion of 
biosociality has ‘failed to account for (Bharadwaj, this volume).
For others, the multi-layred complexity and inherent ambiguity 
of the notion of biosociality has and continues to provide a 
useful entry point for examing these developments, which 
invites and encourages innovation in method, concept and 
critical analysis (Gibbon and Novas 2008: 14).
As Gibbon and Novas claim, the concept of biosociality has enabled us to 
think about ‘how the social and the biological are being (co)-configured in 
relation to developments within the life sciences’ (Gibbon and Novas 2008: 
15). However, it is also clear that these reformulations of the social and the 
biological are multiple; hence the parameters of the concept should be 
consistently questioned and situated across an array of contexts, a project 
that this study is a contribution to. For instance, as will be demonstrated by 
this study, thyroid disease in the United Kingdom is organised and 
experienced around the technical deficiency of current diagnostic an 
treatment strategies -  thus characterising a specific biosocial community 
perusing and enacting a particular kind of biosociality.
In order for the thesis to engage with ways in which the social and the 
biological (co)-configure each other within the context of clinical medicine, 
the following section will review work from within medical sociology that 
addresses the relationship between the social and biological aspects of
33
disease and illness, doctor and patient and explores how they structure the 
clinical encounter.
The changing nature of medical authority
Talcott Parsons, often described as the founding father of medical 
sociology, claimed that illness:
is a state of disturbance in the ‘normal’ functioning of the total 
human individual, including both the state of the organism as a 
biological system and of his personal and social adjustments. It 
is thus partly biological and partly socially defined (Parsons 
1952:431)
According to Parsons, the biological aspects of illness fall under the 
‘technical competence’ (Mol 2002: 10) of physicians leaving the social 
aspects of illness -  job functions, professional structures, doctor-patient 
relations -  to the expertise of the sociologist. Therefore, within medical 
sociology disease is traditionally understood to be an organic cause for a 
disruption in the normal functioning of the body -  an entity that can be seen 
and worked upon by the expertise of the medical profession. In contrast, 
illness is traditionally cast as a subjective condition. ‘Illness’ thus includes 
the social explanations introduced in order to account for personal 
interpretations of disease and the public dimensions of sickness. However, 
the various theoretical and technical innovations described above make it 
clear this distinction between disease and illness is no longer tenable. That 
is, the assumption that disease is simply an asocial disturbance of biology 
has become discredited by the recognition that the biology is the product of 
a dialect with the social. In the following chapter this problematization of 
asocial notions of biology and disease will be demonstrated and its 
consequences for the doctor-patient relationship will be considered.
In a study of the transmission of clinical methods through the practice of 
bedside teaching, Paul Atkinson recounts the following scene of a dialogue 
between a surgeon and his students concerning fluid loss in post-operative 
patients. After the surgeon asked students for sites of fluid loss, the 
following exchange ensued:
Student A: Urine.
Dr.: Yes. (writes on blackboard) How much?
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St A: A litre and a half.
Dr.: (writes on blackboard)
St. B: Skin, sweating?
Dr.: How much?
St. B: Up to two litres.
Dr.: In the tropics, yes
(student laughter)
St. C: A litre.
Dr.: (writes on blackboard 900ml) Any other sites of
fluid loss?
St. D: The site of the operation?
Dr.: Under NORMAL circumstances.
St. B: Vomiting.
Dr.: Under NORMAL circumstances.
St. E: Stool.
Dr.: In the stools. How much in the stools?
St. E: About a hundred mil.
Dr.: A hundred to two hundred mils, (writes on
blackboard)
(Atkinson 1988: 182)
Atkinson identifies two significant features of this sequence. Firstly, the 
surgeon adds up the responses from the students, and treats them as 
complete, when he calculates the final amount of normal fluid loss. 
Secondly, the list is constructed on the basis of what is considered to be 
‘normal’ in the circumstances. For Atkinson, this process demonstrates that 
within medical practice disease is not only socially accomplished via the 
collaborative work of teachers and students, but also rooted in the idea that 
‘disease resides in the unequivocal deviation from universal and biological 
normality’ (Atkinson 1988: 183). That is, as the philosopher of disease 
Georges Canguilhem (1978) recognised, the concept of biological 
‘normality’, such as that described above, is a result of how normality is 
defined within the epistemological culture of modern medicine. Canguilhem 
claims that, biological normality is defined via limits derived from 
population-based data, suggesting that pathology is therefore an excess or 
deficit of a particular variable. (Horton 1995: 317). Therefore, the privileging 
of these numerical methodologies strengthens the authority of biology as a 
scientific endeavour, but also means that qualitative judgements about 
health are marginalised. As Canguilhem concludes, such definitions of 
normality provide us with limited understandings of health, where the 
functioning of the organism as a whole is surpassed by a focus on these 
limited definitions of normality of specific pathologies.
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For instance, and as is explored further in this thesis, the focus on the 
negative feedback loop between the thyroid gland and the pituitary gland 
through the practice of thyroid function blood tests is problematic for two 
reasons. Firstly, often individuals who are found to have abnormal blood 
test results do not feel unwell, subsequently blood test results, particularly 
those that fall on the borderline of thyroid normality/abnormality, cause 
distress and result in the diagnosis of a disease that has no discernable 
symptomatic manifestation for the patient and is therefore difficult to 
manage. Secondly, this focus on strict definitions of ‘normal’ thyroid 
function is also problematic for patients who display symptoms but whose 
blood tests results fall within the normal or borderline range. The strict 
adherence to blood test results in order to diagnose thyroid disease means 
that such patients are often left in a no-mans land where they are 
symptomatically ill, and slightly biochemically abnormal, but cannot secure 
treatment because their individual manifestation of disease is not 
‘abnormal’ enough.
If we think about thyroid function blood tests as artefacts of the numerical 
methodological culture of contemporary medicine, it is possible to conceive 
of them as ethnomedicine -  a set of practices specific to a socio-cultural 
system that defines and impacts upon diseases in a particular way. As 
Bryan Turner notes in his sociological analysis of modern medicine:
Disease is not a fact, but a relationship and the relationship is 
the product of classificatory processes:a disease pattern is a 
class, or niche in a framework. This framework is a means of 
approaching or organizing crude experience, that is, for dealing 
with every day events in the most satisfactory way (Turner 
1996: 200)
As discussed above, medicine, the body, and disease are inextricable from 
the power-knowledges, disciplines and epistemic formations that generate 
and reproduce them (Foucault: 1973). The objects of medicine are 
discursively shaped through language and practice, systems of 
classification, and hierarchies of diagnostic symptoms keyed to specific 
techniques of measurement and calibration. The suggestion that disease is 
simply the result of an organic cause that can be objectively evaluated by 
science and its methods is, from this perspective, naive. Specifically, as this 
thesis will seek to identify, not only are the diagnostic categories discursive 
they are also highly uncertain and are often shaped during the course of
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clinical practice generating a range of, often competing, diagnostic 
categories and identify practices.
In her comparative study of the menopause in Japan and the United States, 
the anthropologist Margaret Lock (1988) notes that increasing life- 
expectancy is of interest to many governments due to the effects of this 
trend for healthcare systems in terms of resource allocation and expertise. 
The menopause, or the end of menstruation, can be seen as a signifier of 
ageing that concretizes this concern. As Lock demonstrates, much of the 
work and data collection that has occurred to define the menopause is 
based on the self-reporting of a small number of North American women 
who describe symptoms of emotional and physical distress during this time 
of life. Moreover, many of these women have had hysterectomies, a highly 
invasive procedure that explicitly medicalises the menopause. As a 
consequence, the symptoms and diagnostic categories of the menopause 
are biased towards a narrow and atypical sample. The resulting 
categorisation of menopause has become the basis for the treatment of the 
end of menstruation in North American and European clinical medicine. 
HRT (Hormone Replacement Therapy) is commonly prescribed to reverse 
the effects of these ‘oestrogen starved’ bodies, such as heart disease, 
osteoporosis and Alzheimer’s disease. However, as Lock also points out, 
not only are the consequences of these ageing female bodies highly 
contested, but the compliance rate for HRT is low - at approximately 15% 
for all women who are passing through this time of life. As this comparative 
study reveals, not only are the iatrogenic effects of HRT generally ignored 
inside of this context, but also these symptoms are not always present 
outside this reified epidemiological population.
In Japan, by contrast, the end of menstruation, or konenki, is not commonly 
marked by the experience of ‘classical’ menopausal symptoms, such as hot 
flushes or night sweats. More commonly shoulder stiffness, headaches and 
dizziness are reported. Moreover, the cause of the disease is strongly 
associated with factors connected to the role of middle-aged women in 
Japanese society, rather than the physiological changes associated with 
the end of menstruation. In fact the rise of the nuclear family, the decline of 
the extended family, increased wealth and subsequent leisure time, are all 
factors which are thought to contribute to the ‘lack of a role’ for middle-aged 
women. Thus the menopause becomes a syndrome whereby the
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vulnerability of the ageing body and its propensity to stress is magnified by 
the social role, or lack thereof, of middle-aged Japanese women. 
Consequently, menopausal syndrome is construed as a luxury disease 
suffered by women who have too much time on their hands due to the 
disappearance of the extended family, whom they would have traditionally 
attended to.
Furthermore, the physicians who see these symptoms in the Japanese 
context do not attribute the lack of Euro-American symptoms to an error in 
the accounts given by Japanese women, but to a biological difference, due 
to factors such as environment, diet or genetics. This results in a subjective 
experience of the end of menstruation in Japanese women that is different 
to those commonly experienced in other contexts. As Lock concludes, what 
this comparative account of the menopause demonstrates is not only the 
construction of bodies and diseases by culture, but also the construction of 
culture by bodies. Whilst the end of menstruation is defined by the North 
American medical paradigm as a problem due to the ageing process, 
damaging the ‘normal optimal pre-menopausal body’, it is also qualitatively 
constructed, as demonstrated in the Japanese account, by the experience 
of the body in other locations. In order to account for this dialect between 
nature and culture, Lock has created the concept of ‘local biologies’ that 
refers:
To the way in which embodied experience of physical 
sensations, including those of well being, health, illness and so 
on, is in part informed by the material body itself contingent on 
evolutionary, environmental and individual variables. (Lock 
2001:483)
Therefore, as with Rabinow's concept of ‘biosociality’, ‘local biologies’ is an 
analytical concept that offers a specific model of the relationship between 
nature and culture, and specifically disease and illness. Consequently, 
following on from this re-framing of the relationship between nature and 
culture, this study will identify how the specific regulatory structures, 
diagnostic and treatment technologies and doctor-patient relations within 
the NHS shape the boundaries and experiences of thyroid disease.
As described previously traditionally medical sociology has tended to 
understand the realm of illness to be a social response to disease, which 
was considered the domain of science. As Annemarie Mol notes, however,
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‘when sociologists realised the power that a strong alliance with physical 
reality grants doctors’ (Mol 2002: 9) they began to question the sanctity of 
disease as a realm purely of science. This change in the focus of medical 
sociology -  from illness to disease/illness -  can be mapped out via the 
fortunes of Talcott Parsons’ concept of the sick role (1952). For Parsons, a 
structural functionalist, all social phenomena is either a stabilizing influence 
on society or a threat to it, or to what he more specifically defines as the 
‘Social System’. In the case of sickness, Parsons asserts that being sick is 
realized as a specific role, which consists of four main constituent parts. 
Firstly, the sick individual is granted temporary relief from certain social 
duties, such as work, via the validation from other sanctioned roles, such as 
the doctor. This validation, therefore, constitutes the second part of the sick 
role, which is the necessity of the sick person to seek professional medical 
help. In turn, this relationship should be entered into an understanding that 
it is asymmetrical, in that the patient will act on the advice of the doctor and 
comply with all treatments that the medical profession prescribe for 
recovery. Finally, if all of the previous conditions of the sick role are met, 
the fourth criteria can be achieved, in that the sick role is meant to be 
temporary and will only last as long as the medical treatment prescribed -  
which it is assumed will be successful and will result in a return to work and 
a ‘normal’ social role.
Whilst it has been noted that Parsons meant the sick role to be applicable 
only to western protestant societies (Shilling Chris 2002), the fact remains 
that the sick role is a highly limited concept through which to assess health 
and disease, especially within a contemporary biomedical context. That is, 
not only does the sick role depend on a highly normative account of social 
relationships and organization, but also it cannot account for contemporary 
models of disease (e.g. chronic, pre-symptomatic) or professional and lay 
interactions (e.g. expert patient movements, complementary and alternative 
therapies). These changes in the understanding of disease and the 
congruent configuration of doctor-patient roles are well demonstrated in 
Michele Crossley’s (1998) study of members of a support group who were 
living long term with a HIV-positive diagnosis. The National Long Term 
Survivors Group (NTLSG) is a patient support group whose members 
approach their disease through a discourse of empowerment. This can be 
defined as an 'insider view' of illness’ that is related to the modern 
philosophy of self-help groups. This approach questions expert knowledge
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and privileges individual experience of the management and treatment for 
disease. This way of inhabiting disease categories, therefore, is tied to 
broader epistemological shifts within biomedicine. The predictive and 
flexible nature of emerging biological innovations, and resultant forms of 
social organization, challenge the authority of the medical profession and 
leave it open to interpretations and dispute by lay individuals and groups.
Improved treatments mean that there is an extensive gap between 
diagnosis and the onset of symptoms of HIV. This in turn challenges the 
first proviso of the sick role -  the temporary relief from work. As Crossley’s 
interviews demonstrate, most of the participants of the study were exempt 
from social responsibility, such as paid employment, and had chosen to 
give up work as a pre-emptive move, a preventative measure that would 
remove the pressure of work, thereby potentially increasing the amount of 
time they could experience pre-symptomatic health. This subversion of the 
sick role is linked to the rise of ‘quality of life’ as an important ‘outcome 
measure’ for medical intervention. As is the case with HIV, preventing 
premature death is no longer the one and only concern of medicine. The 
eradication of acute disease and the rise of chronic disease and the focus 
on improving life, rather than preventing death, has become a central 
concern of the profession. As Armstrong (1984) points out, subjective 
patient meanings are now examined alongside pathology in a clinician’s 
search for the cause, impact and solution for illness. In addition, 
developments within bioethics (respecting the autonomy of the patient) and 
the lifestyle choices associated with the management of chronic disease 
locate the authority to judge quality of life within the expertise of the 
patients (Sullivan 2003). As a result, the relinquishing of social duties, such 
as work, is under the control of patients, as they are the best judges of what 
will improve their quality of life. Thus, whilst the temporary nature of the sick 
role does not fit with the uncertain timescale of pre-symptomatic HIV, the 
exemption from social responsibilities, such as work, and the obligation to 
seek medical help are still present. Although, the terms of exemption are 
now broader and are related to the expertise of the patients as well as the 
medical profession. As the study goes on to demonstrate, the dependence 
on the medical profession is not necessarily harmonious. In fact the 
empowerment approach adopted by groups such as NLTSG directly 
opposes the authority of the medical profession.
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Many members of the NLTSG expressed scepticism at the authority of the 
medical profession. As Crossley notes, haemophiliacs who had contracted 
HIV from contaminated blood were unsurprisingly critical of the medical 
profession. However, beyond this group, and more common to the rest of 
the interview cohort, was a general cynicism due to the uncertain nature of 
the disease progression and its treatment. For instance, the measurement 
of CD4/T4 counts6 was always highly contested by many patients as it did 
not seem to correlate with their own assessment of their health. As one 
patient in Crossley’s study explains:
...Theoretically my T4 cell count is low but that seems to have 
no basis in real life, in the real world...they say that if your T4 
cell count is below a level, then you are ill, you know the 
Americans set up the control definitions of AIDS as a T4 cell 
count below 300. Mine has been around 200 for years and 
nothing happens...! don’t think it makes a great deal of 
difference...it’s a normal thing...(Crossley 1998: 516)
This scepticism was also manifest in the patients’ opinions of how the 
medical staff conducted themselves. Patients often reported feeling that the 
full extent of their disease, and the treatments they were expected to 
comply with, were not adequately revealed to them. They further 
complained that their knowledge of their disease was ignored by physicians 
in the course of treatment. Often patients made sense of their disease and 
state of health by responding to ‘gut feelings’ and ‘listening to their body’, 
via an idiom of positive thinking, whereas, for physicians, such individual 
and subjective testimony was at odds with the necessity for objective 
reliance on established protocol. Similarly, the social roles and rules HIV- 
positive individuals were expected to adhere to in their daily lives were also 
ignored or rejected by medical professionals. For instance, heterosexual 
haemophiliacs tended to affirm their right to have children and homosexual 
men refused to relinquish their right to sexual freedom. As Harry, an HIV- 
positive patient, describes the imperative for him to reclaim his identity in 
Crossley’s study:
I remember one day I was at Open Door, I said, ‘I must take 
back my sexuality’ and I borrowed someone’s leather jacket 
and went up to the Heath and stood by a tree and I would not 
leave that tree until I had got fucked rotten, to put it bluntly. I 
had to take it back, take the power back to me, not let the
6 CD4/T4 lymphocytes are used as a marker of disease progression
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doctors or anybody else, there are plenty of people who say, 
you mustn’t, you drop it all now (...there was a lot of guilt 
associated and fear, ‘you don’t do this and you don’t do 
that’)...(Crossley 1998: 522)
Crossley concludes that certain aspects of the sick role are still useful as a 
way of making sense of the experience of sickness. Although disdain 
seemed to be the most common ‘insider view’ with regard to patient 
opinions of the medical profession, the view tended to over-exaggerate the 
independence of patients from the medical profession. As Crossley notes, 
there is a disproportionate amount of health service provision dedicated to 
HIV/AIDS within the United Kingdom. The continued health of HIV-positive 
individuals is wholly dependant on continued innovation within the field to 
keep them alive. Moreover, it is also noted that the way in which the 
medical profession is demonised could be attributed to the construction of a 
HIV identity that can resolve ‘personal worries, fears and vulnerabilities...by 
mentally passing them onto some other person or group external to the self 
(Crossley 1998: 528). By casting medical professionals as ‘non­
empowered’ others, HIV-positive individuals build an empowered self in 
order to manage their terminal disease.
Finally, whilst the desire to applaud the positive and empowered ownership 
of the HIV diagnosis by such patient movements is compelling, as Crossley 
concludes, that approach is only available to those who have certain 
material and cultural resources to draw upon. This individual-empowered 
approach to HIV, and disease more generally, has a massive implication for 
the wider ‘social body’. As Crossley notes, with reference to the work of 
Nancy Scheper Hughes (1994), there is a clash between the ‘rights of the 
individual’ and the social ethic required for HIV prevention measures. In 
other words, what are the broader implications of Harry’s actions on the 
Heath, beyond his individual need to empower himself with regard to his 
HIV-positive status?
In conclusion, as Lock’s comparative work on menopause in Japan and the 
United States demonstrates, disease and illness (biology and society) are 
socially accomplished categories. Rather than disease being defined as ‘a 
fact’ it is understood to exist in a dialectical relationship with illness, and 
with the wider environment, including factors that affect both individuals and 
populations. From such a vantage point it becomes possible to understand 
how representations of disease are tied, for example, to the dominant
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hegemonies of the time and place in which they are manifest. Similarly, as 
Crossley’s study of the members of the NLTSG demonstrates, an 
empowered approach to a HIV-positive diagnosis hinges on substantial 
resource provision in order to stay alive. So whilst it is undeniable that 
empowered, flexible, contextualized and contingent definitions of disease 
and illness are apparent, it is important to remember that the material 
conditions of these entities are imperative to their particular manifestation. 
Therefore, in assessing the construction and politics of health and 
medicine, it is necessary to interrogate the changing practices that 
constitute them.
Together, these studies underscore the importance of some of the wider 
points emphasised throughout this chapter, including the complex co­
determination of bodies, illness, knowledge, and care. As studies charting 
the biosocial dimensions of illness become more numerous, and more 
diverse, it becomes possible also to attend to the distinctions raised by 
Gibbon and Novas (2008) concerning the limits of the biosocial model, and 
the need for ongoing innovation in understandings of what Rose describes 
as the ‘somatic ethics’ (2006: 6) of approaches to disease. That is, the 
ways in which the new possibilities of the body bought about by biomedical 
innovation, coupled with devolution of the responsibility of the management 
of human health from the state to the individual, results in us relating to 
ourselves through our corporeality. As Rose claims the way in which ‘...the 
corporeal existence and vitality of the self has become the privileged site of 
experiments with the self (2006: 26).
Practicing Medical Knowledge
The recognition that corporeality is a key site of subjectivity results in 
disease becoming a site where social-scientific work can be performed, 
and, subsequently, where the politics and contingencies of the traditionally 
asocial sphere of scientific knowledge can be assessed. This interpretation 
of biomedicine as a realm open to interrogation is particularly useful when 
addressing the rich and highly productive gap between the value-free 
claims of clinical science and the application of such knowledge in clinical 
practice (as this study of thyroid disease aims to do). In the following 
section, the conceptual separation between ‘knowing’ disease via clinical 
science and ‘doing’ disease via clinical practice is extended through a
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consideration of the modes of body knowledge techniques articulated in the 
work of Annemarie Mol (Mol 2002). Latterly, the empirical field of thyroid 
conditions will be introduced as a location where such broad theoretical 
questions can be addressed. Firstly, however, a discussion of work that 
looks at the relationship between clinical scientific knowledge, and how 
such knowledge is applied in practice, will be conducted.
In their study of Familial Hyperlipedeamia (FH), a condition that interupts 
the normal metabolisation of blood fats, Helen Lambert and Hilary Rose 
(1996) introduce the categorisation ‘peculiarly scientific’ to describe the 
absent symptomatology of a disease that can only be ‘seen’ post mortem. 
That is, although FH can cause premature death from cardiac 
arrest/coronary heart disease (CHD), no obvious symptoms of disease are 
present before the onset of these terminal events. FH consequently has no 
symptoms in the daily lives of its sufferers and is only brought into being by 
laboratory indicators -  blood tests that measure raised lipid levels. FH can 
be thought of as a ‘disembodied’ disease, leading Lambert and Rose to 
ask: ‘How...do people make sense of knowledge from the medical science 
which does not look to, or speak to about the body?’ (1996b: 65)
It is only with the advent of effective therapeutic responses that the 
genetically transmitted inability to metabolize fats has become a site of 
medical intervention in the case of FH. The success of medications to lower 
lipid levels, associated dietary measures, as well as identification of the 
aetiology of the disease, means that the condition can be seen within a 
biomedical framework and therefore successfully treated. However, as 
Lambert and Rose are quick to point out, even this seemingly new ability to 
classify FH as ‘a disease’ is relatively partial, due to its genetic and clinical 
heterogeneity. In contemporary medical practice, a differential diagnosis of 
the specific type of FH is rarely sought, and treatment consists of 
monitoring the lipid profile over time and implementing dietary and 
therapeutic responses, as and when they are necessary. In this sense the 
practices of treating FH, rather than how it is perceived as a genetically 
rooted disease, are what constitute FH within the clinical environment. In 
addition, this active process of knowing disease through practices also 
reflects how such a disembodied and pre-symptomatic condition is 
embodied by patients. Through in-depth interviews with FH patients, it 
became clear to Lambert and Rose that the science of FH was understood
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by patients as an involved process, where individuals applied their own 
knowledge, personal and family medical histories to cope with and manage 
the condition. For instance, for most FH sufferers the disease is understood 
in terms of its effects on physical health, rather than its metabolic 
characteristics or genetic determinants. Moreover, in the daily lives of 
individuals who suffer from FH, general dietary practices, encouraged by 
various health policy initiatives to reduce the occurrence of CHD in the 
general population, are used. Often informal networks of family members, 
who all share the disorder, provide forums where treatments and test 
results can be compared and new information sought. Again, this affirms 
the importance of existing social networks and relationships in the process 
of managing this disembodied disorder.
What Lambert and Rose’s investigation into how such a ‘disembodied’ and 
‘peculiarly scientific’ disease is understood demonstrates is the remaking of 
scientific knowledge through clinical practice. That is, although clinical 
science reifies and defines what ‘a disease’ is, in the realm of clinical 
practice these categories are not so straightforward. In practice, other 
concerns take over and practical strategies are deployed in order to treat 
disease. In many ways, the disconnection between the science and 
practice of FH is indicative of the character of contemporary medical 
knowledge. Scientific innovations may enable the identification of FH at a 
molecular, chemical and cellular level, but this in itself does not directly 
translate into how FH is experienced as an illness through symptoms. FH is 
highly tentative: it is treated before it becomes manifest symptomatically. 
Strictly speaking FH is not treated at all, but rather managed through the 
introduction of individual behavioural changes (e.g. diet) alongside 
pharmaceutical interventions, such as cholesterol lowering drugs.
As discussed above, the predictive nature of such disease information 
suggests that the boundaries of the biological body and the certainty of 
biomedical knowledge have to some extent been compromised. For 
example, within social studies of biomedicine there is an extensive body of 
literature that examines a number of syndromes that have no clear 
pathological basis and subsequently ‘are pervaded by medical, social and 
political uncertainty’ (Dumit 2006: 577), such as myalgic encephalopathy 
(M.E) (Cooper 1997), chronic fatigue syndrome (CFS) (Hayden and Sachs 
1998), repetitive strain injury (RSI) (Arksey 1998), and Gulf War syndrome
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(Cohn et al. 2008). Consequently, as the medical sociologist Sarah 
Nettleton (2006) states, such studies enhance and inform broader 
theoretical concerns with regard to ways of living in the postmodern era. As 
the sociologist Zygmunt Bauman (1991) points out, in the postmodern era 
uncertainty is no longer a temporary nuisance but a permanent and 
irreducible state. Fluidity, flux and uncertainty are inherent characteristics of 
the process of globalization and, therefore, traditional and stable forms of 
authority and expertise have been reduced so that attempts to control such 
uncertainty, result in further uncertainty and disorder. As Renee Fox’s 
(1980) work on medical uncertainty demonstrates the more advanced 
medical technologies become the less they able are to deal with clinical 
uncertainties -  the boundaries of life are pushed and manipulated to such 
an extent that further fear and threats to life are created. Therefore, the risk 
information that typifies contemporary medical knowledge and practices 
alters the authority of medical knowledge and the medical profession. For 
instance, in the case of FH, predictive and uncertain disease information 
can result in clinical decisions that are often complex and necessitate 
shared decision making between doctors and their patients. This, to some 
extent, subverts the traditional ‘asymmetrical’ relationship between doctors 
and patients identified by Talcott Parsons, and subsequently threatens the 
authority of the medical profession.
Stabilizing illness
Following the work of fellow sociologist Eliot Freidson (1972), David 
Armstrong (2007) claims that clinical autonomy has remained the defining 
characteristic of the medical profession’s authority despite the many 
challenges to its traditional sources of affirmation. As Freidson claims:
The profession bases its claim for its position on the possession 
of a skill so esoteric or complex that nonmembers of the 
profession cannot perform the work safely or satisfactorily and 
cannot even evaluate the work properly. On this basis, 
nonmembers are excluded from practice and evaluation. Given 
the exclusion and its implied basic concession of autonomy, I 
would argue that in spite of any formal administrative framework 
imposed by the profession, autonomy in controlling its 
technique allows it to temper many elements of that framework 
beyond both the intent and even recognition of its planners and 
chief executives. This is particularly the case for medicine, 
where dangerous consequences can follow upon improper
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work, and where the claim of emergency and of possible 
dangerous consequences is a potent protective device. (1972:
45)
In the last few decades, however, others have argued that medical 
authority has declined in line with the more general changing nature of 
technologies of governance described previously. The economic 
rationalization of health services, and the emergent casting of patients as 
consumers has been claimed to make doctors accountable to fiscal 
imperatives and patient desires rather than their professional judgement 
and traditional expertise. Both of these factors, it is assumed, have 
contributed to the deprofessionalisation (Haug 1973) and proletarianisation 
of the profession (McKinlay and Stoeckle 1988). From this perspective, 
doctors have been seen to take on the characteristics of employees rather 
than professional, self-governing elite. For example, in the United Kingdom 
health policy initiatives, such as ‘Patient Choice’, that attempt to empower 
patients to make decisions about their health and healthcare have 
dislodged the authority of the profession. Shared decision-making between 
doctors and patients is now considered to be integral to a successful 
contemporary clinical consultation (May et al. 2006). Within the parameters 
of such an intiative, the traditional asymmetrical relationships between the 
‘expert doctor’ and the ‘lay patient’ are no longer straightforward nor even 
desirable. However, as Freidson recognised, this story of the decline of 
medical authority is not so straightforward, nor is it reflected in the earning 
power of the profession and their continued self governance through 
institutions such as the British Medical Association (BMA) in the United 
Kingdom. Freidson suggests that, far from losing control, the medical 
profession, particularly the academic elite, have been deploying strategies 
to maintain professional authority. This has taken the form of gaining 
control of their individual members through the formalisation of professional 
practice. The most powerful and recognisable form of this professional 
formalisation is the evidence-based medicine (EBM) movement. This term, 
first coined by a group of clinical epidemiologists at McMaster University in 
Canada, is defined by D.L. Sackett as:
...the conscientious, explicit and judicious use of current best 
evidence in making decisions about the care of individual 
patients...integrating clinical expertise with the best evidence in 
making decisions about the care of individual patients (Sackett 
DL 1996).
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EBM establishes scientific research, rather than an individual clinician’s 
experience, as the basis for medical decision making. The traditional view 
that, by virtue of professional status, physicians can make decisions as to 
what treatment is necessary is questioned. It is recognised that clinical 
decisions can be ‘highly capricious affairs, well in need of some support’ 
(Berg 1998: 226), a situation that it is thought can be remedied by the 
practice of EBM. The production of ‘transferable, evaluatable and scientific’ 
(Berg 1998: 227) evidence by the clinical elite, and the establishment of 
tools such as treatment algorithms and clinical practice guidelines, attempts 
to redefine and re-establish the profession’s authority. That is, they become 
the producers and assessors of a specialist evidence-based culture of 
knowledge production, defining the terms of good clinical practice and 
subsequently asserting the authority of the profession. EBM claims 
authority by developing professional standards for individual clinicians to 
follow. It is assumed this will mean that better diagnostic and treatment 
decisions are made. As Marc Berg notes in his review of the development 
of post-war medical practice:
...the flawed physicians mind is increasingly seen as the 
primary source of medical practice’s problems. More and more, 
the escalating costs of medical care, the public’s dissatisfaction 
with medical practice and the suboptimal quality of care are 
being transformed into problems which result from the individual 
physicians mental incapacities. (1995: 226)
This disciplining of ‘rogue physicians’ through the practice of EBM fulfils two 
aims. Firstly, it re-establishes the professional authority of the medical 
profession, albeit the clinical academic elite, by producing specialist reified 
knowledges and practices that the profession as a whole can adhere to. 
Secondly, its rhetoric of objectivity, through the application of reliable 
scientific evidence in clinical decision-making, attempts to guard against 
capricious clinical decision making. However, as has been discussed 
previously, such rhetoric of objectivity can be considered culturally specific. 
That is, EBM extends the rhetoric of objectivity by positing a value-free, 
experimentally validated and independent body of knowledge of both 
clinical and economic benefit and, further, posits this value as self-evident.
In 2004, the sociologists Eric Mykhalovsky and Lorna Weir stated in their 
critique of EBM that:
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Evidence-based medicine (EBM), the project of reshaping 
biomedical practice by creating an organizing presence for 
clinical research within medical decision making, has taken the 
health care world by storm... EBM has grown into one of the 
most important and successful initiatives to recompose 
contemporary biomedical reasoning and practice. The 
evidence-based movement, as some have described it, has 
been met with remarkable enthusiasm on the part of the elites 
in academic medicine. EBM has been formally incorporated into 
editorial policies, has spawned new journals and approaches to 
reporting biomedical research, and is now routinely taught 
throughout medical schools in North America, the UK and parts 
of Western Europe...(Mykhalovskiy and Weir 2004: 1059)
However, they go on to claim, the social sciences have been slow to 
interrogate the EBM movement, which has come to dominate medical 
practice. At the time of the article’s publication, social scientists had only 
really engaged with the movement using two traditional and ‘empirically 
thin’ approaches -  political economy and humanism. Sociologists using the 
political economic (Armstrong and Armstrong 1996, Leys 2001, Light 2001, 
Navarro 2002) approach have analysed EBM as a naive endorsement of 
the free market principles of capitalist social organization. Ideologically, 
EBM buttresses the authority of the medical profession by reifying the 
scientific nature of medical knowledge and devaluing more traditional forms 
of authority predicated on clinical experience. The privileging of 
epidemiologically-derived statistical calculations as evidence has redefined 
medical outcomes as numerical, thus tying them closely to fiscal 
imperatives and administrative control. EBM’s rationalising ethos is also 
challenged within more humanist analyses (Frankford 1994, Belkin 1997, 
Tanenbaum 1996) of the movement, for example for diminishing the doctor- 
patient relationship. From this perspective, EBM's over-emphasis on 
quantifiable, repeatable and scientific evidence transforms patients into 
standardised units and clinicians into data managers and technicians. 
Mykhalovsky and Weir ask ‘how the formal rationality of EBM connects with 
clinical reasoning’ and in doing so seek to ‘move towards a more complex 
understanding of EBM's relationship to clinical practice’. (2004: 1064). 
Similarly, Timmerman’s and Berg’s (1997) account of oncology and a 
Cardio Pulmonary Resuscitation (CPR) protocol demonstrate how these 
semi-standardized practices have to be significantly adapted to suit specific 
local contexts and practices. Far from becoming cookbook medicine, 
clinical practice is being increasingly understood as a meaning-making 
activity where the formal knowledge of EBM is adapted to local uses by 
individual clinicians (Timmermans and Mauck 2005).
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This recognition that the contextual nature of evidence is applied within the 
clinical encounter is also supported by David Armstrong’s account of how 
G.P.s in the United Kingdom introduce new anti-depressants to their 
prescribing repertoire (2002). As Armstrong demonstrates, the population- 
based evidence used to justify and recommend the new anti-depressant 
drugs is only one of many factors GPs take into account when prescribing 
treatment. Often they prescribe on the basis of the circumstances of the 
individual patient. For instance, they may prescribe drugs to an individual 
on the basis that side effects such as drowsiness would actually help them 
with their symptoms of sleep disturbance. As Armstrong concludes, the 
complex arrangements of social and scientific factors in the clinical 
decision-making process demonstrate a tension between evidence-based 
and patient-centred medicine. The ‘formalised accounts’ of what is the most 
efficacious anti-depressant drug are defined on trial evidence derived from 
populations of patients, but this may be far removed from the clinical 
decisions and prescribing protocols used by G.Ps, which are often based 
on the individual needs of the patient identified over time through doctor- 
patient interactions and relationships. Such studies suggest that not only is 
there a conflict between ‘experience near* and ‘experience far’ clinical 
evidence, but also that it is tied to the quality of the relationship between 
patient and doctor -  something that not only is not measured by EBM 
criteria, but indeed cannot be.. From the perspective of more qualitative 
studies, the character of the clinical encounter may be a better indicator of 
successful treatment than strictly objective indicators based on 
standardised models of patients, doctors and disease. Likewise, the 
stereotype of EBM as the ‘heartless application of scientific knowledge’ 
(Mykhalovskiy and Weir 2004: 1064) can be reappraised as a complex set 
of relationships between social and scientific orders.
This relationship is also apparent in the production of clinical evidence and 
decision-making tools before they are even circulated for use in clinical 
practice. In the anthropologist Tiago Moreira’s ethnographic study of a 
research unit that develops systematic reviews of healthcare, the 
production of such evaluative devices are approached as meaning-making 
activities. As Moreira demonstrates, the systematic review is also a 
translation device, converting one form of data into another:
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[Knowledge making in systematic reviewing is structured upon 
parallel attempts a) to disentangle data from the milieus in 
which they are commonly found (databases, texts, other 
research centres, and b) to re-qualify that data through 
comparison across a variety of ‘platforms’ (tables, graphs, 
equations, and political controversies). (Moreira 2007:180)
The evidence collected from the vast amount of published data on any 
given health intervention during the course of a systematic review is 
transformed by the practices of the reviewers, while at the same time 
reinforcing a new standard of neutrality. Evidence is evaluated, extracted 
and represented in forms that fit in with the requirements of evidence-based 
methodologies, as well as the practical requirements of clinical practice 
guidelines, which require objective criteria for comparison across vast 
aggregate data sets.
Since a systematic review entails an analysis of all the published data on a 
single research question, the aim of a review is to appraise, select and 
synthesize all high quality research evidence relevant to that question. The 
review is intended to provide the best evidence on which to base evidence- 
based tools, which in turn form the base for more rigorous, transparent, 
standardised, and often cost-efficient clinical practice guidelines (CPGs). 
According to the Institute of Medicine, a health policy group created by the 
National Academy of Sciences in the United States, Clinical practice 
guidelines are ‘systematically developed statements to assist practitioner 
and patient make decisions about appropriate healthcare for specific 
clinical circumstances’ (Institute of Medicine, Committee on Clinical 
Practice et al. 1992). Whereas CPGs were once based on the expert 
opinion of senior figures in the medical and scientific fields, they are now 
based on systematic reviews of published data which adhere to the current 
tenets of evidence-based methodology. Published meta-analytical data is 
placed at the top of a hierarchy starting with meta-reviews of randomized 
controlled trials (RCT's)7 and finishing with the results of expert committee 
reports and opinions. The privileging of meta-analysis in RCT's over expert 
opinion neatly summarises the core identity of the EBM movement, namely 
that it is a fundamentally scientific endeavour aimed at improving clinical
7 According to health service researchers Sibbald and Roland (1998) ‘Randomised 
controlled trials are the most rigorous way of determining whether a cause-effect 
relation exists between treatment and outcome and for assessing the cost 
effectiveness of a treatment'
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guidelines through evidence that is based on population-derived, 
quantitative analysis and that has been peer reviewed.
However, the technocratic hyper-rationalisation of EBM meta-review 
methodology has led some commentators to conclude that the resulting 
guidelines are ‘evidence biased’ rather than ‘evidence based’ (Moreira et al. 
2006) and that the aim of EBM to remove clinical experience and opinion 
from diagnostic decisions does not enhance but reduces the quality of 
medical care, as good doctoring is considered to be an artful, as much as a 
scientific, practice. This charge that EBM has paradoxically inaugurated an 
age of ‘evidence biased’ rather than ‘evidence based’ medicine 
recapitulates older discussions about what constitutes good medical 
practice and professional legitimacy. Is it based on the individual 
physician’s clinical expertise -  their ‘personal and private magic’ (Gordon 
1988: 257) -  or should good professional practice be based on the ability of 
the physician to use clinical scientific knowledge to make better patient care 
decisions?
As Moreira’s qualitative ethnographic study suggests, the production of 
guidelines is a key component of the neutrality-driven western scientific 
‘culture of no culture’ described by Sharon Traweek (1992) . The authority 
of systematic reviews is derived from their putative neutrality, based on 
their presumed ability to mine evidence from the vast, complex, 
contradictory mass of published data and reconstitute it as a more objective 
meta-conclusion. For instance, as Moreira demonstrates, ‘at the core of 
systematic reviewing is the practice of neutralising the powers incorporated 
in the texts by their authors’. (2007: 186). Research papers are ‘made 
docile’ (2007: 181) through practices of data abstraction which reviewers 
actively seek and construct the information they require. For example, the 
methods section of a paper is initially assessed in order to ascertain the 
quality of the study, measured by its evidence-based robustness, before 
the results are eligible for inclusion in the meta-review, from which many 
‘inappropriate’ studies are thus excluded. Research is also classified by the 
trial name, the protocol of the trial, the trial aims, the characteristics of 
patients included in the trial, the methodological quality, the comparability of 
trial subjects, the health measurements of subjects at the start of the trial 
and, finally, numerical end points of the health of the trial subjects. All such 
details are entered into a ‘data abstracting template sheet’, a table that is
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used to standardise the classification of research according to a fixed and 
limited set of criteria. The abstraction template thus functions to identify and 
promote consistencies within and across trials, facilitating a construction of 
the best neutralised evidence. In other words, the abstraction template 
consolidates what the review procedures define as meaningful within the 
published evidence. As Moreira concludes, this process fundamentally 
reconstitutes the original research:
The reviewer picks out this information and actively transforms 
it into data. Through this process, the paper loses its material 
appearance of a well ordered sequential set of arguments, 
turning it into a figuration of interrelated, graphically linked 
marks and comments. In a more superficial way, they rewrite 
the paper; and such rewriting is an integral part of the work of 
recalculation that is done while abstracting (2007:189)
However, the process does not end there. As Moreira demonstrates, the 
disentanglement of the published data is followed by a process of re­
entanglement in order to link the technical devices of systematic reviewing 
(e.g. analysis of the statistical validity of a given published study) with the 
social and professional practices that they are anticipated to regulate. As 
Moreira details, this ‘politico-technical’ entanglement is evident in the ways 
in which the laboratory-derived data collected by reviewers is circulated 
outside of the laboratory context, for example, in the form of meetings that 
develop CPGs.
In CPG meetings, the results of systematic reviews undergo a further 
transformation as they are ‘tabulated, summarised and discussed by 
multidisciplinary groups’ (Moreira 2007: 192). As the participants of such 
meetings attempt to produce recommendations for practice from the data 
collected by systematic reviews, they may debate the validity of the meta­
review process. As Moreira demonstrates, the process of translation from 
meta-data into CPG entails taking into account how the results of 
systematic reviews ‘might interfere with the distributions of power and 
accountability within healthcare institutions’. (Moreira 2007: 192). For 
example, in one GPG meeting a consultant, GP and methodologist debated 
the methodologist’s decision to exclude a study from the meta-analysis. 
Speaking from his experience, the consultant attempts to address the 
disproportionate influence of a particular study on the opinons of his peers:
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I think and I have said why we think that the trial does not show 
specific benefits for [drug y]. In one sense it’s easier to kind of 
put the trial to one side. The problem though is that that trial has 
just had one of the most successful marketing campaigns ever 
and most people in primary and secondary care [believe there 
are benefits beyond these of other drugs], and it’s got in the 
[national tabloid] because [they] have been extremely clever 
with their marketing and PR. (Moreira 2007:192)
The consultant questions whether the widespread misconception about the 
efficacy of the drug should be addressed in the guidelines. That is, 
regardless of whether the drug is more or less efficacious than others, the 
fact that it has such a dominant presence means that a tension emerges 
between the results of the meta-analysis and the perception of the drug 
amongst clinical professionals and the general public. For the consultant, 
this issue should be acknowledged in the guidelines, however the 
methodologist feels that such an approach would over-represent the drug, 
which is only relevant ‘down the line in [their] recommendations’ (Moreira 
2007: 192). In addition, and as one of the GPs present notes, this type of 
approach may be met with disagreement by the drug company who 
sponsored the trial. As Moreira concludes, the public acceptance of the 
guidelines ultimately depends on how they align with a variety of actors -  
the systematic reviewers, clinicians, the public and the sponsors of the 
clinical trial (see Moreira 2005) for a detailed ethnographic account of CPG 
committees).
EBM is thus far more complex than the application of the best available 
scientific evidence to clinical decision-making processes. It can be 
understood, as Armstrong claims, as a strategy to re-establish the authority 
of the medical profession, but also as a revolution in medical practice that 
ensures safer and more efficacious interventions. It can also be understood 
as the ‘heartless application’ of scientific knowledge which, in turn, 
facilitates the commercialisation of medical care (Mykhalovskiy and Weir 
2004). As Weir and Mykhalovsky quite rightly point out, any investigation 
into EBM must interrogate the relationship of such social and scientific 
orders across the localities in which they are manifest. Thinking back to the 
previous sections then, EBM can be defined as a form of ‘regulation at a 
distance’ (Rose 2006: 3) that typifies the neo-liberal condition. It can also 
be seen as an attempt to grapple with and regulate the results of the 
concurrent, dissolution and fluidity of the boundaries of health disease and 
illness, the decline in medical authority and the emergence of somatic
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ethics. This complex set of relationships is one that is indicative of the 
management of treatment of thyroid disease within the NHS. That is, as will 
be described, thyroid disease is constituted by various and often 
contentious attempts by patients, clinicans, professional bodies and 
bureaucratic systems, that attempt to define and to attend to it. Therefore, 
thyroid disease is an ideal location in which to contribute to theoretical 
concepts, in particular biosociality, that have attempted to re-conceptualise 
the situated and fluctuating relationship between nature and culture, body 
and society and disease and illness in the twenty first century.
Treating the thyroid
In July 2006, the UK Guidelines for the Use of Thyroid Function Tests were 
published in order to aid primary care physicians, specialist physicians, 
endocrinologists, clinical biochemists and patients in understanding and 
establishing a standardised approach to the diagnosis and treatment of 
thyroid conditions. The guidelines were authored by a drafting committee 
including members of the British Thyroid Association (the BTA, the 
professional association of endocrinologists who treat thyroid disease 
within secondary care), the Association for Clinical Biochemistry (the ACB, 
the professional association of clinical biochemists who develop and 
conduct thyroid function tests), and the British Thyroid Foundation (the 
BTF, a patient organisation that provides support for sufferers of thyroid 
disease and is affiliated via endorsement to the BTA). The purpose of the 
guidelines is to:
[E]ncourage a greater understanding of thyroid function testing 
amongst all stakeholders with a view to the widespread 
adoption of harmonized good practice in the diagnosis and 
management of patients with thyroid disorders. (Association for 
Clinical Biochemistry et al. 2005)
As identified in the introduction to the guidelines and evidenced by a 
substantial body of published literature, all three stakeholders are revealed 
to be uncertain about a number of aspects of the testing of thyroid function 
as a result of the complex and often contradictory relationship between the 
results of thyroid function tests and the clinical symptoms of thyroid 
disease. According to the authors of the guidelines ‘the need for a national 
guideline for something as common as thyroid function testing is self
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evident’ (Association for Clinical Biochemistry et al. 2005: 13) in order to 
provide standard protocols that will resolve such confusion. Evidence- 
based methods are sought in order to clear up the indeterminacy of thyroid 
disease and produce a clear set of standardised guidelines based on the 
findings of a systematic meta-analysis of the best available published 
evidence. Subsequently, as claimed in the introduction, as the guidelines 
are evidence-based they meet the requirements of all three stakeholders. 
That is, the evidence collected in order to produce these guidelines is so 
methodologically robust it can capture, and do justice to, the complexities of 
treating thyroid disease in clinical practice across varied professional and 
patient contexts.
However, in a pattern that proves to be an intractable feature of this area of 
current medical practice, not only in the UK but elsewhere, the uncertainties 
of the various stakeholders mediate the current practices that surround the 
clinical presentation of thyroid disease and the biochemical laboratory- 
based test used to diagnose diseases of the thyroid. As the guidelines point 
out, the huge amount of information available to patients about thyroid 
disease from the internet, as well as various patient support groups and 
doctors, is considered to be confusing and at times inconsistent. Patients 
often find it hard to understand that the diagnosis of thyroid disease is not 
always clear and can vary from patient to patient. For clinicians, the non­
specific nature of thyroid disease symptoms demands definitive evidence, 
in the form of biochemical assays, in order to make a firm diagnosis. 
However, the current variability of testing techniques across laboratories is 
seen to jeopardise the process of making a definitive diagnosis. Finally, due 
to the rapidly rising number of thyroid function tests being requested, the 
laboratories where the tests are carried out need to ensure that the clinical 
grounds for tests are significantly justified. Therefore, it is assumed that the 
problems currently relating to the diagnosis and treatment of thyroid 
conditions are due to a lack of consensus on current diagnostic and 
treatment practices between the stakeholders. However, as will become 
clear throughout the course of the thesis, the problematic aspects of thyroid 
disease extend far beyond normative discussions about how the best 
available evidence is applied in clinical practice. Thyroid disease is not 
simply the sum of the evidence used to define and treat it, nor is it reducible 
to what would count as evidence at all.
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In chapters four and five this ‘counter-empirical’ relationship between the 
knowledge about thyroid disease and the practices of a thyroid outpatients 
clinic in central London is initially described in terms of what counts as 
‘evidence’. By introducing thyroid disease in this way the empirical focus of 
the thesis is identified in part as what can count as an empirical fact. As we 
shall see, evidence for thyroid disease is ordered by various stake holders 
in order to establish particular orders of thyroid biology that represent a 
range of needs, rights and responsibilities with regard to health and health 
services delivery. In turn, this disease and the debates among its many 
stakeholders can be seen to extend further the longstanding debate within 
the social sciences concerning processes of medicalisation, health as a 
regime of biopower, and the gendered body as a site of both agency and 
resistance. Before this discussion is embarked upon the following chapter 
will outline the methodological approaches employed by the project.
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Chapter 3
Methodology: Understanding Thyroid Disease
Er no they’re never really normal they’re either too high or too 
low or, but yeah, I think it’s a very hard thing to regulate and I 
think that it’s a personal thing you’ve got to regulate it yourself, 
so what I do is I take my 25 and if sometimes I don’t, I’m...I 
think to myself oh you know I might need to take a bit more so I 
might, I might take 50 for a couple of days and I do it, sort of 
regulate it myself.
Lorraine -  Graves Disease Sufferer, Post Radioiodine 
Treatment
According to consultant endocrinologist Anthony Weetman in the journal 
Clinical Endocrinology entitled Whose Thyroid Hormone Replacement is it 
Anyway? (Weetman 2006), there is nothing more straightforward than the 
treatment of hypothyroidism. As his article goes onto claim, perceptions 
and practices such as those articulated by Lorraine in the above quote are 
the result of two factors: ‘postmodern’ medical practices and the lack of 
consensus amongst endocrinologists concerning the treatment of thyroid 
conditions. For Weetman, ‘postmodern medicine’ is typified by the 
‘derogation of objective facts’ and the ‘replacement of scientific certainty 
with the view that reality can have multiple meanings’ (2006: 231). 
Consequently, it has become common for patients to develop a distrust in 
doctors and the belief that ‘malevolent science’ perpetuates, and 
sometimes even causes, disease and illness. As a result, Weetman claims 
that patients turn to ‘folk models of disease’ (2006: 231) and the adoption of 
various alternative lifestyle choices, that can be accessed through the 
wealth of health information available on the Internet. For instance, 
Weetman cites Marcia Agnell’s (1996) discussion of the supposed health 
risks of silicone breast implants with regards to connective tissue disease. 
In particular, she draws attention to how women who claimed the 
connection between breast implants and connective tissue disease 
attempted to prove their case by presenting themselves, and not scientific 
research, ‘as the evidence’. As Lorraine can confirm, subjective beliefs 
about the nature of disease are highly visible in the contemporary 
approaches to health services delivery (Armstrong 1984, Sullivan 2003), 
and they shape the biomedical practices that are traditionally assumed to 
be the province of medical experts. Lorraine’s model of self-administration
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of thyroxine is a personal response to, and manipulation of, an evidence- 
based treatment that blurs the boundaries of her biochemically8 measured 
and defined disease. A pressing issue therefore for an investigation into 
thyroid disease, is how to track and assess the dialectical relationship 
between the imagined separate domains of the ‘science of and the ‘cultural 
responses to’ thyroid disease.
This problem of the relationship between the science and culture, or the 
‘actual’ and ‘imagined’, is also one which dominates anthropological theory 
and methodology. In particular the traditional assumption that writing up 
field work is, as James Clifford and George E. Marcus claim ‘...reduced to 
method: keeping good field notes, making accurate maps, writing up 
results’ (1986: 2). That is, the assumption that writing and making 
anthropological texts on a specific culture are neutral acts that do not need 
to be scrutinised in terms of the politics of the representations they 
produce, is no longer tenable. Therefore, as they declare in the introduction 
to their seminal edited volume Writing Cultures: The Poetics and Politics of 
Ethnography (1986), such an ideology has crumbled and as a result the 
essays collected in the volume they see culture ‘as composed of seriously 
contested codes and representations [that] assume that the poetic and the 
political are inseparable, that science is in, and not above, historical and 
linguistic processes’ (Clifford et al 1986: 2). Consequently the ethnographic 
techniques used to represent the phenomena of thyroid disease will not be 
defined as a neutral ‘writing up’ of the clinic. Following Clifford’s definition of 
culture, the representation of thyroid disease in this study is conceived as a 
practice that is inside of, and not above, broader cultural practices, 
conventions, trends, traditions and knowledge systems.
Initially this project was entitled ‘Ethnography of ambiguity: thyroid 
conditions, the promise of genetics and the lived experience of chronic 
illness’. As this title suggests, the study intended to focus on the 
implications of the well-established familial and vague predisposition to
8 Thyroid disease occurs when the gland malfunctions and fails to produce too little 
or too much thyroid hormone. The level of thyroid hormone is measured via a 
blood test and this biochemical measurement translates into the level of health of 
the thyroid. Treatment of a sick thyroid takes the form of either topping up or 
suppressing the production of the gland, Lorraine is altering her dose according to 
how she feels, rather than in accordance with the biochemical measures of her 
disease.
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thyroid disease with regards to how patients managed and understood their 
condition, in particular at the point of reproductive choice and genetic 
counselling. At the time when this study was first being planned my 
personal experience of having a thyroid condition was influenced by my 
interest in the emerging field of qualitative social studies of biomedicine, 
many of which focused on ‘the new genetics’ (Kevles and Hood 1992, Weir 
et al. 1994, Hubbard and Wald 1997). Having been advised that this was 
an area that could potentially garner financial support from a research 
council, I wrote my proposal with this focus in mind -  specifically with 
regards to how vague genetic information might impact on the diagnostic 
categories of thyroid disease. However, it soon became clear that this 
focus was problematic in terms of the prevailing research culture at the 
time. As a referee commented in a failed application for an ESRC/MRC 
PhD studentship:
good idea to study genetic susceptibility to a common chronic 
illness. However, there is a danger that studying patient 
experiences of common susceptibilities will become an industry 
in the way monologic disease has been.
As the referee suggests at the time my application was submitted, social 
scientific studies of genetic conditions were commonplace and had become 
‘an industry’. This industry therefore added to what the anthropologist Paul 
Rabinow termed the ‘hyperbolic discursive tidal wave of hope’ (Rabinow 
1999: 11), where the idea that genetic code would provide a ‘blueprint of 
life’ was not only increasingly unrealistic, (Lock 2005) but led to fears of 
genetic reductionism and determinism (Lippman 1992). The decision not to 
make ‘an industry’ out of the vaguely genetic, specifically the ways in which 
this idiom relates to other forms of disease, information and practices, was 
a cautious response to Rabinow’s ‘hyperbolic discursive tidal wave of 
hope’. Although this proposed research was attempting to think about 
genetic information in context, specifically as a partial and highly 
indeterminate entity, it was still considered by the referees to contribute to 
the ‘industry’ of social studies of genetic disease information. This example 
demonstrates that knowledge about our genes is not simply a matter of 
uncovering biological facts, it is also is intrinsically linked to the politics of 
how and why such research is conducted and how it shapes healthcare 
and identity practices. However, in spite of failing to secure funding, I 
persevered with this research trajectory on the vaguely genetic, which
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proved to be a fruitful starting point for this study. Specifically, it enabled me 
to recognise that many kinds of disease information and evidence are 
partial, indeterminate and worked out through practices during the course 
of care.
The ways in which knowledge about disease is transformed and shaped by 
practice became even more apparent when I entered the thyroid clinic 
during the period of data collection. As will be described in the following 
chapter, within the day-to-day business of the NHS thyroid clinic the well- 
established link between genetic inheritance and the onset of thyroid 
disease (Chistiakov 2005) is barely discussed, and plays almost no role 
whatsoever in diagnostic and management strategies. However far from 
being disappointing, this process of realisation that occurred during the 
early stages of the research actually helped reveal an alternative focus for 
the study. The contradiction between the ‘science’ of thyroid disease, 
exemplified by this partial genetic susceptibility, and the distorted 
application of this science within clinical practice, was just one of many 
instances where ‘knowing’ thyroid disease clashed with, ignored or was 
irrelevant to the practice of diagnosing, treating and suffering from thyroid 
disease. It soon became clear on entering the clinic that not only were other 
issues more relevant to an investigation into thyroid disease than its 
‘vaguely genetic’ character, but also that such a study had to be 
approached in such a way that it created a linkage map between the 
traditionally separate spheres of objective scientific fact and subjective 
ethical value (Konrad 2005). To that end, after the first few instances of 
participant observation, the research questions that were designed to 
explore the specific issue of genetic predisposition to thyroid disease were 
abandoned. What ensued was a process in which the practices of the 
clinic, performed by both the healthcare professionals and patients, were 
observed, became familiar and were latterly mapped onto (often 
discordantly) the ways in which thyroid disease is presented in clinical 
scientific literature (the content of which will be discussed in the following 
chapters). In the following sections the process of gaining access to the 
field, data collection and data analysis is described.
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Gaining access to the field
In December 2004 I approached a Senior Consultant Endocrinologist 
employed by a central-London hospital with a substantial research 
reputation in the field of thyroid disease. He is also a member of the 
development group for the clinical practice guidelines on the Use of thyroid 
function tests (Association for Clinical Biochemistry et al. 2005) and a 
senior member of the British Thyroid Association (BTA). Following his 
response, a meeting was arranged in January 2005, to which he was an 
hour late. This gave me some idea of the time pressures that I would face 
conducting research in such a busy environment. During our short meeting 
the Consultant was very helpful and agreed to grant me access to his clinic 
to do what he termed ‘some type of psychological study’ of patients with 
thyroid conditions. This short introduction to the gatekeeper of the field site 
was followed by a long and complicated process of gaining ethical approval 
to conduct research within the NHS through the Central Office of Research 
Ethics (COREC). No observation within the clinic could occur without this 
approval and it was eventually granted in January 2006, four months after 
the initial application was submitted in September 2005
Renamed the National Research Ethics Service (NRES) in 2007 COREC, 
was a government office that was oversaw all of the Research Ethics 
Committees (REC’s) within the United Kingdom. Each Strategic Health 
Authority (SHA9 in the United Kingdom has a REC and under guidelines 
from the National Patient Safety Agency and consist of a number of 
members who;
are specially trained in research ethics and often have the sort 
of experience which will be useful in scrutinising the ethical 
aspects of a research proposal. These include: patients; 
members of the public; nurses; GPs; hospital doctors; 
statisticians; pharmacists and academics, as well as people 
with specific ethical expertise gained through a legal, 
philosophical or theological background. (National Patient 
Safety Agency 2007a)
The first REC was established in 1966 and such committees have been 
present within individual hospitals (in the form of Local Research Ethics
9 Strategic Health Authorities manage the NHS locally and are a key link between 
the Department of Health and the NHS
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Committees LRECs) and health authorities since that time. Their 
implementation and ethos is a direct response the Word Medical 
Association (WMA) declaration made in 1964 entitled ‘Ethical Principles for 
Medical Research Involving Human Subjects’ (1964). Briefly, this 
declaration states that all experimental procedures involving human 
subjects should be formulated to a clear experimental protocol that has 
been passed via an ethical review process. This ethical review process 
must conform to the laws and regulations of the country in which the 
experiment is taking place and, the ethical review committee must be 
independent from the investigator, sponsor or any other undue influence. 
All adverse events must be reported to the committee as must all detail 
regarding institutional affiliation, project funding and any incentives for test 
subjects. Within the United Kingdom the primary function of REC’s is to 
‘protect the rights, safety, dignity and well-being of all actual or potential 
participants’ (National Patient Safety Agency 2007a).
More recently with the development of COREC in 2004 and latterly NRES 
in 2007, REC’s have been transformed substantially. Until COREC 
introduced an online application form in 2004, all paperwork followed the 
varied formats set by local REC’s. This standardisation of the application 
procedure is part of a move to make ethical approval procedures robust 
and accountable. As Dr Frank Wells, the co-chair of the European Forum of 
Good Clinical Practice, said;
This means that US bodies, such as the Food and Drug 
Administration, will review UK research in a favorable light as it 
will be assured that its ethical review will have been conducted 
to the highest standard (National Patient Safety Agency 2007b)
As I soon found out, by completing this process myself and talking to others 
who had also filled out the COREC form, these measures to make the 
ethical approval process better seemed to be universally despised within 
the field of clinical research! The process implemented by COREC was 
deemed time consuming, expensive and as much about resource allocation 
as than about ethics. As David S. Wald notes in his editorial in the British 
Medical Journal, part D of the 68 page form was essentially a record of 
indemnity to be signed off by the Head of Finance, which in his case 
‘required two drafts, nine phone calls, four faxes, 20 minutes of online 
internet activity, and 7.5 hours of staff time. There were no questions of 
ethics’ (2004: 283). Not only was the COREC form seen as unnecessary
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and obstructive, it was regarded as an affront to the ethical ‘know how’ that 
is embedded in the practice of clinical research and practice. The sentiment 
seemed to be that the independent ethical review of any research that 
involved human subjects was not an issue - the problem was the 
complexity of the process that had been developed to accomplish it. The 
medical value of the research, the assurance of minimal risk to participants 
and the provision of adequate informed consent were seen as the most 
important, obvious and already accomplished aspects of medical research 
culture. Such measures were considered to be embedded in a system of 
unspoken ethical beliefs and procedures that were intrinsic to good medical 
practice and the identity of the profession.
The belief that the COREC procedure was a means of making medical 
practice accountable enabled me to identify yet another area of empirical 
and theoretical interest. The tension between making medical practice and 
research better through standardization and accountability and the 
suspicion that it was a ruse to rationalize resources was also a tension 
commonly observed through the diagnostic and treatment practices used in 
the thyroid clinic and throughout the NHS more generally. Not only did the 
COREC process mean that I was granted access to the clinic, it meant that 
I was to some extent able to experience the pressures that clinicians face in 
their everyday working lives. Consequently, I developed a better 
understanding of the landscape of clinical practice and was able to interact 
with the Consultant who ran the thyroid clinic as if I were a colleague with 
whom I could share my frustration of the ethical approval process with. 
Subsequently, my fear that I would be unable to effectively decipher the 
specialist language and practices of the Consultant were slightly lessened 
by the COREC process. That is, it enabled me to learn the language of 
medical authority and provided me with the means with which to establish a 
good working relationship with the Consultant.
However, as I wasn’t actually treating patients this ability to empathise with 
the Consultant was only ever partial. When I clicked on the qualitative 
research and single site10 options on the online COREC application form it 
was automatically reduced fro 65 to 20 pages (plus supporting
10 Ethical approval has to be sought from the SHA REC and the LREC of each site 
where the research will be carried out. Luckily in the case of this research project 
only the SHA REC and the LREC of the hospital where the clinic is situated had to 
be applied to.
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documentation). This was due to the fact that I would not be directly 
intervening with diagnosis and treatment, administering new drugs or using 
any additional hospital resources during the course of the project. In spite 
of feeling that I was conducting some form of ‘health services research’, the 
form still seemed to jar somewhat with the ethnographic approach of the 
research project, and it soon became a case of making the research fit the 
form, rather than providing an accurate description of how I intended to 
approach the project. Having to fill 20 pages with a thorough description ‘of 
what I will do’ is wholly antithetical to the purposefully ‘see how you go’ 
approach traditionally employed by ethnographic methods. As Sarah 
Franklin and Celia Roberts note in the methods chapter of their 
ethnography of PGD (Preimplantation Genetic Diagnosis), the haphazard 
open ended and exploratory nature of participant observation and 
ethnographic work in general can appear meandering, random, amateur 
and ‘dilettante-ish’ (Franklin and Roberts 2006: 81). This was especially the 
case in the context of a form and set of procedures that demand accuracy 
and accountability. For instance, the change in the initial focus of my 
project/research from genetic predispositions to the accuracy of thyroid 
function blood tests, has rather straightforwardly been absorbed into the 
project as a necessary alteration. That is, the data- rather than hypothesis- 
led approach of ethnographic methods means that changes, such as the 
one described, are an intrinsic and to some extent, a conventional part of 
the research process. In addition, methods such as participant observation, 
where the researcher is expected to immerse themselves in the field, 
making them a ‘human instrument’ (Powdermaker 1966) of the data 
collection process is an anathema in the context of clinical research. That 
is, in the context of a field governed by evidence-based methodology, using 
a researcher’s subjectivity as the medium through which data is collected is 
considered to invalidate the integrity of the research.
In spite of this disparity between the formality of the COREC form and the 
relative informality of the chosen research methods in this context, the 
project was granted ethical approval from both the SHA REC and the 
hospital’s LREC with relative ease. In fact, during application review with 
the ethical review committee, the only comment offered was regarding the 
measures I had taken to ensure my own safety when interviewing patients 
in their own homes, when one of the panel asked, what would I do if a 
patient came at me with a butter knife? I responded that there was very
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little I could do to prevent this occurrence, but that as ‘an anthropologist’ I 
had received training in personal safety within the field. Interestingly this is 
another example of where the formality of the COREC process enabled me 
to reduce my anxiety about conducting research within a clinical 
environment. As demonstrated above it was necessary during the COREC 
process to formally identify my authority and skill as a qualitative 
researcher, which in turn justified my presence within the clinic as a 
‘specialist’ who worked within a particular discipline.
Overall, apart from this concern for my personal safety and a request to 
change the wording on the posters I produced to advertise the study in the 
clinic, the agreement was given relatively quickly after I submitted the 
paperwork. Although the COREC ethical approval procedure was on the 
whole inapplicable to qualitative research, the key ethical criteria set out by 
the British Sociological Association (2002) were met by the process. Briefly, 
this includes the promise of anonymity for all participants; the availability of 
all transcripts of interviews for approval and the destruction of all 
audiotapes of the interviews after the study has been completed.
Navigating the field and data collection
The data collection process for this study consisted of observing a Monday 
afternoon outpatients thyroid clinic over a period of 12 months. I 
interviewed patients and the Consultant who ran the clinic, and conducted 
a review of all relevant literature relating to thyroid disease (peer-reviewed 
published articles and patient support group literature) and health services 
delivery within the NHS. I was also provided with copies of all letters that 
were sent to the patients who attended the clinic after their consultation. 
These letters were written by the Consultant and summarised their 
appointment including: a clinical diagnosis, a summary of treatment 
prescribed, and an outline of any necessary future treatments. Along with 
the field notes produced during the participant observation, the interview 
transcripts and the patient and professional literature described above, 
these letters formed the project data archive. In the following section these 
methods and types of data will be described and reflected upon in terms of 
the specifities of the fieldwork site.
66
Participant observation is the primary technique of ethnographic research. 
However, how one goes about this process is much less clear, as access to 
and participation in the field are so context dependant. In theory the 
practice of a good participant observation lies in the ability of the researcher 
to become what E.E. Evans Pritchard calls a ‘doubly marginal’ person 
(1937), referring to the ability of the researcher to sit between their own 
culture and the one which they are studying. However this process is 
something that is almost impossible to comprehend in the abstract, until a 
researcher has been in and gone through the process of becoming 
immersed in his or her chosen field. What became clear about this process 
is that access, and as a consequence ethnography, essentially relies on the 
process of establishing relationships with subjects in the field. That is, 
relationality itself, the exploration of its character in a particular context, is a 
guiding and potentially fruitful aspect that helps to structure the approach to 
and decipher the ethnographic location.
For example, during the process of negotiating access to and observing the 
clinic, I had very little contact with anyone other than the Consultant. On his 
instruction his secretary forwarded me electronic copies of the clinic letters 
after they had been typed, however, he primarily administered my research 
access and the day-to-day running of the clinic in general. This included 
such tasks as re-scheduling patient appointments and chasing up blood 
test results with colleagues in the hospital laboratory, with whom he had 
developed a good rapport. Although the Consultant seemed frustrated by 
the amount of administrative work he had to perform in order to ensure the 
smooth running of the department/practice, it became clear that this was a 
particular characteristic of running a thyroid clinic. The lack of support he 
received from other members of staff, both clinical and administrative, drew 
my attention to the status of thyroid disease in the discipline of 
endocrinology more generally. It became clear that although thyroid 
disease was a speciality of the Consultant, it was also an aside to the bulk 
of his everyday work where he attended to more serious and clinically 
interesting diseases such as, diabetes, Addison’s disease, Cushing’s 
disease and hyperparathyroidism. Therefore, the nature of my relationship 
to the Consultant, his relationship with his colleagues and thyroid disease 
more generally, provided an invaluable insight into the field. To be precise, 
it enabled me to conceptualise how the specific aspects of thyroid disease, 
in particular its status as a common chronic disease that is apparently
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‘simple’ and ‘straightforward’ to treat, fitted into the politics of healthcare 
provision within the NHS and the structuring and imperatives of clinical 
research.
In the case of this project, as described above, the process of gaining 
access to the field, although long winded was relatively straightforward. 
However as mentioned previously, on entering the clinic the original focus 
of the project seemed incompatible with what was being observed. What I 
wanted to see was not happening and the clinical and professional 
literature I had read during the previous preparatory year did not seem to 
translate into the clinic in the way I had expected. For instance, there was 
often no mention of the aetiology of the disease, not all the patients had all 
the ‘classic’ symptoms, not all of them received the same treatment and not 
all of them felt well or even unwell at the times they were ‘supposed to’ 
during the course of the disease. It soon became apparent that I had to 
stop trying to write my field notes and think through what was occurring in 
the clinic via my preparatory reading and preconceived theoretical notions. 
By the third visit to the clinic I stopped writing in my notebook; I just sat 
there and watched in order to re-learn thyroid disease within clinical 
practice. After a couple of weeks patterns began to emerge, this included 
the complexities between how the disease is supposed to behave and how 
it does behave from patient to patient. I began to record commonalities, 
such as how the thyroid was examined and how the evidence that led to a 
diagnosis was ordered. Soon these similarities and disparities were 
transformed from a problem to the critical focus of the project. The novelty 
and anxiety of being a non-medical professional also wore off. I soon 
realized that a consultation room within a large teaching hospital was 
always punctuated by the comings and goings of various people: nurses, 
and medical students who were also observing the thyroid clinic. As one of 
many who sat at the back of the consultation room, I soon became 
comfortable and fluent in milieu of the clinic -  the status of ‘doubly marginal’ 
to some extent had been reached.
Due to this new-found understanding into the life of the clinic, the anxiety of 
how to approach patients also subsided. Although in the COREC 
application I had stipulated that I would approach patients via a patient 
information sheet (see appendix 1), when entering the clinic, the logistics of 
presenting them with this document became an issue. The speed of the
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clinic was not conducive to handing patient information sheets before, after 
or during each individual consultation, and besides, during the first couple 
of weeks, my assumptions about how much I knew about the disease had 
been problematised, making me nervous about talking to patients about 
their condition. However, the confidence that had been gained from the few 
short weeks of re-learning, plus the Consultant’s increasing wonderment 
about what I was actually doing there Gust sitting and watching?) soon 
dismissed this anxiety. He suggested that I was sent a copy all of the 
clinical letters sent to the patients after their consultation. That way I could 
select those who I wanted to interview in my own time. Moreover, as 
mentioned briefly above, this collection of clinic letters has also proven to 
be an invaluable archive in and of itself. I now have approximately 250 
clinic letters that refer to the first and follow up appointments of 
approximately 150 patients. These letters not only provided me with the 
contact details of individuals and a means of approaching them for 
interviews, but also, became a resource where another representation of 
thyroid disease could be observed. Often these letters took the form of a 
patient history that detailed how the patients had come to be referred to the 
clinic by their GP, the symptoms that they had reported, the signs that the 
Consultant had observed and consequent diagnosis and treatment 
strategies. These reconstructions of the thyroid disease through the clinic 
letter also enabled me to observe how diagnostic endpoints were reached 
and how the evidence used to diagnose thyroid disease was handled an 
evaluated by clinicians and related to the accounts provided by patients. On 
a more practical level the letters helped me prepare for interviews with 
patients recruited from the clinic as they detailed their history of thyroid 
disease.
The shift in focus of the project from the vaguely genetic aetiology of the 
disease, to the tension between the pre-clinical disease model and the 
clinical process and practices of treating it, became an organising principle 
with regards to the selection of participants for interview. Often in 
consultations where the patients seemed dissatisfied with the diagnosis 
and advice the Consultant offered he would often refer them to me in order 
to discuss this matter further. Specifically, he acknowledged that the 
dissatisfaction of such patients was an issue, but one that he could do 
nothing about as it was something that fell outside of the scope of his 
expertise i.e. these problems could not be accounted for through current
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evidence based diagnostic techniques and clinical practice guidelines. 
However, it also has to be noted that the identification of such dissatisfied 
patients was often highly gendered and the identification of such 
biomedically unsanctioned dissatisfaction was most explicitly performed in 
consultations with women. ‘I can’t help you’ and ‘why don’t you talk to 
Megan who is doing a study on this sort of thing’ underlined this gendering 
as it suggested that there was an alternative a therapeutic strategy where 
women could talk about their feelings, personal interpretations of symptoms 
and illness experience. That is, this strategy was an attempt to manage a 
subjective and emotional category of illness that was considered to be 
secondary and residual to the ‘actual’ manifestation of thyroid disease. In 
addition to the selection of the sample through direction from the 
Consultant, many patients also self-selected due to their dissatisfaction with 
the treatment they had received. Often it was an opportunity for them to 
communicate the tangibility of the symptoms that they attributed to thyroid 
disease, a connection that remained unexplained during clinical their 
consultations. The politics of the selection process of participants for 
interview again informed and helped to build up a picture of the range of 
professional and patient experiences that constitute the characteristics of 
thyroid disease within the contemporary NHS. These factors in addition to 
the higher prevalence of thyroid disease in women and the low response 
rate from men resulted in 19 interviews being conducted with women 
between the ages of 24 and 62 and one was conducted with a 45 year old 
man.
Overall the format of the interviews was fairly consistent. After I sent the 
letter and information sheet to patients they contacted me to arrange a 
meeting at their home or in a cafe, which was usually the preferred option 
because other family members at home could, as one interviewee put it, 
‘get in the way’. The only exception to this was when I interviewed one 
participant in the meeting room at his office because he tended to work 
long hours and it was the only time he was able to see me. All interviews 
were recorded on a digital recorder and then transcribed, these transcripts 
were then sent to the interviewees for approval. None of them wanted any 
passages removed for the transcripts and none of the sample withdrew 
from the study after seeing the transcripts of their interviews. Again 
because of the initial focus of the research, the patient information sheets 
sent to prospective participants described the study as one that was
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investigating ‘how genetic predispositions to autoimmune thyroid conditions 
influence their treatment and management.’ However, as had been the 
case in the clinic, this focus was soon superseded by other issues the 
patients felt were central to their experience of the disease. The style of in- 
depth unstructured interviews that was used with the sample, meant that 
more relevant focal points came to the fore. I started the interview by 
asking patients to tell me their story of thyroid disease - when it had first 
been diagnosed, their symptoms and treatments, how they understood 
where it had come from etc. Perhaps unsurprisingly, those who had taken 
the time to be interviewed had much to say with regards to their experience 
of the disease and often had strong opinions about the causes and politics 
linked to it.
As mentioned previously my understanding of the clinical literature changed 
consistently throughout the course of the data collection process. For 
example, at first I was sure that my focus on the vaguely genetic was 
‘correct’ as there was an established research community looking into 
genetic triggers for thyroid disease. However, the literature review became 
a constant process which evolved in response to the course of the 
fieldwork. Moreover, the on-going process of literature review became one 
that consisted of disregarding particular strands of published research as 
well as including relevant sources. Therefore a data archive that consisted 
of particular published texts, field-notes, patient support group websites 
etc., was collated in response to the twists and turns of being in the field. 
For example, three books were recommended by a patient support group 
website, the Consultant, and a couple of patients,- Thyroid disease: the 
facts by R.I.S Bayliss and W.M.G. Tunbridge (1998), Understanding thyroid 
disorders by Dr Anthony Toft (1995) and Fast facts: Thyroid disorders by 
Gilbert H. Daniels and Colin M. Dayan (2006). These books became my 
handbooks for understanding thyroid disease as they were for those who 
suggested I looked at them.
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Figure 2: Cover of Thyroid disease: the facts 
Figure 3: Cover of Understanding thyroid disorders 
Figure 4: Cover of Fast facts: Thyroid disorders
Other patients who w ere dissatisfied with their treatm ent and disagreed  
with the current guidelines of treating thyroid disease also suggested an 
array of material that supported their point of view. In particular a num ber of 
such patients suggested I looked at Dr Barry Durrant-Peatfield’s book, Your 
Thyroid and How to Keep it Healthy (2006), telling m e that it contained as 
one informant put it ‘everything I needed to know about thyroid d isease’. 
Consequently, the am algam ation of the data archive was not only useful 
because it provided a quantity of data that could be analysed. It was also 
useful because its meandering and som etim es confusing course 
contributed to my grasp of the ambiguity of thyroid disease, a characteristic 
that has becom e a key them e of this study, and that has been used to 
contribute to broader debates about the boundaries of health disease and 
illness in western healthcare contexts.
Handling and structuring data
With reference to the theoretical issue raised at the beginning of this 
chapter, the analysis and write up of the data collected in the field has not 
been approached in a ‘m atter of fact’ style. W ithin anthropology the 
assumption that a researcher can travel to a distant part of the world, find ‘a 
culture’ and after three years of field work com e back with a monograph 
that neatly captures it, now seem s impossible and ridiculous. Not only has 
the distance between us (m oderns) and them  (primitives) shrunk due to 
modernization (Eriksen 2001), but the politics of such a dichotomy has, 
rightfully, been called into question. The geographical and epistemological
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boundaries of culture have been blurred, and the produced nature of 
ethnographic accounts has been bought to the fore. Furthermore, as 
discussed, the assertion that ethnography can claim to be a science is 
problematic due to the subjective nature of the data collection process. The 
implications of the problem of the definition of culture, however, have 
opened up new sites in which ethnographic research can take place. The 
recognition that the distinction between the self and other is problematic 
and that cultures are not whole and subsequently amorphous and complex, 
means that the questions that one can ask about a culture and society are 
relevant both at home and abroad. This is particularly true for social studies 
of science where the traditional ‘culture of no culture’ can be intimately 
explored via qualitative methods. Therefore, whilst there has been 
recognition that ethnographic writing is problematic, this has meant that 
more theoretically informed and rigorous approaches have been developed 
(Marcus 1995,Strathern and Association of Social Anthropologists of the 
Commonwealth. Conference 1995,Marcus and Fischer 1999).
For instance, in the case of this study it could be seen as problematic that I 
am both a researcher and sufferer of a thyroid condition. My position as 
both researcher and to some extent subject could be seen to jeopardise my 
ability to be ‘doubly marginal’, as I may be too much of a ‘native’ of thyroid 
disease to be able to conduct a proper data collection process and 
analysis. However, this problematic concept of the researcher who has 
overstepped the boundary between self and other is, to some extent, an 
obsolete epistemological issue. Underlying this problem is the assumption 
that the researcher can through the correct methodological approach be 
and objective recorder of ethnographic data. However, as has been 
discussed this assumption is highly problematic because of the recognition 
of the politics of objectivity with regards to the inherent production 
embedded in the act of writing an ethnographic account. Therefore, rather 
than dismissing ethnographic accounts as pure works of fiction we should, 
as readers and writers of ethnographic accounts, as Geertz suggests ‘learn 
to read with a more percipient eye’ (1988: 24). In consequence, when 
approaching the field I always kept in mind the factors that would shape the 
account of thyroid conditions I would produce. The complexity of the data I 
collected aided me in being mindful of the forces that would generate the 
account. For instance, having hypothyroidism myself when interviewing 
patients about their symptoms, I often found it relatively easy to understand
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and even empathise with them when talking about the slow onset of thyroid 
disease and the often long list of vague and dissipated symptoms. 
However, this was not the case all of the time, sometimes other sufferers 
experiences clashed with or were unrecognisable to mine. Therefore, the 
recognition that I had to be mindful of the account I produced as both a 
sufferer and ethnographer producing work after the ‘post modern turn’, in 
combination with the complexity and ‘situatedness’ of the data collected, 
helped me overcome this issue.
The inability to produce a clean and straightforward ethnographic account 
of an isolated culture is embedded in the substantive focus of this thesis, 
specifically, the ways in which the meaning and value of evidence is 
grappled with by thyroid patients and clinicians. Form and content, 
therefore, have fundamentally influenced each other with regards to the 
data collected and the representation of the data in the analysis. For 
instance, the disparity between the representation of thyroid disease in the 
clinical literature and the performance of thyroid disease in the clinic has 
been transformed from a narrative that doesn’t quite fit together, into an 
account that can evaluate this tension as part of the epistemological 
tradition of biomedicine, where rational science and irrational culture are 
separated and cast as opposing forces. Subsequently, the first step in the 
data analysis was a comparison of the formal accounts of thyroid disease 
(clinical guidelines, journal articles and text books) and the practices and 
alternative accounts of disease that were demonstrated in the data 
collected from participant observation in the clinic, interviews with patients 
and the consultant who ran the clinic. This process of comparing these data 
sources not only provided critical focus for the research, but also allowed 
for a complex understanding of thyroid disease to emerge.
After the period of data collection had finished, after the field notes made 
during clinical observation and interview transcripts were re-read 
thoroughly, I identified a number of key and recurring themes . Due to the 
relatively small sample size, the data was coded manually and all themes 
were colour coded across the transcripts and field notes so they could be 
easily identified for analysis. Once this had been done, the literature on 
thyroid disease that had been read during the preparatory stages of the 
research project was re-analysed in light of the data that had been 
collected through the period of fieldwork. Additional literature that was
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referred to by the Consultant and patients during clinical observation and 
interviews was also investigated/consulted. The Consultant often bought up 
for example ‘the Colorado disease prevalence study’ (Canaris et al. 2000), 
which is explored in detail in chapter five, and as mentioned previously the 
book Your Thyroid and How to Keep it Healthy (Durrant-Peatfield 2006) 
(also see chapter five) was recommended to me by a patient during an 
interview. By revisiting the formal clinical literature in light of the data 
collected from the clinic a more thorough understanding of the field was 
achieved. This deeper understanding of the field of thyroid literature means 
that the choices I made with regards to what literature would be included in 
the analysis were empirically informed. However, this is not to say that 
literature that did not seem relevant to the practices of the clinic was simply 
cast to one side. In fact the recognition that was made during the analytical 
process about the extent to which formal knowledge about thyroid disease 
clashed with the everyday practices of the thyroid clinic has become a 
central finding of the thesis.
Finding a focus
Throughout the process of conducting a preliminary literature review, 
negotiating access to the field, data collection and analysis, a common 
theme emerged. There is a gap between what is known and what is done 
with regard to the diagnosis, management and treatment of thyroid disease. 
For example, if we return to Lorraine’s method of taking thyroxin, this form 
of ‘self regulation’ is contrary to what her doctor prescribed and what 
clinical practice guidelines suggest. Between planning the research, 
submitting an application for ethical approval, and conducting participant 
observation the focus of the research changed. After the practices of the 
clinic, the Consultant and his patients were observed, the initial focus of the 
research (the impact of genetic pre-dispositions to thyroid disease on 
management of the disease) was absent and therefore seemed 
inappropriate as a focus of study. Moreover, when applying for ethical 
approval it became clear that I would have present my intended research 
methods in such a way that they fulfilled the criteria of contemporary styles 
of clinical ethics, even though this jarred somewhat with my disciplinary 
training and the actual approach that was eventually used.
75
Whilst this gap between ‘knowing’ and ‘doing’ thyroid disease was initially 
disconcerting, it eventually helped to identify and structure the critical focus 
of the thesis. That is, the disconnection between knowing and doing thyroid 
disease in particular, the evidence-based approach to diagnosing it and 
patient experiences of it, came sharply into view. How could these different 
accounts of thyroid disease co-exist in the clinic? What was the impact of 
these obvious disconnections on the actual conditions of thyroid health? In 
particular, how does the qualitative embodied evidence provided by 
patients and the quantitative epidemiological evidence provided by thyroid 
function blood tests relate? What is good evidence and why? How is this 
disconnection overcome if at all? Returning to sentiments presented by 
Weetman, who and how id thyroid disease defined when the experiences of 
patients and the expertise of the medical profession often confound each 
other to such a degree?
In the following chapter an entrance into the phenomena of a sick thyroid is 
provided. An account of thyroid disease will be presented that is a bricolage 
of data sources (participant observation, interviews, clinical and patient 
support group literature and NHS policy documentation), and subsequently 
the key issues that will provide the basis for the following substantive 
chapters will be identified. What will become clear from this analysis is my 
struggle to come to terms with the data -  specifically the often competing 
and contradictory accounts of thyroid biology and pathology it represented 
-  has actually become the focus around which my analysis is structured. 
That is, the ambiguity and frustration that typify much of the data collection 
process and the data collected are embedded in the theoretical arguments 
that are made by this thesis. Consequently, ‘the culture’ of thyroid disease 
is revealed to be constituted by Clifford and Marcus’ ‘contested codes and 
representations’ that are concurrently, poetic, political, scientific, historical 
and linguistic processes. Specifically, it is the relationships between these 
disparate knowledges and practices of thyroid disease that seem to 
constitute it within the context of the contemporary NHS in the United 
Kingdom.
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Chapter 4
Ailing Butterflies: Diagnosing and Normalising Abnormal
Thyroid Function
In this chapter I provide an account of thyroid conditions based on a 
collation and analysis of a range of thyroid literature including clinical texts 
(journal articles, books, conference/consultation transcripts, clinical practice 
guidelines etc.), patient support group materials (websites, newsletters, 
information sheets), participant observation in a NHS thyroid clinic and 
interviews with patients who attended the clinic. From an analysis of this 
‘thyroid archive’ a common theme emerges with regard to the tension 
between pre-clinical knowing thyroid disease and the clinical practices of 
treating it. As will be argued throughout the thesis the formal models of 
thyroid physiology and pathology are constantly negotiated, with varying 
degrees of success, by clinicians and patients during the course of the 
diagnosis and treatment. In particular the evidence used to diagnose and 
treat thyroid disease (symptoms and blood tests) become entities through 
which patients and clinicians justify particular, and sometimes oppositional, 
disease management and treatment strategies. This chapter will describe 
how thyroid disease comes to be known and is performed through formal 
clinical knowledge, clinical practices and patient experiences. Towards the 
end of the chapter the relationships and tensions between these realms are 
highlighted, thus introducing the intellectual focus of the thesis -  how the 
‘natural categories’ of thyroid disease are constituted, maintained, but also 
contested by both clinicans and patients in order to fulfil a range of 
particular needs, rights, responsibilities and desires.
As described in the literature review, within medical sociology and 
anthropology disease is understood to be situated and performed within 
broader social relationships via the production of specialist and professional 
knowledge and practices (Good 1994, Lock and Gordon 1988, lllich 1975, 
Freidson 1988, Armstrong 1983). Countless qualitative studies of health 
and disease (Kaufman 2006, Berg 1998, Crossley Michele 1998, Franklin 
1997, Lock 1988, Martin 1987, Martin 1994, Mol 2002, Rapp 1999b, 
Gibbon 2006, Lambert and Rose 1996a) and social studies of biomedicine
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(Rabinow 1996, Oudshoorn 1990, Canguilhem 1978, Foucault 1976, 
Haraway.Rose 2004, Roberts 2002) have interpreted bodies, pathologies 
and subsequent interventions as political constellations, cultural artefacts 
and social relationships, as well as biological entities. As the ethnographer 
and philosopher, Annemarie Mol, points out in her analysis of 
Atherosclerosis, a disease is not a thing ‘...just by pointing at it, saying 
what it is, where it is, or whether it is, but also by handling it. Acting upon it. 
Transforming it[...]They perform it’ (Mol 2002: 10). Although not an end in 
itself, Mol’s method of analysing a disease as an assemblage of objects 
and practices across a number of contexts is one that has been able to do 
justice to the data collected by this study of thyroid conditions. As will 
become clear throughout the thesis there are a number of different, 
contradictory and contentious versions or orders of thyroid biology and 
pathology favoured by various patient and professional groups, all of which 
appear across a number of textual sources (clinical practice guidelines, 
patient group websites etc.) and practices (prescription of medications, 
interpretations of evidence, dosage compliance etc.). Mol’s approach 
(which will be discussed in more detail in chapter six) is able to track these 
various objects and practices that assemble and crosscut pathologies of 
the thyroid gland and in doing so account for both the biological and social 
dimensions of disease and illness.
This chapter provides a descriptive introduction to the field of thyroid 
disease and then moves on to demonstrate, through the specific example 
of the definition of a goitre11, the significant tensions between how 
symptoms are categorised in formal clinical literature and how they are 
manifest within the clinic. In addition to providing a description of thyroid 
disease this chapter will also address a critical issue that will provide the 
basis for discussion in the remaining chapters of the thesis, namely the 
relationship between established biochemical measures of thyroid 
dysfunction and its ‘classic’ clinical symptoms. The following section will 
introduce the ethnographic location of the research - the NHS out-patients 
thyroid clinic, interviews with patients who attended the clinic and clinical 
and patient support group literature.
11 A goitre is the enlargement of the thyroid gland that can be both a symptom of 
thyroid disease, but also a harmless and common abnormality.
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Entering the clinic
The primary informant of the study was a Consultant Endocrinologist who, 
single-handedly, ran the Thyroid Clinic. He also ran a Thyroid Cancer Clinic 
that was not included as a site of the study. Their General Practitioner 
referred all patients to the Consultant and all were expected to have had a 
Thyroid Function Blood Test (TFT) before the clinic, so the Consultant 
could assess how the gland was functioning.
The hospital where the clinic is held is situated in central London. It has 900 
beds, employs approximately 4,900 people, has a major accident and 
emergency service, and houses all branches of surgery and medicine. An 
associated medical school conducts medical research, much of which is, 
the hospital website claims, ‘of an international standard’. This huge, 
austere hospital is situated at the bottom of a hill, which may account for 
the fog that always seems to collect around it. It is also always damp and 
cold and has at least two sides covered in scaffolding at any one time. 
Inside it is typically an NHS hospital built in the late 1970s - clean, but 
slightly faded.
The Thyroid Clinic takes place on the last three Monday afternoons each 
month (the first Monday of the month is reserved for the Thyroid Cancer 
Clinic). Between the hours of 1.45 and 6pm the Consultant sees an 
average of 16 to 25 patients. Each appointment, although scheduled for ten 
minutes, can last up to thirty and occasionally longer. The Thyroid Clinic is 
situated on the first floor of the hospital and is part of a larger outpatient 
section that covers the lower ground, ground and first floors. For patients, 
access to the Monday afternoon Thyroid Clinic is relatively easy, as this 
busy outpatients area is well sign-posted. The outpatient facilities are 
shared with other clinics, each of which exists within a specific time slot and 
does not begin until the designated receptionist and consultant have 
arrived. Consequently, each receptionist is responsible for, and arrives 
with, the particular notes of those patients who are scheduled to attend the 
clinic that day. When the Thyroid Clinic is prepared, all patients, both new 
and returning, report to reception. After reporting, patients then wait in 
seats that line the long corridor close to the consulting room. The location in 
which the Thyroid Clinic takes place is more temporal than physical, as the 
space is part of the ‘ENT Paediatric Clinic’. All consultation rooms have
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ample provisions for children, with a large play area, a basket of toys and a 
child height-chart on the wall. This location bears no relationship to the 
adult patients who attend the Thyroid Clinic. Moreover, the temporary or 
transitional location of the Clinic itself is notable as it can only function 
when the receptionist and Consultant are present. Any delays to their 
arrival will disrupt the afternoon schedule -  a common occurrence due to 
the seemingly impossible schedule of the Consultant.
The Clinic serves patients at various stages of diagnosis, treatment and 
management for their thyroid condition:
• Patients with disease of the thyroid, as well as ‘abnormal’ but non­
toxic (healthy, normal functioning) swellings of the thyroid gland.
• First-time patients as well as follow-up appointments. (Most patients 
had been referred through their GP Sometimes this was for 
particular confirmation of a diagnosis or delivery of specific 
treatment).
• Patients who have requested to see a consultant for a second 
opinion or further information on their condition.
• Patients who are receiving on-going treatment and monitoring for 
more complex and/or recurring thyroid disease.
• Patients who have other diseases and conditions that might make 
the treatment for thyroid disease more complex and vice versa.
After each consultation, patients were sent a copy of the letter that the 
Consultant sent to their GPs and other clinicians who the patients might 
have been seeing and/or who would aid in any treatment required for their 
disease12. The practice of copying all correspondence between clinicians to 
patients concerning their case was implemented in 2004 in response to 
guidelines suggested in the NHS plan (2004) The rationale for this is:
12 For example, Wendy, a female patient in her fifties, was going to the thyroid 
clinic because she had been rendered hypothyroid by the lithium she was taking 
for her bi-polar disorder. Therefore, copies of her clinic letter were sent to her GP 
and psychiatrist so they were kept informed about her condition.
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The NHS has an obligation to involve patients in decisions 
about their health care and communicate with them. Copying 
letters is an effective way of keeping patients up-to-date with 
their diagnosis and treatment and demonstrates a commitment 
to good communications and valuing patients.(Department of 
Health 2003)
However, this policy aim of involving patients was often not met by this 
practice of copying patients into clinic letters. The data collected during the 
interviews suggested that often these letters were not the most effective 
way of communicating with the patient, as they often did not correlate with 
what they thought or remembered had occurred in the consultation. This 
was due to a number of reasons including the use of clinical terms that they 
had not heard of before and errors in the information, such as their dosage 
of medication, or the list of additional conditions they had (or did not have). 
These details were always listed at the top of the letter along with other 
details, such as date of birth and suspected or confirmed diagnosis (See 
appendix 2 for an example of a clinic letter). In addition, it is important to 
note that these letters were not written with the patient as respondent. They 
were essentially communications between the consultant and his 
colleagues (GPs or other consultants the patient was seeing). Therefore, 
the extent to which patients used these letters as a way of ‘keeping up to 
date’ with their diagnosis and treatment is often questionable. Frequently 
these letters were not used by the patients to piece together their account 
and understanding of their thyroid disease. Other information sources, 
such as their memories of specific comments that the consultant made, or 
particular events where certain symptoms developed, seemed to inform 
their understandings and accounts far more than these letters. Often, at the 
end of interviews, the patients would suddenly remember they had been 
sent these clinic letters and ask if I would like to see them, prefixing the 
offer with, ‘I don’t know how useful they will be though’. Therefore, the 
letters initiated to assist patients often do the reverse. As described above, 
they often emphasise the disconnection between medical ‘facts’ and patient 
realities.
In addition to the clinic letters, if further treatment was required, the 
Consultant would also enclose patient information sheets for various 
therapies being considered by the patients (see appendix 3 and 4 for an 
information leaflet the Consultant would send patients who had been 
diagnosed with hyperthyroidism and hypothyroidism). These seemed to be
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read by the patients as they would often refer to them at their follow up 
consultations. However, acknowledgement of this reading of the 
information was often followed by a ‘but’. Frequently, they still wanted more 
discussion with the Clinician in the clinical context and seemed to favour 
this interaction far more than any other form of information gathering that 
happened outside of ‘clinic time’. Moreover, the interaction during clinic 
time became the most effective way of understanding the conditions, for 
both the patients and myself as researcher. The Consultant’s practice and 
focus on treating the cases presented to him, one by one, person by 
person, became a very useful way of filtering the information about the 
conditions gathered from a bewildering array of websites, books and 
articles. Not only did the irrelevant information get ignored, but also, the 
common and repeated rules and phrases, with regards to explaining and 
treating the conditions, became recognisable. Therefore, this situated 
‘disease talk’ was able to translate and condense vast amounts of 
information about thyroid disease and apply it to the individual case of the 
particular patient.
In preparation for observing the clinic, I read extensively about thyroid 
conditions. The more I read, the less the thyroid conditions were 
recognisable as ‘traditional biomedical diseases’ with clear-cut causes, 
categories of symptoms, and regimes of treatment,. Starting with patient 
support group websites (and their subsequent information packs) and 
moving on to the more technical clinical literature, I began to track and 
decipher recurring words such as ‘subclinical hypothyroidism’, ‘euthyroid’ 
and ‘postpartum thyroiditis’. I became familiar with, and could identify, not 
only a basic aetiology of these diseases, but also complications, times of 
elevated risk for specific groups of patients and contested areas of 
knowledge between specialists. Yet a consolidated understanding of what 
thyroid conditions are continued to fall beyond my grasp. Some of this lack 
I can now identify as the result of reading about a condition as a social 
scientist in a manner that would be considered counter-intuitive by, for 
example, an endocrinologist or clinical biochemist. A lack of basic 
understanding of the biological systems and mechanisms in which the 
disease was located, such as autoimmunity or the endocrine system, 
meant that frequently I had to pause to look up words and define concepts. 
However, this anxiety was also a result of the highly non-specific nature of 
the symptoms of thyroid disease and the difficulty in connecting them to
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objective measurements of disease such as the results of diagnostic blood 
tests. The anxiety caused by such a disjointed account of thyroid disease 
remained until I entered the clinic, and realised this discordance was a key 
characteristic of the condition. As the clinical narratives of the many 
observed consultations eventually became more familiar, it became clear 
that in the everyday practice of treating thyroid conditions only particular 
literatures within the field were useful or relevant in the therapeutic realm.
For instance, and as previously described in chapter three, the genetic 
predisposition to thyroid disease is both well acknowledged, but also, 
peculiarly tangential in relation to the diagnostic practices commonly used 
in the clinic. Research that has attempted to develop an understanding of 
the complicated genetic aetiology of predispositions to autoimmune thyroid 
conditions (Hall and Stanbury 1967, Chistiakov 2005, Tomer et al. 1997, 
Tomer et al. 1999, Tomer et al. 2001) may be of interest to, and understood 
by, a consultant physician in a NHS outpatient clinic, but is not necessarily 
used in the process of developing a diagnosis or treatment. On the 
‘frequently-asked questions’ page of the British Thyroid Foundation website 
the following information is provided with regards to the question of whether 
thyroid conditions are hereditary:
Are thyroid disorders hereditary?
It depends on how you define ‘hereditary’. It is not handed down 
from parent to child in every generation. It is ‘hereditary’ in the 
sense that autoimmune disease in your immediate family or 
predecessor’s means that you have an increased risk of a 
thyroid disorder yourself (The British Thyroid Foundation 2006)
Within a clinical consultation, when the Consultant questions a patient 
about a family history of the disease, it is not only to aid in assessing the 
likelihood of the patient having the condition, but also acts as a way for the 
clinician to work out how familiar the patient is with the condition and what it 
might entail symptomatically and in terms of treatment (i.e. if the patient 
already knew what the condition was through the experience of a family 
member, the clinician tended not to go into as much detail when explaining 
causes and symptoms to them). So whilst a molecular biologist could be 
more specific and demonstrate more specialist knowledge than the ‘sort of 
answer supplied by the British Thyroid Foundation with regards to genetic 
susceptibility towards thyroid conditions, in a clinical environment this detail 
is not particularly useful. First, it does not offer a superior diagnostic tool to
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the standard thyroid function blood test and second, knowledge about the 
disease process at a molecular level does not change or influence the 
available treatments.
Moreover, familial dispositions to thyroid disease were conceptualised by 
patients in yet another way. Often the vagueness of the hereditary nature of 
the predisposition to thyroid disease was made sense of by embedding it in 
specific formulations of kin relationships such as shared physical 
characteristics or personality traits. As Carole explains, her thyroid disease 
makes sense due to the ‘likeness’ to her father’s side of the family:
C: My elder cousin of that side of the family [paternal] he died 
actually, urn but I think he had a problem and also my female 
cousin...they both had thyroid problems like their Mum. It didn’t 
occur to me in a million years I would ever get it [a thyroid 
problem] although I am quite like that side of the family. Tall like 
my father, urn my mother’s side are very short my mother is 4’
10” ...well she is now, she was a bit taller. My Grandmother was 
4’ 10”, she was tiny...minute, so they are quite short, they all 
tend to be short on my Mum’s side.
M: So you feel like you are more like your Dad’s side?
C: Oh yes definitely I am more like him as a person too...
The multiplicity of ways in which knowledge about thyroid disease was 
practiced and understood was also reflected in the ways it was embodied 
across the patient population. For example, some patients complained of 
particular symptoms more than others, some patients complained of 
symptoms even when the evidence provided by blood tests suggested that 
disease was not present and vice versa. The realisation of the concurrent 
interrelation, lack of awareness and ignorance between literatures on, and 
experiences of, the same group of conditions of the thyroid gland proved to 
be crucial in grasping, then selecting what would be included and excluded 
when writing an account of the disease. Moreover, the location, patients 
and professionals with whom I was working fundamentally structured the 
form of this account. The everyday milieu of the clinic, the point at which 
clinical trials and best practice guidelines, for example, are brought into 
practice and mingle with the bodies of thyroid patients in the course of 
treatment, all structured this process of learning and selecting what 
information and knowledge was relevant and when. A process which, as 
described above, is also shared with the Consultant and patients through
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the disease talk they perform in the clinic, where information about thyroid 
disease was selected and filtered and m ade it relevant to individual cases. 
Consequently, this account of thyroid conditions is probably very different 
from the one which would have been written if I had chosen to work with 
the m olecular biologist hoping to understand the genetic aetiology of the 
diseases or in a laboratory with a clinical biochemist who analyses blood 
sam ples in order to diagnose thyroid failure. Therefore, this process of 
learning about thyroid disease confirms M ol’s point that diseases are  
assem blages of situated knowledges and practices that shape the 
boundaries and experiences of particular pathologies.
The thyroid and its diseases
The thyroid gland is described as a butterfly-shaped structure that sits over 
the top of the windpipe in the neck, an association that is not lost on the  
various professional and patient groups who chose a butterfly as their motif. 
The two halves, or wings, that sit either side of the windpipe are called 
lobes (left and right) and the body of the butterfly is called the isthmus., The  
entire structure sits just below the larynx (Bayliss and Tunbridge 1998b: 
1).lt averages approxim ately 20  grams in weight (Toft 1995: 1).
Figure 5: The thyroid gland (W ellcom e Collection) 
Figure 6: Logo of the British Thyroid Association (BTA)
The gland is part of the endocrine system that is responsible for the 
production and distribution of hormones around the body; particular glands 
produce specific hormones in order to facilitate a num ber of different 
functions and processes in cells around the body. As the British Thyroid 
Foundation W ebsite explains in its W h a t is the Thyroid G land?’ section:
The thyroid gland is an endocrine gland. This m eans that it is a 
gland that m anufactures certain hormones, which are chemical 
substances secreted into the blood-stream and act as
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messengers to affect cells and tissues in distant parts of your 
body. (The British Thyroid Foundation 2006)
The endocrine system, its glands and the hormones they secrete are 
commonly conceptualised as a communication system in which messenger 
chemicals or hormones ‘regulate’ and ‘tell cells what to do’ to ensure that 
various processes and conditions are maintained in a state of ‘normal 
function’ within the body. This idiom of hormones as the messengers of a 
regulation system found in the clinical and support group literature is also 
emphasised in the consultant’s account of the thyroid gland to patients 
during their first appointment: ‘so your thyroid gland is told by your pituitary 
gland to produce thyroid hormones...’ The thyroid gland produces thyroid 
hormone thyroxine (T4) and, in much smaller quantities, triodothyronine 
(T3). The role of these hormones is to regulate metabolism, i.e. the speed 
at which cells within the body function. So, if there is too much thyroid 
hormone, the body cells work too fast and if there is not enough, the body 
cells work too slowly. According to Bayliss and Tunbridge in their book 
Thyroid disease: the facts:
For example, the growth and development, both physical and 
mental, of a baby depend upon the presence of the correct 
amount of thyroid hormones. We see this in the animal world 
too. Without thyroxine a tadpole will not change into a frog, and 
without thyroxine in the correct amount, a newborn baby will not 
grow properly, nor will his or her brain develop properly. 
(Bayliss and Tunbridge 1998b: 3)
In other words, in the absence of the ‘correct’ amount of thyroid hormones, 
bodies do not grow or function sufficiently. The specific ‘conversation’ that 
the thyroid gland has is orientated around its relationship to the pituitary 
gland. The pituitary gland, described as a ‘pea sized structure, hanging 
from the under surface of the brain just behind the eyes, and enclosed in a 
bony depression at the base of the skull’ (Bayliss and Tunbridge 1998a: 1), 
sends a hormone called thyroid stimulating hormone (TSH or Thyrotrophin) 
to the thyroid gland which ‘tells’ it to make thyroid hormones (T4 and T3). 
The process of thyroid hormone production consists of the cells of the 
gland combining iodine and the amino acid tyrosine to make T3 and T4. Via 
a process commonly described as negative feedback13 (Daniels and Dyan
13 Negative feedback -  feedback that reduces the output of a system, i.e. the TSH  
reduces or increases the production of thyroid hormones in order to retain normal 
level and subsequently normal function.
86
2006: 10), the am ount of T S H  regulates the level of production of thyroid 
hormones ensuring that there is always the right am ount of ‘fue l’ for 
metabolism to take place. This m echanism of thyroid function dependant on 
the relationship between the pituitary and thyroid gland is called the thyroid 
pituitary axis.
TSH
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Figure 7: Diagram representing the feedback mechanism between the hypothalamus, 
pituitary gland and the thyroid gland (Daniels and Dyan 2006: 11).
Again, in keeping with the regulation idiom that describes the endocrine 
system as a whole, the relationship between the pituitary gland, TSH , 
thyroid gland and thyroid hormones is often described within the patient 
support literature as being ‘like a therm ostat’ (Bayliss and Tunbridge  
1998:5), as the following extract from the British Thyroid Foundation 
website dem onstrates, the pituitary gland is the ‘therm ostat’ for the 
metabolism, or ‘central heating’:
The mechanism is very similar to that which regulates the  
central heating in a house where there is a therm ostat in, say, 
the living room, which is set to a particular tem perature and 
which activates the gas- or oil-fired furnace or boiler that heats 
the hot water. In the case of the thyroid, the ‘therm ostat’ 
consists of a little gland, called the pituitary gland, that lies
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underneath your brain in your skull (The British Thyroid 
Foundation 2006)
T 3  and T 4  are released into the blood-stream and are transported 
throughout the body w here they then perform their role of regulating 
metabolism. W hen this system is functioning normally and producing 
thyroid hormones at an acceptable level, thyroid function is defined as 
being Euthyroid. However, as the following diagram from Fast Fact: Thyroid 
Disorders (2006 ) by professor of medicine Gilbert H. Daniels and clinical 
researcher Colin M. Dayan dem onstrates, the thyroid gland fails when this 
m echanism fails to control the level of production of the thyroid gland.
Euthyroid H yp erthyro id ism Prim ary
hypothyro id ism
See te x t/ 
Table 1.1
O th er
com bination
N orm al
TSH*
TSH and T 4 /T 3  testing
H igh TSH  
and 
low  free T 4
U n d e te c ta b le  
TSH  
and 
h igh  T 4  o r T 3
*or TSH, T 4  and T 3  in difficu lt cases.
Figure 8: Guide to interpreting the results of thyroid function blood tests (Dayan and Daniels 
2006: 13)
As the diagram depicts, when the level of TSH  in the blood is low or 
undetectable and the production of thyroid hormones is high it m eans that 
the thyroid gland is producing too much thyroid hormone. That is, in spite of 
the pituitary gland’s attem pt to stem the production of thyroid hormones by 
reducing the amount of T S H  it releases, the thyroid gland is unable to 
respond and continues to overproduce T4  and T3. As the diagram  
illustrates, this state of increased thyroid function is called hyperthyroidism. 
In contrast, when the level of TSH  is high and the production of thyroid 
hormones is low, thyroid under activity occurs. Again this state is a result of 
the failure of the feedback mechanism. That is, in spite of the pituitary 
gland’s effort to encourage the thyroid gland to produce more T 4  and T3  by 
releasing more TSH  it fails - a state that is term ed hypothyroidism.
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Consequently, thyroid disease can be defined as the disturbance of this 
feedback mechanism resulting in various states of thyroid malfunction.
Such pathological states of thyroid function are identified by the 
presentation of particular signs and symptoms (that will be detailed shortly), 
but primarily through a thyroid function blood test (TFT) that measures the 
level of TSH and thyroid hormones in the blood. Once the levels of these 
hormones in a patient’s blood have been established they are then 
compared to reference ranges that represent the ‘normal’ levels of these 
hormones in a reference population of healthy individuals. As Dr Geoff 
Beckett, a Reader in Clinical Biochemistry at the University of Edinburgh, 
explains in an issue of the British Thyroid Foundation newsletter:
When interpreting blood tests, doctors need to know how a 
patient’s results compare with the range of values found in a 
group of selected individuals who are considered healthy. The 
‘healthy individuals’ are known as the ‘reference 
population’...Once the results of the blood tests in the reference 
population are known, the ‘reference range’ is defined as the 
range of values found in the mid 95% of the reference 
population. Thus a reference range, by definition excludes the 
values for the test found in the 2.5% of normal subjects with the 
highest values and the 2.5% of normal subjects with the lowest 
values. This means that 5% (I person in 20) of the healthy 
(‘normal’ population will have a test result that is either slightly 
above or below the reference range. It also means that if your 
doctor does 20 different test on your blood, there is a very good 
chance indeed that one of these blood tests will be ‘slightly’ 
outside of the reference range (i.e. appear to be abnormal) 
even though you may be perfectly healthy. Note the emphasis 
on the word ‘slightly’. A result that is very much higher or lower 
that the reference range is highly likely to indicate that illness is 
the cause of the abnormal result. Since some ‘normal’ 
individuals are excluded from the reference range the use of the 
term ‘normal range’ is considered to be misleading and 
inappropriate: it is thus no longer used. (Beckett 2003: 5)
Consequently, for people whose TSH, T4 and T3 are ‘very much higher or 
lower’ than the reference range (i.e. beyond the 2.5% found at either end of 
the reference range) thyroid dysfunction is present. Currently, according to 
clinical practice guidelines the reference ranges used to measure thyroid 
function are as follows (Association for Clinical Biochemistry et al. 2005: 
56):
Thyroid stimulating hormone 
(TSH)
0.4-4.5 mU/L
Free T4 (FT4) 9.0 -  25 pmol/L
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Free T3 (FT3) 3.5-7.8 nmol/L
Total T4(TT4) 60-160 nmol/L
Total T3 (TT3) 1.2-2.6 nmol/L
However, in addition to these clearly defined states of thyroid function there 
are also subclinical states that suggest that thyroid dysfunction is: mild, too 
mild to treat at the present time and ‘may occur in the future’. These 
subclinical states of thyroid function occur when the TSH is either too high 
or too low, but the production of thyroid hormones remains within the 
reference range. As the Consultant described in the clinic these subclinical 
states can be described as the thyroid pituitary axis working at ‘full pelt’ to 
maintain the normal function of the gland. Currently, the guidelines state 
that subclinical hypothyroidism should only be treated if the level of TSH is 
greater that 10, consequently TSH that is between 4.5 and 10 mU/L 
although abnormal is considered asymptomatic. Decisions to treat 
subclinical hyperthyroidism, defined as a TSH below 0.4 mU/L, FT4 above 
25 and FT3 above 7.8 pmol/L should be referred to a specialist who should 
investigate the underlying cause of the mild dysfunction and decide on 
treatment accordingly. In the case of both subclinical hypo and 
hyperthyroidism where treatment is deferred it is suggested that thyroid 
function should be tested regularly for life or until it becomes overt. 
However, as will be described throughout the thesis these borderlands of 
thyroid disease are fraught with disagreement and uncertainty. Specifically 
a number of patients and sympathetic clinicians believe that even the 
mildest of these subclinical states do cause symptoms. Consequently 
thyroid function tests and the reference ranges used to interpret the results 
are considered by these groups to be inaccurate. In the following sections 
the various pathological states of thyroid function will be described through 
symptomatic and biochemical categories and treatments for them will be 
detailed. As these descriptions unfold, it will become clear that the rules of 
thyroid disease are often ambiguous, and when situated in relation to the 
experiences of patients and the practices of the clinic, become partially 
incoherent, confusing and even frustrating.
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Disease of the thyroid
Figure 9: Illustration depicting the physical states of the body when an individual is 
hyperthyroid (Bayliss and Tunbridge 1988: 42)
Figure 10: Illustration depicting the physical states of the body when an individual is 
hypothyroid (Bayliss and Tunbridge 1988: 93).
As described in the previous section disturbance of thyroid function falls 
into two functional categories - hyperthyroidism or hypothyroidism. The  
disturbance of thyroid function is attributable to a number of factors, all of 
which differ in significance with regards to diagnosis and treatment. 
Therefore, whilst diseases of the thyroid have a number of causes, in the 
clinic they are generally considered to be of secondary importance, as 
treatment is organised around the restoration of the feedback mechanism  
between the pituitary and the thyroid gland, and not the underlying cause of 
dysfunction. These states of dysfunction will now be described through 
published clinical literature, patient support group information, interviews 
with patients and observations from the thyroid clinic.
Hypothyroidism
Hypothyroidism is described as ‘an insidious condition with significant 
morbidity’ (Association for Clinical Biochemistry et al 2005 : 11) because of 
the wide range of non-specific symptoms that it causes. These include a 
goitre (swelling of the thyroid gland that is not necessarily a symptom of
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dysfunction), weight gain, brittle nails, the loss of the outer third of the
eyebrow, constipation and lethargy, (see appendix 5 for a full list of
symptoms from the patient organisation the British Thyroid Foundation).
However, as clinical experts Daniels and Dayan point out their text book
entitled Fast facts: thyroid disorders, the attribution of these clinical
symptoms alone to thyroid disease is problematic:
Both euthyroid and hypothyroid individuals may complain of 
fatigue, weight gain, dry skin, metal torpor, depression or 
constipation. Muscle cramps, joint pains, menorrhagia or 
infertility may be unrecognized clues to the presence of 
hypothyroidism. Marked obesity, or relentless weight gain, is 
seldom caused by hypothyroidism. The clinical diagnosis of 
hypothyroidism is often unreliable. (Dayan et al. 2002: 74)
In sum, they conclude that the non-specificity of thyroid type symptoms, in 
particular those suffered by women such as menorrhagia (heavy periods) 
or infertility, mean that clinical diagnoses based on symptoms alone is 
unreliable. Moreover, often when patients were describing the onset of their 
disease they were quite explicit about how non-specific and slow moving it 
had been. Their accounts described a lengthy process over months and 
even years during which they developed feeling of not being ‘quite right’, 
Therefore a key characteristic of thyroid disease is its highly ambiguous 
symptomatology. As Alexis, a hypothyroid woman in her early thirties, 
recounts;
And remember thinking, oh I just seem to be putting on weight 
for no apparent reason and I was quite tired, and so I went to St 
Lucia and came back and I just thought oh I must be really 
jetlagged all the time. My friend kept ringing me about 7 o’clock 
at night but I was already asleep. And then she kept saying to 
me what is wrong with you, and I says what do you mean, and 
she said well nobody goes to bed at 7 o’ clock you know there’s 
something wrong with you. And I was like well I guess I’m just 
jetlagged you know, and I think you know, I’d put on quite a bit 
of weight even though I wasn’t really eating anything. And I 
was tired all the time and I kept thinking oh I wonder what it is.
The non-specific aspects of the disease are, therefore, not only reflected in 
the clinical symptoms of the disease but also in the ways in which these 
symptoms become manifest in the everyday lives of the sufferers. 
Moreover, (as Alex demonstrates) they are often hard to identify as 
symptoms because they can also be easily attributable to other factors. For 
example, she describes how she initially thought her lethargy was caused 
by jet lag.
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The causes for the disturbance in thyroid function resulting in under activity 
are typically described in text books as the following:
• Iodine Deficiency -  a deficiency in iodine in the diet which means 
that the thyroid gland has no iodine to convert into thyroid 
hormones. Described as ‘rare in the USA and uncommon in 
Western Europe’ due to public health measure such as fortifying 
mains water supplies with iodine where necessary. (Daniels and 
Dyan 2006: 69) This cause of hypothyroidism was not observed in 
the clinic.
• Iatrogenic Hypothyroidism -  Resulting from a surgical removal on 
the gland due to excessive enlargement or radioiodine treatment 
that is also used to stem over-activity, which will be discussed in 
more detail shortly (Toft 1995: 13). Hypothyroidism can also be 
caused as a side effect of Lithium, used in the treatment of Bi-polar 
disorder and Amiodarone (Toft 1995: 26), a drug used to regulate 
the heartbeat.
• Chronic Autoimmune Thyroiditis -  Most commonly called 
Hashimoto's Thyroiditis after the Japanese clinician who first 
described the auto-immune attack on the gland (Dr. Hakaru 
Hashimoto) and the most common cause for hypothyroidism in 
iodine sufficient regions. The immune system attacks the gland as if 
it were foreign, subsequently destroying it (Bayliss and Tunbridge 
1998: 83)
• Postpartum Thyroiditis -  A variant of Hashimotos Thyroiditis which 
is triggered by pregnancy and diagnosed if the disease occurs up to 
one year after pregnancy. After the first occurrence of postpartum 
thyroiditis there is a 50-75% risk it will reoccur in subsequent 
pregnancies. It is often transient, however, in some cases it is 
persistent, even up to two years after pregnancy (Daniels and Dyan 
2006: 101).
• Thyroid conditions also vary in prevalence according to iodine levels 
in different geographic regions. Therefore, in iodine-replete
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populations such as Western Europe and the USA, where public 
health measures have been used to correct iodine deficiency in diet, 
autoimmune thyroiditis is the most common cause of 
hypothyroidism. Thyroid conditions in iodine replete populations, are 
therefore, described as affecting 2% of the population and as being 
ten times more common in women than men (Daniels and Dyan 
2006: 70).
However, as suggested previously, within the clinic the cause of the 
disease is not the primary location of intervention. As the extract below 
outlines, with reference to Hashimoto’s Thyroiditis, the cause of the disease 
is not a factor that can be addressed in treatment:
We have no safe reliable way of modifying the faulty 
immunological system that mistakenly believes your thyroid 
cells are ‘foreign’. Thus the basic cause of Hashimoto’s 
thyroiditis is untreatable, although the symptoms can be totally 
alleviated. (Bayliss and Tunbridge 1998: 86)
As this passage suggests, the treatment of hypothyroidism is relatively 
simple entailing the administration of synthetic T4 replacement called 
thyroxine, which is a generic preparation and is therefore relatively cheap. 
T3, the other hormone that the thyroid gland produces, is not usually 
offered as part of this replacement therapy as the general consensus 
amongst thyroid specialists is that it offers no additional benefit since it is a 
short acting and unstable hormone (Clyde et al. 2003) (Also appendix 6 for 
see the BTA’s executive committees statement on Armour Thyroid (USP) 
and combined thyroxine/ tri-iodine as Thyroid Hormone replacement, an 
issue that will be discussed in more detail in chapters five and six). This 
treatment regime can be administered at GP level and functions alongside 
biannual TFTs that can monitor any changes in thyroid function and 
subsequently adjust dosage as appropriate. However, many of the patients 
did not experience the treatment of thyroid conditions as a straightforward 
procedure conducted by their GP. As Laura reflects:
...I mean you don’t want to have to take medication if you don’t 
have to do you? Especially if you’ve got to take it for the rest of 
your life. No I’m not happy about it...
Often the consultant would stress that having to take thyroxine was not like 
taking medication for the rest of one’s life. Rather it is a replacement
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therapy that merely ‘tops up’ what the thyroid is no longer able to produce. 
This disparity between the attitude of the clinician and the patients, with 
regards to the straightforwardness or seriousness of the treatment for 
hypothyroidism, is linked to how it is conceptualised -  either as a one off 
medical event or a disease that would have to be managed for life. For the 
clinician it was simply a case of restoring the feedback mechanism by 
topping up hormone production; for the patient it was about taking a pill for 
the rest of one’s life. Therefore, the context in which the disease is 
perceived is fundamental to determining its severity. For patients the 
disease extends into the future; for the clinician it is dealt with in the time 
that it takes to diagnose then correct the levels of TSH and thyroid 
hormones in the blood. As will be described in chapter five, the clashing 
temporalities of thyroid disease presented by some patients and clinicians 
can have a significant impact on the success of and satisfaction with 
established treatment practices.
This discrepancy in the seriousness of hypothyroidism can also be found in 
terms of the expertise that is deemed necessary for its treatment. The 
Consensus Statement for Good Practice and Audit Measures in the 
Management of Hypothyroidism and Hyperthyroidism’ (Vanderpump et al. 
1996) states that hypothyroidism can be sufficiently treated at GP level. 
Referral to a specialist is supposed to depend on the presenting signs and 
symptoms, the expertise of the doctor making the referral, access to a 
specialist, local circumstances and patient preference. All of the 
hypothyroid patients who were referred to see the Consultant were usually 
there for one of two reasons: either their GP. was not sure how to treat and 
diagnose the condition and wanted reassurance from a specialist or the 
patient had asked to see a consultant as a preference. In cases of patient 
preference, the Consultant’s views were sought because the patients 
wanted reassurance or a second opinion. Often these reassurances were 
motivated by what some patients felt to be the discrepancy between their 
self-reporting symptoms and the results of their TFTs. Usually these claims 
were countered by the consultant with the seemingly irrefutable evidence of 
a ‘normal’ blood test result, which is regarded as a definitive marker of the 
absence of disease due to the unreliable nature of the many wide-ranging 
and non-specific symptoms. It is this ambiguity and disagreement between 
the types of evidence (symptomatic and biochemical) that will become the 
critical focus of the essay and attempt to address the central research
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question - how and why the ‘natural categories’ of thyroid disease (thyroid 
physiology and pathology) are constituted, maintained but also, contested 
by both clinicans and patients.
Hyperthyroidism
Hyperthyroidism, is described as having significant short term and long 
term morbidity and occurs in 0.5% of the U.S. and U.K. population (Daniels 
and Dyan 2006:26). Hyperthyroidism describes the presence of disease 
due to excessive production of thyroid hormones by the gland. This results 
in metabolism working too quickly causing disease. Again, the symptoms 
of hyperthyroidism are described as insidious and are non-specific, wide- 
ranging (see appendix 7 for a full list of symptoms from the patient 
organisation the British Thyroid Foundation). And again patients felt these 
symptoms manifest as just ‘not feeling quite right’ over months and even 
years. Many patients described how they realised their bodies and their 
minds were working ‘overtime’, leaving them exhausted and irritable. 
However, they also added that they found it impossible to ‘stop’ -  sit down, 
relax, stop thinking and even sleep. For example within the clinical literature 
these ambiguous symptoms are described as follows:
Tiredness is often an early symptom, to be followed by weight 
loss palpitations or increased awareness of your heartbeat, 
nervousness and particularly irritability so that you have ‘a short 
fuse’ and increased sweating. Looseness of the bowels is not 
uncommon and sometimes diarrhoea maybe a prominent 
symptom...You may feel hot and be uncomfortable in hot 
weather. You may complain that the central heating is set too 
high or throw off the bedclothes at night, yet your partner 
complains that it is not that hot. Your skin may itch but there is 
no rash...(Bayliss and Tunbridge. 1998: 41)
Causes for disturbance to the function of the thyroid gland resulting in 
Hyperthyroidism include the following:
• Toxic Nodular Disease -  A condition where clumps of over-active 
cells develop and render the production of the gland excessive. This 
can be in the form of one or many toxic or ‘hot nodules’. Generally 
toxic nodular disease this accounts for 20% of all cases of 
hyperthyroidism seen in clinics. Solitary toxic nodules can also 
occur, where a single hot nodule of overactive cells cause
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hyperthyroidism, this accounts for 5% of hyperthyroidism. (Daniels 
and Dyan 2006: 119-123)
• HCG - HCG (human chorionic gonadotrophin) is an important 
pregnancy hormone that is secreted at the moment of conception. 
Sometimes this hormone can be overproduced and therefore 
stimulate the thyroid gland in a state of over-activity. As this 
condition is transient (i.e. only occurs during the early stages of 
pregnancy), it usually requires no treatment (Daniels and Dyan 
2006: 96). Often called gestational hyperthyroidism, this was not 
observed in the clinic.
• Iodine Induced Thyroxtoxicosis -  Another iatrogenic cause for 
thyroid dysfunction. Pharmacological doses of iodine, found in 
various medications can cause excessive production in the gland 
(Daniels and Dyan 2006: 29).
• Graves Disease -  The most common cause for hyperthyroidism is 
Graves Disease - an autoimmune condition like Hashimoto’s 
disease, where the gland is stimulated by antibodies of the immune 
system into over-production. This disease made up the majority of 
hyperthyroid patients seen in the clinic.
As with Hypothyroidism, the most common cause of Hyperthyroidism is an 
auto-immune condition called Graves Disease, which is named after the 
Irish physician, Robert Graves, who first described the symptoms in detail 
over 200 years ago (Toft 1995: 5). Also, as with Hashimoto’s Thyroiditis, 
Graves Disease is an auto-immune disorder that is considered to be 
familial. However, in contrast, the thyroid ‘stimulating’ antibodies 
encourages the gland to over-produce thyroid hormones, instead of under 
produce as is the case with hypothyroidism. There is evidence to suggest 
that the onset of Graves Disease can be partially attributed to traumatic life 
events, commonly 1 to 2 years before the onset of the disease (Paunkovic 
et al. 1998)14 and smoking. Again it is more common in women than men,
14 This study demonstrated that Graves disease increased significantly during the 
Bosnian War (1992 -  1995) suggesting that Graves disease could often be 
triggered by extreme stress
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but, although, the proportion of male sufferers is higher in comparison to 
hypothyroidism.
In addition to the disturbance of thyroid function, a possible complication of 
Graves D isease is a related eye condition that is also caused by the auto­
immune disease m echanism. In most cases of hyperthyroidism, there are  
som e optical symptoms. A  recognised symptom of the disease is lid 
retraction, w here the upper eyelids are pulled upwards exposing the whites 
of the eyes resulting in a ‘staring quality, like that of an actress when she 
wishes to convey an expression of anxiety or terror’ (Bayliss and Tunbridge  
1998: 63). In addition, lid-lag can occur where the lids are slow to follow the  
m ovem ents of the eye.
However, for patients with Graves Disease, the most common cause of 
Hyperthyroidism, there is, in addition, more specific eye involvement. A  
secondary, yet often related auto-im m une attack m ay occur, which targets  
the muscle tissues that move the eyes. This attack can happen  
independently of Graves D isease or often months or years after, or even  
before its onset. However, it is more common as a related occurrence of 
Graves Disease, and is thought to be the result of a cross reaction between  
the thyroid antibodies and similar antibodies found in the tissue around the 
eyes (Daniels 2006: 39). Approximately 10-20%  of patients with G raves will 
develop eye disease, 5%  of which will be severe cases. The condition is 
more common in men and smokers when com pared with the Graves  
Disease population generally.
Figure 11: A  photograph of the eyes of a patient with Graves disease (W ellcom e Collection)
In cases of auto-im m une eye disease, the eyes are pushed forward due to 
the inflammation of the muscles, becoming puffy and watery due to 
impaired drainage. They feel gritty and sore and are more prone to infection 
as they are less protected by the swollen eyelids. Their m ovem ent 
becom es laboured due to the impairment of the muscles. This muscle
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impairment results in double vision and the increased pressure in this area, 
due to the inflammation, which in some cases can result in restriction of the 
optic nerve that may subsequently mean that eyesight is threatened. Many 
patients with these symptoms also felt that the disease was particularly 
upsetting due to the extreme change to their appearance. As Diane, a 
Grave’s disease patient in her early fifties with extensive eye involvement, 
explains, she ‘feels like a monster’ and ‘feels like people are looking at her 
all the time’.
Treatment for Hyperthyroidism is more complex and must be overseen by a 
consultant in a hospital. Once diagnosed, the first stage of treatment is the 
administration of a drug, most commonly Carbimizole, to suppress the 
activity of the gland. The dosage of this therapy is imperative; if it is too 
high it will cause hypothyroidism and if too low it will not relieve symptoms. 
In order to reach this balance, the dosage of Carbimizole is titrated against 
TFTs (every 4 to 6 weeks) until they eventually enter the normal range and 
a maintenance level has been reached. When this level has been reached, 
TFTs on this dose will be performed every three months. However, this 
treatment is not permanent and will not stop the disease for good, 
something that the consultant made very clear to the patients after they had 
reached a stable maintenance dose. Consequently, in order to overcome 
the disease for good a ‘definitive treatment’ that could halt the over-activity 
of the gland permanently was offered. Traditionally this consisted of the 
removal of the gland through surgery (thyroidectomy), but this is now 
considered to be an out of date and unnecessarily invasive method. 
Currently the preferred treatment is Radioiodine Therapy (Rl) that halts 
Graves Disease, the activity of ‘single hot thyroid nodules’ and ‘multi- 
nodular toxic goitres’ for good. Briefly, Rl is administered through the 
hospital’s Nuclear Medicine department and consists of the patient 
swallowing a radioactive capsule from which radioactive iodine will be taken 
up by the thyroid gland. This, in turn, destroys the tissue of the gland; either 
minimizing its production of thyroid hormones or stopping it functioning all 
together. In some cases, if the hyperthyroidism is severe, more than one 
dose of Rl will be required.
Patients who were undergoing this treatment were required to stop taking 
their Carbimizole a week before their Rl treatment. In addition, patients with 
Thyroid Eye Disease (TED) must take a steroid to protect their eyes, as the
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antibodies found in their gland are also found in their eyes, and could, 
therefore, destroy tissue in that area. The treatment itself is administered 
during an out-patients appointment in the department of Nuclear Medicine -  
a branch of medicine and medical imaging that uses radioactive 
substances in diagnosis and therapy. After this treatment has been 
administered that patient can return home, but they must stay away from 
children under 12 and generally avoid contact with large groups for up to 
two weeks. This part of the treatment, unsurprisingly, was described by 
many of the patients as incredibly upsetting and difficult, especially for 
those who had young children or grandchildren who they had to avoid. One 
woman who underwent the treatment described having the Rl pill, which 
was contained in a sealed glass tube, passed across a table by a 
radiologist who quickly exited the room before she swallowed it. Another 
woman recounted that on leaving the hospital after swallowing the Rl pill 
how her husband jogged in front of her in order to maintain a safe distance!
Post Rl patients require life-long follow up to identify development of 
Hypothyroidism which is the inevitable consequence of ‘knocking the 
thyroid out’, as the consultant described it. Once post-RI patients become 
hypothyroid they will then be placed on a life-long regimen of thyroxine. Not 
surprisingly, many patients found the suggestion of this treatment quite 
shocking. Firstly, because of the danger associated with being fed a 
radioactive capsule, and secondly, because of the outcome of becoming 
hypothyroid and having to take thyroxine for life. In the clinic, I listened to 
many occasions when the Consultant attempted to convince patients with 
Hyperthyroidism taking Carbimizole to opt for Rl, often using the argument 
that Carbimizole was not a definitive treatment and would not get rid of the 
disease and any subsequent degeneration. In terms of being rendered 
hypothyroid by the Rl, the Consultant often used the argument that the 
patient’s body could have attacked the thyroid, either making it 
Hyperthyroid or Hypothyroid. He would then argue that if the immune 
system had destroyed, and not stimulated, the gland they would be taking 
thyroxine anyway. Again, many post-RI patients on thyroxine complained of 
the persistence of symptoms, in spite of their medication.
Through this description of thyroid disease it has become clear that there is 
often a disparity between the formal explanations of and experiences and 
practices of thyroid disease. For instance, as has been described, the
100
biochemical model used as the basis for the diagnosis and treatment of 
thyroid disease often does not relate to the slow onset of the many vague 
clinical symptoms of thyroid disease. Subsequently, as has also been 
described, many patients found it difficult to relate to and accept the 
diagnoses and treatments that were offered on the basis of this rigid 
biochemical model. For example, correction of hypothyroidism and 
hyperthyroidism by ‘simply restoring’ the feedback mechanism between the 
pituitary and the thyroid gland was often questioned by patients. For many, 
the invasiveness of such treatments (Rl and/ or thyroxine for life) seemed 
to be ignored by the straightforward approach of clinicians who focused 
their treatments around the restoration of a euthyroid state of the thyroid 
pituitary axis. Therefore, as claimed at the beginning of the chapter, in the 
process of diagnosing and treating thyroid disease, the basic model of 
thyroid biology and pathology seem partial and unable to account for the 
complexity of the disease, specifically the relationship between the thyroid 
pituitary axis and the non-specific clinical symptoms attributed to thyroid 
disease. In the following section of this chapter the contingent nature of ‘the 
facts’ of thyroid disease will be discussed with regards to a classic clinical 
symptom -  a goitre. Through this discussion it will be further demonstrated 
that in the clinic there is a constant slippage between ideal models of 
thyroid disease and the practices used to attend to it as well as patient 
experiences of it.
Normal abnormality
As well as diseases that interrupted ‘normal’ thyroid function, a substantial 
number of patients presented abnormalities of the gland where no disease 
was present. Typically, these patients presented thyroid enlargement or 
lumps in the thyroid gland called goitres. As the textbook explanation below 
confirms, goitres are highly ambiguous entities:
Many disorders of the thyroid gland may make it bigger. The 
enlargement may be associated with a normal output of thyroid 
hormones, and the patient is then said to be euthyroid. The 
goitre may be associated with an increased secretion of thyroid 
hormone, and the patient is then said to be hyperthyroid. Or it 
may be associated with decreased deficient output and the 
patient is then hypothyroid. From this you will see that the size 
of the thyroid gland bears little relationship to its secretory 
activity or function (Bayliss and Tunbridge 1998:10)
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Generally, patients who presented no symptoms other than a swollen and 
lumpy thyroid were not considered to be suffering form any underlying 
clinical disease and subsequently required no treatment after they had 
been investigated to rule out ‘anything sinister’ (i.e. thyroid cancer), as the 
consultant tended to phrase it.
The examinations of all patients with a goitre, for whatever reason, followed 
a simple protocol. Firstly a physical examination of the gland would occur. 
For this the Consultant stood behind the sitting patient and reached round 
to the front of the lower part of the neck, locating the gland. The Consultant 
would then gently feel and press the gland to determine the form and size 
of the swelling or the number and size of any individual nodules. The 
consultant would then ask the patient to swallow, in order to further 
ascertain the size and positioning of the goitre. Sometimes he would 
comment on how the patient had a ‘nice slim neck’ making the goitre easy 
to see. However, most of the time this physical examination was necessary 
in order to ‘see’ the swelling more clearly and confirm the contours of the 
enlarged gland. Frequently, patients had not realised they had a swelling, 
and sometimes it was a relative or their GP who had first noticed it.
Palpation occurred in all the first consultations with patients and any follow- 
up appointments where the swelling was suspicious or was not clearly a 
side effect of thyroid dysfunction (hyperthyroidism or hypothyroidism) in 
order to monitor changes in a suspicious lump. During one consultation, 
where two medical students were present, the consultant encouraged them 
to take turns in ‘seeing’ the lump through this examination protocol. Telling 
them to ignore the books, where it was suggested to stand in front of the 
patients, the consultant advised them to make sure they always asked the 
patients to swallow and asked them questions, such as, ‘is the swelling 
smooth or nodular?’ or ‘how many lumps can you identify on the left and 
right side and which, if any, is the biggest?’
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Figure 12: A simple non-toxic diffuse goitre (W ellcom e Collection)
Figure 13: A multinodular goitre (W ellcom e Collection)
Often, in individuals from non-iodine replete countries, thyroid swelling 
occurs due to an attempt by the gland to increase its manufacturing 
capacity of thyroid hormones. This process is explained in the following 
case history taken from ‘Understanding Thyroid D isorders’ by Dr Anthony 
Toft a Consultant Physician and Endocrinologist and form er President of 
the British Thyroid Association (BTA):
Ahm ed was born in a village in the high mountains of northern 
Pakistan where he spent most of his childhood. At the age of 20  
he cam e to London to study engineering when, at a routine 
medical examination, he was noticed to have a goitre. He felt 
well and his thyroid tests were normal. The cause of the goitre 
was attributed to an iodine deficiency when Ahm ed told the 
doctor that most of the people in his village also had a goitre.
His diet had contained enough iodine to prevent the 
developm ent of Hypothyroidism, but his goitre is likely to 
remain, even though he has decided to live the rest of his life in 
a part of the world where there is an adequate am ount of iodine 
in his diet (1995: 4)
In the clinic being observed by this study, Ahm ed appeared in m any guises, 
as this case history was applicable to a num ber of patients both male and 
fem ale who w ere not of British origin. There was a middle-aged woman  
from Eritrea, a thirty year old man from Ethiopia and an elderly lady from  
Poland. In fact, the Clinician often explained the swelling to these patients 
as something that is common for people from certain parts of the world 
where the iodine in the w ater was low, adding that it was also significantly 
more common for those who lived in these environments until ‘around the 
age of tw elve’.
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Within medical literature, iodine deficiency is attributed to the consumption 
of produce in locations where the soil has low iodine content such as 
mountainous areas, hence the origin of Toft’s archetypal Ahmed in the 
‘mountains of northern Pakistan’. Areas in which the diet contains anti­
thyroid or goitre-producing substances (goitrogens15) also have a high 
prevalence of goitres in the population. In areas such as these, goitres are 
found in more than 20% of the population and are therefore considered 
endemic -  a ‘natural’ characteristic of the people of the region. Where 
goitres are endemic there is also usually the addition of one major socio­
economic causal factor - iodine deficiency and subsequent thyroid swelling 
which is the result of malnutrition. In fact, it is believed that 500 million of 
the world’s population have goitres, the majority of whom live in developing 
countries. This tends not to be thought of as a causal factor in the U.K. as it 
is considered to be an iodine-replete community, where malnutrition is 
uncommon. When iodine deficiency is discussed epidemiologically within 
various literatures, with regard to Western Europe, it is described as mild 
and specific to lowland areas and/or those situated far from the ocean. For 
instance, in the U.K. a goitre is traditionally known as ‘Derbyshire Neck’ 
(Bayliss and Tunbridge 1998:115) as it used to be a common feature of the 
population in the county due to the low local iodine levels, before corrective 
public health measures were taken to fortify salt and bread with iodine. 
Thus, in contemporary literature directed at the investigation of the goitre in 
iodine replete communities another explanation is offered. Where no 
disease is present, the development of a goitre is attributed to unknown yet 
‘complex reasons’ (Toft 1995: 35) - a common abnormality that happens to 
a substantial proportion of the population. The ‘normality’ of a goitre is 
something that much of the literature is quick to point out. For example;
It isn’t normally a problem appearance wise - quite the opposite 
as far as some people are concerned. For example, the great 
seventeeth and eighteenth century artists often added a goitre 
to the female figure to enhance her beauty! (Toft 1995: 36)
The correct term for a goitre that is the result of a uniform swelling of the 
gland is a Simple Non-Toxic Diffuse Goitre. Simple implies that the gland is
15 Goitrogens are foods such as those of the brassica variety (broccoli, kale, 
cabbage), or even milk from cattle fed on such foods, that can suppress the 
function of the thyroid gland by interfering with the synthesis of thyroid hormones. 
As Bayliss and Tunbridge (1998) note goitres are common in some parts of Africa 
where cassava (a woody shrub and goitrogen) root is a staple food. It is also a 
staple in parts of South America, India and Indonesia.
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uniformly enlarged, not hard and benign, Non-toxic implies that it shows no 
signs of a disease causing autoimmune process (Graves Disease or 
Hashimoto’s Thyroiditis) and Goitre simply means enlargement. As 
consultant endocrinologists Bayliss and Tunbridge state in their book 
Thyroid Disease: The Facts, a ‘Simple Non-toxic Diffuse Goitre’ is a ‘time 
honoured clinical description of a certain type of goitre’ yet there is ‘nothing 
simple about a simple non-toxic goitre!’ (Bayliss 1998: 111) i.e. where no 
disease or environmental factors are present a goitre is an unexplained and 
complex phenomena of the thyroid gland.
Therefore, in a clinical context, whilst goitres are defined as an abnormality 
of ‘normal thyroid physiology’, without the accompaniment of symptoms or 
abnormal thyroid function blood tests, they tend to be left alone. The only 
exception to this process of diagnosing a goitre as a ‘safe abnormality’ is if 
it enlarges too much. Sometimes this benign process can result in the need 
for treatment, as goitres can become so large they put pressure on the 
windpipe, or become involved with surrounding nerves or the vocal cords, 
resulting in a ‘hoarse voice’. In cases such as this, the thyroid is surgically 
removed (a thyroidectomy) resulting in the necessity of thyroxine therapy 
for life in order for the patient to substitute thyroid manufacture lost by the 
elimination of the gland. However, this level of enlargement is rare and 
tends to be reserved for extreme cases where, as was the case with one 
woman who had visited the clinic, there was ‘retrosternal extension [growth 
down behind the breast bone] and severe tracheal compression’ (extract 
from clinic letter to the general surgeon who would perform the total 
thyroidectomy).
Figure 14: An x-ray of a retrosternal extension. (Wellcome Collection)
Over time, Simple Non-toxic Diffuse Goitres may become smaller, or larger, 
or more irregular and eventually develop nodules and become a multi- 
nodular goitre. Often, the Consultant would tell patients with this 
presentation that this sort of thing can ‘just happen’, the thyroid gland ‘is
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like breast tissue, it can change and get lumpy’, the thyroid can simply swell 
in this manner ‘out of the blue’. This nodular pattern of enlargement, as well 
as being a symptom of the aforementioned endemic and unexplained 
thyroid swelling, is also symptomatic of ‘hot nodules’ which, as described 
earlier, cause hyperthyroidism. Because of the stronger association 
between disease and multi-nodular goitres, hot nodules tend to fall under a 
regime of long-term surveillance rather than a one-off diagnosis of 
harmless enlargement of the gland.
When these types of swellings appeared in the Clinic, the patients were 
usually sent to undergo an ultrasound scan to ascertain the number and 
size of the nodules. In cases where there was a large, fast growing or 
unequal distribution of nodules between the lobes of the thyroid, a Fine 
Needle Aspiration (FNA) test was performed. This test consists of a needle 
being passed into the nodules in order to remove cells for analysis, and 
ascertain the cytology of the nodule - benign or malignant. The likelihood of 
thyroid cancer was explained by the Consultant as one-in-twenty and 
throughout the literature is defined as extremely rare:
Compared with the incidence of malignant disease elsewhere in 
the body, thyroid cancer is responsible for less than 0.5 per 
cent of all deaths from cancer. Thus thyroid cancer is rare 
(Bayliss and Tunbridge 1998: 127).
Moreover, as the following extract demonstrates, much of the literature is 
concerned with drawing attention to the rarity of thyroid cancer rather than, 
for example, encouraging self examination for it:
Although people who develop thyroid nodules often worry that 
the lump may be cancer, this rarely turns out to be the case.
(Toft 1995: 43)
Often, FNA tests came back inconclusive and were performed again, as too 
much blood and not enough cells were collected, so no ‘definitive cytology’ 
could be decided upon. On these occasions, the Consultant would refer 
patients to a Radiologist at a neighbouring hospital (but belonging to the 
same Trust) whose expertise with this type of test was highly regarded, 
especially if the nodules were in ‘awkward places’. Much of the work done 
by the Consultant in these cases was to reassure the patients that the 
lumps were not sinister. For instance, in a follow up letter to one patient’s
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GP the Consultant wrote that ‘For reassurance I have organised for her to 
have an ultrasound scan plus FNA to obtain a definitive cytology’. Many 
goitres are, therefore, defined not only by how they look and feel, but also 
by how they are not a symptom of any underlying disease; being instead a 
‘common’ and ‘benign’ ‘abnormality’.
Many patients who passed through the clinic had various lumps and bumps 
double-checked and monitored and after investigation, were reassured they 
posed no threat to their health. They could live with them quite normally. 
After their lumps had been investigated and deemed safe, these patients 
tended to be discharged from the clinic after two appointments. Typically, 
the Consultant would reassure them at the end of the process that they 
were more than welcome to return to the clinic if they felt their thyroids had 
got bigger and had begun to cause problems. However, the idea of a lump 
that would be left alone was often unacceptable and confusing for some 
patients, as they were often not quite convinced of the safety of leaving 
such abnormalities. They often asked the Consultant, after he had 
delivered his assessment, if he ‘was sure’ about leaving their lump or goitre 
alone. In addition, some patients wanted their goitres removed for 
cosmetic, as well as what they (and not the clinician) perceived as health, 
reasons. One woman, who was referred to the clinic with a thyroid 
swelling, wanted to discuss the option with the consultant of being given 
replacement thyroid hormone (thyroxine) to shrink her goitre, which she felt 
had been steadily getting bigger over a number of years. The consultant 
quickly responded saying there was no evidence that this worked at all and 
was an unnecessary treatment. He also added, after an examination of her 
neck, that she was like a number of women who tended to lay a fat pad on 
their neck, which in her case made her goitre look bigger than it actually 
was. In the follow up letter to this patient and her GP the Consultant added 
that there is no family history or documented thyroid dysfunction, surmising 
that:
In these circumstances I think it highly unlikely that any therapy 
will make any major cosmetic difference to her and I did not 
think it was warranted. I reassured her that all was well and 
certainly there was nothing in the clinical picture here to 
suggest any sinister aetiology and I have been as reassuring as 
possible. She will continue to have an annual check of thyroid 
function from now on. So the existence of a goitre can clinically 
mean a number of things - the presence of a number of
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diseases that disturb thyroid function, as well as ‘normal’ and 
‘non-pathological’ abnormality.
What is thyroid disease?
As I have argued in this chapter, when thyroid conditions are described 
through specialist and professional texts, patient support group literature, 
observations of clinical practice and patient accounts, they lose their shape 
and are difficult to see as the result of a straightforward pathological 
process. In exploring these representations and analysing them here, I 
have deliberately pointed to their indeterminacy as a means of emphasising 
what I perceived as a strong common thread throughout both the literature I 
read and the conversations I observed and participated in; namely that to 
understand thyroid conditions and the experiences of people who suffer 
from thyroid conditions it is necessary to acknowledge, and even to 
prioritise, the substantial grey areas that prevent easy distinctions between 
normal and abnormal, diseased vs healthy, euthyroid/hyperthyroid, 
euthyroid/hypothyroid and knowledge/practice. As I have tried to show, the 
experience of the disease shared by most patients of ‘not feeling quite right’ 
due to the array of non-specific symptoms they suffer from over months, 
weeks and even years, means that their understanding of the disease is 
overwhelmingly ambiguous. Repeatedly in interviews it was impossible for 
the patients to decide when they first started feeling the symptoms of their 
thyroid dysfunction. Moreover, it was difficult to decide if these ‘symptoms’, 
even after diagnosis had been confirmed, were a result of the thyroid 
disease or just life in general -  work, childcare, aging, stress, diet, 
relationships, etc. Amidst this fog of symptomatology, a key area of 
ambiguity that often caused confusion and sometimes even anger in the 
clinic, was the essential, but often opaque, relationship between the 
function of the thyroid pituitary axis, measured by TFTs, and the clinical 
signs and symptoms with which these levels were assumed to be 
correlated. Due to their non-specifity signs and symptoms are considered 
by clinicians to be unreliable forms of evidence that cannot be directly 
attributed to a pathological state of thyroid function. That is, the symptoms 
of thyroid dysfunction are often considered to inhabit the realm of illness, 
and are therefore considered to be social and subjective (Turner 1996:198) 
indicators of disease that are not based on scientific fact - what is ‘actually 
going on’ in an individual’s thyroid gland.
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However, and to the dismay of patients and clinicians alike, the difficulties 
of diagnosing vague and incoherent thyroid symptoms actually seems to be 
escalated by the practical responses deployed to treat it. The 
transformation of vague thyroid symptoms into laboratory-based 
biochemical measures is so disconnected from its symptomatic 
presentation that its clinical diagnosis often contributes to the disjointed and 
awkward narrative of thyroid biology and pathology, rather than alleviating 
it. Although clinical texts and medical experts can accept the vagaries of 
the disease when elucidating its symptomatic presentation, they cannot 
easily translate this understanding when explaining and delivering 
treatment to patients, especially within the narrow and rigid biochemical 
idiom that defines current treatment procedures. Descriptions of disease in 
the clinic, in textbooks and in patient support group literature are effective in 
linking the often bizarre list of symptoms together to create a realistic 
account of what it feels like to have a thyroid disease. However, when the 
business of treatment needs to be attended to, this complexity is lost and 
symptomatic ambiguity is abandoned. Indeed, as will be discussed in the 
following chapters, some clinical symptoms are entirely ignored as factors 
relevant to the decision as to whether treatment is required or has been 
successful. As a consequence many patients are left distressed, confused 
and even angry due to a high degree of ‘existential uncertainty’ that such a 
paradigm of clinical care produces. To be precise, the technical and 
explanatory deficiency of TFTs to account for thyroid disease in some 
patients compounds and amplifies the feelings of uncertainty that are 
already inherent to the state of being ill.
As the sociologist Christopher Adamson notes with regards to his study and 
personal experience of Bowel Disease and Avascular Necrosis (1997) we 
most commonly and intensely experience uncertainty during periods of 
illness. As Adamson goes on to describe patients, in collaboration with 
medical professionals, perform a number of tasks related to diagnosis and 
treatment and in doing so confront a range of uncertainties. For instance: 
those associated with the disease course, diagnosis, prognosis and 
treatment, the competence of medical personnel and continuity of care. In 
the case of thyroid disease where there is a high degree of epistemological 
uncertainty with regards to pathological, symptomatic and diagnostic 
categories and practices such existential uncertainty is amplified. As a
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consequence, as the presentation of data throughout this chapter has 
demonstrated, it is the high degree of existential and epistemological 
uncertainty that characterises the manifestation of thyroid disease is within 
the context of the contemporary NHS.
Moreover such epistemological existential and clinical uncertainty is not 
merely of interest because it demonstrates a disconnection between 
specialist knowledge of disease, embodied experiences and clinical 
practice. It is also significant because it index factors that are beyond the 
specific location of the thyroid clinic and the experience of being a thyroid 
patient. For example, I often interpreted the Consultant’s retreat into an 
overtly mechanical mode of delivering treatment as a response to the way 
in which patients perceived his specialist knowledge and professional role, 
as well as their own status as sufferers. When a patient entered the clinic 
asking for particular diagnostic techniques or treatments for his or her 
condition that they had read about on the internet the Consultant’s face 
would often glaze over. This response could be attributed to the patients 
asking for treatments and medications that were simply not available 
through the NHS, but also, perhaps, to his feeling that if that is what they 
really wanted there was ‘no point in him being there’. I.e. if they wanted to 
indulge in treatments for which, in his opinion, there was no sound 
evidential base, such as dietary measures or herbal remedies, what was 
the point in him taking the time to treat them otherwise? Whilst this opinion 
could be negatively construed as a medical professional protecting his 
bruised ego, it was also apparent that this view was embedded in the 
pressures on NHS resource allocation and a prevailing ethos of 
professional medical care. From the point of view of resource allocation, 
time and efficiency are at a premium, leaving little time to discuss the many 
theories about the diagnosis and treatment generated by a Google search 
on the Internet. There is also the associated quandary of the extent to 
which clinicians should listen to patients and take their views and opinions 
on board, but also, how far to ‘go along with’ patients’ attempts at self- 
diagnosis and treatment derived from often unreliable and conflicting 
Internet sources.
Often the Consultant’s sighs of disbelief at the demands of the patients 
were expressed in the brief periods between patients during the tightly 
packed appointment schedules that were a routine feature of the over
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stretched and under staffed clinic, where there was simply no time to 
discuss unsubstantiated and biomedically speculative theories. In addition, 
some patients seemed to reproach the Consultant in response to his frosty 
reception of their preferences for treatment, assuming that he was 
behaving in this way because he was too narrow-minded in the methods he 
employed in treatment of thyroid disorders. This clash of professional and 
lay biomedical models would often mask another key reason for the 
Consultant’s dogmatism with regards to the treatment algorithm. He didn’t 
entertain some treatments because he believed, and in some cases had 
seen, how these other methods could make patients unwell. For example, a 
number of patients attending the clinic were doing so because they were 
being treated for hyperthyroidism due to the over administration of thyroid 
replacement therapy, by either themselves or other clinicians16.
As I have suggested, the conflicts that are manifest within the experience, 
diagnosis and treatment of thyroid conditions, in particular the existential 
uncertainty wrought by current explanatory models of thyroid biology and 
pathology, bring into relief broader practical issues with regards to current 
health care policy within the U.K. The Patient Choice Initiative that 
encourages patients to become informed about their health and healthcare 
and the Evidence Based Medicine (EBM) movement that believes that 
clinical decisions and interventions should primarily be based on the best 
available published scientific literature, are both implicated in the conflicts 
over the diagnosis and treatment of thyroid disease. On the one hand, 
within the context of the NHS there is the aim to encourage patients or 
‘health care users’ to become more interested and involved in the 
management of their disease. However, the biochemical model of thyroid 
function that is currently used to diagnose thyroid disease, often does not 
represent how patients embody and experience their thyroid disease 
though clinical symptoms. Therefore, on the other hand, evidence based
16 There were at least five occasions observed in the clinic where patients had 
been referred to the consultant because they had become hyperthyroid due to the 
over-prescription of thyroid replacement. Often these cases of iatrogenic 
hyperthyroidism were a result of private clinicians, who questioned the accuracy of 
TFTs, prescribing on the basis of the alleviation of symptoms, hence sometimes 
increasing thyroid function into the realm of hyperthyroidism. Sometimes patients 
actively sought to have this over prescription corrected through their GP and the 
Consultant as they felt unwell. However on other occasions these patients were 
sent to the Consultant by GPs so he could convince them to stop taking so much 
thyroid replacement due to threat of various long term health risks even though 
they found hyperthyroidism a desirable state due to the energy it gave them and 
weight loss it resulted in.
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diagnostic and treatment strategies, embodied by TFTs, mean that such 
patients are often alienated from the clinical care they receive and thus 
cannot overcome the existential uncertainty the state of thyroid related 
illness brings with it.
As Rose and others have claimed, EMB and patient centred medicine are 
both contemporary neo-liberal technologies of governance that facilitate 
devolution of the management of human health from the state to, amongst 
other things, various professional groups and individual citizens through the 
process of responsibilization. In the case of thyroid disease these two 
governmental technologies clash, and ironically fail to govern the health of 
the thyroid population. That is, the technical deficit of current technologies 
of thyroid disease result in patients rejecting this standardised evidence 
based approach and seeking alternative expertise and treatments from 
outside of the medical establishment in order to overcome ill health. 
Therefore, although such patients are engaging with the improvement of 
their health and well-being they are doing so because of the inadequacy of 
health technologies.
The following chapters will discuss this conflict in more detail, exploring the 
disconnection between the types of evidence used to diagnose and guide 
treatment for thyroid disease and how they are understood and handled by 
various groups of patients and clinicians. Specifically, the remaining 
chapters of the thesis will focus on how the evidence of thyroid disease is 
negotiated and coordinated to various orders of thyroid biology, all of which 
are a response to the wants, needs, rights and responsibilities of these 
various groups. In particular, the thesis will focus on how the disconnection 
between symptom based and biochemical based orders of thyroid biology 
and pathology identify and provide an interesting addition to the concept of 
biosociality. Specifically, the ways in which the remaking of thyroid biology 
through practice is based, not on biomedicine’s ability to control and 
engineer thyroid pathology, but on its inability to fully grasp and control this 
non-compliant and ambiguous pathology.
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Chapter 5
Circulations of evidence: defining the boundaries of thyroid
disease
In the previous chapter I suggested that once thyroid disease is tracked 
experientially -  be it by a patient or a clinician -- it can no longer be 
understood as a straightforward set of diagnostic categories and 
procedures. In particular, as I observed in the clinic, the biochemical 
reference ranges used to ‘definitively’ diagnose thyroid dysfunction often do 
not translate into the symptoms that individual patients report. I further 
argued that the very means of attempting to reconcile a diverse and often 
indeterminate array of symptoms against a range of standardised test result 
calibrations can itself become the cause of greater suffering. In this chapter 
I examine the disparity between the types of ‘evidence’ used to diagnose 
and treat thyroid disease, and the further ramifications of this discrepancy. I 
conclude by suggesting some of the implications this might be seen to have 
for existing social scientific models of embodiment, medicalisation, somatic 
ethics, care of the self and in particular biosociality.
In this chapter, I begin with a further examination of the difficulty in 
attributing symptoms to an underlying pathological cause situated within the 
thyroid gland and the inadequacy of the thyroid function tests introduced in 
an attempt to resolve this issue. This is followed by an account of the 
uncertainty of both symptomatic and biochemical evidence used in the 
diagnosis of thyroid disease, emphasising the ways in which both clinicians 
and patients rely upon the indeterminate aspects of these sources to 
construct discrepant versions, or ‘orders’, of thyroid biology that 
correspondingly fulfil an array of rights, responsibilities, desires, and 
consequent management and treatment strategies. I conclude by 
suggesting that thyroid diseases provide a highly relevant context in which 
to further evaluate the analytical purchase of Rabinow’s concept of 
biosociality. Specifically, I examine how the community that collects around 
thyroid pathologies is bound together by an array of often contradictory 
techniques and practices that attempt to take control of the lack of 
technique that most prominently characterises current methods used to 
diagnose, treat and manage thyroid disease. In other words, I try to suggest 
in this chapter that, in the case of thyroid disease, it is the lack of control
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over thyroid pathology that results in the development of various techniques 
that remake its biology through cultural practices. I further demonstrate that 
it is this lack of technique and control which generates much of the 
solidarity -  again among both clinical and patient communities -  that might 
be described as ‘biosocial’ in its focus on a specific disease.
The problem of symptoms
According to the medical text book DeGowin's Diagnostic Examination 
(2004) the word symptom:
is derived from the Greek word meaning ‘something that has 
befallen one.’ A symptom is usually considered to mean 
abnormal sensation that is perceived by the patient, in 
contrast to a sign that can be seen, felt, or heard by the 
examiner. (DeGowin et al. 2004: 25)
As DeGowan et al point out, a symptom is a subjective indication of 
disease provided by the patient. A sign, on the other hand, is an 
abnormality that is observed by a doctor during a clinical examination. The 
distinction between signs and symptoms is not always clear. When a doctor 
observes a symptom reported by a patient, the symptom is also a sign. 
Some symptoms, however, cannot be seen by a doctor and therefore 
cannot also be classed as signs. For example, a goitre is both a sign and a 
symptom of thyroid disease as it can be observed by both patients and 
doctors. In contrast, sore muscles and increased sensitivity to the cold, 
symptoms of hypothyroidism, can only be classed as symptoms because 
they can only be felt by the patient and not observed by the doctor. On the 
other hand, the results of thyroid function tests can only be classed as a 
sign because although a patient may think they have a thyroid problem 
through the experience of symptoms, they cannot observe this dysfunction 
until it is revealed through blood test results provided by hospital 
laboratories. Therefore, the results of thyroid function blood tests are 
considered to be superior evidence of thyroid disease because they are 
signs of disease that can be observed by the doctor independently of the 
subjective accounts of individual patients. Moreover, they are able to 
attribute illness to an underlying pathological cause, for instance the under 
or over production of thyroid hormones by the gland. Consequently, whilst 
symptoms can be useful indicators of disease, they are also considered to
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be too subjective and too general and therefore can complicate and 
mislead the process of diagnosis. For example, as De Gowan et al also 
note, when a patient history is taken ‘the patient’s description of symptoms 
must be clarified and quantified’ (DeGowin et al. 2004: 25). The symptoms 
can then be transformed into clearly defined clues that will facilitate a 
robust and thorough diagnostic decision:
The chief purpose of the history is to furnish clues for diagnosis.
As the narrative unfolds, you should be simultaneously 
performing three operations (a) the accumulation of facts 
(obtaining the history), (b) evaluation of the facts (testing 
credibility of symptoms, seeking more details of time and 
quantity, and (c) preparation of hypotheses. Having formed a 
list of hypotheses, question the patient about other symptoms 
specific for diseases on the list, either to support or to discard 
the hypothesis (DeGowin et al. 2004: 25)
Therefore, within the established diagnostic protocols of western medicine,
symptoms are approached with caution as they are considered to be
inherently subjective and could undermine the integrity of objective and well
hypothesised clinical reasoning. As Foucault demonstrates in The Birth of
the Clinic (1973), this organisation or ‘spatialisation’ of symptoms, signs
and pathology is key to understanding the discourse of modern medicine
that emerged during the nineteenth century:
The space of configuration of the disease and the space and 
localization of illness in the body have been superimposed, in 
medical experience, for only a relatively short space of time -  
the period that coincides with the nineteenth century medicine 
and the privileges accorded to pathological anatomy. This 
period that marks the suzerainty of the gaze, since in the same 
perceptual field, following the same continuities or the same 
breaks, experience reads at a glance the visible lesions of the 
organism and the coherence of pathological forms; the illness is 
articulated exactly on the body, and its logical distribution is 
carried out at once in terms of anatomical masses. The ‘glance’ 
has simply to exercise its right of origin over truth.(Foucault and 
Sheridan 1973: 3)
According to Foucault, during the eighteenth century symptoms were 
treated as the illness. For example, stomach ache was considered to be the 
illness itself, rather than the effect of one. This two dimensional model of 
illness was replaced during the nineteenth century with the emergence of 
the clinic and of hospital medicine, where symptoms, signs and pathology 
became the framework through which disease was understood. In this 
‘three dimensional’ framework, the symptoms presented by patients were
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evaluated alongside signs that were observed by skilled clinicians, both of 
which indicated an underlying pathological lesion that was the disease. 
Consequently, the clinical examination became a process in which the body 
of the patient was mapped out in order to find the exact location and form of 
the disease-causing lesion. For example, in 1873 the first description of 
hypothyroidism was published by the physician Sir William Gull (1873- 
1874). Through a close examination of a female patient referred to as ‘Miss 
B’, Gull’s account carefully recorded a number of clinical signs and 
symptoms such as the size of the tongue, the colour and texture of the skin 
and the behaviour of the patient. These clinical signs and symptoms were 
then placed alongside pathology reports that indicated a wasting, and even 
the absence, of the gland. Thus, hypothyroidism -  a pathological condition 
of the thyroid gland -  was revealed.
Therefore the triangulation of signs, symptoms and pathology in the 
specialist space of the clinic meant that illness was no longer seen primarily 
through the subjective realm of symptoms but through the clinical expertise 
(or what Foucault terms ‘the gaze’ (1973: 45) of the doctor. Throughout the 
nineteenth and twentieth century, the gaze of the medical profession and 
the subjugation of patient symptoms developed further through the 
expansion of an array of technologies (x-rays, blood tests, cytological tests 
etc.) designed to observe pathology in increasing detail (Armstrong 1995). 
For example, in the 1970’s thyroid function tests were developed that could 
measure the negative feedback loop between the thyroid and pituitary 
glands as well as the level of hormone production of the thyroid gland. This 
meant that the pathological process that caused thyroid disease, as well as 
its results (under or over production of thyroid hormones) became available 
to the clinical gaze. As a consequence, the symptoms of thyroid disease 
are perceived to be un-reliable diagnostic evidence - unlike blood tests - 
because they can only suggest and not prove the presence of disease 
within the thyroid gland. However, as will become clear throughout this 
chapter, far from creating a better and more precise definition of thyroid 
disease such tests have resulted in increasing levels of uncertainty and 
contestation. In fact, the process of ‘tidying up’ thyroid disease into clearly 
defined biochemical reference ranges has meant that many patients feel 
that their symptoms and experiences are ignored.
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Disciplining evidence
As the UK Guidelines for the Use of Thyroid Function Tests claim, 
‘Hypothyroidism is an insidious condition with significant morbidity and the 
subtle and non-specific symptoms and signs may be mistakenly attributed 
to other illnesses, particularly in post-partum women and the elderly’ 
(Association for Clinical Biochemistry et al. 2005: 11). This suggests, the 
symptoms of thyroid disease are problematic because firstly they are 
incredibly general and can be indicative of a plethora of other diseases. 
Secondly, they are highly subjective and therefore difficult to attribute to an 
underlying dysfunction in the gland. For example, in the case of 
hypothyroidism the symptoms of low mood and lethargy could also indicate 
mild depression and the ‘symptom’ of weight gain could be a result of 
eating too much. In order to overcome the problem of the uncertain aspects 
of symptoms, a thyroid function test has been developed to definitively and 
objectively identify pathology within the gland. As described in chapter four, 
this blood test measures the negative feedback loop between the pituitary 
and thyroid glands, as well as measuring the amount of thyroid hormones 
that the thyroid gland produces. Thyroid function blood tests, then, are 
used to differentiate whether ‘thyroid type symptoms’ are in fact a result of 
thyroid dysfunction or some other cause.
For example, in the clinical text book Thyroid Disease: The Facts written by 
consultant endocrinologists R.I.S Bayliss and W.M.G.Tunbridge, continuing 
depression in patients whose blood test results demonstrate that their 
thyroid is healthy is explained as follows:
Persistent depression after correction of thyroid deficiency is 
quite common and is a cause for patients being dissatisfied with 
their response to thyroxin treatment. It is, of course, essential 
that the correct replacement is being given and most patients 
with thyroid deficiency feel at their best when the dosage of 
thyroxin raises their free thyroxin level towards the upper end of 
the normal range, or even a little above it. If you have received 
for several months the amount of thyroxin that meets these 
criteria but still continue to feel generally unwell, it is likely that 
your ill health is due to a persistent degree of clinical 
depression, which merits treatment in its own right. Fortunately 
there are many psychotropic drugs, with few side effects, that 
will correct this situation. (Bayliss and Tunbridge 1998a: 164)
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As Bayliss and Tunbridge explain, it is common for patients who have had 
their thyroid function returned to a level within the accepted reference range 
to complain of persistent symptoms. However, without the ‘definitive’ proof 
of thyroid dysfunction, provided by blood tests, such lingering symptoms 
are attributed to other possible causes such as depression. In spite of this, 
many patients refuse to accept that their thyroid disease has been treated 
and that their symptoms have been eradicated. As Alex, a hypothyroid 
woman in her mid-thirties recounted in an interview at her home in London, 
the level of replacement thyroxin she had been prescribed on the basis of 
thyroid function tests did not return her to an acceptable level of health. 
When describing why her dosage ‘isn’t right’, Alex expresses a view 
common among the patients interviewed that TFT results are misleading 
and lead to incorrect dosages that fail to alleviate symptoms:
I’ve only got to look at the vacuum cleaner to see how much 
hair is falling out, and it’s full of my hair. I run through my hair 
and I just think oh, it does fall out in surprising amounts, my hair 
is very thin. According to the Doctor your hair is on a two year 
cycle, so it will be another year before I get it back, or once I 
have found a right dosage for me, but as I say I only have to 
turn the vacuum and look at the rollers and it’s stuffed full of my 
hair, and it does fall out in large quantities, so it can’t be right. If 
you speak to other people who have thyroid problems they say 
their hair only falls out when their tablets aren’t right, and they 
have been taking their tablets for years so erm...l’ve never 
found a happy medium so I don’t really know, a year down the 
line I’m still no closer...perhaps I’m a bit closer. My current 
dosage...I don’t know the average, but mine isn’t right...
Although Alex acknowledges that thinning hair takes time to correct itself,
even after thyroid replacements are prescribed, she still feels that there is
an underlying problem with her thyroid function and supports her view by
relying on the authority of more experienced patients. Therefore, as
demonstrated by Alex and claimed by a number of patient groups (e.g.
Thyroid U.K, Thyroid Patient Advocacy, Stop The Thyroid Madness!!!), the
process of diagnosing thyroid disease primarily on the basis of biochemical
assays seems to ignore symptoms of disease experienced by patients after
biochemical evidence suggests that normal thyroid function has been
restored. As claimed by the patient support-group Stop the Thyroid
Madness!!!, the idea that there is a rigid ‘normal range’ of thyroid function is
erroneous and dubious to begin with.
...we are HELD HOSTAGE to a lab [test] called the TSH 
(thyroid stimulating hormone) with its erroneous and dubious
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‘normal’ range. Patients note that when in that ‘normal’ range, 
they continue to have symptoms.(Stop the Thyroid Madness!!
2006)
This tension between the embodied evidence presented by patients and 
the biochemical evidence preferred by current best practice guidelines 
returns us to a broader conflict within western healthcare, namely that 
between Evidence Based Medicine (EBM) and the patient-centred 
medicine, as discussed in chapter two. The medical sociologist David 
Armstrong (2007: 77) notes that proponents of the patient-centred model 
believe that ‘EBM denies the individuality of the patient and their particular 
therapeutic needs’ (2007: 77). Dr G.R.B Skinner, a practicing clinician who 
endorses the treatment of biochemically euthyroid (‘healthy’) but clinically 
hypothyroid individuals, supports this contention:
[l]t is increasingly unusual for family practitioners, physicians 
and endocrinologists to diagnose and treat hypothyroidism in 
clinically hypothyroid patients unless free thyroxin (FT4) and/or 
thyroid stimulating hormone (TSH) falls outside of the 95% 
reference intervals. This arises from the current misconception 
that evidence based medicine means laboratory-based 
medicine wherein clinical observation-albeit of an objective 
nature, for example pulse rate or blood pressure -is accorded a 
lower evidential weight than laboratory 
measurements!...](Skinner et al. 2000: 115)
According to Skinner, the ‘increasingly unusual’ practice of diagnosing 
thyroid disease on the basis of clinical signs and symptoms demonstrates 
that EBM erodes the individual needs and experiences of patients. The 
reference ranges that Skinner refers to, as described in chapter four of this 
thesis, are the range of thyroid function values (TSH free T4) found in the 
mid 95% of a reference population. It is claimed by Skinner and other like- 
minded colleagues that such population-based reference ranges are 
misleading because they frequently do not account for those individual 
cases of thyroid disease that do not fit into such biochemical population- 
derived diagnostic categories. For instance, some patients may have overt 
hypothyroidism in spite of blood tests that suggest that their thyroid function 
is normal. Consequently, Skinner claims that the practice of extrapolating 
these references ranges to account for an individual’s thyroid function is 
abstract, intangible and unrealistic. This approach to thyroid disease 
therefore considers symptoms to be a more reliable indicator of thyroid
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disease because they can be experienced by patients and observed by 
clinicians through clinical examination.
The criticism that clinicians such as Skinner level at thyroid function tests 
also reveals another aspect of the EBM debate, in which it is claimed that 
clinical reasoning primarily based on scientific method erodes the skill and 
authority of doctors. As Dr Barry Durrant-Peatfield, a retired GP and 
supporter of diagnosing disease on the basis of clinical symptoms, 
declares:
We find ourselves in the grip of a medico-technocracy. The 
blood test is God, and eventually takes over the diagnostic 
process. I deeply deplore this state of affairs, since I was taught 
and have never had any reason to doubt, that the best 
diagnostic weapons of all are the Mark I eyeball and the Mark I 
earhole. Look and listen. The other excellent lesson I learnt was 
that if the blood test doesn’t bear out your diagnosis, believe in 
your own learning and experience (Durrant-Peatfield 2006: 70).
However, in terms of the tenets of EBM the extreme form of patient-centred 
medicine and experienced-based clinical reasoning, favoured by Skinner 
and Durrant-Peatfield, exemplifies and encourages ‘ineffective and 
inefficient practice (Armstrong 2007: 77). For example, Skinner’s belief that 
symptoms and not blood test results should be the target of treatment 
rejects the triad of symptoms, signs and pathology which, as discussed 
earlier, defines modern medicine. Hence, such approaches are considered 
by ‘establishment’ endocrinologists to be ineffective and inefficient for two 
reasons: firstly they are treating symptoms that may not be the result of 
thyroid disease; secondly they are prescribing medication and providing 
annual tests to monitor thyroid dysfunction in individuals who may not even 
have thyroid disease. This in turn, it is claimed by proponents of EBM, has 
a negative effect on the distribution of health service resources. For 
example, the canon of established thyroid literature places the incidence of 
hypothyroidism, (the number of people who fall under the biochemical 
reference range of thyroid function) at 1 to 2% of the general population 
(Flynn et al. 2004). However, according to Durrant-Peatfield, symptoms 
should also count as definitive evidence of disease, and the incidence of 
hypothyroidism in the population is therefore estimated at 30% (Durrant- 
Peatfield 2006: 125). Therefore treating this 30% is considered to be 
ineffective by supporters of blood tests because it is done on the basis of a 
clinical reasoning that is unable to provide a causal link between disease of
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the thyroid gland and the onset of non-specific symptoms. Furthermore, 
such a strategy would also be inefficient because it would mean that people 
would be prescribed thyroid replacement therapy on the basis of clinical 
anecdote and not scientific facts. Consequently, this issue of clinical 
decision making is also related to the efficient distribution of NHS resources 
through which thyroid replacement therapy is prescribed to individuals 
where efficacy can be definitively demonstrated.
This disagreement within the medical profession with regard to how a 
diagnosis of thyroid disease is reached is also compounded by the 
campaigns of a number of patient activist groups who are highly critical of 
treating thyroid disease primarily on the basis of blood test results. As 
discussed in Chapter three of this thesis, Professor Anthony Weetman's 
2006 article Whose Thyroid Hormone Replacement is it Anyway? (2006) 
suggests that changing attitudes towards the medical profession and 
scientific knowledge are the cause of the dissatisfaction with treatment for 
hypothyroidism. When discussing the reasons why some patients demand 
treatment for their thyroid disease in spite of blood test results that fall 
inside of or on the borders of the reference range, Weetman claims it to be 
a result of the subversion of scientific knowledge in the contemporary era. 
The derogation of objective facts in contemporary Western culture, he 
complains, corrodes conventional hierarchies of knowledge and any single 
sense of what is ‘real’. Moreover, this corrosion of medical authority means 
that factors outside of the realm of biomedicine are currently guiding how 
patients make sense of and interact with their health, for example in terms 
of lifestyle and consumer choices. As Weetman claims:
[T]he rise of ‘healthism’17... has been characterized by the 
following features: high health awareness and expectations, 
information seeking, self-reflection, distrust of doctors and 
scientists, healthy and often alternative lifestyle choices, and a 
tendency to explain illness in terms of folk models of invisible 
germ-like agents and malevolent science (2006: 232)
Therefore, according to Weetman, disagreement amongst the medial 
profession coupled with the rise of ‘healthism’, results in the corrosion of a 
single, scientifically rigorous definition of thyroid disease - specifically, the
17 The term healthism was first coined by the political economist Peter Crawford in his article 
Healthism and the medicalization of everyday life (1980) Healthism describes the shift in the 
responsibility of health from the state to the individual in late capitalist societies through 
practices of consumption.
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claim that thyroid disease can be diagnosed on the basis of clinical 
symptoms alone.
In 2005, the UK Guidelines for the Use of Thyroid Function Tests were 
developed in an attempt to solve the confusion and disagreement between 
clinicians and patients with regard to the interpretation of thyroid function 
tests. The purpose of the guidelines is outlined as follows:
It is hoped that the document will provide guidance for primary 
care physicians, specialist physicians, endocrinologists, and 
clinical biochemists. The accompanying patient information sets 
have been especially designed to explain thyroid function 
testing and to summarise the main recommendations in the 
guidelines in everyday language. The purpose of the guidelines 
is to encourage a greater understanding of thyroid function 
testing amongst all stakeholders with a view to the widespread 
adoption of harmonised good practice in the diagnosis and 
management of patients with thyroid disorders. The guidelines 
are also intended to provide a basis for local and national audit 
and each section offers recommendations that are suitable for 
the audit process. (Association for Clinical Biochemistry et al.
2005: 5)
As briefly described at the end of Chapter two of this thesis, these 
guidelines were produced by a development group that consisted of 
endocrinologists, biochemists and patients, who were represented by 
Janice Hickey and Betty Nevens, the Director and Office Manager of the 
British Thyroid Foundation (BFT), respectively18. The group met on a 
number of occasions, and subgroups were created to take responsibility for 
chapters related to particular themes: hyperthyroidism, hypothyroidism, 
thyroid function and pregnancy, thyroid function testing in thyroid cancer 
and laboratory aspects of thyroid function testing. The whole group then 
considered each draft chapter. The guidelines do not question the validity 
of TFTs, rather the aim was to encourage a greater understanding of TFTs 
and their widespread adoption in order to develop ‘harmonised good 
practice’ (Association for Clinical Biochemistry et al. 2005: 5). This objective 
entailed the eventual development of a process of local and national audits
18 BFT is associated with the British Thyroid Association (BTA) a professional 
organisation of thyroid clinicians and scientists within the U.K. Both of these 
organisations agree that treatment for thyroid disease should primarily be based on 
thyroid biochemistry. This relationship and shared approach to diagnosing and 
treating thyroid disease is made explicit on the website of both of these 
organisations. Moreover, the BTA and BFT websites both warn about the danger of 
other websites that provide misleading and information that is not endorsed by 
'medical research’.
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intended to monitor the uptake and effectiveness of the guidelines. Hence, 
the assumption that the biochemical evidence provided by TFTs is superior 
to clinical signs and symptoms is a priori within these guidelines.
Consequently, it is unsurprising that Dr Gordon R.B. Skinner made the 
following response to the first draft of the guidelines on the Thyroid Patient 
Advocacy Groups19 website:
One of the difficulties with Guidelines in modern day medicine is 
that they cannot be divorced from political and regulatory 
influences!...[It is thus crucial that the medical profession 
acknowledge and state in the public domain that Guidelines are 
there to assist practitioners but are not sticks to beat them if 
they fall out of line. (Thyroid Patient Advocacy UK 2005)
In this statement, Skinner is rehearsing the argument that evidence-based 
guidelines are not simply apolitical tools that ensure better and safer 
practice. He is claiming that they are tools used to regulate and rationalise 
medical knowledge through the collation of heavily selected trial data. 
Specifically, he is inferring that the production of guidelines for the use of 
thyroid function tests is a scheme by the established community of thyroid 
professionals to regulate the practice of individual clinicians such as 
himself. As Skinner goes on to claim:
[...]if a patient has high TSH level or a low FT4 level, then that 
patient is likely to be unwell and suffering from the clinical 
features of hypothyroidism. The mischief lies in the assumption 
of the reciprocal, and I am unaware of any evidence which 
teaches us that if you have clinical features of hypothyroidism 
with reasonably normal thyroid chemistry, the patient does not 
suffer from hypothyroidism and will not benefit from thyroid 
replacement (Thyroid Patient Advocacy UK 2005)
Therefore, Skinner concludes in his response that he disagrees with the 
guidelines because he believes, in his experience, that the exclusion of 
hypothyroidism through blood test results that fall inside the reference 
range ‘results in patients being chronically under treated’. Interestingly, 
Skinner’s solution to this predicament is the development of a ‘properly
19 The Thyroid Patient Advocacy Group UK (TPAUK) is a patient support group 
based in the United Kingdom that believes that the current diagnosis and treatment 
practice(s) espoused by the established medical profession are inaccurate and 
“ignores and/or dismisses relevant physiology that has been known to medical 
science for nearly 40 years, ignores medical ethics, and ignores the human rights 
of patients”. This claim will be addressed in greater detail later when the concept of 
'orders of thyroid biology’ is introduced.
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controlled clinical trial’ that can investigate the efficacy of treatment in 
euthyroid but symptomatic individuals. Consequently, it is clear that Skinner 
and other like-minded clinicians believe that adjusting the primacy of 
biochemical evidence in relation to clinical signs and symptoms will aid in 
the identification of thyroid disease in biochemically euthyroid but 
symptomatic individuals. Moreover, by suggesting that clinical trials should 
be conducted to investigate this claim, they are suggesting that it is 
possible to prove that symptoms themselves can be scientifically rigorous 
evidence of thyroid disease. That is, through a clinical trial it is possible to 
quantify the efficacy of treating patients on the basis of symptoms alone.
In sum, the deployment of standardised biochemical tests as definitive 
markers of disease is one measure that could offset the expensive 
consequences of ‘anecdotal thyroid disease’ and its potential drain on busy 
clinicians, nursing staff and the NHS. As a result, the practice of 
administering thyroxin exclusively to individuals who are biochemically 
hypothyroid, is construed by some clinicians and patient groups to be an 
ideologically conservative response based on a traditional ‘faith’ in 
biochemical evidence. For example as the patient group Stop the Thyroid 
Madness!! advise patients on their website:
you have to now make a paradigm shift in the way society and 
doctors have taught you to ascertain whether you are 
hypothyroid or not, or whether you are adequately treated or 
not. Namely, you have to make SYMPTOMS your primary clue,
NOT lab work like the TSH. Lab work should only serve as 
additional information, NOT as the initial force of reality. If you 
continue to look at lab work as THE answer, you are no better 
than hundreds of thousands of doctors around the world who 
have kept thyroid patients SICK! (Stop the Thyroid Madness!!
2006)
At first glance, the claims of clinicians such as Skinner and patient support 
groups such as Stop the Thyroid Madness!!! appear to suggest an example 
of the misguided confusion presented by Professor Anthony Weetman (as 
described in chapter 3). However, there is a growing body of literature that 
demonstrates that the relationship between thyroid biochemistry and 
clinical signs and symptoms remains indeterminate.
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In 2007, the Cochrane Collaboration 20 produced a systematic review 
entitled Thyroid replacement for subclinical hypothyroidism (Villar et al.
2007). The purpose of the review was to assess the effects of thyroid 
hormone replacement on subclinical hypothyroidism, and therefore asses 
the effectiveness of prescribing thyroid replacement to patients whose 
thyroid biochemistry is on the borders of the reference and who, according 
to the established thyroid literature, should be asymptomatic. The overall 
conclusion of the review was that replacement therapy for subclinical 
hypothyroidism did not result in decreased cardiovascular morbidity21 or a 
significant improvement of health-related quality of life and symptoms 
between intervention groups. Moreover, there was some evidence that 
indicated that thyroid replacement treatment improves some parameters of 
lipid profiles and left ventricular function (the health of the lower chamber of 
the heart that can be impaired by high cholesterol). However, the Cochrane 
Collaboration review noted that, although the results of the published data 
suggested that treating subclinical patients was not definitively efficacious, 
there are a number of studies that demonstrate some benefits as well as 
disadvantages to this course of treatment. As the review summarises:
Thyroid substitution could prevent progression to overt 
hypothyroidism, improve neuropsychiatry symptoms and 
somatic symptoms, mood disorders, cognitive dysfunction, 
atypical responses to standard psychiatric therapeutic 
interventions, and minimize deleterious effects on 
cardiovascular function and lipid levels. However, there may 
also be adverse effects from replacement doses of thyroxin, 
these include nervousness, palpitations arterial fibrillation, and 
exacerbation of angina pectoris. Reduction in bone density of 
the spine, femoral neck, distal radius, and femoral trochanter 
can also occur. The over-treatment with thyroxin probably 
contributes to the development of osteoporosis in post­
menopausal women, and an undetectable TSH level suggests 
over treatment. (Villar et al. 2007: 6)
Furthermore, as this review concludes, until better evidence is available, 
decisions to treat subclinical hypothyroidism should be based on ‘clinical 
judgement and patient preferences.’ (Villar et al. 2007: 12). Consequently, 
even with access to the most reliable and exhaustive evidence available, 
the authors of the Cochrane Collaboration systematic review struggle to
20 Founded in 1993 and based on the vision of Archie Cochrane (1973) the father 
of EBM, the Cochrane Collaboration review and publish the effects of health care 
interventions tested in biomedical randomized controlled trials.
21 One of the symptoms of hypothyroidism is high cholesterol. It is thought that this 
may occur and result in morbidity even for individual who are mildly hypothyroid.
125
negotiate the competing values embedded in the biochemical and 
symptomatic evidence used to diagnose and treat thyroid disease. To be 
precise, they are unable to definitively prove that there is no benefit to 
treating patients whose biochemistry suggests mild thyroid failure and 
whose symptoms may have no sound physiological basis.
To summarise the previous section, then, it is clear that there is a tension 
between the blood test results and the clinically-observed symptoms that 
constitute evidence in the diagnosis and treatment of thyroid disease. In my 
analysis I point to a growing body of literature that suggests this tension is 
itself symptomatic of the shifting ethical, political and economic values and 
priorities guiding health service provision -  and is in some ways epitomised 
by the conflict between evidence-based and patient-centred models of 
health care. The categorisation of thyroid disease in terms of population 
based biochemical reference ranges is an example of how clinical practice 
is becoming increasingly infused with the scientific values of EBM. TFTs 
offer the possibility of disciplining the non-specific symptoms of thyroid 
disease within a scientific, population-based and biochemically-defined 
disease management infrastructure, thus also appealing to the post-audit 
culture values of transparency, efficiency and accountability (Power 1999). 
However, as will be detailed further later in this chapter, attempts to reduce 
the indeterminacy of thyroid disease through hyper-rationalised diagnostic 
strategies has many disadvantages. As the proponents of patient-centred 
approaches to health insist, TFTs, EBM and the like require the 
suppression of individual patient’s evidence and experience based on their 
everyday lives. Clinicians are also critical of the EBM paradigm, claiming it 
undermines their professional expertise and relies on a reductive model of 
illness that may even exacerbate existing pathology. Some patients and 
clinicians suggest EBM is itself the source of iatrogenic illness -  a claim for 
which, ironically, an increasing amount of statistical evidence can be 
mobilised to support.
Consequently, this study suggests that because both the biochemical and 
symptomatic evidence of thyroid disease are highly indeterminate, neither 
can be used to discipline thyroid disease. It is for this reason that the very 
‘vagueness’ of thyroid disease may make it a powerful model of both 
medicalisation and management in the context of shifting expectations and 
knowledges concerning health, health care, and the self-management of
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patients. In other words, it is because thyroid disease provides a weak 
context for medicalisation that it becomes valuable as a contested site in 
which the boundaries of disease can be seen to belong to changing and 
conflicting orders of biology, medicine and science presented by both 
patients and clinicians. In the following section, the negotiation of these 
actively contested dimensions of thyroid disease will be described in terms 
of how they are used to discuss and justify various diagnostic and 
treatment strategies.
Opinionated evidence
As described above, the indeterminacy of the evidence for thyroid disease 
presents it as weak context for medicalisation. That is, when considered in 
light of a discussion of the problem of the evidence sources used to 
diagnose thyroid disease, it is impossible for the medical profession to 
discipline it into a biochemically circumscribed disease category. 
Consequently, physicians who practice outside of established theories of 
thyroid disease, and patients who are dissatisfied with their treatment, are 
able to use the gaps in the evidence to negotiate an order of thyroid 
disease that satisfies their various rights, want, needs, desires and 
responsibilities. Therefore, such negotiations can be described as what 
Margaret Lock would call a ‘local biologies,’ of thyroid disease - the ways in 
which physical sensations (well being, health, and illness) are in part 
informed by the material body, which is itself contingent on evolutionary, 
environmental and individual variables. Subsequently, the ‘local biology’ of 
thyroid disease consists of the construction of various orders of thyroid 
disease and biology that attempt to explain physical sensations through the 
shifting ethical, political and economic values and priorities guiding health 
service provision within the NHS (epitomised through the evidence based 
and patient centred models of healthcare). Specifically, this ‘local biology’ 
sees the construction of particular orders of thyroid biology and pathology 
that attempt to fill the explanatory gaps left by the established model of the 
thyroid pituitary axis and the unreliability of symptomatic evidence.
If we compare two interpretations of thyroid symptoms, it is apparent that 
their ambiguity can be mobilised to construct different accounts of the
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disease. Samantha is a patient in her early thirties with Grave’s disease. 
She describes the onset of her disease as follows:
So I was writing up my PhD so this would be, a long time...err 
lets see that was 1998 to 2005 when I started this one, so 
probably about 2002/2003. And what was happening 
confusingly at that point was that I was feeling quite, erm low in 
mood I think really was the kind of thing that was going on and 
really very tired, and yeah I think increasingly putting on weight 
and things like that, erm, and I was kind of because of my 
psychology background I was kind of interrogating myself 
saying could this, could I just be depressed is that what’s going 
on here, and I thought not really it, there isn’t any kind of 
cognitive cause for it and it’s not that I feel kind of despairing or 
self blaming or anything I just feel kind of exhausted and a bit 
stuck and not moving forward and not energetic...
If you contrast this account to a list of hypothyroid symptoms listed by 
Diana Holmes in her book Tears Behind Closed Doors-Failure to diagnose 
an underactive thyroid: the truth behind the tragedy (Holmes 2002), the 
symptoms are interpreted very differently. In fact, the non-specificity of 
symptoms is increased and the category of the ‘symptom’ is expanded to 
incorporate additional entities.
The patient is overweight and puffy 
or thin and worn out**
Goitre 
Exhaustion 
Lethargy 
Dizziness 
Weight gain 
Swollen Ankles*
Puffy Face and Hands 
Thick tongue*
Brittle nails 
Dry Hair
Hair loss over parts of the body* 
Thinning eyebrows 
Feeling cold 
Overheating**
Headaches*
Migraines*
Dry Mouth and sore throat* 
Swallowing difficulties 
Slow Speech 
Slow thinking 
Loss of appetite 
High blood pressure**
Allergies*
Sensitive to the sun*
Loss of balance
Pains over the heart and crushing 
feelings in the chest*
Poor memory and concentration 
Morbid thoughts 
Insomnia**
Dreams*
Visual disturbances*
Nervous and jumpy**
Anger and irritability**
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Aching limbs and joints, also Panic attacks**
cramps Anxiety**
Lower back pain Hallucinations
Carpel Tunnel Syndrome* Voices in the head*
Palpitations** Guilt*
Deafness* Suspicious of people’s motives*
Pallor Persecution complex*
Constipation Cry or get upset easily*
Diarrhoea** Lack of confidence*
Swollen stomach* Claustrophobia**
Menstrual problems Agoraphobia**
Shaky Hands, Shaky body, Mood swings*
Juddering in the spine** Depression
Pins and Needles* Low libido
Numbness* Heavy eyelids
Decreased Sweating*
Hoarse Voice
General problems including loss of balance, florid complexion (florid
hypothyroidism), fear of what is happening to your body, clenching teeth,
being an ‘emotional wreck’.*
*Not in the BFT list of symptoms
**Also a symptom of hyperthyroidism
Contrasting Samantha and Diana Holmes’ descriptions of symptoms reveal 
two issues of note. Firstly, both of the accounts describe physical and 
psychological sensations that are borderline symptoms, sensations that 
could also be interpreted as ‘normal’ feelings that are not necessarily the 
result of disease. Secondly, in spite of the fact that Samantha and Diana 
describe a number of the same symptoms, they are in fact talking about 
different diseases of the thyroid. Samantha has been diagnosed with 
Grave’s disease and Holmes is referring to hypothyroidism. These 
accounts demonstrate not only the indeterminacy of the symptoms of 
diseases of the thyroid, but also the way in which these symptoms form the 
basis for a particular construction of the disease. For example, Holmes’ 
position as patient activist impacts not only on how symptoms are 
represented, but also on which symptoms are attributable to thyroid 
disease. Some of the symptoms of thyroid disease can be understood as
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responses to the politics of thyroid disease as well as forming 
interpretations of physical and psychological sensations. As Holmes’ 
description of ‘guilt’ demonstrates:
I felt so guilty about being unwell and at one time doubted my 
own perceptible abilities. I found myself on the defensive most 
of the time and not liking myself at all. My self esteem was at its 
lowest ebb (Holmes 2002: 58).
It is difficult to discern whether this sense of guilt is a symptom or a 
personal reflection on the state of having a disease. Are these ‘symptoms’ 
of guilt and doubt a result of being placed in the category of ‘a problem, 
time-wasting patient’ who ignores professional expertise and contests their 
disease on the grounds of unsubstantiated biomedical theories? Is it a 
symptom of a social category rather than a pathological one? How can we 
think about the relationship between physical sensations and personal 
feelings and experiences?
The relationship between different forms of evidence of disease is perhaps 
best described by the philosopher Ian Hacking’s concepts of ‘making up 
people’, (Hacking 1986) and ‘looping effects’ (Hacking 1995), which he 
describes as follows:
... ‘Making up people’ referred to the ways in which a new 
scientific classification may bring into being a new kind of 
person, conceived of and experienced as a way to be a person.
The second, the ‘looping effect’, referred to the way in which a 
classification may interact with the people classified (Hacking 
2002: 285)
If we consider thyroid disease in these terms, the scientific classification of 
particular levels of thyroid function (hypothyroid, subclinical hypothyroid, 
euthyroid, subclinical hyperthyroid and hyperthyroid) that are used to order 
the indeterminate phenomenological experience of thyroid disease, calls 
afflicted individuals into a specific type of being. ,These classifications that 
have ‘made up people’, are in turn informed by the people being classified. 
For instance, the classification of thyroid dysfunction on the basis of the 
discipline of clinical biochemistry means that subclinical patients who 
complain of symptoms do not fit into this established diagnostic system. As 
a result, new categories are established or become related to the 
phenomena, such as the somatoform disorder, described by Weetman as 
over-informed problem patients who have read unreliable information on
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the Internet. Again this discussion demonstrates that the clinical signs and 
symptoms and laboratory measures used to categorise thyroid disease are 
by no means definitive. Consequently, the next step in a discussion of the 
boundaries of thyroid disease is to explore how such ambiguity is organised 
into particular categories. What are the politics of making sense and 
managing such ambiguity?
In her book Tears Behind Closed Doors (Holmes 2002), Diana Holmes 
refers to an article that appeared in the British Thyroid Foundation 
newsletter by Dr Peter Daggett, a Consultant Physician and 
Endocrinologist, entitled The Perils and Pitfalls of Unnecessary Thyroid 
Replacement (Daggett 2000). In the article, Daggett describes a 
hypothetical case of a patient who claims to have hypothyroidism, but who 
has blood test result that fall inside the reference range. Daggett begins by 
describing hypothyroidism as follows:
An underactive thyroid gland produces many symptoms, which 
make people feel unwell, and because the condition develops 
slowly, affected individuals have often felt ill for a long time. The 
stress and strains of modern life, however, commonly cause 
similar symptoms and when the effect of our miserable weather 
is added, it is not surprising that many people are convinced 
that their thyroid gland is abnormal, even when it is not. Picture 
the scene. A middle aged lady (and it is usually ladies who are 
affected) feels tired and cold (it s cold in January). She is 
gaining weight (too much of the poor diet) and her hair is dry 
(the wrong shampoo). Her GP suspects that she is suffering 
from an underactive thyroid gland, but the laboratory report 
nothing wrong. She is not convinced and goes for a second 
opinion. (Daggett 2000: 1).
Daggett then describes the patient’s experience with the clinician who 
provides the second opinion. She is told that she has clinical symptoms of a 
slow pulse and low temperature, which are indicative of an underactive 
thyroid and she is given a natural thyroid replacement which the clinician 
believes to be superior to standard synthetic thyroxin. The result of this 
prescription is that ‘the lady feels great (placebo effect)’ (Daggett 2000: 2) 
but eventually, after a few months, becomes unwell again and is told to 
increase her dose. However, after a few months, she feels unwell again. 
The patient then goes back to her GP who discovers that she is thyrotoxic 
(has an overactive thyroid gland because of the excessive dose of natural 
extract thyroid given to her by the second clinician). Her G.P. asks her to 
cease taking the natural thyroid extract but she does not want to do this
131
and asks to see a hospital specialist, ‘pity the poor endocrinologist’ 
(Daggett 2000: 2). The endocrinologist finds that her thyroid gland is 
working normally but it is impossible to read her TFTs because they are 
being distorted by the thyroid hormones she is taking. The only option left 
is to treat the patient by stopping the hormone-replacement so that her 
endocrine system can return to normal. Daggett’s hypothetical concludes:
She is unhappy. The GP is unhappy because he has been 
bypassed and the endocrinologist is unhappy -  he has seen 
this sequence many times and is tired of getting into trouble for 
telling patients that he does not agree (Daggett 2002: 2).
Daggett’s article ‘feminises’ the symptoms of thyroid disease, specifically 
psychological impairments, in order to deal with experiences of the disease 
that do not fit into the formal model of thyroid dysfunction that is arbitrated 
by biochemical reference ranges. The characterisation of hysterical middle- 
aged women claiming to have thyroid disease when they have simply used 
the ‘wrong shampoo’ infers that all patients who express dissatisfaction with 
their diagnosis and treatment are hypochondriacs and timewasters who 
place unrealistic expectation upon clinicians and the health service. 
Dissatisfied patients become cast as attention seekers who demand 
recognition from the medical profession in order to fulfil an unobtainable 
sense of well being. That is, the ordering of thyroid biology they have 
deployed in order to rid themselves of symptoms is deemed not only to be 
un-scientific, but also hysterical and self-interested. Moreover, such 
patient-led criticisms of the current management strategies for thyroid 
disease, are considered to jeopardise the professional ability of the ‘poor 
endocrinologist’ whose expertise is questioned by such troublesome 
patients.
Given opinions like Daggett’s, the grievances of dissatisfied patients also 
include the bedside manner of doctors when approaching their problem. 
For instance, in 2006, the Society for Endocrinology newsletter received a 
petition raised by Diana Holmes (see appendix 8) of over 2000 signatures 
registering:
...a formal complaint against the clinical practice of the majority 
of the medical profession with regards to the diagnosis and 
management of hypothyroidism’ including ‘the over reliance on 
blood tests...emotional abuse and blatant disregard...over the
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suffering experienced by untreated/incorrectly treated thyroid 
patients (Holmes 2007)
As the above patient and professional accounts of thyroid disease have 
demonstrated, the symptoms can be defined as a result of thyroid disease, 
but also, as subjective assessments of health and well-being. 
Consequently, experiences of thyroid disease do not fit into the 
biochemically established categories and thus their corresponding clinical 
symptoms slip from the status of ‘supported and validated phenomena’ and 
become liminal thyroid abnormalities that fall within the ‘experience’ of the 
‘individual’. As has also been demonstrated, one of the mechanisms 
through which this is done is the feminisation of ‘bad’ evidence that does 
not fit into the established evidence-based regime that dominates current 
medical practice within the NHS and western healthcare systems more 
generally. However, in spite of this, such strategies still fail to account for 
the symptoms that some patients complain of, despite TFT results, that fall 
within the reference range and, therefore, fail to silence the dissenting 
voices of dissatisfied patients and sympathetic clinicians. Having discussed 
how symptomatic evidence is deployed by various thyroid stakeholders, the 
following section will explore the socially embedded nature of the 
biochemical reference ranges which, it is claimed, provide more ‘reliable’ 
evidence of thyroid disease.
Evidence of what?
The Consultant who manages the thyroid clinic on which this study is based 
gave two explanations for the dissatisfaction of some individuals with 
regard to the diagnosis and treatment of their thyroid disease. According to 
the ‘conventional academic medical’ explanation, patients who fall within 
the reference range of normal thyroid function, but who still suffer from 
symptoms, are suffering from a functional somatoform disorder. A 
functional somatoform disorder is a psychiatric condition in which 
individuals complain of chronic varied physical symptoms that have no 
identifiable physical origin (Sharpe and Carson 2001). As discussed, this 
label is also used as a polite way of accusing dissatisfied patients of the 
charges brought against them by clinicians such as Daggett. That is, as 
Weetman claims in quote below, often this diagnostic label is misused and
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not explained to patients properly. Consequently, it is perceived by patients 
as a rejection of their experience of symptoms and suffering:
Most patients with functional somatoform disorders are given 
explanations which are experienced as either a rejection of the 
reality of the symptoms or a simple collusion and acquiescence 
to the patient’s own biomedical theory. (Weetman: 2006; 233)
Interestingly, Weetman does not believe that the way to tackle thyroid 
disease is through the derision of the patients and their various biomedical 
theories. Unlike Daggett, Weetman asserts that it is important to 
communicate with, and not simply ridicule such patients. In doing so, he 
claims that patients can be empowered to understand their problems 
further and ‘reduce the demands they make on health services’ (Weetman 
2003: 233). Therefore, although both Daggett and Weetman agree that 
there is no thyroid disease without abnormal thyroid biochemistry, they 
approach patients who claim otherwise in very different ways. These 
different approaches are important to highlight because, as demonstrated, 
the dissatisfaction is not only exacerbated by the established science of 
thyroid disease, but also by the ways in which patients are handled by the 
medical profession during the clinical encounter.
The second explanation, or set of explanations, for patients claims of 
malingering symptoms, identified by the Consultant is a number of, as yet, 
unsubstantiated biomedical theories that prove that some biochemically 
normal/borderline patients do in fact have a biological basis for their illness. 
Briefly, these explanations can be listed as; Genetics, the problem of 
standard thyroid replacements and thyroid autoimmunity. Each of these 
potential explanations are described further belowl.
Genetics
One explanation which has been advanced suggests that genetic variation 
between individuals with regards to thyroid metabolism, receptor affinity or 
receptor (Walsh 2002b: 717) located around the deiodinase type II gene. 
Briefly, this theory suggests that certain organs may find it harder to break 
down T4 into active T3, resulting in slow metabolic function. As will be 
discussed below, this could have an impact on the efficacy of the standard 
synthetic T4-only replacements that the clinical practice guidelines currently
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endorse (Association for Clinical Biochemistry et al. 2005). However, this 
theory is currently unsubstantiated:
...recent animal experiments indicate that only the combination 
of T4 and T3 replacement, and not T4 alone, ensures 
euthyroidism in all tissues of thyroidectomized rats. It is indeed 
the experience of many physicians that there exists a small 
subset of hypothyroid patients who, despite biochemical 
euthyroidism, continue to complain of tiredness, lack of energy, 
discrete cognitive disorders and mood 
disturbances...Confirmatory studies on this issue are urgently 
awaited. It could well be that a slow-release preparation 
containing both T4 and T3 might improve the quality of life, 
compared with T4 replacement alone, in some hypothyroid 
patients (Escobar-Morreale et al. 2005: 2490)
In addition, when discussing this issue with the Consultant who ran the 
thyroid out-patients clinic studied as part of this thesis, he suggests that 
these ‘confirmatory studies’ may not be merited, as they do not account for 
the ‘normal’ status of the pituitary gland which is ascertained through the 
measurement of TSH as part of standard thyroid function blood tests. As 
the Consultant explained to me during an interview:
...the alternative view is that it’s for some reason the thyroid 
hormone, although it’s normal in the blood is not normal in parts 
of their tissues, but the evidence supporting that is non-existent 
and is extremely speculative because the whole idea is that the 
pituitary gland is the most sensitive part of us, that monitors our 
status and so the big sort of key feature is that if the pituitary 
gland is making, if you’ve got an intact pituitary gland, as an 
assumption which usually is the case, urn, then if the pituitary 
gland is happy then your bones, your brain, your muscle, your 
heart, they’re all seeing the same amount of hormone.
Standard Thyroxine Replacement 
As outlined above, there is some evidence (Escobar-Morreale HF et al. 
1996) to suggest that there may be a biologic basis to the dissatisfaction 
that some individuals feel when taking a course of standard L-thyroxin 
replacement. It is claimed that this preparation is not appropriate for all 
patients, as they cannot successfully convert the stable T4 into active T3 in 
the tissues of some organs of the body. This problem of conversion is not 
picked up by standard thyroid function tests because they only measure the 
levels of TSH, T4 and T3 and not the process of hormone action. That is, 
according to the patient support group Thyroid UK , such individuals appear 
to have normal function because tests are measuring the thyroid hormones 
that are ‘hanging around’ in the blood and not what is being converted into
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a form that will fuel metabolism. Subsequently, many of these dissatisfied 
patient groups and sympathetic clinicians claim that a combination of T4 
and T3 replacement, or even natural thyroxin derived from the thyroid 
glands of pigs, would provide a better therapy because the treatments are 
more natural and mirror what a ‘normal’ thyroid gland would produce 
(Durrant -Peatfield Barry 2006: 132). However, as the Consultant reflects, 
this theory is untested by evidence-based research methods and, therefore, 
cannot be introduced to the practices of the clinic:
There have been one or two animal studies that have tried to 
look at the T4 and T3 levels in different tissues and have 
suggested that they might not be quite as straight forward as 
that, but any study that’s tried in a double blinded randomised 
way to look at the beginning problems into normal people for 
comparing T4, T3 or whatever and it’s not actually been able to 
consistently demonstrate that people do any better. So, in the 
current era of evidence based medicine, it is actually if very 
difficult...
Moreover, the established professional thyroid community disapproves of 
‘natural’ preparations, because they are considered to be unstable and 
unsafe and they are currently un-licensed in the United Kingdom. As the 
British Thyroid Foundation states:
There is no current evidence of any advantages of taking 
natural thyroid extract over synthetic thyroxine. The 
disadvantages are that because it is made from pooled thyroid 
glands from animals, which may vary from batch to batch in 
their thyroxine levels, the exact dose of thyroxine cannot be 
estimated precisely. Therefore one dose from one batch of 
tablets may well create different thyroxine levels from the same 
dose in a second batch of tablets. As a result, endocrinologists 
have abandoned using this in favour of the pure form of 
thyroxine, which is chemically exactly the same as that which is 
made by the normal thyroid gland. In this sense, thyroxine 
treatment is as natural as possible (The British Thyroid 
Foundation 2006)
Subsequently, as the two extracts above demonstrate, this disagreement 
about what form thyroid replacement should take embodies the broader 
debates that surround EBM. The established thyroid community, 
represented by the BFT, support the prescription of synthetic thyroxine 
because it addresses broader concerns about standardised protocols of 
efficacy and safety. The alternative thyroid clinicians, such as Dr Durrant 
Peatfield, endorse the prescription of ‘natural’ thyroxine because it is
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considered to be a better match to the hormones that individual patients 
produce.
Thyroid Autoimmunity 
As described previously, the most common cause of thyroid disease is an 
autoimmune response that attacks the gland and hinders its ability to 
produce thyroid hormones normally. There is a theory that the presence of 
auto-antibodies in individuals might cause ill health through mechanisms 
that are independent of hypothyroidism, specifically depression (Pop et al. 
1998). Therefore the persistent symptoms that some biochemically 
euthyroid individuals complain of may not stem from a somataform 
disorder, but from this autoimmune mechanism. However, there is little 
evidence to support this.
Since these factors are as yet unsubstantiated, they have little impact in the 
established guidelines and practices within the clinic -  apart from when 
they are raised by dissatisfied patients who have independently researched 
possible explanations for continued ill health. As discussed in the previous 
chapter, hypothyroidism is usually treated within the primary care system. 
Difficult patients are sent to the Consultant for what is termed 
‘reassurance’, meaning that ‘problem patients’ will hopefully stop contesting 
their diagnosis and treatment in the light of what the more experienced 
specialist advises. However, much to the bemusement of the Consultant in 
the clinic that was observed for this study, often this did not happen. As he 
reflects in the following quote, his expertise was often questioned:
Urn, I think it’s odd that people can say my uncle had that, or 
my grandmother or the cats nephew had radio-iodine there and 
didn’t do well there so, I’m not doing it and I just sort of think if I 
went to QuickFit [?] and said I need, you know, and they said, 
look, part three of your exhaust needs doing, I don’t go well, I 
think it’s actually part two and I just think it’s odd that people 
just don’t believe me.
Therefore, although these alternative theories of thyroid disease remain 
unsubstantiated, they do have an impact on the clinic and the practice of 
the Consultant, as much of his work is concerned with convincing 
dissatisfied patients that there is nothing wrong with their thyroid gland. 
Subsequently, these alternative theories saturate the practices of the clinic 
and are also performed alongside the established biochemical standards
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and treatments of thyroid disease. However, the lack of evidence to support 
them means that they are weak in terms of the evidence based discourse 
of contemporary health service delivery that guides the practice of the 
Consultant. Due to this weakness, there is currently very little work being 
done to develop them, therefore maintaining the current definitions of 
disease, specifically the dichotomous and hierarchical relationship between 
biochemical and symptomatic evidence.
This maintenance of the biochemical model of thyroid disease, and the lack 
of investment in research of alternative models of disease, is unsurprising 
as the potential impact of alternative models of thyroid disease would 
include complex and expensive diagnostic tests, for example a genetic test 
to ascertain an individual’s thyroid receptor affinity. In addition, the 
development of a new form of thyroid replacement therapy would almost 
certainly cost exponentially more than the current generic preparation. It 
should be noted that failure to follow up on these research trajectories 
rehearses the EBM patient centred debate, where economic concerns and 
scientific rationality are valued at the expense of patient care. However, as 
the following discussion will demonstrate, this caution is also necessary 
due to the ambiguity of even the most ‘scientific’ of evidence, especially 
when it is situated within the everyday experience of thyroid disease.
Negotiating biochemistry
In February 2000, The Colorado Disease Prevalence Study (Canaris et al. 
2000) was published in Annals of Internal Medicine. Referring to a familiar 
problem, it states that the prevalence and significance of thyroid 
dysfunction remains controversial due to the poorly delineated systemic 
effects of abnormal and, specifically, mild thyroid failure and the unclear 
relationship between symptoms and biochemical thyroid function. Thus, the 
paper sought ‘[t]o determine the prevalence of abnormal thyroid function 
and the relationship between (1) abnormal thyroid function and lipid levels 
and (2) abnormal thyroid function and symptoms using modern and 
sensitive thyroid tests’ (Canaris et al. 2000: 256). The study recorded the 
biochemical thyroid function (TSH and T4), lipid profiles and responses of 
25,862 individuals who completed a hypothyroid symptom questionnaire at 
a state health fair in Colorado during 1995. As detailed in appendix 5, high 
cholesterol is a symptom of hypothyroidism and there is an established
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relationship between mild and subclinical hypothyroidism and raised lipid 
profiles. It is seen, therefore, as a risk factor that could affect cardiovascular 
health. Moreover, this relationship could provide a reason to treat 
subclinical hypothyroidism since prevention of raised lipid profiles could 
influence long-term coronary health.
The Colorado Disease Prevalence Study revealed a prevalence of elevated 
TSH (subclinical hypothyroidism) at 9.5% and decreased TSH (subclinical 
hyperthyroidism) at 2.2%, both of which correspond to similar studies 
(Flynn et al. 2004,Vanderpump et al. 1995). Of those already diagnosed 
with hypothyroidism, 40% had abnormal TSH levels, suggesting that 
clinicians need to monitor patients on thyroid replacement more frequently 
in order to make sure that the regimen fully corrects the inhibited production 
of the gland. Significantly, it was found that ‘lipid levels increased in a 
graded fashion as thyroid function declined’ (Canaris et al: 2000: 526), 
suggesting a long term issue of cardiovascular health. Symptoms were 
reported more often in hypothyroid than euthyroid individuals. Moreover, if 
symptoms were reported to have developed in the last year, the presence 
of the disease, confirmed biochemically, was more likely. The confirmation 
of newly developed symptoms affirms their difference to ‘normal feelings’ 
that may be confused for the many non-specific symptoms of thyroid 
disease. However, in spite of the link between the amount of symptoms 
presented and the temporal onset of such symptoms, the study concludes 
that the relationship between symptoms and biochemistry is ‘weak’ 
(Canaris et al: 2000: 533). The study found that although symptoms 
increased as thyroid function depleted, there was no clear pattern to the 
type of symptoms suffered and the severity of disease. The fact that 
sensitivities of symptoms are low means that disease cannot be ruled out 
even if a symptom is not reported. The possible existence of disease 
without perceptible symptoms compromises the validity of the symptom as 
evidence of disease. The poor predictive power of symptoms means that 
they can produce false positive results.
As this study of disease prevalence demonstrates, within this range of 
evidence, ‘reliable’, ‘repeatable’ and epidemiologically-defined levels of 
thyroid function cannot be linked to their less reliable, individual, 
symptomatic evidential cousins. It shows that even definitive abnormal 
biochemistry is not always tied to symptoms, a point that was often brought
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up by the Consultant in ‘reassurance’ consultations with dissatisfied 
patients in the clinic. For instance, as he reflects:
Nearly 10 % of subjects not taking thyroid medications had a 
thyroid abnormality, which was probably unknown to them, and 
the abnormality was detected because of testing
In the clinic, the deployment of this research was used to destabilise the 
status of symptoms as evidence. Although in some respects this strategy 
also destabilises biochemistry as evidence, it also recapitulates the 
established hierarchy of evidence. Symptoms remain less reliable markers 
of disease than biochemistry and, moreover, ones that are more difficult to 
interpret and connect to a cause with any certainty due to their ambiguity. It 
would seem that current studies of symptomatic evidence acknowledge the 
complexity and indeterminacy of the evidence but, ultimately, opt for the 
treatment option that is safest in terms of the prevailing evidence-based 
tenets of contemporary clinical practice. As stated by a clinician and 
researcher from another hospital who interviewed for this study in 
connection to the administration of T3 and natural thyroxine:
So, in the current era of evidence based medicine, it is actually 
very difficult... you would not get a, you would not get a 
chemotherapy drug on that basis, you wouldn’t start a new 
[unclear] breast cancer prophylactics or a new heart attack drug 
so if you apply the same principles that we have to, to 
everything else, then just because one or two people report 
feeling better, I’m afraid, that doesn’t stand up.
Therefore, even though the biochemical evidence for thyroid disease is 
fraught with ambiguity, it is used selectively by both clinicians and patients 
and coordinated to various orders of thyroid biology that value specific 
diagnosis and treatment strategies. However, due to its evidence-based 
endorsement it maintains the position of the most reliable data with which 
to make diagnostic and treatment decisions. As the Consultant comments 
above, ‘in the current era of evidence based medicine’ such principles have 
to be adhered to.
Deploying indeterminacy through ‘biologisation’
As discussed previously the symptoms of thyroid disease were first 
observed and carefully documented by the renowned clinical physicians 
William Gull (hypothyroidism), in 1874 , and Robert Graves
140
(hyperthyroidism), in 1835. In the last thirty to forty years this initial 
observational ‘evidence’ of disease has been transformed into population- 
derived, standardized reference ranges assessed in the laboratory -  now 
considered the ‘frontline test’ (Association for Clinical Biochemistry 2006) in 
the diagnostic process. However, the assumption that the technology of the 
blood test has simply made professional practice better, standardised and 
more reliable is a gross over-simplification. The measurement of the thyroid 
pituitary axis, the creation of reference ranges of function and the increased 
sensitivity of such tests have meant that sub-clinical measures of thyroid 
function have come into being. These sub-clinical measures suggest mild 
glandular failure and/or evidence that the gland may fail in the future. 
Ironically, therefore, the ‘hard’ biochemical evidence that is supposed to 
make diagnosis more reliable has in fact created a new realm of 
uncertainty: it is not clear if these subclinical categories cause symptoms or 
not. Furthermore, this transformation of the disease from one understood 
through symptoms to one based on biochemistry has led to the subjugation 
of the medium through which most individuals understand and experience 
their disease no matter how severe it is. This disparity produces immense 
frustration on an individual level, as expressed by Janice, a hypothyroid 
woman in her forties:
Yeah, some are, they are quite good at fobbing you off, you 
know, because they think, yeah, well, that’s in this level, 
therefore it’s this. If it’s in this level it means this. They don’t 
think, well, actually, this... Hang on a minute. Step back. This 
person’s showing... If perhaps you look at that, plus her 
symptoms, maybe it does mean that; that we’re not all going 
suddenly into compartments. They want to quickly put you in a 
compartment. You’re in that compartment... Yeah, the results of 
the blood test and they didn’t seem to be very holistic in their, 
you know... I’m someone who strongly believes in a holistic 
approach to health and I’m very into sort of alternative things.
You know, aromatherapies and I have Chinese massage at the 
moment, Indian neck massage, you know, all those sort of 
things as well and looking... And that, I feel, I just feel that 
sometimes they’re not looking at the whole picture...
Moreover, this frustration is not only centred on a tension between 
professional, alternative and lay models of medical practice. It also affects 
how patients experience the symptoms of disease in relation to their 
biochemistry. As Janice recounts:
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I’ve got friends who have got massively high thyroid levels erm, 
and they get the opp, they get opposing symptoms. They get 
what you get with low, and then I’ve got a friend who’s got such 
low thyroid levels she’s on 200 micrograms or milligrams a day, 
and she’s’ a total skinny little rake....Yeah she’s got racing 
heart, erm all the things so I don’t think always its as cut and 
dry with thyroid.
It can be argued, therefore, that biochemically-defined thyroid disease is a 
version of the disease which complicates thyroid pathology and results in it 
becoming even more ill-defined. Conversely, however, this model of 
disease can also represent an individual experience of thyroid dysfunction 
more than sufficiently. As the Consultant who ran the thyroid clinic pointed 
out, many of the patients who attended his clinic were there because they 
were dissatisfied and it was his job as a specialist to reassure them that 
they were getting the correct care. He also added that the majority of 
patients were happy with their treatment and it was successfully treated 
within primary care using evidence based methods. Therefore, it is 
important to note that although the evidence for thyroid disease is 
uncertain, it does not mean that all patients are dissatisfied. The evidentiary 
forms that represent both of these experiences intertwine to comprise the 
definitions and practices of thyroid disease: laboratory tests that measure 
the biochemical activity of the thyroid gland, the palpation of the thyroid 
gland within the outpatients clinic, the symptoms that patients report, and 
the symptomatic detective work that leads a patient’s G.P. to order a 
thyroid function test in the first place.
It is therefore impossible to separate ‘evidence’ that is scientifically 
substantiated from ‘evidence’ which is anecdotal and subjective. Firstly, 
because the symptoms of thyroid disease are difficult to identify as discrete 
entities, they cannot be separated from individual assessments of health 
and well being. Secondly, the disease will not always manifest itself 
symptomatically, even when there is irrefutable biochemical evidence -  as 
demonstrated by the 10% of the respondents in the Colorado Disease 
Prevalence study who were biochemically hypothyroid but who did not 
complain of symptoms. As a consequence again it is clear that the 
technology of the thyroid function blood test, developed to make the 
diagnosis of thyroid disease more straightforward and reliable, has 
fundamentally shaped how thyroid disease has come to be defined and 
attended to within the clinic. This again destabilises the idea that there is a
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single, pre-existing form of evidence that can be unearthed by clinicans or a 
specific pathological lesion in the body identified.
As the medical historian Keith Wailoo (1997) describes in his history of 
haematology, technologies that have been developed throughout the 20th 
century to assist clinicians in their work have become embedded in the 
identity of the disease they have been designed to attend to:
In the twentieth century, doctors have learned to think and act 
through their technologies. That is, two key features of twentieth 
century medicine have been the deployment of technologies by 
specialists and the ways in which technologies such as EKGs 
and fetal heart monitors have assigned coherent meaning to 
particular symptoms and bodily features, guiding the physician’s 
mind and hand. Such technologies have played a large role in 
assigning and ‘identity’ to diseases (Wailoo 1997: 1).
For example, as Wailoo demonstrates, in the early 1980s the acquired 
immune deficiency syndrome (AIDS) was a fragmented collection of rare 
diseases (Kaposi’s sarcoma, pneumonia, tuberculosis). Only after a test for 
human immunodeficiency virus was developed did AIDS become a 
‘discrete, immunologically defined entity’ (Wailoo 1997 :4). This shaping or 
‘looping’ effect on disease by diagnostic and therapeutic technology is 
clearly demonstrated in the case of thyroid disease. The invention of tests 
that, with increasing sensitivity, have focused on the negative feedback 
loop between the thyroid and pituitary gland has transformed the identity of 
thyroid disease over the last century. The collection of non-specific and 
idiosyncratic symptoms caused by various states of thyroid dysfunction, 
have been calibrated to the thyroid pituitary axis. Subsequently, they have 
been reigned into the narrative of thyroid biochemistry, ordering them and 
the overall disease into a more coherent linear form. Moreover, as well as 
making the disease legible and pulling it into line with the current tenets of 
EBM, the technology of the thyroid function blood test has also 
fundamentally changed its traditionally symptomatically-defined borders.
Clinicians who are sympathetic to the grievances of dissatisfied patients are 
critical of the increasingly biochemical definition of thyroid disease and see 
it as proof of the negative consequences of EBM on good clinical practice. 
Clinicians such as Dr Gordon R.B. Skinner and Dr Barry Durrant-Peatfield, 
for example, believe that reliance on thyroid biochemistry erodes the 
clinical skills traditionally used to translate symptoms into a clinical
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diagnosis. In contrast, clinicians and patients groups (such as the BTA and 
its affiliated patient group the BTF) who think that the diagnosis and 
treatment of thyroid disease should be led by evidence-based biochemical 
reference ranges believe that such an approach ensures safe and 
efficacious practice. In addition, as Armstrong (2007) would claim, such 
evidence-based practice also protects the profession from threats to their 
expertise by commercial and state pressures. That is, biochemical 
reference ranges provide a firm, professionally-mediated categorisation of 
thyroid disease that can, to some extent, deflect and debunk lay theories of 
disease and subsequent demands for untested treatments. Moreover, this 
firm definition of thyroid disease means that established and economically 
viable treatments are maintained as the standard. However, this tension 
between these evidence based and patient centred approaches to thyroid 
disease, and the partial explanation of thyroid disease they generate, often 
provides the basis for further strategies that attempt to attend to this non- 
compliant pathology. As has been described a number of patient activist 
groups, dissatisfied with the treatment they receive, use the indeterminacy 
of evidence to construct an order of thyroid biology that can account for 
their suffering and justify additional treatment strategies. For instance, 
patients and sympathetic clinicans imbue symptomatic evidence with 
greater authority on the grounds that they are a more accurate expression 
of their individual biology. They also claim that thyroid extracts derived from 
animals are a more efficacious treatment because they are more ‘natural’ 
and therefore absorbed by their bodies more efficiently.
Thyroid disease, therefore, is not only medicalised by clinicians (through 
the application of the thyroid pituitary axis), but is also ‘biologised’ by 
various groups of dissatisfied patients. That is, patients make themselves 
objects of an alternative biology of the thyroid gland in order speak to, and 
then contest, the language of the thyroid clinic and hopefully secure their 
desired diagnosis and treatment. As Charis Cussins (1996) claims in her 
ethnography of an infertility clinic in the United States, such acts of 
objectification give patients agency and actually enable them to participate 
in the process of their treatment. That is, individuals objectify their bodies 
during various points in the therapeutic process in order to ‘bring about 
desired changes in her [their] identity’ (Cussins 1996: 600). In the case of 
the infertility clinic, the desired change is pregnancy and motherhood, and 
in the case of the thyroid clinic, the desired change would be a symptom-
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free life. In so doing, the traditional humanist argument that ‘selves need to 
be protected from technological objectification to ensure agency and 
authenticity’ (Cussins 1996: 575) is undermined.
For example, the process of ‘Objectification as Medical Operationalization’, 
identified by Cussins, renders particular body parts visible through various 
technological practices in order to make them available to intervention. A 
pelvic examination identifies fibroids, cysts and, therefore, potential causes 
of infertility and subsequent treatments and procedures that can overcome 
them. Similarly, in the thyroid clinic the results of blood tests isolate thyroid 
disease to thyroid and pituitary axis. Therefore, patients in both of these 
locations make themselves compatible with the instruments, drugs, 
procedures and material surroundings of the clinic that promise to bring 
about the desired changes in identity. This process of forming a ‘functional 
zone’ where things of different kinds (individuals, tests, tools) can be 
coordinated is what Cussins calls ‘ontological choreography’. Such 
objectifications allow the coordination of ‘things’ that will realise the desires 
of the subject (e.g. blood test results hopefully identify a cause of 
symptoms that can then be treated).
However, as Cussins also notes, this process does not necessarily 
‘guarantee a seamless and successful solution’. (Cussins 1996: 575). As 
evidenced in the thyroid clinic, such objectifications are only successful, 
and can only facilitate ‘ontological choreography’, if they maintain a 
‘metonymic relation’ to the subject. That is, as soon as the instruments, 
drugs, procedures and material surroundings of the clinic become 
incompatible with, or fail to meet, the desires of the patient, the functional 
zone in which ‘ontological choreography’ takes place disintegrates. 
Consequently, ontological choreography is not achievable for dissatisfied 
thyroid patients because the central tool of the thyroid clinic, the TFT blood 
test, is ultimately incompatible with their subjective desire to eradicate 
symptoms (i.e. the rejection of symptoms by the medical profession as a 
reliable measure of disease means that symptoms are not the focus of 
clinical intervention). Therefore, the desire of dissatisfied patients to rid 
themselves of such symptoms is not sufficiently addressed by established 
tools and practices of the clinic.
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In spite of this, the technical deficit of such established tools does not result 
in the silencing of the desire for a symptom-free life. In fact the technical 
deficit of thyroid function tests (i.e. their ability to account for thyroid type 
symptoms in subclinical and euthyroid individuals) actually enables 
dissatisfied patients to construct orders of thyroid biology that have the 
potential to rid them of their symptoms. That is, the inadequacy of current 
thyroid function tests, coupled with the indeterminacy of the evidence used 
to justify them, results in the ability of patients to negotiate solutions to their 
problems. To be precise, the thyroid treatment gap results in a situation 
where patients and doctors deploy their orders of thyroid biology, and 
specifically hierarchies of evidence, to enter a process whereby they 
negotiate and try reach compromises or even reconcile the ambiguities of 
the disease and each other.
As Rabinow notes, the development of the concept of biosociality was 
motivated by the empirical realisation that molecular control over the 
genome had the potential to remake nature through technique. This ability 
to intervene on the progression of disease within our genes led Rabinow to 
claim that:
it is not hard to imagine groups formed around chromosome 17, 
locusl6,256, site 654,376 allele variant with a guanine 
substitution. Such groups will have medical specialist, 
laboratories, narratives, traditions, and heavy panoply of 
pastoral keepers to help them experience, share, intervene and 
‘understand’ their fate. (1996: 102)
As Rabinow suggests, the ability to intervene in human health at the 
molecular level has had significant implications for how individuals relate to 
themselves and others who might share their faulty genes. He predicted 
that the techniques that promise control of genetic pathology would have 
the social effect of catalysing a collective aspirational quest uniting 
individuals who share faulty genes, and those who care for them, in order 
to gather information and potentially develop cures. In contrast, as 
demonstrated throughout this chapter, the technologies of thyroid disease 
do not facilitate this level of intervention. The inability of blood tests and 
symptomatic schemas to cure -  or even to accurately diagnose -- thyroid 
disease, at first glance, disables patients as individuals intervening in their 
disease. On closer inspection, this technical deficit actually facilitates the 
ability of patients to intervene in their thyroid disease via the construction of
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a thyroid biology that can meet their needs and support their desired 
medical interventions.
In conclusion, it is clear, that ‘definitive biochemical’ and ‘partial 
symptomatic’ evidence are not wholly separable. If we were to reflect on 
the constellations of evidence within the treatment of thyroid disease, it tells 
us as much about the epistemological landscape of contemporary 
biomedicine as it does about the ‘biology’ of thyroid disease. This tension 
between biochemical and symptomatic evidence is a specific example of 
the tension between evidence-based and patient-centred models of clinical 
care. The importance placed on biochemistry strives to rid clinical practice 
of inconsistent and opinion-based clinical decision-making, whilst the 
privileging of symptoms strives to attend to the individual experiences and 
therapeutic needs of the patient.
What is clear from the data collected by this study is that patients and 
clinicians deploy the uncertain aspects of thyroid disease to construct 
particular orders of thyroid biology. That is, the gaps left by the 
indeterminate relationship between biochemical and symptomatic evidence, 
are filled with versions of thyroid biology that deploy this uncertainty to 
satisfy a range of needs, rights and responsibilities. Subsequently, thyroid 
disease is revealed as a weak context for medicalisation because it is 
impossible for the medical profession to discipline thyroid disease into a 
biochemically circumscribed disease category. Instead, thyroid disease 
becomes a location around which a number of thyroid biologies can be 
negotiated and enacted, all of which are intersected by additional social, 
biological, political and bureaucratic trajectories.
Dissatisfied patients implant their lingering, ambiguous symptoms into the 
gap left by the disjunction between the model of the thyroid pituitary axis 
and the symptomatic evidence of thyroid disease. The ambiguous 
symptoms experienced by patients following treatment are thus 
transformed into ‘proof that their individual thyroid disease is not 
represented by the formal biochemical reference ranges currently used to 
diagnose and manage thyroid disease. Consequently, an order of thyroid 
biology is constructed that attends to each individual’s experience of thyroid 
disease through symptoms. Moreover, such patients bolster this particular 
order of biology further by co-opting strategies employed by health policy
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initiatives that facilitate ‘patient choice’. Often patients seek referral to a 
Consultant in order to bypass the ‘generalist’ advice provided by their G.P. 
and to secure specialist expertise that can account for their complex 
biology. Therefore, dissatisfied patients do not reject medical expertise 
completely. Instead they negotiate the terms of thyroid disease by 
restructuring and altering its formal biomedical categories and creating a 
biological order that relates to their symptomatic experience. In the 
concluding chapter I turn to an examination of attempts to coordinate the 
instruments, drugs, procedures and material surroundings of the clinic to 
particular orders of thyroid biology among many of the actors introduced in 
this study so far. In doing so, I attempt to further characterise the process 
that might be described as ‘technically deficient biosociality’ in order to 
trace its implications in both new and not so new directions.
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Chapter 6
Awkward compromises: practicing thyroid disease
Well, the way I think of this is that if I'm writing a national 
guideline, you have to be very black and white in what we say 
so that’s what I call the macro level, i.e., you’re talking about a 
big population. You can then go down to the micro level, which 
is you in your own hospital and what you might do here... then 
the nano level is what you do with an individual patient in your 
office. So, I do different things, at three levels... Consultant, 
weekly outpatients’ thyroid clinic.
There is a difference between what is written, in the form of clinical 
guidelines, and what is practiced within the clinic. However, as the 
Consultant quoted above implicitly acknowledges, these differences are an 
inevitable consequence of the treatment of thyroid disease. As he states, 
guidelines have to be clear and not context-dependent -  ‘very black and 
white’ - as they are widely disseminated and are produced in order to 
regulate practice across a large population. However this does not mean 
that within the practice of a hospital department or during an individual 
consultation, guidelines are -  or indeed should be - strictly adhered to: 
guidelines are produced in broad terms so that they may be applicable to 
varied situations and localities and employed differently within them. This is 
particularly the case when attending to thyroid disease and is due to the 
ambiguity that surrounds how patients experience it and the indeterminacy 
of the evidence used to inform and justify diagnostic and treatment 
strategies. In fact, as referred to at the end chapter two the very existence 
of the guidelines (see Association for Clinical Biochemistry et al. 2005) for 
the diagnosis and treatment of thyroid disease are themselves an attempt 
to reconcile the varied and competing accounts of thyroid disease and the 
practices used to attend to it within the NHS22. Therefore, guidelines are not 
merely a collation of the best available scientific evidence that can be used 
to inform and improve practice. They are, as the creation of the guidelines 
for the diagnosis and treatment of thyroid disease can attest, generated 
from and a dynamic response to the complexity, variability and contingency
22 In a section of the guidelines entitled The Need for National Guidelines’ the 
authors state that it is clear that the different stakeholders of thyroid disease 
(patients, clinicians, laboratory workers) ‘uncertain about many aspects of thyroid 
function testing’ (Association for Clinical Biochemistry et al. 2005: 13). Hence ‘the 
need for national guidelines for something as common as thyroid function testing is 
self-evident.
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of practice across the healthcare landscape. This is clearly apparent in the 
above quote from the Consultant where the varied and often competing 
scales and levels of thyroid disease are navigated by in an array of ways 
through the deployment of the guidelines.
As suggested in the previous chapter, the high level of ambiguity that 
characterises thyroid disease means that it is difficult to discipline through 
established medical models: symptoms and experiences of thyroid disease 
vary to such a degree that broadly applicable terms of practice cannot be 
established. The authority of the biochemical model derives from its status 
as a source of objective evidence, but in the case of thyroid disease this 
diagnostic procedure and its corresponding treatment protocols are 
constantly undermined by the ambiguous and indeterminate relationship 
within and between categories of symptomatic and biochemical evidence. 
The validity of a ‘medicalised’, or specifically ‘biochemicalised’ model of 
thyroid disease, therefore, is weakened and replaced by diverse and 
competing versions of medical and biological knowledge which allow for -  
and derive from -  that uncertainty. This variable knowledge is co-ordinated 
-  or choreographed -  by actors to establish orders of thyroid disease which 
are then negotiated by clinicians and dissatisfied patients in the hope that a 
satisfactory model of thyroid disease can be reached and subsequent 
treatments can be prescribed. What we recognise as ‘thyroid disease’ is 
consequently dependant on a complex array of micro-practices that enable 
us to see and act upon a set of variable conditions. In Mol’s terms, thyroid 
disease is ‘done’: it is enacted through practice -  practices, Mol claims, 
makes disease ‘visible, audible, tangible and knowable’ (Mol 2002: 37).
In this final chapter I engage in a close reading of the work of medical 
philosopher and ethnographer Annemarie Mol to argue both that her work 
offers a useful framework through which to understand thyroid disease, and 
that thyroid disease can offer some additional dimensions to Mol’s 
praxiographic model of disease. In particular, due to the need for both 
patients and clinicans to consolidate specific orders of thyroid biology in the 
pursuit and justification of particular treatments, they can demonstrate how 
the dispersed practices of doing disease, are reconsolidated, arguably 
something that is missing from Mol’s monograph. In the context of thyroid 
disease such dispersed disease practices are performed with the aim of 
constructing rhetorical orders of thyroid biology and pathology that embody
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the possibility of the fulfilment of various needs, rights, desires and 
responsibilities.
Tracking practice
The coordination through practice of various knowledges that ‘hang 
together’ to form what we recognize as a ‘disease’ is an approach to social 
studies of biomedicine developed by Annemarie Mol in her study of 
atherosclerosis. In her study Mol states:
If we no longer presume ‘disease’ to be a universal object 
hidden under the body’s skin, but make the praxiographic shift 
to studying the bodies and disease while they are being 
enacted in daily hospital practices, multiplication follows. In 
practice a disease, atherosclerosis, is no longer one. (Mol 2002:
5)
According to Mol a disease is not an object or thing. It is ‘as much the
practices that intervene in it: the two [practices and objects] go together*
(Mol 2002:156) For example, as Mol demonstrates in the case of
atherosclerosis, the plaques that build up in arteries and cause them to
harden can only become visible through the practice:
‘A microscope is used to look at plaque, while plaque, if it is to 
be practically relevant in a hospital, needs a microscope (and 
dissection, slicing and staining techniques) to make it visible’
(Mol 2002: 156)
Consequently, Mol claims that such ‘Praxographic stories have composite 
objects’ (Mol 2002: 156) - diseases. Therefore, a disease is not ‘a universal 
object hidden under the body’s skin’ nor is it a ‘singular object’ because the 
practices of enacting a disease are multiple. For instance, in the pathology 
laboratory, atherosclerosis is the thickness of an artery, practiced through 
dissection, slicing and staining techniques. However in the clinic, 
atherosclerosis is the pulsations of arteries felt by a clinician during a 
physical examination and the measurement of blood pressure in the leg. 
Therefore, as soon as the practices of atherosclerosis are observed it 
becomes a multiple entity, that is, it is constituted by a number of 
contrasting practices throughout various locations within the hospital. This 
is not to suggest that such multiple enactments are merely different 
disciplinarily perspectives on the disease -  according to Mol they are the 
disease. The ontology of a disease is these multiple practices and through 
enactments of coordination adjustment and shifting they somehow ‘hang
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together1 to constitute a broad understanding of the disease and possible 
ways in which it can be attended to (Mol 2002: 84). As Mol describes, for 
example, test results are added together in order to reach a single definitive 
diagnosis. This addition comes in two forms:
The first form of coordination on which coherence-in-tension depends is to 
add up test outcomes. It comes in two varieties. One of the forms of 
addition projects a common object behind various test outcomes:- ‘the 
disease’. If the projections do not overlap, one of them is made to win. A 
hierarchy is established and the discrepancy between the tests is explained 
away. The second form of addition comes with no worries about 
discrepancies. It does not suggest that tests have a common object. 
Instead, it takes tests as suggestions for action: one bad test outcome may 
be a reason to treat; two or three bad test outcomes give more reason to 
treat (Mol 2002: 84)
Therefore, coordinations are not always smooth, and test results are often 
contradictory. However, these tensions are, as Mol demonstrates, worked 
out through the course of practice and eventually grounds for action are 
provided. In the case of thyroid disease, coordination through hierarchy is 
performed in response to the tension between evidence sources 
(biochemistry and symptoms) that some patients’ reports. Blood test results 
are deemed more reliable as they are considered to be ‘more scientific’ and 
separate from individual feeling of well being. Moreover, coordination with 
‘no worries’ about discrepancies also occurs - patients who display more 
than one established clinical symptom and have ‘perfectly dysfunctional’ 
thyroid biochemistry fulfil the criteria of a ‘classic case’ of thyroid disease. 
This was observed in the only male patient interviewed for the study. 
Robert, an accountant in his early forties, relayed during his interview that 
his level of TSH was 217 m/UL, an according to his Consultant a ‘record’ 
level. He then described that after he had taken thyroxin for about two 
weeks he managed to loose about 30 pounds in weight. Therefore, this 
patient was ‘perfectly dysfunctional’ and also ‘perfectly treated’ as his blood 
test results demonstrated overt hypothyroidism that went on to be treated 
successfully in a short space of time.
The second form of coordination, according to Mol, is the ‘calibration of test 
outcomes’ (2002: 64). This consists of making the results of different tests
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calibrate with each other in order to provide a singular robust diagnosis. 
That is ‘the threat of incommensurability is countered in practice by 
establishing common measures’ (Mol 2002: 85). Subsequently, the various 
tests are made to speak of the same object, which can then be used to 
localize and quantify ‘the disease’. For example, as discussed in detail 
previously, the focus of thyroid disease is the negative feedback loop 
between the pituitary and the thyroid gland - the thyroid pituitary axis. This 
focus means that the action of thyroid hormones at a cellular level is mostly 
ignored. As the Consultant points out, there is probably a lot of ‘silent stuff 
going on at this level. However, as there is no evidence to back these 
theories, the tests for thyroid disease focus on this ‘evidence based’ 
explanation.
According to Mol, therefore, it would be expected that over the course of 
diagnosing and treating thyroid disease the very practices that account for 
its multiplicity are those through which it becomes a manageable object that 
can be attended to in a clinical environment. Therefore, although Mol’s 
study concerns atherosclerosis, it demonstrates the importance of taking 
the praxographic aspects of disease more seriously. As Mol claims:
...’[Ajfter the shift from an epistemological to a praxographic 
appreciation of reality, telling about what atherosclerosis is isn’t 
quite what it used to be. Somewhere along the way the 
meaning of the word ‘is’ has changed. Dramatically. This is 
what the change implies: the new ‘is’ is one that is situated. It 
doesn’t say what atherosclerosis by nature, everywhere. It 
doesn’t say what it is in and of itself, for nothing ever ‘is’ alone.
To be is to be related. (Mol 2002: 53-54)
This focus on clinical practice for the social study of biomedicine is
something that Steven Hass and Stefan Timmermans consolidate in a
recent article that appeared in the Sociology of Health and Illness. They
define practice as follows:
‘Practice refers here to the actual contingent, situated process 
of performing tasks, doing work together, and transforming 
something into something different. An analysis of practice 
concerns, who does what, when, where, and with what 
consequences. By following clinicians and patients around, we 
can map the ways specific diseases foreshadow trajectories 
that are simultaneously deeply clinical, social, therapeutic, 
iatrogenic, political, and bureaucratic. Biology is no longer the 
invisible canvas for social action but both biology and social 
arrangements are continuously recreated as intertwined 
entities...(Hass and Timmermans 2008: 7).
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Mol’s provides an excellent means through which to analyse thyroid 
disease, specifically the ways in which the indeterminacy of evidence is 
enacted in order to construct particular orders of thyroid biology. Moreover, 
in return, this study adds to the purchase of Mol’s work as it provides a 
situation where the closure of enactments and coordinations can be 
observed - an issue, in my opinion, that is not substantially addressed in 
Mol’s monograph. That is, the tension that is indicative between the 
symptomatic and biochemical evidence used to diagnose and treat thyroid 
disease is so great and provides such an unsatisfactory explanation, that 
both dissatisfied patients and clinicians censor such ambiguity, and create 
robust orders of thyroid biology and pathology in order to reach satisfactory 
modes of explanation. Dissatisfied patients evaluate and coordinate 
evidence to a model of thyroid biology that acknowledges a pathological 
basis for their symptoms in spite of ‘normal’ or ‘borderline’ blood test 
results. Clinicians evaluate and coordinate evidence to a model that can 
satisfy the epistemological and economic constraints of evidence based 
practice. Specifically, they privilege biochemical evidence over and above, 
and sometimes in spite of symptoms, because symptoms cannot be linked 
directly to underlying thyroid pathology. In the following section of this 
chapter enactments that coordinate these orders of thyroid biology and 
pathology will be described. The first is in terms of how thyroid biology is 
coordinated to the temporalities biochemical and symptomatic orders of 
thyroid biology. The second is in terms of how particular symptoms are 
attributed and un-attributed -  medicalised and de-medicalised -  in relation 
to these two competing orders of thyroid biology.
Thyroid and Time
If we return to a description of the negative feedback mechanism between
the thyroid and pituitary, gland referred to in chapter four, the relationship is
conceived as being incredibly straightforward. As this description from
Understanding Thyroid Disorders demonstrates:
In healthy people the amounts of T3 and T4 are maintained 
within narrow limits by a hormone known as thyroid stimulating 
hormone (TSH) or thyrotrophin. TSH is secreted by the anterior 
pituitary gland, which is a pea-sized structure hanging from the 
under surface of the brain, just behind the eyes and enclosed in 
a bony depression in the base of the skull. When thyroid
154
disease causes thyroid hormone levels in the blood to fall, TSH 
secretion from the pituitary is increased; when thyroid hormone 
levels rise, TSH secretion is switched off -  a relationship known 
as ‘negative feedback’, familiar to engineers and biologists.
(Toft 1995: 1)
However, if we look at the following quote from Alex, a hypothyroid patient
in her mid-thirties, the relationship between a disturbance in this
mechanism, visualised through the results of a thyroid function blood tests
and the onset of disease experienced through symptoms, is not so simple.
Specifically the symptoms of dysfunction can be present for a number of
years, and often it is unclear that they are the result of a medical problem:
A:...interestingly one of my friends, who’s a nutritionist, she, 
she wanted to ask me if I had it about 10 years ago, but she 
didn’t like, she thought it would be rude to ask me, so she didn’t 
ask me.
M:‘So what, why, what made her think that?
A:‘Coz my eyebrows are partly missing.’
M: ‘Oh and that’s it, the left, the outer third?’
A: ‘Yeah. The outer third of my eyebrows are missing and she 
spotted that and she wanted to ask me.’
M: ‘Is that the only thing she spotted, just that?’
A: ‘Apart from I was really fat. Emm, no it could have been that,
I was a lot fatter.’
M: ‘Were you?’
A: ‘I was a lot fatter, yes. I think I was, probably. I was about 12 
stone at that point. It wasn’t the heaviest I’ve been. I’ve been a 
lot heavier than that.
What is interesting here is that Alex is suggesting that there was potentially 
a decade between her developing an under-active thyroid gland, with 
consequent symptoms, and it being diagnosed and treated. Therefore, 
although the biochemical narrative of thyroid disease is helpful, it is also 
problematic because its straightforwardness is often too ‘theoretical’ in 
relation to patients’ experiences of the disease, i.e., the simple cause and 
effect process presented by the biochemical narrative of thyroid disease 
does not map onto the slow and non-specific onset of symptoms that can 
occur over a period of months and even years. The central location of this 
disconnection is the temporality of these two descriptions of thyroid 
disease. The description of the relationship between the thyroid and
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pituitary glands is decidedly lacking in time, or to be more specific, an 
embodied context that provides a narrative that is within the experience of 
patients. Consequently the cause, onset and effect of such a dysfunction 
seems regimented, consistent, and therefore, artificial. Subsequently, the 
relatively straightforward story of how the thyroid gland fails, which is often 
communicated to patients in the accelerated time of the fraught and busy 
clinic, does not match the embodied experience of ambiguous symptoms.
This anomaly is further compounded by what the sociologist Everett 
Hughes (Hughes 1984: 346) identifies as the incommensurability between 
the ‘routine’ of the doctor and the ‘emergency’ of the patient. The routine 
manner in which the consultant approaches ‘yet another’ case of thyroid 
disease is directly opposed to that of the patient, who will be coming to 
terms with an event where their ‘normal’ health has been disrupted. This is 
particularly meaningful in the case of thyroid disease (hyperthyroidism and 
hypothyroidism), as it will have to be managed for life via a daily dose of 
thyroid hormone replacement (or in the case of patients with Graves 
disease, after Radio Iodine treatment). As Alex goes on to state in her 
interview, this disassociation between the model of disease, the symptoms 
that have been suffered over a long period of time and the treatment for the 
condition, seem to be under-acknowledged during the clinical encounter:
A: I’m the kind of person that says no, I don’t want to take 
anything. I’ve never taken tablets in my life, why do I want to 
start now? And especially if someone tells you you’ve got to 
take them for the rest of your life. It’s just like, no thanks.
M: It’s a big deal, yes?
A: Yeah, no, I just walked away and said no I don’t want that. I 
was absolutely adamant. So I thought, well, I’ll do a bit of 
research. I need to come to terms with it on my own not 
someone sitting there saying, ‘oh don’t be silly. Off you go.
Take the tablets. Off you go.’ And you’ve only got 5 minutes to 
discuss an illness that’s going to affect the rest of your life. 
That’s all you’ve got with the doctors. They don’t give you 
anymore time than that.
This disassociation between the routine work of the clinician and this critical 
event in the life of the patient is further demonstrated by the different 
approaches to the prescription of thyroxin, which has to be taken for life. 
Where clinicians see thyroxin as a replacement for what a damaged thyroid 
gland no longer makes, many patients (such as Alex) experience thyroxin
156
as a drug - as something that isn’t natural - which artificially supports their 
metabolism in the long-term, meaning that their disease, whilst managed 
and hopefully asymptomatic, is nonetheless permanent. As Alex claims, 
she usually ‘is the type of person that says no I don’t want to take anything’. 
Therefore, she felt like she needed to ‘research’ thyroxin in order ‘to come 
to terms’ with a disease that she would have for the rest of her life. The 
seriousness of such of such a decision, as Alex demonstrates, seems to be 
undermined by the time of the clinic, where...’ You only have ‘5 minutes to 
discuss an illness that’s going to affect the rest of your life’. The 
straightforwardness, or the assumed ‘obviousness’ of the relationship 
between the thyroid and pituitary gland is reflected in the time that a 
clinician will take to explain thyroid dysfunction and consequent treatment. 
Again this is an example where the biochemical model of thyroid disease 
cannot relate to how patients experience thyroid disease temporally. It 
assumes that this ‘simple mechanism’ can be quickly and easily remedied, 
even though such a treatment will be required for life, often after the 
experience of years of symptoms that have frequently been unidentified 
and undiagnosed.
As one study found (McMillan et al. 2006), the communication of the
diagnosis and treatment of thyroid disease can have a substantial impact
on patient satisfaction. This questionnaire-based survey found that half the
patients who took part (N=138) reported negative experiences of treatment
around the time of diagnosis. This dissatisfaction was centred on delays in
diagnosis and prescription of T4 treatment and/or lack of information
provided about the condition and treatment. The study concluded that
more consultation time may be required initially when a patient is told that
they have a condition that requires life long treatment. Therefore, the clash
between the routine of the doctor and the crisis of the patient impacts on
the quality of care patients feel that they receive. As Emily, a hypothyroid
woman in her sixties explains:
‘... and then I told him. I actually took him a list [of symptoms 
and questions], he was so rushed off his feet he really didn’t 
give a monkeys, to be honest with you. So much for National
Health and this time when I went in he was very perfunctory,
‘Well it’s alright, you’re in the right dosage now. Fine, go to your 
GP test in a year...’
As Emily and also Alex can demonstrate, the temporality of thyroid disease 
is not only multiple, but in conflict. On the one hand the Consultant is
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required to spend time with his patients in order to explain and reassure 
them about their thyroid disease and its treatment. On the other hand, he is 
also required to make sure that he sees as many patients during the clinic 
and so not keep them waiting in the corridor for too long. He is required to 
give both efficient and quality care, a task that, as Emily can attest to, is 
almost impossible and almost always ends in failure.
The measurement of the relationship between the pituitary and thyroid
gland derives its authority from an individual’s thyroid function being
compared against biochemical reference ranges that denote particular
levels of function obtained from an epidemiological population. The
rhetorical robustness of such results deems them ‘unequivocal’. Therefore,
when they are related to the ambiguity of symptoms, they appear to be
definitive because they provide a clear ‘evidence based’ explanation of
symptoms. However, it is clear from talking to patients, such as Alex and
Emily, the certainty of blood tests provide an awkward explanation of a
disease that has, in their experience, been messy, nebulous and embodied
through symptoms that have seeped into their everyday lives over a
number of years. Therefore, blood tests seem an inappropriate means
through which to explain and attend to thyroid disease because they are
too far removed from this experience ‘of not being quite right’. Moreover, as
Alex claims, the clinical endpoint of this model -  the prescription of
synthetic thyroxin for life -  seems crass, as it does not relate to the
creeping temporality of the period leading up to diagnosis, nor the ‘event’ of
being told that one has to take medication for life. The conflict of these two
temporalities and the privileging of the biochemical model of thyroid
disease in current clinical practice guidelines, means that patients are not
only disconnected from the explanation of their symptoms, but also their
treatment. The biochemical model of thyroid disease does not put them at
the centre of care -  they are not treated, their blood test results are. As
Alex reflects, when discussing a private doctor she went to see, and who
prescribed her additional T3 to supplement the standard T4 replacement:
‘Because the thrust of it is, a doctor who’s practicing and who 
is, who suffers, (I think he’s over, over or underactive himself,) 
one of the key issues that he fought against is the way people 
are badly treated in this country when they’ve got a thyroid 
complaint, and that they are very badly dealt with. The thrust of 
it is, why they’re badly treated is because, one of his answers is 
that the doctors are quite blinkered and they say, ‘here are your 
blood results and you must be feeling like this because that’s 
what your results say. They’re not actually listening to you.
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And I know that from other people that have said,’Well I’m 
feeling terrible, but my blood results are great and therefore I 
must be feeling great and that’s not the case’. They’re treating 
the blood result and not the person.
The decentralisation of their personal experiences, in the diagnostic and 
treatment process, goes against current idioms of patient centred medicine 
that are espoused by health policy initiatives, such as the ‘Patient Choice 
lnitiative’(The Department of Health 2006) in the United Kingdom. 
Consequently, in terms of the rhetoric of patient choice, Alex and Emily are 
not receiving good care because all choice, or more specifically, the 
opportunity to be included and relate to clinical decisions made about their 
care, does not occur due to the mechanistic and straightforward character 
of the biochemical model of thyroid disease. Hence this ‘lack of care’ or to 
be more specific, the subjugation of symptoms as evidence in order to pin 
down thyroid disease into an acceptable evidence based object, causes 
some patients to reject the biochemical model of thyroid disease. The 
inability of such a model to account for individual patient experiences leads 
some dissatisfied patients to redress this imbalance through the 
construction of an order of thyroid biology and pathology that can account 
for their individual experience of symptoms. Perhaps, unsurprisingly, such 
constructions draw on current rhetoric of patient centeredness and patient 
choice that permeate contemporary health policy discourses. However, 
disciplining of thyroid disease through the idiom choice, can also cause 
problems for its diagnosis and treatment.
As Annemarie Mol claims in her recent book The logic of care: health and 
the problem of patient choice’ (Mol. A 2008) that although the inclusion of 
patient choice is a widely celebrated ideal, it can actually jeopardise good 
care rather than ensure it. As Mol goes on to demonstrate through an 
ethnography of a Dutch diabetes clinic, and by progressing the conceptual 
work developed in The Body Multiple, bodies with disease are impossible to 
control - they are often unpredictable and erratic (Mol 2008: 12). This 
characterisation of disease is confirmed by the data collected by Mol and 
by this study of thyroid disease. Moreover, it is one that is also recognised 
by health care workers. For example, as the Consultant reflects in the 
introductory quote to this chapter, there are different and competing orders 
of thyroid disease, some of which fall outside of the explanatory models 
and technologies that have been developed to attend to them. This
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approach to thyroid disease is what Mol calls the ‘logic of care’ (2008: 2) as 
Mol states:
The care that I will come to talk about, is not opposed to, but 
includes, technology. And the technology that I will come to talk 
about is not transparent and predictable, but has to be handled 
with care (2008:5)
However, this understanding of disease is eroded by what Mol calls ‘the 
logic of choice’ that characterises current approaches to health care. The 
injection of choice into health services means that the language of the 
market is mobilised: patients are customers and diseases are products that 
consist of, for example, expected levels of kindness and attention (I Mol 
2008:18). As Mol claims, the problem with interpreting diseases as 
products is that the often erratic and unpredictable course -  or process - of 
disease cannot be accounted for. In the context of thyroid disease, the 
transformation from process to product is even more acute: it responds not 
only to the patient consumption of health care, but also to another order of 
knowledge - the standardisation of medicine, specifically the 
‘biochemicalisation’ of thyroid pathology.
On the one hand, patients such as Alex and Emily are using the idiom of 
choice that saturates NHS health service delivery (Wanless 2004), asking 
for care that is tailored to them as individuals. At first glance it is an odd 
thing to criticise, as giving patients the choice to select treatments that are 
appropriate for them as individuals appears to positively democratise health 
care delivery and transforms patients from passive objects of medicine into 
subjects who have a right to make choices about their own health. 
However, in order that patients can choose an intervention that suits them, 
thyroid disease and its treatment needs to be pinned down -  and so 
transformed into a product - and yet the ambiguity of thyroid disease 
evades such definition. Thyroid disease ‘as a product’ therefore directly 
contradicts and clashes with its ambiguous character, and leaves Alex and 
Emily with a set of expectations that cannot be met. It is sometimes 
impossible to predict if the treatments prescribed for thyroid disease will 
alleviate the many non-specific symptoms of the disease -  symptoms that 
may or not be caused by thyroid dysfunction in the first place.
In addition, the purpose of the biochemical model of thyroid disease is to 
eliminate subjective accounts of disease and transform thyroid pathology
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into a clean evidence-based object. The idiom of standardized medicine, 
specifically its ability to provide an objective account of thyroid disease, 
contradicts the choice model of health care. The choices patients could 
make about their disease management are removed by the over­
standardisation of thyroid disease. The grey areas that are apparent 
between forms of evidence and the diagnostic categories of disease, are 
glossed over and ignored in order to provide a clear biochemical identity of 
the thyroid that is robust enough to be applicable across the general 
population and that results in a standard treatment regime that can be 
implemented in a uniform manner across the health service. Subsequently, 
the disciplining of thyroid disease by order of patient choice and 
standardization, creates two competing accounts of the disease, neither of 
which can fully allow, or account for, the ambiguity of thyroid disease.
If we return to the competing temporalities of thyroid disease, the 
constructions of an alternative and ‘symptoms and person first’ order of 
thyroid biology and pathology can be observed. For dissatisfied patients, 
whose thyroid function falls on the borders of the reference ranges, it is 
claimed that the measurement of TSH does not represent the action of their 
thyroid hormones. As outlined in the previous chapter, many believe that 
the relationship between biochemical measures and symptoms is 
questionable because the model is only looking at a ‘snapshot’ of function. 
I.e. only how much TSH and T4/3 is being produced at the time of the blood 
test and not how thyroid hormones are being utilized at a cellular level for a 
sustained period of time.
As introduced in chapter five, Thyroid U.K. is a patient organization that
campaigns on behalf of people who are experiencing symptoms of thyroid
disease, but whose blood test results are ‘normal’ or ‘borderline’. They also
provide support for individuals who still suffer symptoms after treatment.
They claim, with regard to thyroid function tests, that:
With all of these tests, your results could be anywhere within 
the range and you would be classed as ‘normal’. If you are at 
the very edge of the range, either at the bottom or at the top, 
you could be classed as ‘borderline’. Neither you nor your 
doctor truly knows what your normal is, if you did not have a 
blood test done before you became ill. There are also particular 
reasons why the blood tests remain in the normal range. If you 
are not converting from T4 to T3 or if your cells are not taking 
up the T3 normally, your T4 levels and your TSH levels will still 
show as normal. (Thyroid U.K)
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This rehearses a more general disparity between the individual experience 
of thyroid dysfunction and the population-derived reference ranges that are 
commonly used to define thyroid health (by defining the action of their 
thyroid hormones at a cellular level, i.e. how they are utilised (or not) once 
they have either been produced by the gland or supplemented via 
replacement thyroxine). The problem identified by Thyroid U.K. and other 
such groups can be broadly interpreted as the inability of the biochemical 
model to fully account for the functions of the thyroid beyond the thyroid 
pituitary axis. Not only, as Thyroid U.K. claim, is this model unable to relate 
to symptoms, but it also excludes the action of thyroid hormones once they 
have been produced/supplemented. Therefore, for dissatisfied patients and 
sympathetic clinicians, the issue of thyroid function has two dimensions -  
production and consumption. As Thyroid U.K. state in the ‘why blood tests 
go wrong’ section of their website:
...All these tests are subject to errors which have to be carefully 
borne in mind when interpreting them:
The blood tests themselves are not sensitive enough and each 
laboratory that undertakes them uses different methods and 
may have different reference ranges.
They represent a snapshot of levels of thyroid hormones in the 
bloodstream which are subject to daily, even hourly, variation, 
so that the time of day and circumstances of the test may cause 
inaccuracies.
In hypothyroidism the circulation is slowed to a variable degree, 
interfering with accurate estimation.
In hypothyroidism the blood is subject to a degree of 
concentration, also resulting from the slowed circulation, and 
this has the effect of raising blood levels above their true figure. 
Most important is the slowed T4 to T3 conversion, together with 
the slowed uptake of T3 into tissues affected by low 
metabolism, so that the mechanisms within the cell to aid the 
passage of thyroid hormones into the cell are damaged. The 
action of the cellular power source, the mitochondrion, is 
similarly slowed. This means blood levels may be raised 
because thyroid hormone is not being used in the normal way. 
Many doctors lack the basic training in thyroid medicine to 
interpret the results of the tests correctly. Frequently they hope 
that the laboratory results will do the interpretation for them; but 
without a full clinical history, and perhaps other tests available, 
the interpretation may be wrong.’ (Thyroid U.K: 2007)
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The broad criticism made by groups such as Thyroid U.K. against the 
standard thyroid function blood test is of its inability to place the disease in 
context and interpret it as a process - more specifically, as a process that 
conforms not only to their biological theories of thyroid function, but also to 
their temporal experience of symptoms. For example, as outlined above, 
blood tests only provide a ‘snapshot’ of thyroid function where there is a 
‘concentration’ of thyroid hormones in the blood and do not necessarily 
reflect the true ‘circulation’ and ‘action’ of thyroid hormones in the body. 
This snapshot, it is claimed, could be the reason why they have symptoms 
in spite of euthyroid blood test results i.e. there is something else going on 
with the thyroid and thyroid hormones that is not picked up by this 
‘snapshot test’.
Thyroid urine tests are an alternative means of measuring thyroid function 
that may better provide a ‘full picture’ than blood tests. Alternative thyroid 
practitioners and dissatisfied patient activists consider thyroid urine tests to 
be more reliable because they measure the consumption of thyroid 
hormones over time (24 hours). As described on the IWDL Genova 
Diagnostics website (a private testing laboratory endorsed by such 
dissatisfied patient groups), the thyroid urine test is useful because:
The diagnosis of hypothyroidism is usually made almost 
exclusively from measurements of Thyroid Stimulating Hormone 
(TSH) and Thyroxin (T4) levels found in blood tests. However 
this method is thought to be largely ineffective at diagnosing 
cases of milder hypothyroidism, more accurately termed 'thyroid 
dysfunction'. Laboratory blood test techniques give information 
only about the hormonal status of a patient at a particular point 
in time. The elevation of hormone levels in urine, however, 
assess tissue exposure to thyroid hormones over a 24-hour 
period.
The urine thyroid test therefore serves as a valuable tool for 
detecting thyroid dysfunction that may otherwise go undetected 
through standard blood tests. It is important to use this test as 
an adjunct to other indicators of thyroid function, such as body 
temperature, symptomology and standard blood thyroid tests 
(IWDL Genova Diagnostics 2006)
This test, therefore, embodies a biological order of thyroid disease that 
relates to the idiom of patient choice. It reflects their individual embodiment 
of disease and provides an explanation for their disease as they experience 
it. It is a model that can account for those elements of the formal
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biochemical model of disease with which such activist groups are 
dissatisfied.
Whilst these fringe practices claim greater authority through deeper
understanding of thyroid hormone action, their approach is not practiced by
the established clinical thyroid community, including the clinic that was
observed for this study. Within the clinic and the pressurized environment
of the NHS, only ‘the proven’ evidence-based methods of diagnosis and
treatment are used. As the Consultant pointed out when talking about such
alternative diagnostic and therapeutic approaches to thyroid disease:
So, in the current era of evidence based medicine, it is actually 
very difficult... you would not get a chemotherapy drug on that 
basis. You wouldn’t start a new [unclear] breast cancer 
prophylactics or a new heart attack drug. So if you apply the
same principles that we have to everything else, then just
because one or two people report feeling better, I’m afraid, that 
doesn’t stand up.
The Consultant calibrates and coordinates thyroid disease to the time of the 
established model of the thyroid pituitary axis -  in spite, as he admits, of 
the fact there may well be a lot of ‘silent stuff going on that such a model 
cannot account for. However, as demonstrated above, there is an 
alternative order of thyroid disease that is also bought into the clinic. This 
order harnesses a version of thyroid biology which has a temporal narrative 
that relates to the quality of life and health expectations of individual 
patients. Moreover, it harnesses the possibility of the ‘silent stuff that 
maybe occurring and uses it as a further justification that supports their 
order of thyroid biology.
The practice of these thyroid biologies, in Timmerman’s words, are 
foreshadowed by trajectories that are ‘deeply clinical, social, therapeutic, 
iatrogenic, political, and bureaucratic.’ (Hass and Timmermans 2008: 7) 
The ambiguity of thyroid pathology is made available to medical knowledge 
and intervention by stabilising it biochemically, an approach which is in turn 
influenced by attempts to standardise and rationalise medical practice. In 
response, patients for whom this formal model is inadequate, deploy the 
idiom of ‘patient choice’ embedded in current healthcare policy initiatives 
(also ironically intended to rationalise the health service) in order to have 
their disease understood through a biological order which relates to their 
individual experience of the disease. The cooption of this market driven 
approach to healthcare means that these dissatisfied patients (intentionally
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or not) become customers who demand a product (diagnosis, treatment, 
level of service) that addresses their individual needs. Subsequently, the 
biology of thyroid disease becomes intertwined with these particular social 
arrangements. Because it is vague and ambiguous it provides a context 
where the negation of these competing orders is possible. Thus thyroid 
disease, is again revealed as a weak context for medicalisation, or 
specifically, biochemicalisation, because its biology is so non-compliant.
In the following section, these various orders of thyroid disease will be 
discussed in terms of the symptoms of the disease and their medicalisation 
and de-medicalisation in relation to thyroid pathology. It will be 
demonstrated that the tensions between these varied orders are such that 
their negotiation is often fruitless and fails to co-ordinate an approach to 
identifying and treating thyroid disease that is workable.
Medicalising and De-medicalising
The process of de-medicalising and re-medicalising certain types of 
evidence is an aspect of thyroid disease most apparent within the practice 
of the clinic. In the clinic, symptoms are frequently de-medicalised and 
deemed the result of something other than thyroid disease. This is 
especially the case for hypothyroid (both primary and post Rl) individuals 
who complain of the persistence of symptoms in spite of thyroid 
biochemistry that falls within the reference range. In similar cases 
encountered as part of this study, the Consultant would simply confirm that 
the blood test results were within the reference range and that any 
continuing symptoms were not caused by thyroid dysfunction. For the 
Consultant, treatment outside of the parameters set by the thyroid pituitary 
axis was thoroughly unethical. However, he admitted to adjusting the 
position of the TSH within the reference range in order to provide treatment 
with a placebo effect (i.e. He moved TSH levels up to the high end of the 
reference range by administering thyroxine because some patients 
believed that this higher end of the reference range made them feel better). 
However, the Consultant was adamant that there were limits to this practice 
of ‘fooling a patient’. As he explains:
The problem with the placebo effect, you might say well, why 
don’t we just use it then is that it’s, it’s not sustained. So, if you 
have a bad relationship with your husband and you attribute
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that to your thyroid status, if you correct that thyroid status and 
you believe this will improve. If you have a bad relationship with 
your husband, a year or two later it’s going to reappear so I just 
think there’s something fundamentally wrong in a sense, fooling 
a patient for not making them address what is the issue. Why 
someone should be told that actually, you know it’s not their 
thyroid really, but here’s some T3 and it will get better.
Therefore, although he is manipulating the level of TSH by prescribing a 
little extra thyroxin he is doing it to make biochemical measures of thyroid 
function more convincing. These adjustments still do not mean that the 
patient’s thyroid function falls outside the reference range. Consequently, in 
spite of this manipulation the Consultant can still be considered to be 
practicing ethically and within clinical practice guidelines. However, this 
practice also indicates that there is something inadequate about the 
biochemical model. That is, if there is no discernable difference in 
symptomatic presentation between patients whose thyroid function fall at 
different points within the reference range, and the placebo effect is 
unsustainable, why does the consultant engage in this practice? Moreover, 
by deploying this tactic isn’t he in fact treating patient preferences and 
beliefs and not thyroid pathology? It is impossible and un-helpful to 
suppose why such practice occurs. However, what this vignette 
demonstrates yet again, is the slippage between biochemical and 
symptomatic orders of evidence - the indeterminacy between and the 
impossibility of making these two orders account for each other. As a 
consequence, it is perhaps no surprise that patients find such evidence 
frustrating and nonsensical. In spite of claims to the otherwise it is clearly 
not definitive as it is manipulated in multiple ways through the course of 
diagnosis and treatment. Therefore, although the rhetorical models of 
thyroid biology and pathology presented by the professional clinical 
organisations and affiliated patient groups (e.g. The BTA and BFT) and 
dissatisfied patients groups and sympathetic clinicians (e.g. Thyroid UK, 
The TPA, Dr Barry Durrant-Peatfield and Dr Gordon RB Skinner) have the 
persona of neat ordered entities, they are in fact borne out of the very 
ambiguity and indeterminacy of thyroid disease and its associated 
evidence. They are attempts to consolidate the ambiguity of thyroid 
disease, that draws on the available discourses of the clinic (for example 
EMB and patient centeredness), and transform it into an object that can be 
intervened upon. They are what Mol (2002: 69), drawing on the work of 
STS scholar John Law (Law 1994), would call ‘modes of ordering’, mini 
discourses that are embodied and performed by patients and clinicans, and
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that interact with each other during the course of navigating and acting 
upon thyroid pathology.
As has been consistently demonstrated throughout the thesis, such
attempts often fail and can never quite fully account for the non-compliant
biology of thyroid disease. As a result orders of thyroid biology ‘do the best
they can’ to explain and develop strategies to attend to thyroid disease.
This can be seen in another vignette provided by the Consultant in an
interview. In the following extract he describes a consultation in which a
post Rl woman complains of symptoms despite receiving a maintenance
dose of thyroxin that has rendered her thyroid biochemistry within the
reference range:
I saw a girl privately last week who feels a lot worse now with 
the normal thyroid function than she did when she had Graves 
disease. So all I could say to her was that there were 
psychological issues. But even then, her test was normal, and it 
can be up to a year before you feel like that [normal]. She 
clearly was having panic attacks because I did a breath 
challenge and she went all panicky and that reproduced the 
symptoms. So there was a clear anxiety issue. She was young 
girl in her 30s, single; I didn’t quite know what was going on.
But there’s quite a lot of psycho-pathology around as well, so 
she wasn’t one of life’s copers at this point and, urn, and it’s 
when you say ‘well just go on a holiday’, you know there were 
lots of reasons why she couldn’t do that...I’m thinking well these 
people are just... it’s just desperation for a physical label. 
People aren’t prepared to accept psychological diagnosis. I 
mean, with thyroid disease I don’t think we do it very well but 
with diabetes we have a psychologist on board and I would say, 
whenever I send anyone she would say 100%, a little 
depressed so, and if you look at Addison’s disease, which is 
another hormone deficiency, steroid hormone, if you do quality 
of life test they’re twice as bad as the general population.
This negotiation of orders of potential intervention involves what Mol would 
call the ‘calibration’ of thyroid disease to the thyroid pituitary axis. That is, 
the Consultant attributes the continuing psychological symptoms to a 
‘psycho-pathology’ which is present in spite of normal blood tests and, 
which is therefore, a separate issue to the thyroid disease (that is ‘no longer 
present’). However, the Consultant’s account also reveals a significant 
amount of uncertainty as to what is actually ‘going on’. The de-medicalising 
and re-medicalising of psychological symptoms thus calibrates this 
woman’s thyroid disease to the thyroid pituitary axis only in part. As the 
consultant describes, all he could tell her was that there ‘were 
psychological issues’ but that even then ‘he wasn’t sure what was going
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on’. The ensuing ‘desperation for a physical label’ demonstrates not only 
feelings of stigmatization bought about by a psychological label, but also 
the failure of the model of the thyroid pituitary axis to provide a physical or 
biological label. As the Consultant’s account demonstrates, diagnosing and 
managing thyroid disease is fraught with uncertainty and ambiguity. The 
indeterminacy that is left by the model of the thyroid pituitary axis means 
that the Consultant’s expertise is questioned, not only by patients, but also 
by himself. In this instance, the Consultant relays the limits to the certainty 
with which he can calibrate symptoms to thyroid disease.
The medicalisation, specifically, biochemicalisation of thyroid disease is 
also shown to be problematic when treating patients with biochemistry 
outside of the reference range, but who display no symptoms. In contrast to 
the ‘problem population’ of those who claim an under-active thyroid gland 
through the manifestation of symptoms and borderline biochemistry, this 
population has the disease but very few symptoms that are considered to 
be perceptible and/or problematic. As Beth, a Graves patient in her mid­
twenties, explains:
You know, I just, I didn’t, I just thought it was me. Because I am 
a bit manic. I am a bit all over the place. I’ve always been like 
that, urn, a bit kind of like oh, about doing ten things at one 
time. But I think that feeling unwell on the tube, I just attributed 
it to me running late and it being hot. But I never really thought 
that, I didn’t think anything of it, the sweating and that kind of 
thing, I’ve got to get out of here, like, because my heart’s 
beating really fast. And every night I was, kind of, finding it 
really hard to get off to sleep because it was always at night 
that it was worse. So, it all kind of started to fit into a bit of a 
picture, that perhaps I’d acclimatised slightly to, or I just 
attributed it to just normal stress and normal stresses of 
everyday life.
Furthermore, the Consultant explains, and as evidenced by the Colorado 
Disease Prevalence Study (Canaris et al. 2000) discussed in chapter five, 
sometimes there is little rhyme or reason as to why some people are 
symptomatic and others are not:
Basically all of us are miserable and most of us are gaining 
weight, most of us have dry hair, losing hair, dry skin. You 
know, they’re all things we all have and just because your TSH 
is four, five, three, two or one doesn’t really make much...I have 
seen people with a TSH of more than 100 that feels fine so, you 
know...
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Again, this Consultant acknowledges the weakness of the biochemical 
model of thyroid disease: he claims that thyroid function tests were 
originally developed to locate the thyroid pathology underlying thyroid type 
symptoms. By stating that ‘I have seen people with a TSH of more than 
100 that feel fine so, you know...’ is the Consultant acknowledging that the 
link between thyroid biochemistry and thyroid disease can be as uncertain 
as the link between symptoms and thyroid disease. However, even though 
he is aware of this disparity, he perseveres with the coordination of thyroid 
disease to the biochemical model because it is the only one available to 
him. Given that he is not prepared to offer treatment that is contrary to the 
guidelines, he has no other options. Although he is aware that the current 
tools used to diagnose thyroid disease may be insufficient for some 
patients, there is no evidence-based alternative currently at his disposal. 
He goes on, then, to suggest how little he and his colleagues are able to do 
for patients who are within the biochemical reference range of healthy 
thyroid function yet whom complain of symptoms:
So I think that, you know, as my, I’ve got a very, the top 
thyroidologist in America and I was at a meeting with him last 
week and I said what do you do when a person with a TSH of 
1.5 on Thyroxin has symptoms of hypothyroidism? He says 
there’s nothing I can do.
The pressure brought about by the insufficiency of the thyroid pituitary axis
model is heightened by the dissatisfied patients who take information about
alternative biologies of thyroid disease to the clinic. As the Consultant
explains, in cases such as this he feels cornered:
Maybe there’s a way of dressing it up, but actually I’m not sure.
I mean, usually in that sort of consultation I’m thinking if I get 
away without a complaint here I’ve done well. With that sort the 
focus is on escaping alive and you know, I know I’m never 
going to help them without even saying anything...
The Consultant’s desperate wish to ‘escape alive’ is caused by the 
response of dissatisfied patients to the inertia of the biochemical model of 
thyroid disease when it is applied to their order of thyroid disease. As 
discussed in the previous chapter the lack of an explanation for their 
symptoms causes distress and a worsening of their symptoms, even the 
development of new symptoms related to emotional and mental stress. For 
instance, as Diana Holmes’ petition to the Society of Endocrinology states,
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current established treatment strategies are considered to constitute 
‘emotional abuse’ by the medical profession. Moreover as the TPA claim on 
their website:
Medical practitioners shelter themselves behind test results, 
which are routinely used to claim more than they test. They 
refuse to listen to their patients or even credit the evidence of 
their own eyes, leaving their patients to remain ill for the rest of 
their lives. It is because of this disgraceful state of affairs that 
TPA-UK was founded (Thyroid Patient Advocacy UK 2005)
Therefore, at the point where the biochemical order of thyroid disease 
cannot provide an evidence-based alternative to explain symptoms, in spite 
of normal biochemistry, and symptoms are unacceptable evidence in terms 
of evidence based practice, both dissatisfied patients and clinicians, who 
feel they are under attack, fill this gap with their own modes of ordering. 
That is, the nature of thyroid disease is so anomalous the patient-expert 
divide becomes to some extent, symmetrical, as both sides are frustrated 
with the inadequacy of approaches to thyroid disease and attempt to 
construct alternative explanatory models that are relevant to them. The 
result of this failure to coordinate thyroid disease to particular biological and 
medical orders means that negotiation between these orders becomes 
impossible. This failure generates a cycle of blame in which these orders 
become increasingly dogmatic and oppositional.
Pathological Blaming
As emphasised in chapter five and again in this chapter, the evidence that 
constitutes the diagnostic categories of thyroid disease is indeterminate 
and uncertain, and as a result that diagnosis can become a stressful and 
conflictual process, but also, as I have suggested, itself a source of 
suffering. This is possibly the most important reason why ‘thyroid disease’ 
cannot be understood as a neutral and singular pathological fact, but is 
arguably more usefully understood as a set of biosocial orders that 
dynamically relate to each other. Returning to Rabinow’s concept of 
biosociality introduced in chapter two, -  it is possible to suggest that 
dissatisfied patients and clinicians engage in what Mol would call ‘modes 
of ordering’ thyroid biology and pathology through particular evaluations 
and deployments of evidence. However, in contrast to the original
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formulations of biosociality, such practices are not a result of new found 
molecular control over biology. They are a result of a lack of technique and 
control. ‘Modes of ordering’ thyroid biology are, therefore, an attempt to 
make sense of the explanatory gap that characterises thyroid disease 
through the fulfilment of an array or rights, desires, needs and 
responsibilities, such as: choice over health care intervention, a symptom 
free life, the ability and responsibility to practice within evidence-based 
guidelines, that are to hand within the governmental discourses of 
healthcare in the United Kingdom. Consequently, the ‘local biology’ of 
thyroid disease is not geographical, but located around the non-compliant 
biology of thyroid pathology, which eludes all attempts at standardisation 
(either through biochemistry and evidence-based medicine or symptoms 
and patient centred medicine). Specifically, the ‘local biology’ of thyroid 
disease is one of non-compliance that eludes any straightforward 
'medicalisation', ‘biochmicalisation’ or more generally standardisation.
Thus such biosocial ordering demonstrates that thyroid disease provides a 
weak context for medicalisation, because such orders are in part the result 
of a symmetrical relationship between doctors and patients, bought about 
by the ambiguity of thyroid disease. That is, due to the indeterminacy of the 
disease, both clinicians and dissatisfied patients can produce convincing 
accounts of its biology and pathology. However, as has also been 
demonstrated, both of these accounts are partial. Thus the power to define 
and discipline the disease is highly dispersed, but also, ultimately elusive. 
As a consequence such modes of ordering do not result in a smooth 
process of negotiation and eventual treatment. Sometimes such biosocial 
orders are so contradictory, negotiation between them and attempts to fill 
the thyroid diagnosis and treatment gap fail. Specifically, the trajectories of 
patient choice and medical standardisation that foreshadow the thyroid 
clinic, shut down the ambiguity of thyroid pathology. That is, the politics 
embedded in these orders, and in the relationship between them, again 
makes it impossible to account for the ambiguity of thyroid disease. The 
insufficiency of their terms renders consultants ‘lost for words’ and patients 
dumbfounded, distressed and consequently instigates the further retreat 
into their preferred mode of ordering in the hope that an explanation may 
eventually be provided.
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The inability of either order to fully account for thyroid disease results in the 
production of two rhetorical models around which dissatisfied patients, 
sympathetic clinicians and the established clinical thyroid community 
collect. The established evidence-based biochemical order relies on thyroid 
biochemistry to ‘clear-up’ the non-specificity of thyroid type symptoms and 
reach a ‘definitive’ and scientifically reliable diagnosis. On the other hand, 
the non-establishment ‘symptoms first’ order considers thyroid biochemistry 
to be poor evidence of disease because it cannot account for the symptoms 
in a sizeable minority of patients with borderline or normal blood test 
results, often even after ‘successful treatment’. Subsequently, at this point 
these two orders can no longer be negotiated and they are transformed into 
two polarised positions around subjectivity/symptoms/choice and 
objectivity/biochemistry/standardization. Clinicians accuse dissatisfied 
patients, who question the established diagnosis and treatment strategies, 
of wasting time and having unrealistic health expectations. With equal 
vehemence, patients blame clinicians for being unsympathetic and 
practicing ‘technocratic’ medicine. The frustration that these extreme 
oppositional models reveal saturates the day-to-day business of the clinic. 
As the consultant describes his approach to ‘difficult’ patients: ‘I know I’m 
never going to help them without even saying anything because I know 
what peoples’ ideas are...’
So what are the implications of this cycle of blame when it is clear that
these conflicting biosocial orders of thyroid disease all have some degree
of ‘truth’. Thinking back to Adriana Petryna’s (2003) insightful response to
her informants’ accounts of health and disease in her ethnography of post-
Chernobyl Urkraine, it is useful to recall her observation that the role of
such studies is not to apportion blame, but to ‘paint a clearer picture of the
dynamic interplay between scientific and social orders, and how those
orders come to define actual conditions of health’ (2003: 12). For example,
if we return look at what some of the dissatisfied patients say about their
suffering, it seems to revolve around the feeling that they are never
optimally treated and are left to struggle with residual symptoms on their
own. For instance, as Briony, a hypothyroid woman in her late thirties, who
feels that her thyroid function fluctuates in spite of consistent blood test
results within the reference range, muses:
I guess I am sort of conscience of the weather. I’m thinking oh, 
what if it turns cold am I going to start suffering more because 
your body won’t be able to respond as fast, it will be slower to
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respond. I did, erm, we had a terrible long winter and spring, 
when it was just cold endlessly and I it did really feel that. I 
don’t know if other people were moaning about it as much as I 
did but...
As Briony demonstrates, there is a constant worry about when symptoms
will appear and if they are due to a disturbance in thyroid function. It is this
uncertainty and consequent worry that seems to contribute to the feelings
of ill health in such patients. This liminal state of thyroid disease therefore
becomes the way in which physical feelings and sensations are analysed
and expressed, as for example, feeling the cold becomes inextricably linked
to the spectre of under-treated thyroid disease, as well as the changing of
the seasons. This constant wrestle with such liminal and ambiguous
categories of thyroid disease seems to seep into all parts of these patients’
lives. For example, as the following quote from Briony demonstrates:
But I’m feeling incredibly tired, incredibly tired. I just know that 
even if I have 9 hours sleep, I had 9 hours sleep Saturday, you 
know Saturday morning I woke up after 9 hours and I just felt 
drained. Sunday I did the same and I just felt drained. And I 
know that I’m really struggling to get out of bed and that isn’t, 
you know that it’s just not working. If I have 8 hours sleep and I 
still can’t get out of bed then I know it’s not right. It’s not right. 
Because I know that when I was a little bit overactive I would be 
ping, wide awake, after 10 minutes. I’m not a morning person, 
now maybe it’s because of thyroid problem that I’m not. I know I 
never have been, but this morning I was just thinking, god I 
must try and get out of bed. Even after I’ve taken the tablets, to 
be honest, it was still like, I don’t know why. The chopping and 
changing of the weather, maybe that’s got something to do with 
it, because you’re body’s got to constantly adjust and readjust 
‘coz, oh, it’s one minute it’s hot, next minute it,s cold, next 
minute its hot. So that could be something to do with it. I don’t 
know, but I’m not, I’m really not right at the moment. But it’s 
surprising, given that after taking the same as I was when I was 
slightly over.
In this interview extract the focus on thyroid disease is expressed through 
the amount of sleep Briony gets and feels she needs. She is constantly 
questioning herself. Does she feel tired because of the symptoms of under- 
treated thyroid disease or is it because she’s just not a ‘morning person’, 
she never really has been after all? But is this in itself because of her 
thyroid problem? Or is it because of ‘the chopping and changing of the 
weather?’ Ultimately this line of questioning ends as many explanations of 
thyroid disease do, with utter uncertainty. As Briony concludes, ‘I don’t 
know, but I’m not, I’m really not right at the moment’. Therefore, this extract 
demonstrates the ambiguity and frustration that surrounds the definitions of
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thyroid health actually contributes to the ill health of patients who find 
themselves in this position. Specifically, as demonstrated by Briony and 
throughout the preceding two chapters, thyroid disease provides a context 
where the imperative of scientific discourses to standardise, has failed. 
Moreover, what results is not a coherent discourse of power but a multiple 
and discordant discourses of power, or ‘modes of ordering’, that attempt to 
muddle through the unusual landscape of this discordant pathology.
In conclusion, it is clear the there are no broadly applicable terms of thyroid 
disease. The thyroid pituitary axis, which has been developed in an attempt 
to establish the boundaries of thyroid health, is constantly undermined by 
the indeterminacy of the evidence it generates (blood tests results), but 
also, the indeterminacy of its relationship to symptomatic evidence. 
Therefore, the deployments of particular evidentiary models of thyroid 
disease can perhaps be best understood as the choreographing and 
coordination or ‘modes of ordering’ of these ambiguous forms of evidence 
through a set of complex micro-practices. To be precise, thyroid disease 
can be defined as a range of ‘attempts’ that ‘do the best they can’ to 
develop a satisfactory model of disease, through the management and 
evaluation of the available, albeit partial and ambiguous, evidence.
As has been described, biochemical and symptomatic evidence is 
coordinated to particular temporalities in an attempt to prove their intrinsic 
authority and justify specific diagnostic and treatment strategies. On the 
one hand, the thyroid pituitary axis, and as a consequence a blood test 
result, is considered to a better and more reliable source of evidence 
because it can be extracted from the subjective and social milieus of the 
illness experience. The straightforward cause and effect narrative of this 
‘simple’ modulated mechanism is lacking in time and as a consequence 
can side-step the subjective nature of individual patients narratives and get 
at the ‘real’ thyroid pathology contained within the gland. On the other 
hand, for dissatisfied patients and sympathetic clinicans, symptomatic 
evidence is more authoritative because it can relate to narratives of 
symptomatic experience. That is, the truth of symptoms is derived from 
their ability to coordinate with the subjective and social milieus of the illness 
experience.
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Therefore, the logics contained in these orders are polarised and often 
mean that they and their protagonists are unable to relate and negotiate 
with each other. For instance, it became clear that the simple 
straightforwardness of the biochemical model espoused by the Consultant, 
often left patients with an unsatisfactory explanation of their thyroid disease 
and a feeling that the care they were receiving was inadequate. That is, his 
simple explanation did not do justice to their experience of suffering and the 
prospect of having to take thyroid replacement therapy for life. In response, 
the Consultant was at a loss about how to respond. He was offering them a 
clear ‘evidence based’ explanation of their disease and ‘subsequent’ 
proven and ‘effective’ treatments. What more could he do? The failure of 
these two orders and groups to relate to each other and feelings of 
dissatisfaction are most effectively shown by the practice and results of 
medicalising and de-medicalising symptoms. As described, the Consultant 
only attributed symptoms to thyroid disease when biochemical evidence 
was present. However, he was often left flummoxed and troubled by the 
continued complaints of patients. He became lost for words because the 
biochemical model he deployed could not explain this gap, and nor could, 
as far as he was concerned, the un-substaniated biomedical theories 
presented by dissatisfied patients and sympathetic clinicans. As a 
consequence, it seems to be the case that the suffering that thyroid disease 
produces is, in part, a result of the inability of either of these orders to fully 
account for it.
In spite of the production of technologies such as blood tests and clinical 
practice guidelines, attempts to standardise thyroid pathology have failed. It 
is clear that both patients and clinicans are aware that the tools through 
which they attempt to understand thyroid disease are inadequate. However, 
in the absence of anything else they muddle through as best they can in 
order to attend to the disease. What is being maintained through this 
process of ‘muddling through’, therefore, is not a rule driven model of 
disease constructed by medical authority, but a collection of dispersed 
practices that gather around and attempt to intervene upon this non- 
compliant pathology. That is, the ‘local biology’ of thyroid disease can be 
characterised as a range of often unsuccessful attempts by clinicans and 
patients to medicalise, standardise or more accurately ‘biochemicalise’ and 
‘biologise’ the non-compliant biology of thyroid disease that results in 
varying degrees of success.
175
Chapter 7
Conclusion: making biology meaningful and the management of
disease
Well, I can’t understand. I mean, I can’t believe I’ve made a 
career out of it. Because I mean, a lot of the people I trained 
with just take the piss. It either goes up or it goes down [thyroid 
function][...]They can’t believe what goes on. But I think if we 
were in the Second World War, I don’t think we’d be worried 
about a TSH of 5.5. Consultant, weekly outpatients’ thyroid 
clinic
As the consultant reflects above, treating thyroid disease should be simple. 
If thyroid function becomes too low and the production of thyroid hormones 
is insufficient, thyroid replacement therapy should be prescribed. If thyroid 
function becomes excessive, the gland should be ‘shut down’ with a dose 
of radioactive iodine and thyroid replacement therapy should be prescribed. 
However, the thyroid does not just go up or down -  it can sit on the 
borders, or leave the realm of biochemistry altogether and seep into 
subjective assessments of health. It may even be a far more complex 
pathology than current ‘evidence based’ diagnostic tools and treatment 
strategies can account for. What is clear is, due to the complex relationship 
between the indeterminate aspects of thyroid disease, the ability of the 
medical profession and patients to control and/or discipline it, is limited and 
elusive. Even the Consultant, who has observed thousands of patients with 
thyroid disease through the course of his career, questions his expertise, 
due to the continuously non-compliant nature of thyroid pathology. On one 
hand, he ‘can’t believe’ he has a ‘made a career’ out of such a simple and 
straightforward disease. On the other, his colleagues ‘can’t believe what 
goes on’, and ‘take the piss’ out of how such a simple disease is so difficult 
to manage. The Consultant attempts to explain this situation by inferring 
that thyroid pathologies themselves have not changed. They are as 
straightforward as they have always been, but what has changed, is patient 
expectations of health and the health service. By suggesting that ‘if we 
were in the Second World War, I don’t think we’d be worried about a TSH 
of 5.5’, he is inferring that the increased health awareness of the population 
is detrimental to the delivery of health care. To be more precise, as the 
endocrinologist Dr Anthony Weetman claims, there is the suggestion that:
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[...] we [clinicians] are practising in the age of post-modern 
medicine. A cardinal feature of post-modernism is the 
derogation of objective facts, which are the defining 
characteristic of science and the replacement of scientific 
certainty with the view that reality can have multiple meanings. 
(Weetman 2006: 231)
Hence, patients, often through access to information found on the Internet, 
will refuse to believe what doctors tell them, will claim they have thyroid 
disease and ask for subsequent treatment strategies, for which, as yet, 
there is no sound evidence base.
As has been demonstrated at points throughout the thesis, biomedical 
knowledge about thyroid disease is by no means comprehensive and 
certain. Using the praxographic approach, developed by Annmarie Mol, and 
through an analysis that charts how formal biomedical knowledge 
(contained in documents such as clinical practice guidelines) interacts with 
the practices of the clinic and the bodies of patients, it becomes clear that 
thyroid disease is at times singular and straightforward, but at others, 
multiple and complex. For example, genetic predispositions to thyroid 
disease are well established, yet almost tangential to their diagnosis and 
treatment. A goitre is a ‘classic’ physical sign and symptom of thyroid 
disease, but can also be considered a ‘normal abnormality’ that does not 
necessarily impair thyroid function. Some patients found that their disease 
could be sufficiently explained and treated through the application of the 
biochemical model of thyroid function. However, others found that this 
model did not represent their thyroid disease sufficiently, and as a 
consequence not only failed to alleviate their suffering, but increased it 
through the frustration and distress caused by the failure to define and 
attend to it through the methods currently favoured within the NHS.
It can be argued, therefore, that the standardisation of thyroid disease 
through biochemically, circumscribed states of normalcy and pathology, is a 
successful strategy of intervention. It clears up the ambiguity of thyroid 
disease by disciplining in into a clear-cut set of diagnostic entities that can 
satisfy the requirements of EBM. Specifically, it provides a population- 
based category of disease that ensures that treatment is only given to 
patients who can be diagnosed with certainty, or to be more precise, 
certainty derived from rigorous scientific methodology. However, this ‘mode 
of ordering’ thyroid disease is also insufficient. The certainty that is
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apparently derived from biochemically ascribed categories of thyroid 
disease, when investigated qualitatively, is at times highly uncertain and 
results in unsatisfactory treatment outcomes. In particular, the population- 
based biochemical reference ranges, used to denote states of thyroid 
function, cannot account for the expression of thyroid pathology, specifically 
the experience of symptoms, in all patients. Often patients who fall on the 
borderline between healthy and unhealthy thyroid function and who 
experience symptoms, or those who have received treatment and also still 
experience symptoms, are not dysfunctional enough in terms of the tenets 
of standardised care. In particular, their experience of symptoms does not 
satisfy the evidentiary requirements of the biochemical mode of ordering 
thyroid disease, because symptoms are considered to be anecdotal and 
non-specific and therefore unreliable. Consequently, such patients inhabit a 
liminal category between health and disease; they can demonstrate the 
‘classic’ clinical symptoms of thyroid disease but not the biochemical 
evidence that is needed to justify treatment within the contemporary NHS, 
espoused in clinical practice guidelines (Association for Clinical 
Biochemistry et al. 2005).
The limits of the biochemical mode of ordering ironically provide a location 
through which dissatisfied and frustrated patients can potentially overcome 
their unsanctioned experience of thyroid pathology and suffering. As 
described in chapter five, such patients draw on the palpability of their 
symptoms and current rhetorics of patient-centred medicine and develop an 
order of thyroid biology, pathology and treatment that can account for their 
biochemically, no-compliant thyroid disease. Therefore, the limits of the 
biochemical order of thyroid disease are revealed and re-ordered by such 
patients. Specifically, a mode of ordering is developed, where the hierarchy 
of evidence that privileges the results of thyroid function tests, over and 
above the symptoms, is reversed. In contrast to the biochemical mode of 
ordering, signs and symptoms are considered to be more an authoritative 
and reliable form of evidence because they are embodied by patients and 
can be clearly observed and touched by clinicans during the clinical 
encounter. That is, the embodiment of symptoms, far from making them 
unreliable, makes them undeniable evidence of thyroid disease. 
Consequently, patients who order their thyroid disease in this way are able 
to attribute their suffering to an underlying thyroid pathology and potentially 
negotiate treatment for their symptoms.
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The strategic re-ordering of the dominant order of thyroid biology by 
dissatisfied patients and clinicans is particularly meaningful in terms of the 
concept of medicalisation. Irving Zola’s (1972) original formulation of this 
concept can be defined as the process through which the normal aspects of 
everyday life and individual behaviour become placed under the control of 
medical expertise and subject to various biomedical and technical 
solutions. Therefore, the ‘biologisation’ (described in detail at the end of 
chapter five) of non-specific symptoms, by dissatisfied patients, is an 
interesting empirical addition to this concept. The non-specific symptoms of 
thyroid disease, that are also normal feelings and sensations we all 
experience at one time or another, are medicalised or more specifically 
‘biologised’ by patients and transformed into ‘irrefutable’ evidence of 
disease. It is the authority and expertise of patients (their embodied 
experience of suffering) and subsequent re-ordering of thyroid biology and 
pathology, that transforms such non-specific symptoms into a medical 
problem. However, in contrast to the process of medicalisation, this process 
of ‘biologisation’ is practiced by patients in order to contest the formal 
medical model of thyroid disease and transform it into a pathological entity 
that fits with their experience of symptoms and desire for a symptom-free 
life. Specifically, the authority that enables this process comes not from the 
medical profession, but from patients who are dissatisfied and frustrated by 
the inadequacy of the standardised biochemical model thyroid disease.
As a consequence, this reformulation of the concept of medicalisation, 
through ‘autobiologisations’ preformed by patients, has interesting 
implications for the concept of biosociality and more generally, theories of 
govemmentality. Rabinow’s now famous claim that groups will collect 
around specific pathologies, identified by molecular biology, and gather 
together a multitude of experts in order to ‘understand’ their ‘fate’, (1992: 
102) are in part a result of the ability to engineer our vitality, but also, 
reflective of what Rose calls the governmental technologies of ‘advanced 
liberalism’ (2006: 25), where the power of the state over the management 
of human health has devolved to the individual citizens and ‘quasi- 
autonomous regulatory bodies’ (Rose’ 2006: 25). That is, hand in hand with 
the ability to maximise life and health, comes responsibility of citizens to 
maintain their health through practices of ‘care of the self. Governmental 
technologies, that ‘regulate at a distance’ (Rose. 2006: 25), through various
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non-state regulatory bodies, for example, medical associations, or through 
tools such as clinical practice guidelines, are also an attempt to intervene 
upon and control the health of the population. In the classic Foucaldian 
sense, both of these governmental technologies share the same 
imperatives - the management of human health and reproduction - at the 
level of the individual and the population.
What is interesting, in the case of thyroid disease, is the rupture between 
these two abstract systems of governance. Although dissatisfied patients 
and sympathetic clinicans collect around and remake thyroid pathologies, 
(in an attempt to maximise health and act upon themselves through the 
language and practices of biomedicine), they do so in response to the 
technical deficit of current diagnostic and treatment strategies for thyroid 
disease. As described in chapters five and six, the indeterminacy of the 
evidence used to diagnose and treat thyroid disease, results in a number of 
practices, in particular the reversal of the hierarchy of symptomatic and 
biochemical evidence. This reversal, however, is in direct conflict with the 
evidence-based treatment strategies that are offered by the NHS and, as 
has been described, results in the polarisation of these two orders of 
thyroid biology. In this sense, the ‘biologisation’ that patients perform is 
both a form of biocitzenship, in the sense that they are attempting intervene 
upon their biology in order to optimise their health, but also an example of 
how these subjective health practices actually clash with other technologies 
of governance, i.e. EBM.
As I conclude, I would like to suggest that in the thyroid clinic, the 
assumption that ‘the care of the self is intrinsically and straightforwardly 
linked to the internalisation of broader neoliberal structures of governance, 
is an inaccurate description of what is going on. That is, although such 
patients are practising what Rose calls ‘somatic ethics’ (2006: 26), they are 
doing so in a way that is out of step with other forms of governance. Whilst 
dissatisfied patients attempt to optimise their health, due to the lack of 
control they and the medical profession have over thyroid pathology, they 
are doing so by drawing on a range of uncertain theories of thyroid disease. 
Therefore, in the thyroid clinic, the relationship between the governance of 
the individual and the governance of the population is far more stratified 
and unintended than theories of govemmentality suggest.
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The results of these various and often contradictory attempts to standardise 
and order the elusive and non-compliant nature of thyroid biology, is a 
situation where these competing orders end up ‘muddling through’, in 
attempts to reach some form of agreement and grounds for therapeutic 
action. That is, using and adapting Lock’s term, the ‘local biology’ of thyroid 
disease can be characterised as a range of often unsuccessful attempts by 
clinicans and patients to medicalise, standardise, ‘boichemicalise’ and 
‘biologise’ the non-compliant biology of thyroid disease. This troubled 
relationship between the individual and epidemiological plains of thyroid 
disease, often stabilises the traditional categories of power, in particular 
categories of gender. It is clear that the anecdotal evidence provided by the 
largely female population of dissatisfied patients, is often attributed to the 
character of the irrational, over emotional and ‘hormonal’ female patient (for 
example see Daggett: 2000). Thus, as a number of studies (Bharadwaj 
2008, Gibbon 2008, Roberts 2008), and Rabinow (1996: 103), himself 
pointed out, biosocial practices are capable of reinforcing traditional 
categories, such as gender and ethnicity, as well as questioning and 
reformulating them. However, the latent uncertainty that remains, due to the 
current inadequate biomedical model of thyroid disease, also results in the 
continual undermining of this category and diagnostic categories of thyroid 
disease more generally. The uncertainty that remains is typified by the 
Consultant’s underlying feeling of ‘not quite knowing what is going on’.
This thesis has consisted of an investigation into the diagnosis, treatment 
and management of thyroid disease. In doing so it has described how this 
disparate, non-compliant 'biology' eludes any straightforward 
'medicalisation', 'biochemicalisation' -- or to be precise, standardisation. In 
lieu of any successful standardisation, thyroid disease is a context of failed 
standardisation, in which procedures, speech, acts, documents and 
guidelines are relied upon, even though everyone knows they are 
inadequate. As a consequence of being under pressure to be coordinated 
to an effective and efficient clinical treatment system, thyroid disease 
becomes ambiguous and ambivalent, hit and miss, awkward, contested 
and disappointing for clinicians and patients.
In the introduction to this thesis I asked if there was something about the 
contemporary clinical encounter that made this well established, common 
and straightforward disease unnecessarily so complicated. Ironically, as I
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hope I have demonstrated, what seems to have complicated thyroid 
disease are a number of strategies that compete with each other in their 
attempts to discipline this non-compliant biology, the health practices of 
patients and the clinical practices of clinicans. EBM and the more general 
audit culture of the NHS makes thyroid biology accountable. However, in 
doing so, it clashes with the patient-centred business model that also 
governs the NHS, as it often cannot satisfy the experiences of individual 
patients. The failure of both of these models to fully discipline thyroid 
biology and pathology creates neither an accountable nor enterprising 
approach to diagnosing and treating thyroid disease. Instead, what is left is 
a system where the gaps left by these competing rationales are muddled 
through by patients and clinicans in an attempt to reach compromises over 
health care. Therefore, it could be said that what has changed about the 
contemporary clinical encounter, embodied and revealed by the vagueness 
of thyroid disease, is the inclusion of a number of strategies to govern 
health, all of which jostle for position in the process of trying to reach a 
consensus. Thyroid biology and pathology is to some extent a ‘matter of 
choice’, but it is also a set of population-based biochemical reference 
ranges. It is the battle between these evidentiary sources and broader 
systems of govemmentality that largely define the conditions of thyroid 
health and the health of NHS patients more generally.
182
References
ADAMSON, C. (1997) Existential and clinical uncertainty in the medical 
encounter: an idiographic account of an illness trajectory 
defined by Inflammatory Bowel Disease and Avascular 
Necrosis. Sociology of Health and Illness, 19,133-59
ANGELL, M. (1996) Evaluating the Health Risks of Breast Implants: The 
Interplay of Medical Science, the Law, and Public Opinion. N Engl J 
Med, 1513-1518.
ARKSEY, H. (1998) RSI and the experts : the construction of medical 
knowledge, London, UCL.
ARMSTRONG, D. (1983) Political anatomy of the body : medical 
knowledge in Britain in the twentieth century, Cambridge, 
Cambridge University Press.
ARMSTRONG, D. (1984) The Patients View. Social Science & Medicine, 
18, 737-744.
ARMSTRONG, D. (1995) The Rise of Surveillance Medicine. Sociology of 
Health & Illness, 17, 393-404.
ARMSTRONG, D. (2002) Clinical autonomy, individual and collective: the 
problem of changing doctors' behaviour. Social Science & Medicine, 
55, 1771-1777.
ARMSTRONG, D. (2007) Professionalism, Indeterminacy and the EBM 
Project. BioSocieties, 2, 73-84.
ARMSTRONG, D. & CALDWELL, D. (2004) Origins of the Concept of 
Quality of Life
in Health Care: A Rhetorical Solution to a Political Problem. Social Theory 
& Health, 2, 361-371.
ARMSTRONG, P. & ARMSTRONG, H. (1996) Wasting away : the 
undermining of Canadian health care, Toronto ; Oxford, Oxford 
University Press.
ASSOCIATION FOR CLINICAL BIOCHEMISTRY, THE BRITISH THYROID 
ASSOCIATION &THE BRITISH THYROID FOUNDATION, (2005) 
UK Guidelines for the Use of Thyroid Function Tests.
ATKINSON, P. (1988) Discourse, Descriptions and Diagnoses: 
Reproducing Normal Medicine, Kluwer Academic Publishers.
BANKOFF, G. (1947) The Conquest of the unknown [S.I.], Macdonald.
BANTING, F. G. & BEST, C. H. (2007) The internal secretion of the 
pancreas (Reprinted from the Journal of Laboratory and Clinical 
Medicine, vol 7, pg 251-266, 1922). Indian Journal of Medical 
Research, 125, A251-A266.
BARRY, A., OSBORNE, T. & ROSE, N. S. (1996) Foucault and political 
reason : liberalism, neo-liberalism and rationalities of government, 
London, Routledge.
BAUMAN, Z. (1991) Modernity and ambivalence, Oxford, Polity.
BAYLISS, R. I. S. & TUNBRIDGE, W. M. G. (1998) Thyroid disease : the 
facts, Oxford, Oxford University Press.
BECK, U. & RITTER, M. (1992) Risk society : towards a new modernity, 
London, Sage Publications.
BECKETT, G. (2003) Thyroid function tests and reference ranges. BTF 
News 7.
BELKIN, G. S. (1997) The technocratic wish: Making sense and finding 
power in the "managed" medical marketplace. Journal of Health 
Politics Policy and Law, 22, 509-532.
BERG, M. (1995) Turning a Practice into a Science - Reconceptualizing 
Postwar Medical-Practice. Social Studies of Science, 25, 437-476.
183
BERG, M. (1998) Order(s) and Disorder(s): Of Protocols and Medical 
Practices. IN MARC BERG AND ANNEMARIE MOL (Ed.) 
Differences in Medicine: Unraveling Practices, Techniques and 
Bodies. Durhan and London, Duke University Press.
BERNARD, C. (1974) Lectures on the phenomena of life common to 
animals and plants, Springfield, Charles C Thomas
BHARADWAJ, A. (2008) Biosociality and biocrossings: Encounters with 
assisted conception and embryonic stem cells in India. IN GIBBON, 
S. & NOVAS, C. (Eds.) Biosocialities, genetics and the social 
sciences: making biologies and identities London, Routledge.
BORELL, M. (1985) Organotherapy and the Emergence of Reproductive 
Endocrinology. Journal of the History of Biology, 18,1-30.
BORELL, M. (1987) Biologists and the Promotion of Birth-Control 
Research, 1918-1938. Journal of the History of Biology, 20, 51-87.
BOSTON WOMEN’S HEALTH BOOK, C. (1974) Our bodies, ourselves : a 
book by and for women, New York, Simon and Schuster.
CANARIS, G. J., MANOWITZ, N. R., MAYOR, G. & RIDGWAY, E. C. 
(2000) The Colorado thyroid disease prevalence study. Arch Intern 
Med, 160, 526-34.
CANGUILHEM, G. (1978) On the normal and the pathological, Dordrecht, 
Holland ; Boston, D. Reidel Pub. Co.
CANGUILHEM, G. & DELAPORTE, F. (1994) A vital rationalist: selected 
writings from Georges Canguilhem, New York, Zone Books.
CANNON, W. B. (1932) The Wisdom of the Body, pp. xv. 312. Kegan Paul 
& Co.: London; printed in U.S.A.
CHISTIAKOV, D. A. (2005) Immunogenetics of Hashimoto's thyroiditis. J 
Autoimmune Dis, 2,1.
CLIFFORD, J., MARCUS, G. E. & SCHOOL OF AMERICAN 
RESEARCH(SANTA FE N.M.) (1986) Writing culture: the poetics 
and politics of ethnography: a School of American Research 
advanced seminar, Berkeley, University of California Press.
CLYDE, P. W., HARARI, A. E., GETKA, E. J. & SHAKIR, K. M. (2003) 
Combined levothyroxine plus liothyronine compared with 
levothyroxine alone in primary hypothyroidism: a randomized 
controlled trial. Jama, 290, 2952-8.
COCHRANE, A. L. (1973) Effectiveness and efficiency: random reflections 
on health services, [London] ([3 Prince Albert Rd, NW1 7SP]), 
Nuffield Provincial Hospitals Trust.
COHN, S., DYSON, C. & WESSELY, S. (2008) Early accounts of Gulf War 
illness and the construction of narratives in UK service personnel. 
Social Science & Medicine, 67,1641-1649.
COOPER, L. (1997) Myalgic encephalomyelitis and the medical encounter. 
Sociology of Health & Illness, 19, 186-207.
CORNER, G. W. & ALLEN, W. M. (1929) PHYSIOLOGY OF THE 
CORPUS LUTEUM: II. Production of a Special Uterine Reaction 
(Progestational Proliferation) by Extracts of the Corpus Luteum. Am 
J Physiol, 88, 326-339.
CRAWFORD, R. (1980) Healthism and the Medicalization of Everyday Life. 
International Journal of Health Services, 10, 365-388.
CROSSLEY, M. (1998) 'Sick Role' or 'Empowerment'? The ambiguities of 
life with an HIV positive diagnosis. Sociology of Health and Illness, 
Vol.20 No. 4 1998.
CUSSINS, C. (1996) Ontological choreography: Agency through 
objectification in infertility clinics. Social Studies of Science, 26, 575- 
610.
DAGGETT, P. (2000) The perils and pitfalls of unnecessary thyroid 
hormone replacement. Brit. Thyroid Found. Newsl, 1-2.
184
DANIELS, G. H. C. & DYAN, C. M. (2006) Thyroid Disorders, Oxford, 
Health press Limited.
DAYAN, C. M., SARAVANAN, P. & BAYLY, G. (2002) Whose normal 
thyroid function is better-yours or mine? Lancet, 360, 353.
DEGOWIN, R. L., LEBLOND, R. F. & BROWN, D. D. (2004) DeGowin's 
diagnostic examination, New York, McGraw-Hill Professional ; 
London : McGraw-Hill.
DEPARTMENT OF HEALTH (2004) The NHS improvement pian : putting 
people at the heart of public services : executive summary, London, 
Department of Health.
DEPARTMENT OF HEALTH (2003) Copying letters to Patients: Good 
practice guidelines.
DOUGLAS, M. (1966) Purity and danger: an analysis of concepts of 
pollution and taboo, London: Routledge & Kegan Paul.
DUDEN, B. (1991) The Woman beneath the skin : a doctor's patients in 
eighteenth-century Germany, Harvard University Press.
DUMIT, J. (2006) Illnesses you have to fight to get: Facts as forces in 
uncertain, emergent illnesses. Social Science & Medicine, 62, 577- 
590.
DURRANT-PEATFIELD, B. (2006) Your thyroid and how to keep it healthy, 
London, Hammersmith Press.
EHRENREICH, B. A. E. & ENGLISH, D. (1973) Witches, midwives and 
nurses. A history of women healers ... Reprinted, Detroit: Black & 
Red.
ERIKSEN, T. H. (2001) Small places, large issues: an introduction to social 
and cultural anthropology, London, Pluto.
ESCOBAR-MORREALE HF, DEL RAY FE, OBREGON MJ & GM:, D. E. 
(1996) Only combined treatment with thyroxine and triiodothyronine 
ensures euthyroidism in all tissues of the thyroidectomized rat. 
Endocrinology, 2490-2502.
ESCOBAR-MORREALE, H. F., BOTELLA-CARRETERO, J. I., DEL REY, 
F. E. & DE ESCOBAR, G. M. (2005) REVIEW: Treatment of 
hypothyroidism with combinations of levothyroxine plus liothyronine. 
Journal of Clinical Endocrinology and Metabolism, 90, 4946-4954.
EVANS-PRITCHARD, E. E. (1937) Witchcraft, oracles and magic among 
the Azande, Oxford, Clarendon Press.
FAUSTO-STERLING, A. (1985) Myths of gender: biological theories about 
women and men, New York, Basic Books.
FEATHERSTONE, M., HEPWORTH, M. & TURNER, B. S. (1990) The 
body: social process and cultural theory, London, Sage.
FLYNN, R. W. V., MACDONALD, T. M., MORRIS, A. D., JUNG, R. T. & 
LEESE, G. P. (2004) The thyroid epidemiology, audit, and research 
study: Thyroid dysfunction in the general population. Journal of 
Clinical Endocrinology and Metabolism, 89, 3879-3884.
FOUCAULT, M. (1976) The birth of the clinic : an archaeology of medical 
perception, London,.
FOUCAULT, M. (1981) The history of sexuality /  Vol.1, An introduction, 
Harmondsworth, Penguin.
FOX, R. C. (1980) The Evolution of Medical Uncertainty. Milbank Memorial 
Fund Quarterly-Health and Society, 58, 1-49.
FRANKFORD, D. M. (1994) Scientism and Economism in the Regulation of 
Health-Care. Journal of Health Politics Policy and Law, 19, 773-799.
FRANKLIN, S. (1997) Embodied progress : a cultural account of assisted 
conception, London, Routledge.
FRANKLIN, S. & ROBERTS, C. (2006) Bom and made : an ethnography of 
preimplantation genetic diagnosis, Princeton, Princeton University 
Press.
185
FREIDSON, E. (1972) Profession of medicine : a study of the sociology of 
applied knowledge, New York, Dodd, Mead & Company.
FREIDSON, E. (1988) Profession of medicine : a study of the sociology of 
applied knowledge : with a new afterword, Chicago, University of 
Chicago Press.
GEERTZ, C. (1988) Works and lives : the anthropologist as author, 
Cambridge, Polity Press.
GIBBON, S. (2007) Breast cancer genes and the gendering of knowledge : 
science and citizenship in the cultural context of the "new" genetics, 
Basingstoke [England]; New York, Palgrave Macmillan.
GIBBON, S. & NOVAS, C. (2008) Biosocialities, genetics and the social 
sciences : making biologies and identities, London, Routledge.
GIDDENS, A. (1990) The consequences of modernity, Cambridge, Polity in 
association with Blackwell.
GOLDING, T. C. (1952) A Breif History of Thyroid Disease. Historical 
Bulletin, 16.
GOOD, B. (1994) Medicine, rationality, and experience : an anthropological 
perspective, Cambridge ; New York, Cambridge University Press.
GORDON, D. R. (1988) Clinical Science and Clinical Expertise: Changing 
Boundaries Between Art and Science in Medicine. IN LOCK, M. M. 
& GORDON, D. R. (Eds.) Biomedicine examined. Dordrecht; 
Boston, Kluwer Academic Publishers.
GRAVES, R. (1835) New observed affection of the thyroid gland in 
females. (Clinical lectures.). London Medical and Surgical Journal, 
7,516-517.
GULL, W. W. (1873- 1874) On a cretinoid state supervening in adult life in 
women. Trans Clin Soc Lond, 7,180-185.
HACKING, I. (1986) Making Up People. IN HELLER, T. (Ed.) 
Reconstructing Individualism. Stanford University Press.
HACKING, I. (1995) The Looping Effect of Human Kinds. IN D., S. (Ed.) 
Causal Cognition: An Interdisciplinary Approach. . Oxford, Oxford 
University Press.
HACKING, I. (2002) Kinds of People: Moving Targets Proceedings of the 
British Academy, 151 285-318.
HAHN. ROBERT A & KLEINMAN. ARTHUR (1983) Biomedical Practice 
and Anthropological Theory: Frameworks and Directions. Annual 
Review of Anthropology,, Vol.12 (1983),pp.305-333.
HALL, R. & STANBURY, J. B. (1967) Familial studies of autoimmune 
thyroiditis. Clin Exp Immunol, 2, Suppl:719-25.
HARAWAY, D. J. (1990) Simians, cyborgs, and women : the re-invention of 
nature, London, Free Association.
HARINGTON, C. R. & BARGER, G. (1927) Chemistry of Thyroxine. 
Biochem. J., 21, 169-183.
HASS, S. & TIMMERMANS, S. (2008) Towards a sociology of disease. 
Sociology of Health & Illness, 30.
HAUG, M. (1973) Deprofessionalization: an alternative hypothesis for the 
future.. Sociological Review Monograph, 2,195-211.
HAYDEN, L. C. & SACHS, L. (1998) Suffering, hope and diagnosis: On the 
negotiation of chronic fatigue syndrome. Health Affairs, 2 pp. 175- 
193.
HELEN LAMBERT AND ROSE HILARY (1996) Disembidied Knowledge: 
Making Sense of Medical Science. IN BRIAN, I. A. A. W. (Ed.) 
Misunderstanding Science. Cambridge, Cambridge University 
press.
HOLMES, D. (2002) Tears Behind Closed Door -Failure to diagnose an 
Underactive Thyroid: The Truth Behind the Tragedy, Normandi 
Publishing Ltd.
186
HOLMES, D. (2004) We can make a difference, available at: 
http://www.thvroidtears.co.uk/wecanmakeadifference.html [Acessed 
on 20th March 2006]
HORTON, R. (1995) Canguilhem,Georges - Philosopher of Disease. 
Journal of the Royal Society of Medicine, 88, 316-319.
HORWITZ, A. V. & WAKEFIELD, J. C. (2007) The loss of sadness : how 
psychiatry transformed normal sorrow into depressive disorder, New 
York ; Oxford, Oxford University Press.
HUBBARD, R. & WALD, E. (1997) Exploding the gene myth : how genetic 
information is produced and manipulated by scientists, physicians, 
employers, insurance companies, educators, and law enforcers, 
Boston, Beacon Press.
HUGHES, E. C. (1984) The sociological eye : selected papers, New 
Brunswick, N.J., U.S.A., Transaction Books.
ILLICH, I. (1975) Medical nemesis: the expropriation of health, London,.
INSTITUTE OF MEDICINE. COMMITTEE ON CLINICAL PRACTICE, G., 
FIELD, M. J. & LOHR, K. N. (1992) Guidelines for clinical practice : 
from development to use, Washington, DC, National Academy 
Press.
IWDL GENOVA DIAGNOSTICS (2006) Urine Thyroid Hormone T3/T4, 
available at:
http://www.adx.uk.net/index.php?option=com qpanel&ltemid=2&tas 
k=view&id=29 [accessed on 12 April2006]
JACKSON, I. M. D. & COBB, W. E. (1978) Why Does Anyone Still Use 
Desiccated Thyroid Usp. American Journal of Medicine, 64, 284- 
288.
KAUFMAN, S. R., RUSS, A. J. & SHIM, J. K. (2006) Aged bodies and 
kinship matters: The ethical field of kidney transplant. American 
Ethnologist, VOL 33; NUMB 1„ 81-99.
KEVLES, D. J. & HOOD, L. E. (1992) The Code of codes : scientific and 
social issues in the human genome project, Cambridge, Mass, 
Harvard University Press.
KONRAD, M. (2005) Narrating the new predictive genetics : ethics, 
ethnography, and science, Cambridge, UK ; New York, Cambridge 
University Press.
LAMBERT, H. & ROSE, H. (1996b) Disembodied Knowledge: Making 
Sense of Medical Science. IN WYNNE. B AND INWIN A. (Eds.) 
Misunderstanding Science. Cambridge, Cambridge University 
press.
LANE, C. (2007) Shyness : how normal behavior became a sickness, New 
Haven, Yale University Press.
LATOUR, B. (1993) We have never been modern, New York ; London, 
Harvester Wheatsheaf.
LAW, J. (1994) Organizing modernity, Oxford, Blackwell.
LEYS, C. (2001) The British National Health Service in the face of 
neoliberalism. . IN. ARMSTRONG, P H. ARMSTRONG & 
COBURN, D. (Eds.) Unhealthy times: Political economy
perspectives on health and care in Canada Toronto, Oxford 
University Press.
LIGHT, D. W. (2001) Comparative institutional response to economic policy 
managed competition and govemmentality. Social Science & 
Medicine, 52,1151-1166.
LIPPMAN, A. (1992) Led (Astray) by Genetic Maps - the Cartography of the 
Human Genome and Health-Care. Social Science & Medicine, 35, 
1469-1476.
LOCK, M. (1988) New Japanese Mythologies: Faltering Discipline and the 
Ailing Housewife, Vol. 15, No. 1, Medical Anthropology. (Feb.,
187
1988), pp. 43-61. American Ethnologist Vol. 15, No. 1, Medical 
Anthropology. (Feb., 1988), pp. 43-61.
LOCK, M. (2001) The Tempering Of Medical Anthropology: The Troubling 
of Natrual Catagories. Medical Anthropology Quaterly, 15 (4), 478- 
492.
LOCK, M. (2005) Eclipse of the gene and the return of divination. Current 
Anthropology, 46.
LOCK, M. M. (1994) Encounters with aging : mythologies of menopause in 
Japan and North America, Berkeley, University of California Press.
LOCK, M. M. (2002) Twice dead: organ transplants and the reinvention of 
death, Berkeley, University of California Press.
LOCK, M. M. & GORDON, D. (1988) Biomedicine examined, Dordrecht ; 
Boston, Kluwer Academic Publishers.
LOCKE, J. & GOLDIE, M. (1994) Two treatises of government, London, 
Everyman.
MACGREGOR, A. (1961) Why Does Anybody Use Thyroid Bp. Lancet, 1, 
329-&.
MARCUS, G. E. (1995) Technoscientific imaginaries : conversations, 
profiles, and memoirs, Chicago, University of Chicago Press.
MARCUS, G. E. & FISCHER, M. M. J. (1999) Anthropology as cultural 
critique : an experimental moment in the human sciences, Chicago, 
London, University of Chicago Press.
MARKER, R. E., WAGNER, R. B., ULSHAFER, P. R., WITTBECKER, E. 
L., D.P.J, G. & C.H, R. (1947) Steroidal sapogenins. Journal of the 
American Chemical Society 69 (1947) pp. 2167-2171.
MARTIN, E. (1987) The woman in the body : a cultural analysis of 
reproduction, Beacon Press.
MARTIN, E. (1994) Flexible bodies : tracking immunity in American culture : 
from the days of polio to the age of AIDS, Boston, Beacon Press.
MARTIN, E. (1998) Fluid Bodies, Managed Nature,. IN BROWN. B AND 
CASTREE N (Ed.) Remaking Reality: Nature at the Millennium. 
London, Routledge.
MARTIN, E. (2007) Bipolar expeditions: mania and depression in American 
culture, Princeton, Princeton University Press.
MAY,C., RAPLEY.T., MOREIRA.T., FINCH,T. & HEAVEN,B. (2006) 
Technogovernance: Evidence, subjectivity, and the clinical
encounter in primary care medicine. Social Science & Medicine, 62, 
1022-1030.
MCKINLAY, J. & STOECKLE, J. (1988) Corporatisation and the social 
transformation of doctoring. International Journal of Health Services, 
18, 191-205.
MCMILLAN, C., BRADLEY, C., RAZVI, S. & WEAVER, J. (2006) 
Psychometric evaluation of a new questionnaire measuring 
treatment satisfaction in hypothyroidism: The ThyTSQ. Value in 
Health, 9, 132-139.
MEDVEI, V. C. (1993) The history of clinical endocrinology : a 
comprehensive account of endocrinology from earliest times to the 
present day, Carnforth, Parthenon Pub. Group.
MOL (2002) The Body Multiple: Ontology In Medical Practice., Durham, 
NC: Duke University Press.
MOL. A (2008) The Logic of Care: Health and the problem of patient choice 
London, Routledge.
MOREIRA, T. (2005) Diversity in clinical guidelines: the role of repertoires 
of evaluation. Social Science & Medicine, 60, 1975-1985.
MOREIRA, T. (2007) Entangled evidence: knowledge making in systematic 
reviews in healthcare. Sociology of Health & Illness, 29, 180-197.
188
MOREIRA, T., MAY, C., MASON, J. & ECCLES, M. (2006) A new method 
of analysis enabled a better understanding of clinical practice 
guideline development processes matter. Journal of Clinical 
Epidemiology, 59,1199-1206.
MURRAY, G. R. (1891) Note on the treatment of myxoedema by 
hypodermic injections of an extract of the thyroid gland of a sheep. 
BMJ, 2, 796.
MYKHALOVSKIY, E. & WEIR, L. (2004) The problem of evidence-based 
medicine: directions for social science. Social Science & Medicine, 
59, 1059-1069.
NATIONAL PATIENT SAFETY AGENCY (2007a) About NRES, available 
at: http://www.nres.npsa.nhs.uk/applicants/about/NRES.htm.
[acessed on 31st October 2008]
NATIONAL PATIENT SAFETY AGENCY (2007b) Launch of National 
Research Ethics Service. International Journal of Pharmaceutical 
Medicine, 1 1-113.
NAVARRO, V. (2002) The political economy of social inequalities : 
consequences for health and quality of life, Amityville, N.Y., 
Baywood Pub. Co.
NETTLETON, S. (1995) The sociology of health and illness, Oxford ; 
Cambridge, Mass, Polity Press.
NETTLETON, S. (2006) 'I just want permission to be ill': Towards a 
sociology of medically unexplained symptoms. Social Science & 
Medicine, 62, 1167-1178.
NHS DIRECT (2006) NHS Direct Online Health Encyclopaedia, Patient 
choice, available at:
http://www.nhsdirect.nhs.uk/articles/article.aspx?articleld=572. 
[accessed on 20th November 2006]
OAKLEY, A. (1980) Women confined : towards a sociology of childbirth, 
Oxford, Martin Robertson.
OAKLEY, A. (1984) The captured womb : a history of the medical care of 
pregnant women, Oxford, Basil Blackwell.
OUDSHOORN, N. (1990) Endocrinologists and the conceptualization of 
sex, 1920-1940. Journal of the History of Biology, 23, 136 - 186.
OUDSHOORN, N. (1994) Beyond the natural body: an archaeology of sex 
hormones, New York ; London, Routledge.
PARKES, A. S. (1966) Rise of Reproductive Endocrinology 1926-1940 - Sir 
Henry Dale Lecture for 1965. Journal of Endocrinology, 34, R20-&.
PARSONS, T. (1952) The Social System, pp. xviii. 575. Tavistock 
Publications: [London;] printed in the U.S.A.
PAUNKOVIC, N., PAUNKOVIC, J., PAVLOVIC, O. & PAUNOVIC, Z. (1998) 
The significant increase in incidence of Graves' disease in eastern 
Serbia during the civil war in the former Yugoslavia (1992 to 1995). 
Thyroid, 8, 37-41.
PETRYNA, A. (2003) Life exposed : biological citizens after Chernobyl, 
Princeton, N.J., Woodstock, Princeton University Press.
POP, V. J., MAARTENS, L. H., LEUSINK, G., VAN SON, M. J., 
KNOTTNERUS, A. A., WARD, A. M., METCALFE, R. & WEETMAN,
A. P. (1998) Are autoimmune thyroid dysfunction and depression 
related? Journal of Clinical Endocrinology and Metabolism, 83, 
3194-3197.
PORTER, R. (1997) The greatest benefit to mankind : a medical history of 
humanity from antiquity to the present, London, HarperCollins.
POWDERMAKER, H. (1966) Stranger and friend : the way of an 
anthropologist, New York, W. W. Norton.
POWER, M. (1999) The audit society: rituals of verification, Oxford, Oxford 
University Press.
189
RABINOW, P. (1992) Artificiality and Enlightenment: From Sociobiology to 
Biosociality. IN CRARY, J. & KWINTER, S. (Eds.) Zone 6: 
Incorporations. Cambridge, Mass, MIT Press.
RABINOW, P. (1996) Essays on the anthropology of reason, Princeton, 
N.J, Princeton University Press.
RABINOW, P. (1999) French DNA : trouble in purgatory, Chicago, London, 
University of Chicago Press.
RAPP, R. (1999) Testing women, testing the fetus : the social impact of 
amniocentesis in America, New York, Routledge.
ROBERTS, C. (2002) ‘A matter of embodied fact’ Sex hormones and the 
history of bodies. Feminist Theory, vol. 3(1): 7-26.[1464- 
7001(200204) 3:1 ;7—26; 022063].
ROSE, N. (2001) The politics of life itself. Theory Culture & Society, 18.
ROSE, N. (2003) Neurochemical selves. Society, 41, 46-59.
ROSE, N. & NOVAS, C. (2004) Biological citizenship. IN ONG, A. & 
COLLIER, S. (Eds.) Global Assemblages: Technology, Politics, and 
Ethics as Anthropological Problems. Malden MA, Blackwell.
ROSE, N. S. (2006) Politics of life itself : biomedicine, power and 
subjectivity in the twenty-first century, Princeton, N.J. ; Woodstock, 
Princeton University Press.
SACKETT DL, R. W., GRAY JAM, HAYNES RB, RICHARDSON WS. .. 
(1996) Evidence based medicine: what it is and what it isn't. British 
Medical Journal, BMJ ;312:71-2.
SCHEPER HUGHES NANCY (1994) Aids and the Social Body. Social 
Science and Medicine, 39, 7, 991-1003.
SCHIEBINGER, L. L. (2000) Skeletons in the Closet: The First Illustrations 
of the Female Skeleton in Eighteenth-Century Anatomy. Feminism 
and the body. Oxford, Oxford University Press.
SHARPE, M. & CARSON, A. (2001) Unexplained’ somatic symptoms, 
functional syndromes, and somatization: do we need a paradigm 
shift? Annals of International Medicine, 926-930.
SHILLING, C. (2003) The body and social theory, London ; Thousand 
Oaks, California, SAGE Publications.
SHILLING CHRIS (2002) Culture of the Sick Role and the Consumption of 
Health. The British Journal of Sociology, 53:621-638.
SIBBALD, B. & ROLAND, M. (1998) Understanding controlled trials - Why 
are randomised controlled trials important? British Medical Journal, 
316, 201-201.
SKINNER, G. R. B., HOLMES, D., AHMAD, A., DAVIES, J. A. & BENITEZ, 
J. ( 2000) Clinical Response to Thyroxine Sodium in Clinically 
Hypothyroid but Biochemically Euthyroid Patients. J Nutr Environ 
Med, 10, 115-124.
STOCKL, A. (2007) Complex syndromes, ambivalent diagnosis and 
existential uncertainty: The case of Systemic Lupus Erythematosus 
(SLE), Social Science and Medicine, 65, 1549-1559
STOP THE THYROID MADNESS!! (2006) Long and Pathetic List of 
Thyroid Symptoms, available at:
ttp://www.stopthethyroidmadness.com/long-and- 
pathetic/?PHPSESSID=a21d72683c359416d23dee3406bce172 
[accessed on 12 April 2006]
STRATHERN, M. (1992a) After nature: English kinship in the late twentieth 
century, Cambridge ; New York, Cambridge University Press.
STRATHERN, M. (1992b) Reproducing the future : essays on 
anthropology, kinship and the new reproductive technologies, 
Manchester U.P.
STRATHERN, M. & ASSOCIATION OF SOCIAL ANTHROPOLOGISTS OF 
THE COMMONWEALTH. CONFERENCE (1995) Shifting contexts :
190
transformations in anthropological knowledge, London ; New York, 
Routledge.
SULLIVAN, M. (2003) The new subjective medicine: taking the patient's 
point of view on health care and health. Social Science & Medicine, 
56, 1595-1604.
TANENBAUM, S. J. (1996) "Medical effectiveness" in Canadian and US 
health policy: The comparative politics of inferential ambiguity. 
Health Services Research, 31, 517-532.
TEW, M. (1990) Safer childbirth? : a critical history of maternity care, 
London, Chapman and Hall.
THE BRITISH SOCIOLOGICAL ASSOCIATION (2002) Statement of 
Ethical Practice for the British Sociological Association (March 
2002)
http://www.britsoc.co.uk/equality/Statement+Ethical+Practice.htm.
THE BRITISH THYROID FOUNDATION (2006) available at: http://www.btf- 
thvroid.org/
THE DEPARTMENT OF HEALTH (2006) Choice Matters: Increasing 
choice imporves patients' experiences.
THE DEPARTMENT OF HEALTH (2009) The NHS Constitution. IN 
CROWN COPYRIGHT (Ed.).
THE WORLD MEDICAL ASSCOCIATION (1964) Ethical Principles for 
Medical Research Involving Human Subjects 
http://www.wma.net/e/policy/b3.htm.
THYROID PATIENT ADVOCACY UK (2005) Dr. Gordon Skinner Response 
to BTF, available at: http://www.thyroiduk.org/ the blood tests pg. 
[accessed on 24 June 2005]
THYROID UK (2007) available at: http://www.thvroiduk.org/
TIMMERMANS, S. & BERG, M. (1997) Standardization in action: Achieving 
local universality through medical protocols. Social Studies of 
Science, 27, 273-305.
TIMMERMANS, S. & MAUCK, A. (2005) The promises and pitfalls of 
evidence-based 10.1377/hlthafT.24.1.18 medicine. Health Affairs, 24, 
18-28.
TOFT, D. A. (1995) Understanding Thyroid Disorders, Banbury, Family 
Doctor Publications.
TOMER, Y., BARBESINO, G., GREENBERG, D. A., CONCEPCION, E. & 
DAVIES, T. F. (1999) Mapping the major susceptibility loci for 
familial Graves' and Hashimoto's diseases: evidence for genetic 
heterogeneity and gene interactions. J Clin Endocrinol Metab, 84, 
4656-64.
TOMER, Y., BARBESINO, G., KEDDACHE, M., GREENBERG, D. A. & 
DAVIES, T. F. (1997) Mapping of a major susceptibility locus for 
Graves' disease (GD-1) to chromosome 14q31. J Clin Endocrinol 
Metab, 82, 1645-8.
TOMER, Y., GREENBERG, D. A., BARBESINO, G., CONCEPCION, E. & 
DAVIES, T. F. (2001) CTLA-4 and not CD28 is a susceptibility gene 
for thyroid autoantibody production. J Clin Endocrinol Metab, 86, 
1687-93.
TRAWEEK, S. (1992) Beamtimes and lifetimes : the world of high energy 
physicists, Cambridge.
TURNER, B. S. (1996) The body and society: explorations in social theory, 
London ; Thousand Oaks, Calif, Sage Publications.
VANDERPUMP, M. P., AHLQUIST, J. A., FRANKLYN, J. A. & CLAYTON, 
R. N. (1996) Consensus statement for good practice and audit 
measures in the management of hypothyroidism and 
hyperthyroidism. The Research Unit of the Royal College of 
Physicians of London, the Endocrinology and Diabetes Committee
191
of the Royal College of Physicians of London, and the Society for 
Endocrinology. Bmj, 313, 539-44.
VANDERPUMP, M. P., TUNBRIDGE, W. M., FRENCH, J. M., APPLETON,
D., BATES, D., CLARK, F., GRIMLEY EVANS, J., HASAN, D. M., 
RODGERS, H., TUNBRIDGE, F. & ET AL. (1995) The incidence of 
thyroid disorders in the community: a twenty-year follow-up of the 
Whickham Survey. Clin Endocrinol (Oxf), 43, 55-68.
VILLAR, H. C. C. E, SACONATO, H, VALENTE, O. & ATALLAH, A. N. 
(2007) Thyroid hormone replacement for subclinical hypothyroidism. 
Cochrane Database of Systematic Reviews, -.
WAILOO, K. (1997) Drawing blood : technology and disease identity in 
twentieth-century America, Baltimore, London, Johns Hopkins 
University Press.
WALD, D. S. (2004) Bureaucracy of ethics applications. Bmj, 329, 282-4.
WALSH, J. P. (2002a) Dissatisfaction with thyroxine therapy - could the 
patients be right? Curr Opin Pharmacol, 2.
WAN LESS, D. (2001) Securing our future health : taking a long-term view; 
interim report, Great Britain, Treasury, Public Enquiry Unit.
WAN LESS, D. (2004) Securing good health for the whole population : final 
report, Norwich, HMSO.
WEETMAN, A. P. (2006) Whose thyroid hormone replacement is it 
anyway? Clinical Endocrinology, 64:3 231.
WEIR, R. F., LAWRENCE, S. C. & FALES, E. (1994) Genes and human 
self-knowledge : historical and philosophical reflections on modern 
genetics, Iowa City, IO, University of Iowa Press.
WIERSINGA, W. M. (2001) Thyroid hormone replacement therapy. 
Hormone Research, 56.
WILSON, E. O. (1976) Sociobiology: the new synthesis, Cambridge, Mass 
; London, Belknap Press of Harvard University Press.
YOUNG, A. (1995) The harmony of illusions : inventing post-traumatic 
stress disorder, Princeton, Princeton University Press.
ZOLA, I. (1972) Medicine as an Institution of Social Control. Sociological 
Reveiw, 20: 487-504.
192
Appendices
1. Patient information sheet
2. Sample of clinic letter
3. BTA patient information sheet on the management of
hyperthyroidism
4. BTA patient information sheet on the management of
hypothyroidism
5. BFT list of hypothyroid symptoms
6. BFT list of hyperthyroid symptoms
7. Thyroid petition (raised by Diana Holmes)
8. BTA statement on Armour Thyroid (USP) and combined thyroxine/ 
tri-iodothyronine as Thyroid Hormone Replacement
193
PIS V2 11/05
Patient Information Sheet
Title of Study - Genetic Predispositions and Chronic Disease: A qualitative study of the 
implications of genetic predispositions on the definition, patient understanding and 
management of thyroid conditions.
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. Thank you for taking the time to read through this 
information.
What is the purpose of this study?
This 12 month study will examine how genetic predispositions to autoimmune thyroid 
conditions influence their treatment and management. Autoimmune thyroid conditions tend to 
run in families, in the sense that if your parents have these conditions you are more likely to 
develop them, and this study will be particularly interested in this component.
This study will investigate how familial information about thyroid conditions, from the 
perspective of patients, is understood in terms of how it influences its diagnosis, the treatment 
you receive in the clinic, how you understand the disease, and how you choose to manage 
your condition.
Why have I been chosen?
You have been chosen because you have or are attending the thyroid clinic at the 
■ ■  as a patient for treatment for your thyroid condition. If you agree to take part in the 
study you will be one of approximately 15 patients who will be involved in the project.
Do I have to take part?
It is up to you to decide whether or not to take part, if you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time without giving reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care you 
receive.
What will happen to me if I take part?
You will be interviewed in your home, or an alternative mutually agreed location, twice over a 
twelve-month period. These interviews will be recorded, last approximately one to two hours, 
and will involve a series of questions that are designed to find out about your experience of 
having a thyroid condition. There are no right or wrong answers to these questions and you 
can talk about anything that you feel is relevant to your thyroid condition and its treatment. 
You will not be expected to attend any additional appointments with your consultant or GP in 
order to take part in the study.
What do I have to do?
To take part in the study you have to agree to the interviews in your home or another mutually 
agreed location. The interviews will take place at a time convenient for you and there will be 
no additional interventions in terms of how you will be treated by your consultant for your 
thyroid condition.
What is the drug or procedure that is being tested?
There is no drug or procedure being tested, this study is non-clinical and involves only 
interviews.
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What are the possible disadvantages and risks of taking part?
It is possible that during the interviews you may feel that some of the issues addressed in 
relation to your thyroid disease are sensitive or embarrassing. If you do feel like this you must 
raise it with the interviewer. In this instance you could ask the interviewer to move on to 
another subject or terminate the interview all together. You may also pull out of the study at 
any time if you choose to do so, this will in no way affect your treatment.
What are the possible benefits of taking part?
There are no direct benefits to your treatment if you take part in this study. It involves no 
interventions or new treatments for your thyroid condition. However, it is hoped that this study 
will add further to the understanding of thyroid conditions, specifically with regards to 
understanding how patients manage and understand the disease.
What if new information becomes available?
As this is a non-clinical study your doctor will communicate all possible new information about 
the treatment of your thyroid condition to you. It is not within the remit or expertise of this 
study to pass on clinical information or advice. If new information about the study specifically 
becomes available you will be informed immediately via the contact details you will have 
provided on your consent form.
What happens when the research study stops?
Your treatment will continue as normal as it did during the duration of the study, you will not 
be expected to take part in any further interviews or be observed ain any additional 
appointments.
What if something goes wrong?
As this study is non-clinical it will not effect your treatment, therefore, there is no risk of harm 
and no special compensation arrangements in terms of negligence with regards to your 
treatment. Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of this study, the 
normal National Health Service complaints mechanism should be available to you.
In addition, there are also contact details for senior supervisory staff for the project at the 
London School of Economics and Political Science, these can be found at the end of this 
information sheet in the contact for further detail section.
Will my taking part in the study be kept confidential?
All information that is collected about you during the course of the research will be kept strictly 
confidential. Any information about you that leaves the hospital/surgery will have your name 
and address removed so that you cannot be recognised from it. In addition permission will 
also be sought from your GP for your inclusion in the study, something to which you must 
agree in order to take part in the study.
The approved this study, under the assurance that high
standards of ethical protocol will be observed.
What will happen to the results of the research study?
All transcripts and tape recordings of the interviews will be kept in secure storage at the 
London School of Economics, and only those involved in the study will have access to them. 
If you wish you may also have copies of interview transcripts. In addition to the availability of 
the interview transcripts you will also be provided with a report of the study summarising its 
findings near the end of the project.
Megan Clinch a graduate student in the BIOS Centre at the London School of Economics and 
Political Science will use, the data collected to form the basis of a PhD thesis. This thesis will 
be approximately 70,000 to 100,00 words long and is expected to be completed by October 
2007, it may also form the basis for additional papers and articles that may be published in 
relevant professional journals and presented at conferences. You will be informed of such 
instances as they occur and be sent a summary of the research when it is completed.
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Who is organising and funding the research?
The research is the basis for a PhD thesis organised by Megan Clinch a student in the BIOS 
Centre at the London School of Economics and Political Science and it has received funding 
from the institution through which it is being conducted. The research has been conceived 
through a supervisory relationship with BIOS Associate Director Professor Sarah Franklin and 
sponsored by the convenor of the BIOS Centre and the Department of Sociology Professor 
Nikolas Rose.
Who has reviewed the study?
In addition to the review of the study by the study had
been reviewed via a through process by the department of Sociology at the London School of 
Economics and Political Science, the institution through which the PhD will be awarded.
Contact for further information
Megan Clinch a PhD student at the London School of Economics and Political Science in a 
research Centre called BIOS that is an affiliated to the department of Sociology is conducting 
the study. Attached is a leaflet on BIOS for you to look at, there is also a website 
www.ise.ac.uk/bios
If you would like to contact Megan to find out more about the study please do so, her details 
are as follows.
BIOS
The London School of Economics and Political Science
Houghton Street
London
WC2A 2AE
m.l.clinch@lse.ac.uk
Office: 0207 107 5211
Mobile: 07866 455 408
It is important that you feel that your participation in the study has been handled with respect 
and sensitivity with regards to your condition.
If once enrolled in the study, you do not feel the correct protocols have been followed, please 
contact the senior project supervisors listed below.
Professor Sarah Franklin
PhD Supervisor and Associate Director of BIOS
The London School of Economics and Political Science
Houghton Street
London
WC2A 2AE
s.franklin@lse.ac.uk
020 7955 6465
Professor Nikolas Rose
Director of BIOS, Professor of Sociology and Convenor of the Department of Sociology
The London School of Economics and Political Science
Houghton Street
London
WC2A 2AE
n.rose@lse.ac.uk
020 7955 7533
Please keep these details just in case a situation of this nature arises.
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How do I take part in the study?
To take part in the study please fill out the consent form including your contact details and 
then return it to Megan Clinch in the stamped addressed envelope provided. Megan will then 
contact you to arrange a convenient time for interview.
Thank you for taking the time to read through this information, we look forward to hearing 
from you if you decide to take part in the study.
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DEPARTMENT OF ENDOCRINOLOGY
Direct Line: 
Fax:
MV/ag/Hosp No.
Thyroid Clinic: 18 September 2006
Typed: 27 September 2006
Diagnosis: Treated hypothyroidism
Past history of atrial fibrillation
Osteoporosis
Treated type 2 diabetes
This lady's thyroid function now is fine on thyroxine 225^g daily. Her current FT4 is 
22.4pmol/l with a  TSH right within the middle of the reference range at 2.4mu/l. She 
should thus remain on this dose in the long term and I simply suggest she had an annual 
check of thyroid function from now on. The only other thing to correct from my previous 
letter is that she was on Flecainide not Amiodarone.
With best wishes
Yours sincerely
Hyperthyroidism -  clinical features and treatment
1. The causes of hyperthyroidism
The thyroid is a gland in the neck that produces two thyroid hormones, thyroxine (T4) and tri­
iodothyronine (T3). Thyroxine is inactive and is converted by the tissues and organs that need it 
into tri-iodothyronine. The role of thyroid hormones, put simply, is to regulate the metabolism of 
virtually all cells in the body. In health, the production of these thyroid hormones is tightly 
regulated by the secretion of thyroid stimulating hormone (TSH; also known as thyrotropin) from 
the pituitary gland in the brain. When the thyroid gland becomes affected by disease, sometimes 
the production or release of thyroxine and tri-iodothyronine can be abnormally high, leading to 
increased levels in the blood; a state of thyroid overactivity known as hyperthyroidism or 
thyrotoxicosis. If this happens, the body’s metabolism speeds up and this can be manifest by 
changes in various, and seemingly unrelated tissues, that are listed below. In this state of 
hyperthyroidism, a blood test will show an elevated amount of these thyroid hormones circulating. 
Conversely, the TSH level in the blood almost always becomes suppressed, because the pituitary 
gland senses (‘sees’) the abnormally high levels of thyroid hormones, which are more than is 
needed by the brain.
The prevalence of hyperthyroidism is about 1% and it is about six times more common in women. 
There are two main causes of hyperthyroidism in the UK:
1). Autoimmunity causing stimulation of the thyroid gland
2). Overproduction of hormones by benign tumours in the thyroid gland.
1). In autoimmune thyroid overactivity, the thyroid cells are stimulated by an abnormal antibody 
which is specifically targeted at the TSH-receptor on the thyroid gland causing stimulation of the 
thyroid to produce excess hormones. This also causes the thyroid cells to grow, and together with 
immune cells congregating in the gland, this leads to thyroid enlargement, called goitre.
An early description of this form of autoimmune thyroid disease was made by an Irish physician 
called Robert Graves, so it is often termed Graves’ disease. Graves’ disease is almost always 
accompanied by the presence of the TSH-receptor autoantibodies in the blood and very frequently 
by thyroid peroxidase (TPO) autoantibodies which may both be a useful tool for diagnosis. In 
addition, about a third of people with Graves’ disease develop a variety of eye problems including 
a staring appearance, grittiness and soreness, protruding eyeballs, and (rarely) double vision or 
sight problems. This is termed “thyroid eye disease” or “Graves’ ophthalmopathy”. Cigarette 
smoking increases the risk of developing thyroid eye disease in patients with Graves' disease.
2). The other common cause of thyroid overactivity is that the thyroid develops one or more benign 
tumours (technically follicular adenomas but often simply called “nodules”) that secrete excess 
thyroid hormone in an unregulated manner. This nodular hyperthyroidism becomes commoner 
with advancing age and is termed “solitary toxic nodule” or “toxic multinodular goitre", depending 
on the number of nodules.
Together these two types of hyperthyroidism account for well over 90% of all cases. Rarer causes 
include inflammatory conditions of the thyroid called thyroiditis, which sometimes is the result of 
pregnancy, viruses or drugs such as amiodarone or interferon. All the types of hyperthyroidism 
just mentioned are usually classified as primary, meaning that they result from an excess 
stimulation or release of thyroid hormone from the thyroid gland. Very rarely, there may be 
secondary thyroid overactivity as a result of a pituitary problem where the pituitary gland 
manufactures an excess amount of TSH (thyroid stimulating hormone). This leads to thyroid 
overactivity with normal or high blood TSH. More commonly blood tests that have the same 
pattern as primary thyroid overactivity can result from taking an excess of thyroid hormone tablets, 
such as levothyroxine.
2. The symptoms and signs of hyperthyroidism
Common complaints include fatigue, heat intolerance, sweating, weight loss despite good 
appetite, shakiness, inappropriate anxiety, palpitations of the heart, shortness of breath, tetchiness 
and agitation, poor sleep, thirst, nausea and increased frequency of defecation. The elderly may 
complain predominantly of heart problems with a fast or irregular heart beat, breathlessness and 
ankle swelling, whereas children tend to hyperactivity, with a short attention span. Signs include 
shaky and hot hands, fast or irregular heart beat, inability to sit still, flushing of the face and upper 
trunk, fast tendon reflexes, an enlarged thyroid gland and prominent or bulging eyes. Nowadays 
patients often are diagnosed at an early stage of disease, owing to increased awareness and 
improved biochemical testing. Therefore some patients have relatively few of the classical signs 
or symptoms. In addition, none of the symptoms or signs just listed is sufficiently sensitive or 
specific for the diagnosis of hyperthyroidism, even when combined together. Thus, it may take 
three to six months to diagnose hyperthyroidism, during this time the person can feel very unwell. 
It is not uncommon for people to worry that they have cancer, because of the associated weight 
loss.
3. Treatment of hyperthyroidism
Graves’ disease and nodular thyrotoxicosis 
Betablockers
Betablockers are a group of drugs that tend to improve some of the symptoms and manifestations 
of hyperthyroidism. In particular, they can improve palpitations, slow the heart down and improve 
tremor. They have no effect on curing the thyroid overactivity, but do make many people feel 
better. Betablockers should not be taken if the patient has asthma or a wheezy chest.
Antithvroid drugs
Carbimazole (Neomercazole) and propylthiouracil are antithyroid drugs that are effective in 
reducing the production of thyroid hormones in the majority of people with hyperthyroidism. In 
people with Graves’ disease, treatment with one of these drugs for between 6 months and 2 years 
results in a long-term remission in around half of patients, once the drug is stopped.
Both drugs have the common side effects of rash and joint pains, and more rarely (less than 1 in 
500 cases) a serious reduction in the circulating white blood cells (agranulocytosis) may occur 
during treatment. The dosage of these antithyroid drugs can either be adjusted every 6 to 8 weeks 
according to thyroid hormone levels in the blood, to keep the person’s thyroid hormone levels in 
the normal range (titrated dose regimen) or kept at a fixed, higher dose and levothyroxine 
replacement added to maintain normal thyroid hormone levels (block and replace regimen). In 
nodular hyperthyroidism (solitary toxic nodule or toxic multinodular goitre), antithyroid drugs do not 
result in cure, just a temporary reduction in thyroid hormone levels. A more permanent solution is 
often sought, called a definitive treatment.
Radioiodine
Radioiodine is a radioactive isotope of iodine (131"l) that is taken up and concentrated selectively by 
the thyroid gland. In most people, this small dose of radioactivity is sufficient to gradually destroy 
the thyroid tissue, over 6 weeks to 6 months following a single dose. Patients with Graves’ disease 
have a high rate of permanent thyroid underactivity following radioiodine (about 80%), whereas 
patients with nodular thyroid overactivity tend to preserve their thyroid function better, with only 
around half eventually becoming underactive. Patients are monitored for underactivity following 
the dose and promptly treated with thyroxine, should this develop. The common outcome of 
thyroid underactivity is an accepted consequence of radioiodine therapy because hyperthyroidism 
is a serious condition whereas replacement treatment with levothyroxine is simple and has no side 
effects at the correct dose.
Radioiodine is a safe treatment for thyroid overactivity, with no overall excess of cancers in many 
hundreds of thousands of patient years of follow up (JAMA 1998; 280: 347-355; Lancet 1999; 353: 
2111-5). Patients with ophthalmopathy require careful evaluation, as radioiodine may worsen
thyroid eye disease: this can be prevented by a short course of steroid tablets. There is no 
damage to fertility or to hair growth, but women are advised not to become pregnant for 6 months 
following a dose, as the baby’s thyroid could be damaged. Men should avoid fathering a child 
within 4 months of treatment. Following a standard dose of radioiodine, other precautions are 
necessary to minimise radiation exposure of others but these restrictions are usually easily 
accommodated by the patient. Radioiodine may trigger airport security alarms up to eight weeks 
following a dose and patients should carry a letter about the treatment if they travel in this period. 
Radioiodine is the most cost effective and certain treatment for thyroid overactivity and about 
10,000 doses annually are given in the UK.
Thyroid surgery
Surgery to remove most or all of the thyroid gland (subtotal or total thyroidectomy) is another way 
of definitively treating thyroid overactivity. This is a straightforward operation when carried out by 
an experienced thyroid surgeon, with a low risk of complications. Hypothyroidism is a recognised 
side effect of surgery for which levothyroxine replacement will be needed, lifelong. Thyroidectomy 
is a good treatment option for people with a large goitre and for those with thyroid eye disease. 
Prior to thyroid surgery, thyroid overactivity needs to be controlled, usually with antithyroid drugs to 
make an anaesthetic safe. This is because an anaesthetic in a hyperthyroid person has a high risk 
of precipitating a dangerous hyperthyroid crisis or “thyrotoxic storm”.
Treatment of thyroiditis
Many forms of thyroiditis are ‘self-limiting’, meaning that the overactivity recovers spontaneously 
and no treatment may be required. If the person has severe symptoms of thyrotoxicosis, 
betablockers are helpful. However, in some cases thyroiditis can be painful or prolonged and anti­
inflammatory tablets or steroids may be helpful. Furthermore, in some cases a period of thyroid 
underactivity may follow the thyrotoxicosis, and this may require levothyroxine treatment, if 
causing severe symptoms.
Subclinica! hyperthyroidism
In subclinical hyperthyroidism, the TSH is suppressed but the free thyroid hormone levels are 
normal. Endocrinologists regard this condition as a precursor of overt or clinical hyperthyroidism 
but there is some debate over whether this mildest of degree of hyperthyroidism should be treated 
(JAMA 2004; 291: 228-238, J Clin Endocrinol Metab. 2007 ;92:3-9.). Further research is being 
conducted in this area. At present treatment is a matter for individual clinical evaluation and 
discussion between patient and doctor, although there is a consensus that treatment may be 
worthwhile in the elderly, particularly if the heart rhythm becomes abnormal or there is thinning of 
the bones or low-impact bone fractures.
Hypothyroidism -  clinical features and treatment
1. The causes of hypothyroidism
The thyroid is a gland in the neck which makes two thyroid hormones, thyroxine (T4) 
and tri-iodothyronine (T3). Thyroxine is inactive and is converted by the tissues and 
organs that need it into tri-iodothyronine. The role of thyroid hormones, put simply, is 
to regulate the metabolism of virtually all cells in the body. When there is too little 
thyroid hormone (hypothyroidism) the body’s metabolism slows down and this is 
manifested by changes in various tissues that are listed below. Around 80% of tri­
iodothyronine in the body is derived from conversion of thyroxine in the tissues (a 
process mediated by deiodinase enzymes), the remainder coming directly from the 
thyroid gland. Most (>99%) of the thyroid hormone in the blood is bound to proteins 
and is not available to cells. The free fraction of T4 and T3 in the blood is therefore a 
more useful measure of thyroid hormone levels than the total amount of these 
hormones. This is what is meant by free T4 (FT4) and free tri-iodothyronine (FT3).
The prevalence of hypothyroidism is about 2% and this is ten times more common in 
women. There are two main causes of hypothyroidism in the UK, namely 
autoimmunity and as a side effect of treatment for an overactive thyroid or for thyroid 
cancer. In autoimmune thyroid diseases, the thyroid cells are destroyed by white 
blood cells (lymphocytes) which attack the thyroid. Autoimmune thyroid disease is 
usually accompanied by the presence of thyroid peroxidase (TPO) autoantibodies 
which can be detected in the blood and are therefore a useful tool for diagnosis. In 
patients who have an overactive thyroid or thyroid cancer, treatment may consist of 
surgery or radioiodine, both of which destroy the diseased gland but inevitably result 
in a significant proportion of patients developing hypothyroidism.
Together these two types of hypothyroidism account for well over 90% of all cases. 
Rarer causes include inflammatory responses in the thyroid (sometimes as the result 
of viruses or drugs such as amiodarone or lithium), abnormal thyroid development in 
the foetus and genetic defects in thyroid function (leading to congenital 
hypothyroidism which should usually be picked up during neonatal screening). Iodine 
deficiency is still a common cause of hypothyroidism in some parts of the world but is 
very rarely encountered in the UK. All the types of hypothyroidism just mentioned 
are usually classified as primary, meaning that they result from direct impairment of 
the thyroid gland’s function.
Impaired thyroid function may also occur as a result of pituitary disease, because the 
pituitary manufactures TSH (thyroid stimulating hormone) which is the most important 
internal factor controlling thyroid function. If the pituitary is damaged and cannot 
make TSH, the thyroid stops working. Although uncommon, such secondary 
hypothyroidism is important as the normal blood test used to test for the presence of 
primary hypothyroidism (namely the TSH level) can be misleading. Such patients 
usually have other clinical features suggestive of pituitary disease, so a careful 
history and clinical examination will point to the correct blood tests that need to be 
undertaken if hypothyroidism is suspected.
2. The symptoms and signs of hypothyroidism
Common complaints include fatigue and lethargy, cold sensitivity, dry skin and 
lifeless hair, impaired concentration and memory, increased weight with poor appetite 
and constipation. Patients may also fairly often experience a hoarse voice, tingling of 
the hands (carpal tunnel syndrome), heavy and, later, absent periods, deafness and 
joint aches. In childhood there may be delayed development and in the adolescent 
precocious puberty. The elderly may develop memory disturbance, an impaired 
mental state or depression, and in rare cases coma can occur, resulting in death if 
left untreated. Signs include slow movements, ‘myxoedema facies’ in which the face 
looks puffy due to the accumulation of subcutaneous fluid, cool dry skin, slow pulse 
rate, thinning of the hair including the eyebrows, slow tendon reflex relaxation time, 
slow pulse rate and hoarse voice. The thyroid may be enlarged (causing a goitre) in 
some patients due to accumulation of lymphocytes (Hashimoto’s thyroiditis), but in 
others the thyroid is destroyed by the time of diagnosis and there is no goitre.
Nowadays patients often are diagnosed at an early stage of disease, due to 
increased awareness and improved biochemical testing. Therefore many patients 
have relatively few of the classical signs or symptoms just listed. In addition, none of 
the symptoms or signs is sufficiently sensitive or specific for the diagnosis of 
hypothyroidism, even when combined together.
3. Treatment of hypothyroidism
Thyroxine
Thyroxine (or levothyroxine) is the current standard thyroid hormone replacement 
recommended in the British National Formulary (BNF). Patients in the UK who 
require thyroxine can obtain an exemption certificate, which means that they do not
have to pay for prescriptions of this drug. This is the standard treatment for thyroid 
hormone deficiency. It has a half life of 7 days and is readily converted into tri­
iodothyronine (by a process called peripheral deiodination) in the body’s tissues. This 
same process occurs with the thyroxine secreted by the thyroid.
Goal of treatment with thyroxine
The goal of treatment in primary hypothyroidism is to reverse the symptoms of 
hypothyroidism by normalising the blood TSH level. The most recent UK guidelines, 
published by the Association of Clinical Biochemists and the British Thyroid 
Association (BTA) in 2005, state The aim of treatment should be to restore and 
maintain the TSH level within the reference range’ 
(http://www.acb.ora.uk/docs/TFTQuidelinefinal.pdf).
The TSH blood test is successful in establishing the correct dosage of thyroxine 
because there is a feedback loop between thyroid hormone in the blood and the 
pituitary. When thyroid hormone levels are low, TSH levels rise, and conversely 
when thyroid hormone levels are high, the TSH levels fall. The pituitary is very 
sensitive to changes in circulating thyroid hormone levels and the amount of TSH it 
secretes is therefore a useful yardstick to measure how much thyroid hormone the 
whole body is exposed to.
Prolonged periods of overtreatment with thyroid hormone (associated with a 
reduction of TSH levels below the reference range) increase the risk of developing 
atrial fibrillation (an irregular heart rhythm associated with a risk of stroke) and bone 
thinning (summarised in JAMA 2004; 291; 228-238).
Measurement of serum T4 or T3 levels on their own are not recommended for 
monitoring thyroid hormone replacement in primary hypothyroidism, as the levels 
may change through the day after ingestion of a tablet and the levels do not reflect 
the tissue response to thyroid hormone in the way TSH does. For instance, if a 
patient omits thyroxine tablets for a few weeks the TSH levels will rise, but the FT4 
level will be normal if the patient then remembers to take thyroxine for a day or two 
before attending clinic.
Subclinical hypothyroidism
In subclinical hypothyroidism, the TSH is elevated but the free thyroid hormone levels 
are normal. Endocrinologists regard this condition as a precursor of overt or clinical 
hypothyroidism but there has been considerable debate over whether even this
mildest of degrees of hypothyroidism can be associated with symptoms and whether 
it should be treated (JAMA 2004; 291: 228-238, J Clin Endocrinol Metab 2005; 90: 
581-585). Further research is being conducted in this area. At present treatment is a 
matter for individual clinical evaluation and discussion between patient and doctor, 
although there is a consensus that treatment is usually worthwhile if repeated TSH 
levels exceed 10mU/L.
Use of tri-iodothyronine
Around 80% of circulating T3 arises from the peripheral tissues by deiodination of T4 
and only around 20% is directly secreted by the thyroid gland. Thyroxine treatment 
in hypothyroid individuals is predicated on the assumption that this ‘missing’ 20% of 
T3 can be compensated for by increased peripheral deiodination.
There have been recent trials of tri-iodothyronine replacement in combination with 
replacement of thyroxine. However T3 given as a liothyronine (or tertroxin) tablet 
does not reflect a physiologically relevant replacement. Firstly, its half life is 24 hours 
and administration results in undesirable, non-physiological peaks of serum T3. 
Secondly, a molar ratio of 14:1 T4:T3, delivering around 100mcg T4 and 6mcg T3 
per day, would be optimal for an average adult patient. Liothyronine tablets are 
20mcg in size, making any approach to mimic normal T3 replacement extremely 
difficult with standard sized tablets, especially in those who still have a degree of 
thyroid remnant function.
Despite initially promising results in a small trial, the benefits of T3 and T4 
combination treatment in patients with hypothyroidism have not been borne out by 
several large and more prolonged trials. Data from 11 independent randomised 
control trials (1216 patients) were pooled and reviewed in J Clin Endocrinol Metab 
2006; 91: 2592-2599).
There was no overall objective evidence of benefit in terms of symptom scores (body 
weight, depression, fatigue, quality of life) or other physiological markers (serum 
cholesterol, triglyceride levels, low or high density lipoprotein. At present, 
combination treatment is not recommended by endocrinologists. Future work is 
needed to determine whether any benefits might occur with sustained release T3 
preparations which are not yet developed for use.
Armour thyroid extract
Armour thyroid extract is desiccated animal thyroid extract which was superseded by 
synthetic thyroxine in the 1960s. It must be obtained from the USA. Although not 
normally prescribed in the UK, because it is not licensed for use, it can be given 
through the NHS if specific arrangements are made on a named patient basis. 
According to the Medicine and Healthcare Products Regulatory Agency, it is the 
decision of individual NHS Trusts as to whether an unlicensed product like Armour is 
made available on a NHS or private prescription.
Armour thyroid extract is not recommended by endocrinologists as standard thyroid 
hormone replacement treatment, as the amount of thyroid hormone is more variable 
between batches than it is in thyroxine tablets. Furthermore, the ratio of T3 to T4 in 
Armour thyroid extract tablets is higher than is normally secreted by human thyroid 
tissue, resulting in potentially harmful levels of T3 (one grain, about 60 mg, of 
desiccated thyroid extract contains about 38mcg of T4 and 9mcg of T3). The 
position of the BTA is set out in a statement (http://www.british-thvroid- 
association.org/armour.htm). Although some patients wish to take Armour, for 
instance, because they perceive it to be ‘natural’ rather than ‘synthetic’, there have 
been no scientific studies that compare it to thyroxine, and there is a theoretical 
reason based on the ratio of T3 to T4 to believe it could have adverse effects.
Thyroid hormone treatment in euthyroid individuals
Only one prospective study has been conducted to assess the possible benefit of 
thyroxine treatment in euthyroid individuals (Brit Med J 2001; 323: 891-895). In this 
controlled trial there was no effect of thyroxine. There are also strong theoretical 
reasons to believe that such treatment is futile. The full position of the BTA is 
summarised in a joint statement with the Society for Endocrinology 
(http://www.british-thyroid-association.org/thyroid_statement.pdf).
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Signs and Symptoms of 
Hypothyroidism
Also known as Underactive Thyroid, 
Myxoedema and Hashimoto’s Disease
• General tiredness
• Excessive need of sleep
• Increased awareness of the cold
• The skin may become dry and thick and feels cold
• The hair may begin to thin out become dry and coarse
• Unusual loss of body hair -  eyebrows may become sparse, and hair on 
forearms short and stubbly
• Flaking, splitting nails
• The voice may become hoarse or croaky
• Constipation
• Muscle weakness, cramps and aches; difficulty climbing stairs
• Sore muscles
• Pins and needles in the fingers and hands
• In women of reproductive years the periods may become heavier and 
longer, but sometimes can prematurely stop
• Fertility problems -  failure to conceive, miscarriage.
• Unexplained weight gain
• Puffy face and bags under the eyes, change in facial appearance
• Slow speech, movements and thoughts
• Low mood, depression
• Memory problems and lack of concentration
• Slow heart beat and slightly raised blood pressure
• Increased cholesterol
• Anaemia
• Hearing problems
• Swelling at the front of the neck
• Sensation of a lump in the throat
• Although rare, in severe cases, unsteadiness on their feet, mental 
disturbance and even hallucinations may be experienced
• Loss of libido / impotency
British Thyroid Foundation - www.btf-thyroid.org
http://www.btf-thyroid.org/main_frame/pages/hyposymptoms.htm 23/07/2009
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Signs and Symptoms of 
Hyperthyroidism
Also known as Overactive Thyroid and 
Graves’ Disease:
• Palpitations -  undue awareness of heart beat
• Rapid and sometimes irregular heart beat
• Breathlessness
• Hair loss
• Brittle nails
• Unexplained weight loss
• Swelling and or tenderness at front of throat
• Hyperactive behaviour. Children tend to be clumsy and drop things
• In children they may have grown faster than their peers so that their height 
is greater than normal for their age
• Difficulty sleeping
• Nervousness / Anxiety
• Irritability
• Aggressive behaviour
• Sweating
• Heat intolerance
• Thirst
• Tremor in hands and fingers
• Looseness of the bowels, diarrhoea
• Weak muscles -  the upper muscles of your legs and arms are most likely to 
be affected. You may have difficulty in getting up from the squatting 
position without using your arms or find it hard to lift a heavy package 
down from a high shelf
• Rapid pulse
• Warm moist hands
• Increased appetite
• Lack of concentration and memory loss
• Eye pain, double vision
• Swelling or protrusion of the eyes
• Development of painless red lumps, usually on the shins
• In women of reproductive years the periods may become scant and 
sometimes can prematurely stop
• Impaired fertility
• Osteoporosis
http://www.btf-thyroid.org/main_frame/pages/hypersymptoms.htm 23/07/2009
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• Low cholesterol
• Low blood pressure
• Loss of libido / impotency
British Thyroid Foundation - www.btf-thyroid.org
http ://www.btf-thyroid.org/main_ffame/pages/hypersymptoms .htm 23/07/2009
THYROID PETITION
We the undersigned [thyroid patients, familie^friends] wish to lodge this petition with the 
General Medical Council as a formal complaint against the clinical practice of the majority of 
the medical profession with regard to the diagnosis and management of hypothyroidism on 
four counts: -
1. Over reliance on thyroid blood test results and a total lack of reliance on signs, symptoms, 
history of the patient and a clinical appraisal.
2. The emotional abuse and blatant disregard by the majority of general practitioners and 
endocrinologists over the suffering experienced by untreated/incorrectly treated thyroid 
patients and their lack of compassion over the fate of these patients.
3. Stubbornness by the majority of general practitioners and endocrinologists to treat patients 
suffering with hypothyroidism with a level of medication that returns the patient to optimum 
health. In addition, the unwillingness to prescribe alternative thyroid treatment for patients on 
individual clinical grounds. For example a combination of T4/T3, T3 alone or a natural thyroid 
treatment such as Armour Thyroid.
4. The ongoing reluctance to encourage debate or further research on hypothyroidism.
In addition we formally request an independent investigation into patients who are 
hypothyroid, which includes examination of clinical results of patients treated by private 
doctors (whose work is outside NHS directives), and comparative examination of clinical results 
of patients treated by NHS practitioners who diagnose and manage hypothyroidism.
Failure  to  address these issues w ill resu lt in  a vote o f no confidence in  the G eneral M edical C ouncil.
N A M E  IN  C A P ITA LS TO W N PO STC O D E SIG N A TU R E
D ATE: T O T A L N UM BER OF SIG NATURES O N  T H IS  SHEET:
Armour Thyroid (USP) and combined thyroxine/ tri-iodothyronine as Thyroid Hormone
Replacement
A Statement from the British Thyroid Association Executive Committee
February 2007
Part 1. Use of Armour Thyroid
A. Armour Thyroid contains both thyroxine (T4) and tri-iodothyronine (T3) extracted from the 
thyroid gland of pigs. One grain, about 60 mg, of desiccated pig thyroid extract contains about 
38mcg of T4 and 9mcg of T3, a ratio of around 4 to 1. The normal concentration of these hormones 
in the human thyroid is, however, at a ratio of 14 to 1. In other words, Armour thyroid extract 
contains excessive amounts of T3 relative to T4 when used to replace thyroid hormone in man. 
Moreover, as pig thyroid contains other substances apart from T4 and T3, Armour Thyroid is not a 
pure preparation of thyroid hormones. Historically, extracts of animal thyroid glands were the only 
way to treat thyroid underactivity, but since the 1950s pure synthetic thyroid hormones have been 
available in tablet form (thyroxine sodium [T4] and liothyronine [T3]).
B. The concentration of thyroid hormones in Armour Thyroid USP is regulated by the manufacturer 
to United States Food and Drug Administration (FDA) standards. Despite this, there have been 
significant problems with the stability of Armour Thyroid in recent years, prompting a massive 
recall of tablets.1 Because of these stability problems with Armour Thyroid, there is potential for 
fluctuations in thyroid hormone levels in the blood of patients treated with Armour Thyroid. These 
fluctuations may be unpredictable and have adverse effects on patients’ health.
C. There is no evidence to favour the prescription of Armour Thyroid in the treatment of 
hypothyroidism over the prescription of thyroxine sodium, as supplied in the United Kingdom. 
There has never been a direct comparison of these two treatments. The BTA committee cannot 
recommend a treatment with possible side-effects, when a safe and equally well-established 
treatment exists.
D. Armour Thyroid is not on the British National Formulary and is not a licensed therapy in the 
UK. Mr. G. Matthews, the Pharmaceutical Assessor of the Medicines and Health Care Products 
Regulatory Agency, in a letter sent to BTA dated 19 October 2005, has clarified that “The 
regulations on medicine allow doctors to prescribe an unlicensed medicine for a patient to meet 
such a special clinical need, on their own direct personal responsibility. Where these unlicensed 
medicines are not available in the UK they can be imported by appropriately licensed medicines 
wholesalers, for supply to a doctor or pharmacy, to meet these needs.”
E. The cost of Armour Thyroid may be up to £20 per month, compared to an equivalent cost of £1 
per month for thyroxine. Furthermore, Armour Thyroid is not eligible to be claimed on the 
prescription exemption certificate (FP10).
Part 2. Use of Combination Thyroxine/ Tri-iodothyronine f Liothyronine] Therapy
A. There is no currently available tablet preparation containing thyroxine and tri-iodothyronine 
(T4/T3) in a combination that adequately reproduces the relative quantities of these hormones 
produced by the human thyroid gland. Neither is there a preparation that produces a sustained 
release of thyroid hormones in a pattern similar to that from the human thyroid gland.
B. Having been disregarded as a therapeutic approach to the treatment of hypothyoidism since the 
1970s, interest in combination thyroxine/tri-iodothyronine (T4/T3) therapy was re-ignited by a 
study of 31 patients published in 1999.2 Although this study showed promising results, with 
improvement in quality of life, wellbeing and brain (psychometric) function with combination 
therapy, the majority of the patients in the study had been treated previously for thyroid cancer. The 
relatively high doses of thyroxine that formed the routine treatment for thyroid cancer (compared to 
a lesser replacement dose that would be normal in hypothyroidism) could have confounded the 
results of the study.
C. Since this initial study, there have been a further seven rigorously conducted (“randomised, 
double-blind, placebo-controlled”) studies, encompassing more than 900 hypothyroid patients 
(summarised in refs. 3 & 4). None of the subsequent studies showed a beneficial effect of combined 
T4/T3 therapy on measures of wellbeing, health and mental functioning. Three of the seven studies 
show harmful or undesirable effects of the T4/T3 combination.
D. In three of the subsequent studies of combination treatment, the patients were asked which 
treatment they preferred, and in two of these 3 studies more patients preferred the combination 
T4/T3 therapy. There is no obvious explanation for these observations, and it may or may not be a 
reproducible effect.
E. The BTA keeps an open mind about whether using an appropriate formulation of T4/T3 
combination tablet would, in the future, provide health and quality of life benefits in the treatment 
of hypothyroidism for a subgroup of patients. However, based on the current evidence from 
rigorous studies of large numbers of patients using the currently available formulations of synthetic 
thyroid hormones, combined T4/T3 cannot be recommended because of a lack of benefit and a 
small number of undesirable and harmful effects seen on combination treatment.
British Thyroid Association Executive Committee, March 2007
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